Decision Making in Patients Undergoing Coronary Artery Revascularization : A New Era in Clinical Trial Design and Evidence-Based Practice by Milojevic, M. (Milan)
Milan Milojevic
Decision Making in Patients 
Undergoing Coronary Artery 
Revascularization
A New Era in Clinical Trial Design and 
Evidence-Based Practice
Decision Making in Patients 
Undergoing Coronary Artery 
Revascularization
A New Era in Clinical Trial Design and Evidence-Based Practice
Milan Milojevic
Designed by: Guus Gijben 
Printed by: ProefschriftMaken, Utrecht, The Netherlands
ISBN: 978-94-6380-382-3
© Milan Milojevic
All rights reserved. No part of this publication may be reproduced or transmitted 
in any form or by any means, electronic or mechanical, including photocopy, 
recording, or any information storage or retrieval system, without the prior 
written permission of the holder of the copyright.
Decision Making in Patients Undergoing 
Coronary Artery Revascularization 
A New Era in Clinical Trial Design and Evidence-Based Practice
Thesis 
to obtain the degree of Doctor from the
Erasmus University Rotterdam
by command of the 
rector magnificus
Prof.Dr. R.C.M.E. Engels
and in accordance with decision of the Doctorate Board.
The public defence shall be held on
Friday 28th of June 2019 at 13:30 hours
By
Milan Milojevic
born in Belgrade, Serbia
Doctoral Committee:
Promotor: Prof.dr. A.P. Kappetein
Other members:
Prof.dr. A.J.J.C. Bogers
Prof.dr. R.J.M. Klautz 
Prof.dr. M. Sousa-Uva
Compromotor: 
Dr. S.J. Head
Financial support by the Dutch Heart Foundation for the publication of this thesis 
is gratefully acknowledged.
For my dearest family 

“I don’t care that they stole my idea. I care that they don’t have any of 
their own.”
− Nikola Tesla.
TABLE OF CONTENTS
Chapter 1 General Introduction 13
Chapter 2 Aims and Outline 21
PART 1 CURRENT PRACTICE IN BYPASS SURGERY
Chapter 3  Life-long clinical outcome after the first myocardial  29 
revascularization procedures: 40-year follow-up 
after coronary artery bypass grafting and percutaneous 
coronary intervention in Rotterdam
    Milojevic M, Thuijs DJFM, Head SJ, Domingues CT, Bekker MWA,  
Zijlstra F, Daemen J, de Jaegere PPT, Kappetein AP, van Domburg RT,  
Bogers AJ. 
    Interact Cardiovasc Thorac Surg. 2019; In press.
Chapter 4  Current Practice of State-of-the-Art Surgical Coronary 47 
Revascularization
    Head SJ, Milojevic M, Taggart DP, Puskas JD.
   Circulation. 2017;136:1331-1345.
Chapter 5  Heart Team decision-making and long-term outcomes for 79 
1000 consecutive cases of coronary artery disease
    Domingues CT, Milojevic M, Thuijs DJFM, van Mieghem NM,  
Daemen J, van Domburg RT, Kappetein AP, Head SJ. 
   Interact Cardiovasc Thorac Surg. 2019; 28:206-213.
PART 2 BYPASS SURGERY VERSUS STENTING
Chapter 6  Mortality after coronary artery bypass grafting versus 103 
percutaneous coronary intervention with stenting for  
coronary artery disease: a pooled analysis of individual  
patient data
    Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, 
Domanski MJ, Farkouh ME, Fuster V, Flather M, Papageorgiou G,  
Holm NR, Hlatky M, Hueb WA, Kamalesh M, Kim YH, Mäkikallio T,  
Mohr FW, Park SJ, Rodriquez AE, Sabik JF, Stables RH, Stone GW,  
Serruys PW, Kappetein AP.
   The Lancet. 2018;391:939-948.
Chapter 7  Causes of Death Following PCI Versus CABG in Complex 133 
CAD: 5-Year Follow-Up of SYNTAX
    Milojevic M, Head SJ, Parasca CA, Serruys PW, Mohr FW, Morice MC,  
Mack MJ, Ståhle E, Feldman TE, Dawkins KD, Colombo A, Kappetein AP, 
Holmes DR Jr.
   J Am Coll Cardiol. 2016;67:42-55.
Chapter 8  Stroke Rates Following Surgical Versus Percutaneous 167 
Coronary Revascularization
    Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, 
Domanski MJ, Farkouh ME, Fuster V, Flather M, Papageorgiou G,  
Holm NR, Hlatky M, Hueb WA, Kamalesh M, Kim YH, Mäkikallio T,  
Mohr FW, Park SJ, Rodriquez AE, Sabik JF, Stables RH, Stone GW,  
Serruys PW, Kappetein AP.
   J Am Coll Cardiol. 2018;72:386-398.
Chapter 9  Tranexamic Acid in Patients Undergoing Coronary-Artery 195 
Surgery
   Milojevic M, Kappetein AP, Head SJ. 
   N Engl J Med. 2017;376:1892.
Chapter 10  Incidence, Characteristics, Predictors, and Outcomes of 201 
Repeat Revascularization After Percutaneous Coronary 
Intervention and Coronary Artery Bypass Grafting:  
The SYNTAX Trial at 5 Years
    Parasca CA, Head SJ, Milojevic M, Mack MJ, Serruys PW, Morice MC,  
Mohr FW, Feldman TE, Colombo A, Dawkins KD, Holmes DR Jr,  
Kappetein AP.
   JACC Cardiovasc Interv. 2016;9:2493-2507.
Chapter 11  Hierarchical testing of composite endpoints: applying the 243 
win ratio to percutaneous coronary intervention versus 
coronary artery bypass grafting in the SYNTAX trial
   Milojevic M, Head SJ, Andrinopoulou ER, Serruys PW, Mohr FW,  
Tijssen JG, Kappetein AP.
  EuroIntervention. 2017;13:106-114.
Chapter 12  The impact of chronic kidney disease on outcomes 265 
following percutaneous coronary interventions versus  
coronary artery bypass grafting in patients with complex 
coronary artery disease: 5-year follow-up of the SYNTAX trial
   Milojevic M, Head SJ, Mack MJ, Mohr FW, Morice MC, Dawkins KD,  
Holmes DR Jr, Serruys PW, Kappetein AP.
  EuroIntervention. 2018;14:102-111.
Chapter 13  Bypass Surgery or Stenting for Left Main Coronary Artery 295 
Disease in Patients with Diabetes
   Milojevic M, Serruys PW, Sabik JF, Kandzari DE, Schampaert E,  
van Boven AJ, Horkay F, Ungi I, Mansour S, Banning A, Taggart DP,  
Sabaté M, Gershlick A, Bochenek A, Pomar J, Lembo N, Noiseux N,  
Puskas JD, Crowley A, Kosmidou I, Mehran R, Ben-Yehuda O,  
Généreux P, Pocock SJ, Simonton CA, Stone GW, Kappetein AP.
  J Am Coll Cardiol. 2019;73:1616-1628.
Chapter 14  Influence of practice patterns on outcome among countries 325 
enrolled in the SYNTAX trial: 5-year results between 
percutaneous coronary intervention and coronary artery  
bypass grafting
   Milojevic M, Head SJ, Mack MJ, Mohr FW, Morice MC, Dawkins KS,  
Holmes DR Jr, Serruys PW, Kappetein AP.
  Eur J Cardiothoracic Surg. 2017;52:445-453.
PART 3 IMPROVING OUTCOMES IN CARDIAC SURGERY
Chapter 15  Compliance with guideline-directed medical therapy in 357 
contemporary coronary revascularization trials
    Pinho-Gomes AC, Azevedo L, Ahn JM, Park SJ, Hamza TH, Farkouh ME, 
Serruys PW, Milojevic M, Kappetein AP, Stone G, Lamy A, Fuster V,  
Taggart DP.
   J Am Coll Cardiol. 2018;71:591-602.
Chapter 16  Clinical guidelines on perioperative medication in 395 
adult cardiac surgery
   Based on: 
   2017 EACTS Guidelines on perioperative medication in adult cardiac 
surgery
    Sousa-Uva M, Head SJ, Milojevic M, Collet JP, Landoni G, Castella M, 
Dunning J, Gudbjartsson T, Linker NJ, Sandoval E, Thielmann M,  
Jeppsson, Landmesser U.
   Eur J Cardiothorac Surg. 2018;53:5-33.
    2017 EACTS/EACTA Guidelines on patient blood management in  
adult cardiac surgery
    Pagano D, Milojevic M, Meesters MI, Benedetto U, Bolliger D,  
von Heymann C, Jeppsson A, Koster A, Osnabrugge RL, Ranucci M,  
Ravn HB, Vonk ABA, Wahba A, Boer C.
   Eur J Cardiothorac Surg. 2018;53:79-111. 
   J Cardiothorac Vasc Anesth. 2018;32:88-120.
Chapter 17  Mixing ‘apples and oranges’ in meta-analytic studies: 445 
dangerous or delicious?
   Milojevic M, Sousa-Uva M, Durko AP, Head SJ. 
   Eur J Cardiothorac Surg. 2018;53:1294-1298.
PART 4 SUMMARY AND DISCUSSION
Chapter 18 Summary 453
Chapter 19 General Discussion 461
POSTSCRIPT 
Chapter 20 Nederlandstalige Samenvatting 481
Chapter 21 PhD-Portfolio 491
Chapter 22 List of publications 497
Chapter 23 Acknowledgements 505
Chapter 24 About the author 515

Chapter 1
General Introduction
14
Chapter 1
15
1
General introduction
GENERAL INTRODUCTION
Coronary artery disease (CAD) remains the single leading cause of death in 
Europe, accounting for more than 860,000 deaths annually in men (19%) and 
875,000 deaths annually in women (20%) (Figure 1) despite massive resources 
dedicated to research and treatment (1). With an estimated hospital admission 
rate of approximately 19.5 per 1000 patients and the average length of stay of 8.7 
days, the treatment of CAD also represents a significant disease burden with 
severe economic and social impact (2).
Figure 1. Causes of death in Europe (A) among men and (B) women. Source: WHO Mortality 
Database 2016 (1). Note: no data available for Andorra.
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In general, all patients with CAD require lifestyle modification and lifelong 
optimal medical therapy to improve angina symptoms, decrease the progression 
of the disease, and reduce the risk of death, myocardial infarction and heart 
failure (3, 4). The decision to proceed with revascularization by either coronary 
artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI) 
is reserved for patients with disabling symptoms despite intensive medical 
therapy, those in whom intensive medical treatment is not well tolerated or 
want to increase their physical activity level, and patients with complex coronary 
anatomy (e.g. left main coronary disease and multivessel coronary disease) for 
which myocardial revascularization has a clearly establish survival benefit over 
medical therapy (5). 
It should be noted that the use of PCI and CABG procedures still remarkably 
varies across European countries (Figure 2). Cross-country variability reflects 
different clinical practice on a national level as a consequence of the variation in 
reimbursement policy, health-care infrastructure, and the health status of the 
nation (6), but also suggests a lack of high-quality evidence to identify the target 
population of patients who will undoubtedly benefit from the specific treatment 
with PCI or CABG:  
“It’s not hard to make decisions once you 
know what your values are.” 
Roy E. Disney
Ideally, the choice between CABG and PCI should be based on data accumulated 
from clinical trials, and patient preferences when appropriate (7, 8). However, 
myocardial revascularization with both CABG and PCI is rapidly evolving. PCI is 
undergoing improvements in long-term safety and efficacy of coronary stents, 
while CABG is improving by better perioperative care, use of more arterial 
grafts, and adherence to secondary prevention medications (9, 10). Moreover, 
new treatment strategies for both PCI and CABG include the use of functional 
revascularization assessment to avoid unnecessary revascularization. These 
continually evolving treatment strategies have led to a continuous debate on 
which of these two procedures provides the best care among various subsets of 
patients (11).
17
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Figure 2. Rates of percutaneous coronary intervention (A) and coronary artery bypass grafting 
(B) in Europe in 2017 (2).
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Despite the recent developments in PCI practice, with the introduction of drug-
eluting stents, it remains to be determined whether the efficacy and relative safety 
of PCI has improved compared to contemporary outcomes of CABG. Therefore, to 
identify the most appropriate revascularization modality for a particular patient, 
more high-quality data from modern clinical practice are needed. Moreover, 
for most patients with complex CAD, the most critical determinants of long-
term survival are age, diabetes mellitus, chronic kidney disease, left ventricular 
ejection fraction, and the severity and location of coronary lesions, but it remains 
mostly unclear how contemporary PCI and CABG compare in these particular 
subsets.
The development and update of clinical guidelines are based on an evaluation 
of the latest data from contemporary clinical studies. Modern clinical practice 
emphasizes the value of evidence-based medicine for daily activities as one of 
the ultimate requirements for best patient care. Clinical guidelines are aimed at 
helping medical practitioners, and health-care authorities bridge the gap between 
the best available evidence and local practice, treatment costs, and patient choice 
(12). More importantly, changes in clinical practice depend on the dissemination 
and evaluation of clinical guidelines, the existence of which should be vigorously 
pursued supported through all available informal and formal informational 
channels: 
“Guidelines do not implement themselves.”
Marilyn J. Field and Kathleen N. Lohr, 1992.
The focus of this thesis is on the management of patients with complex CAD 
by means of PCI or CABG, to improve outcomes and potentially lead to an 
individualized treatment selection based on the risk profile of a particular patient. 
Moreover, our clinical research focuses on an integrated care model to incorporate 
decision to proceed with CABG in conjunction with established pillars of i) the use 
of optimal surgical techniques, and ii) aggressive risk-factor modification through 
guideline-directed pharmacological therapies and lifestyle modifications. 
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2
AIMS
The aims of this thesis are to study the comparative effectiveness of coronary 
artery bypass graft surgery (CABG) versus percutaneous coronary intervention 
(PCI) and to critically assess the available evidence, resulting in practical 
recommendations for improved treatment decision-making in patients needing 
myocardial revascularization. 
More specifically, the following research questions are addressed:
1. What is the current status of surgical myocardial revascularization?
2. What are the outcomes of contemporary CABG versus PCI? 
3. Is bypass surgery the preferred revascularization strategy over PCI in patients 
with specific clinical profiles?
4. How do globalization and use of the composite outcomes affect the 
interpretation of clinical trial results?
5. How to improve health care quality, patient outcomes, and costs with the 
current body of evidence in cardiac surgery; development of evidence-based 
clinical practice guidelines.
24
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OUTLINE
Part 1 of this thesis focuses on the contemporary indications, treatment strategies 
and outcomes of surgical revascularization. The 40-year clinical outcome and life 
expectancy after venous CABG surgery is established. Moreover, the feasibility 
and safety of a Heart Team approach to myocardial revascularization and the 
long-term results are studied in real life settings. 
Part 2 aims to investigate the most appropriate revascularization strategy in 
specific patients with complex coronary artery disease. We compare the long-
term outcomes of CABG versus PCI in patients with and without diabetes, 
chronic kidney disease, and patients with multivessel and/or left main coronary 
disease. The main focus of this section is to investigate the outcomes that are of 
critical importance for decision-making including mortality, stroke, myocardial 
infarction and need for repeat revascularization. Furthermore, a new hierarchical 
approach is applied to test the primary composite endpoint to capture meaningful 
clinical effects of CABG versus PCI. A specific analysis of differences in practice 
patterns among countries enrolled in clinical trials is performed, highlighting the 
recommendations for the design of future studies and identify interventions for 
improvement in particular countries.
Part 3 examines the adherence to guideline-directed medical therapy following 
myocardial revascularization in the landmark clinical trials and provides 
evidence-based recommendations for perioperative medication management in 
patients undergoing cardiac surgery to improve short- and long-term prognosis. 

Part 1
Current Practice
in Bypass Surgery

Chapter 3
Life-long clinical outcome after the first myocardial 
revascularization procedures: 40-year follow-up 
after coronary artery bypass grafting and 
percutaneous coronary intervention in Rotterdam
Milojevic M, Thuijs DJFM, Head SJ, Domingues CT, Bekker MWA, 
Zijlstra F, Daemen J, de Jaegere PPT, Kappetein AP, van Domburg RT, 
Bogers AJ. 
Interact Cardiovasc Thorac Surg. 2019; In press.
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ABSTRACT
AIM: Our goal was to evaluate the outcomes of the first patients treated by venous 
coronary artery bypass grafting (CABG) or percutaneous coronary interventions 
(PCI) with balloon angioplasty at a single centre who have reached 40 years of life-
long follow-up. 
METHODS AND RESULTS: We analyzed the outcomes of the first consecutive 
patients who underwent (venous) CABG (n=1041) from 1971 to 1980 and PCI (n=856) 
with balloon angioplasty between 1980 and 1985. Follow-up was successfully 
achieved in 98% of patients (median 39 years, range 36-46) who underwent 
CABG and in 97% (median 33 years, range 32-36) of patients who had PCI. The 
median age was 53 years in the CABG cohort and 57 years in the PCI cohort. A 
total of 82% of patients in the CABG group and 37% of those in the PCI group had 
multivessel coronary artery disease. The cumulative survival rates at 10, 20, 30 
and 40 years were 77%, 39%, 14% and 4% after CABG, respectively, and at 10, 20, 30 
and 35 years after PCI were 78%, 47%, 21% and 12%, respectively. The estimated life 
expectancy after CABG was 18 years and 17 years after the PCI procedures. Repeat 
revascularization was performed in 36% and 57% of the patients in the CABG and 
PCI cohorts, respectively.
CONCLUSIONS: This unique life-long follow-up analysis demonstrates that 
both CABG and PCI were excellent treatment options immediately after their 
introduction as the standard of care. These procedures were lifesaving, thereby 
indirectly enabling patients to be treated with newly developed methods and 
medical therapies during the follow-up years.
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INTRODUCTION
Since the introduction of the modern coronary artery bypass grafting (CABG) 
with venous and internal mammary artery (IMA) grafts in 1964 and percutaneous 
coronary intervention (PCI) with balloon angioplasty in 1977, these procedures 
have been performed extensively to treat coronary artery disease (CAD) worldwide 
(1, 2). According to results from the Eurostat Database, coronary revascularization 
is one of the most common major hospital interventions performed in the 
European Union with an average rate of 258 per 100,000 inhabitants (3). 
Advancements in both techniques and guideline-directed medical therapies have 
improved life expectancy and quality of life (4). However, although long-term 
follow-up is available (5, 6), data on the life-long outcomes after CABG and PCI are 
still not published. Despite revascularization treatment has significantly changed 
and improved since its introduction, it is essential to establish the outcome 
of the first routinely treated patients, because life-long results (i) provide an 
opportunity to establish risk factors that show late sequelae, (ii) lend credibility 
for future studies and iii) provide more insight into the real prognosis of patients. 
Therefore, we determined the outcome from life-long follow-up after the first 
CABG and PCI procedures. 
METHODS
Study population
The study population and methods were described previously in detail (5, 6). 
Briefly, the CABG population of this study comprised 1041 consecutive patients 
who underwent a first elective isolated coronary surgery with venous grafts 
between 1971 and 1980 at the Erasmus Medical Center. During that period, internal 
mammary artery (IMA) grafts were not yet used at our institution. Indications 
for surgical revascularization were stable or unstable angina despite intensive 
pharmacological therapy. The intent was to achieve complete revascularization 
of significantly obstructed proximal coronary segments of the major arteries. 
Patients with any previous or concomitant cardiac surgical procedures were 
excluded from the current study. 
The PCI cohort comprised 856 consecutive patients who underwent a first balloon 
angioplasty procedure between 1980 and 1985 at the Erasmus Medical Centre. 
Seventy-six patients were treated for acute myocardial infarction (MI), and 
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other patients had either stable or unstable angina. At that time, all patients had 
intensive pharmacological therapy with beta-blockers, calcium channel blockers 
and nitrates, with intravenous heparin for unstable patients. Before the PCI 
procedure, 250 mg of acetylsalicylic acid and 100 mg of unfractionated heparin 
were administered intravenously, following additional boluses of 50 mg per hour. 
At hospital discharge, conventional treatment included acetylsalicylic acid of 500 
mg daily for at least 6 months as well as a high dose of nifedipine. 
The primary end point of this study was all-cause death. Secondary end 
points were repeat revascularization and a composite of death and repeat 
revascularization. Patients with multivessel disease were defined as having 2or 
3-vessel disease. Left ventricular (LV) dysfunction was defined as an ejection 
fraction < 50%. For this observational study, patients were not subject of additional 
treatment or diagnostic procedures; neither was any mode of behaviour imposed 
other than as part of their regular treatment. Therefore, according to Dutch law 
at that time, written informed consent for a patient to be enrolled in this study 
was not required. This study was conducted according to the privacy policy of 
the Erasmus Medical Centre and to the Erasmus Medical Centre regulations for 
the appropriate use of data in patient-oriented research, which are based on 
international regulations, including the Declaration of Helsinki.
Follow-up
Patients who had CABG or PCI were followed from the date of the index 
procedure until the time of death or the time of the last available follow-up. Data 
regarding death or repeat revascularization were updated at 12 months after 
the index procedure and every 5 to 7 years after that, by reviewing hospital and 
general practitioner records and the civil registry or by telephone interviews with 
patients/family members. Follow-up was complete in 98% of patients who had 
CABG and 97% of patients who had PCI who were recruited in the cohorts. The 
survival status of 22 patients who had CABG and 25 patients who had PCI could 
not be retrieved because they had emigrated, and these patients were censored 
at the date of the last follow-up. Since the early 1980s, all data were prospectively 
entered into a dedicated database.
Statistical analysis
No statistical comparisons were performed between PCI and CABG because 
the entry criteria differed as to inclusion period, clinical presentation and the 
complexity of the CAD. 
Data are presented using descriptive statistics, as a percentage, count of sample 
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size or median ± interquartile range (IQR). Cumulative time-to-event Kaplan-
Meier estimates were used to assess the clinical outcomes after PCI at 35 years 
and CABG at 40 years among overall cohorts and according to the number of 
diseased vessels. Life expectancy (LE) after CABG and PCI was calculated from 
the area under the Kaplan-Meier curves (5). The expected survival in a reference 
population was calculated using ageand gender-specific mortality data from 
the Netherlands during the study period (www.cbs.nl) and was compared with 
survival rates of patients after CABG and PCI. Multivariable Cox proportional 
hazards models were constructed to identify independent prognostic factors 
for very long-term mortality rates using baseline characteristics: age, gender, 
history of smoking, diabetes, hypertension, dyslipidaemia, 3-vessel disease and 
LV dysfunction. A 2-sided p-value of <0.05 was considered to be statistically 
significant. Analyses were performed using SPSS Statistics version 21.0 (IBM 
Corporation, Armonk, NY USA). 
RESULTS
Coronary artery bypass grafting cohort
The median age was 53 years (interquartile range (IQR), 48-58 years), and 88% were 
male (Table 1). A total of 9% had diabetes, 31% had a diagnosis of LV dysfunction and 
the majority 73% had multivessel disease. 
Median follow-up was 39 ± 2 years (range 36-46), during which 979 deaths occurred. 
Cumulative survival rates were 77% at 10 years, 39% at 20 years, 14% at 30 years, and 
4% at 40 years (Fig. 1). Estimated LE was 18 years. 
The number of diseased vessels was strongly correlated with higher mortality rates 
(Fig. 2A). The survival rates in patients with 2-vessel disease were significantly higher 
compared to those in patients with 3-vessel disease at 10 years (82% vs 71%), 20 years 
(46% vs 28%), 30 years (16% vs 9%) and 40 years (4% vs 2%). Independent predictors 
of the 40-year mortality rate were age, diabetes, hypertension, LV dysfunction and 
3-vessel disease (Table 2). 
A total of 668 repeat revascularizations were performed in 375 patients (36%). 
Of those patients who required repeat procedures, repeat CABG procedures 
were needed in 315 (84%) patients, and 164 patients underwent at least 2 repeat 
revascularizations (Fig. 3). The hazard of repeat revascularization was highest 7 
to 13 years after the initial procedure (Fig. 4A). Freedom from death or repeat 
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revascularization was 60% at 10 years, 19% at 20 years, 6% at 30 years and 1% at 40 
years (Fig. 1). 
Table 1. Baseline characteristics.
Characteristic CABG (n=1041) PCI (n=856)
Age, IQR 53.0 (47.7-58.4) 56.9 (50.4-62.7)
 Range 28-70 22-80
Male 915 (87.9) 684 (79.9)
Smoking (history) 589 (57.8) 497 (58.0)
Diabetes 82 (8.6) 99 (11.6)
Hypertension 224 (21.6) 338 (40.5)
Dyslipidemia 232 (22.4) 241 (27.4)
LV dysfunction 274 (31.4) 104 (16.6)
 Normal (≥50%) 601 (68.6) 523 (83.4)
 Moderate (30-49%) 247 (28.3) 97 (15.5)
 Low (<30%) 27 (3.1) 7 (1.1)
Vessel disease
 1-vessel 192 (18.4) 543 (63.4)
 2-vessel 320 (30.7) 198 (23.6)
 3-vessel 445 (42.7) 97 (11.8)
 Left main 84 (8.1) 11 (1.3)
Numbers are presented as n (%) or as median with IQR. CABG, coronary artery bypass grafting; PCI, 
percutaneous coronary intervention; LV, left ventricular; IQR, interquartile range.
Percutaneous coronary intervention cohort 
The median age at the time of PCI was 57 years (IQR, 50-63 years), and 80% were 
men (Table 1). Diabetes was present in 12%, LV dysfunction in 17%; the majority 
(63%) had 1-vessel disease. 
Mean follow-up was 33 ± 1 years (range 32-36), during which 707 deaths occurred. 
Cumulative survival rates were 78% at 10 years, 47% at 20 years, 21% at 30 years and 
12% at 35 years (Fig. 1). Estimated LE was 17 years. 
The number of diseased vessels at baseline was an essential determinant of an 
increase in mortality rates (Fig. 2B). Cumulative survival rates were markedly 
higher among patients with 2-vessel disease versus those with 3-vessel disease at 
10 years (78% vs 56%), 20 years (40% vs 31%), 30 years (17% vs 9%) and 35 years (10% 
vs 5%). Independent predictors of the 35-year mortality rate were age, history of 
smoking, hypertension, LV dysfunction and 3-vessel disease (Table 2). 
37
Life-long clinical outcome after the first myocardial revascularization procedures
3
Figure 1. Survival and event-free survival estimates after CABG and PCI. Values are Kaplan-Meier 
event rates. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; 
Revasc., revascularization.
Table 2. Independent predictors of long-term mortality.
HR (95% CI) P-Value
CABG cohort (n=1041)
Age (per 5-year increments) 1.30 (1.23-1.37) <0.001
Male 1.22 (0.97-1.54) 0.092
Smoking (history) 0.91 (0.78-1.05) 0.21
Diabetes 1.31 (1.01-1.70) 0.042
Hypertension 1.24 (1.04-1.48) 0.018
Dyslipidemia 0.95 (0.80-1.14) 0.60
Three-vessel disease 1.17 (1.08-1.27) <0.001
LV dysfunction 1.79 (1.53-2.10) <0.001
PCI cohort (n=856)
Age (per 5-year increase) 1.40 (1.31-1.48) <0.001
Male 1.01 (0.81-1.27) 0.93
Smoking (history) 1.29 (1.08-1.55) 0.005
Diabetes 1.19 (0.88-1.61) 0.25
Hypertension 1.20 (1.01-1.44) 0.039
Dyslipidemia 0.86 (0.69-1.07) 0.17
Three-vessel disease 1.53 (1.19-1.96) 0.001
LV dysfunction 1.38 (1.09-1.75) 0.007
CABG, coronary artery bypass grafting; CI, confidence interval; HR, hazard ratio; LV, left ventricular; 
PCI, percutaneous coronary intervention. 
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Figure 2. Death after CABG (A) and PCI (B) according to the number of diseased vessels. Values 
are Kaplan-Meier event rates. CABG, coronary artery bypass grafting; PCI, percutaneous coronary 
intervention; LM, left main; VD, vessel disease.
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Figure 3. The proportion of patients undergoing the different numbers and types of repeat revascularization 
after CABG (blue) and PCI (red). Striped rectangles represent repeat CABG revascularization. *Percentage of CABG 
procedures. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
A total of 831 repeat revascularization procedures were performed in 484 patients 
(57%). A CABG procedure was performed in 325 of these patients (67%), and at 
least 2 repeat revascularizations were required in 201 patients during the follow-
up period (Fig. 3). The hazard of repeat revascularization reached its peak during 
the first year after the initial procedure (Fig. 4B). Freedom from death or repeat 
revascularisation was 38% at 10 years, 17% at 20 years, 7% at 30 years and 3% at 35 
years (Fig. 1).
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Figure 4. Instantaneous risk of death and repeat revascularization after CABG (A) and PCI (B). 
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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DISCUSSION
To our knowledge, the presented data on life-long results after the first isolated 
venous CABG and PCI with balloon angioplasty procedures provide the longest, 
most unique and most complete follow-up information published to date. The 
main findings of this analysis can be summarized as follows: (i) Overall LE after 
venous CABG and PCI with balloon angioplasty was 18 and 17 years, respectively; 
(ii) the degree of complexity of the coronary disease had a significant impact 
on long-term survival, especially after PCI; (iii) in addition to the degree of 
coronary complexity, independent predictors of the 40-year survival rate were 
age, hypertension, diabetes, smoking and LV dysfunction; and (iv) rates of repeat 
revascularization were highest during the first year after PCI and during the 7-13 
years follow-up period after CABG.
The coronary artery bypass grafting cohort
Advancements in the whole spectrum of patient care have led to significantly 
improved outcomes after CABG, which is still the standard of care in patients with 
advanced complex CAD (7, 8). Whereas other studies have reported 20 to 35 years of 
follow-up (9-11), this is the first study that provides life-long follow-up results after 
CABG surgery, with only 2% of the patients being lost to follow-up. Impressively, 
the 10-year survival rate is comparable to the findings from the more recent trials 
(12, 13). We found that venous CABG was associated with acceptable survival rates, 
probably for the following reasons: First, the majority (75%) of patients were under 
58 years of age with preserved LV function and without significant comorbidities 
such as diabetes, thereby prolonging the lifespan of venous grafts. Secondly, 
considering that all patients were treated in the pre-PCI era, in situ stents did not 
complicate the surgical technique (14). Lastly, secondary prevention medications, 
modification of risk factors and repeat treatment interventions have changed 
notably during the follow-up period, which may have improved the life-expectancy. 
The rate of repeat revascularization increased significantly 7 years after the initial 
CABG, most likely due to the loss of graft patency. However, these findings were 
derived before the widespread use of statins as secondary prevention, control of risk 
factors and modified surgical techniques that may have resulted in improved venous 
graft patency (15, 16). Furthermore, although the benefits of arterial grafts tend to 
increase with the duration of the follow-up (17), current European and American 
practice guidelines for arterial grafts are recommended for younger patients 
whose life expectancy is beyond the observed benefit of the vein graft (8, 18). This 
observation has motivated the design of the ongoing Arterial Revascularization Trial 
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(ART) study that compares the 10-year survival rates of patients with bilateral versus 
single internal mammary artery (IMA) grafting. The recent results of an interim 
analysis performed at 5 years follow-up show no significant differences between 
the 2 groups in  the rates of major adverse events (19). However, considering our 
results, an increase in cardiac adverse events can be expected in the 5to 10-year 
follow-up period, which may result in the benefit of multiple arterial grafts at the 
10-year as the ART study hypothesis. Nevertheless, the use of even the single IMA as 
the gold standard conduit for CABG produced surprisingly suboptimal results in 
recent studies (20), making the current results still clinically meaningful.
The percutaneous coronary intervention cohort
Treatment with PCI has evolved significantly over the last 40 years and has 
become a life-saving procedure in patients with acute indications (21) but also a 
treatment of choice for many patients with stable disease (8). Only a few studies 
have reported survival results longer than 10 years after PCI (22), whereas no very 
long-term follow-up data are available. In our study, only 3% of patients who had 
PCI were lost to follow-up, thereby providing an accurate estimate of long-term 
survival. 
In 2012, Yamaji et al. reported a mortality rate of 59% at 20 years (22) compared 
to 53% in our study. However, the present study enrolled younger patients, 
only a few of whom had diabetes and a history of MI. In the Bypass Angioplasty 
Revascularization Investigation (BARI) clinical trial, the 10-year mortality rate was 
55% in patients with diabetes compared to 23% in patients without diabetes (23). 
Patients with diabetes presenting for PCI are more likely to have more extensive 
CAD with accelerated atherosclerosis, thereby increasing the risk of MI, repeat 
revascularization and death (24). A recent pooled analysis of individual patient 
data from clinical trials shows that diabetes is one of the most critical determinants 
of the 5-year survival rate after PCI (25). We did not find diabetes to be a predictor 
of long-term death, probably because of the low number of patients who had 
diabetes. Additionally, the number of diseased vessels had a crucial impact 
on long-term survival after PCI. Similarly to results from previous trials using 
balloon angioplasty or bare-metal stents (26), the presence of 3-vessel disease was 
associated with a 3-fold increase in the mortality risk at 5 years compared to that 
of singleor 2-vessel disease. These data reflect the historical trends in PCI and may 
serve as a baseline for comparisons with the results of future PCI studies. 
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We found that the first PCI procedures with balloon angioplasty, in general, were 
associated with a high risk of repeat revascularization during the first year of 
follow-up. This risk was similar to rates reported from large randomized trials (27). 
However, it should be noted that the introduction of bare-metal stents and drug-
eluting stents (DES) and the change from anticoagulation to antiplatelet therapies 
have markedly improved the efficacy of PCI by reducing acute coronary occlusion 
or the process of restenosis and hence the need for repeat revascularization (28). 
Furthermore, the results from the Synergy Between Percutaneous Coronary 
Intervention with Taxus and Cardiac Surgery (SYNTAX) trial showed that the use 
of DES stents significantly decreased the necessity for repeat CABG procedures 
among patients randomized to the PCI group, although this was only assessed up 
to the 5-year follow-up (29). Nevertheless, the results from recent clinical trials 
comparing newer-generation DES with CABG have shown that the significant 
advantage of CABG over PCI concerning the incidence of repeat revascularization 
has remained, especially in patients with multivessel disease (30).
Study limitations
Our study has several significant limitations. Firstly, it is a cohort study of (s)
elective patients from a tertiary referral centre that was designed 40 years ago. At 
that time, knowledge about the existence of risk factors was almost nonexistent. 
Therefore, only a limited number of baseline variables were collected. Secondly, 
surgical and percutaneous technology and techniques, periprocedural therapy 
and long-term guideline-directed secondary prevention medication have 
changed substantially since the time that the procedures in the current study 
were performed. Our findings therefore are not directly translatable to the 
current practice of CABG or PCI. In addition, no data were available on MIs and 
strokes occurring during the follow-up period.
CONCLUSIONS
Our findings demonstrate that CABG and PCI turned out to be excellent, durable 
treatments immediately after becoming a routine treatment, with a life expectancy 
of 18 and 17 years, respectively. Life-long follow-up studies such as these provide 
essential information for patients, clinicians and health care systems and may serve 
as landmark results for future life-long CABG and PCI reports. 
44
Chapter 3
REFERENCES
1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978;1(8058):263.
2.  Head SJ, Kieser TM, Falk V, Huysmans HA, Kappetein AP. Coronary artery bypass grafting: Part 1--the 
evolution over the first 50 years. Eur Heart J. 2013;34(37):2862-72.
3.  Organisation for Economic Cooperation and Development. Health at a Glance: Europe 2016: State of 
Health in the EU Cycle. OECD Publishing; 2016.
4.  Niebauer J. Is There a Role for Cardiac Rehabilitation After Coronary Artery Bypass Grafting? Treatment 
After Coronary Artery Bypass Surgery Remains Incomplete Without Rehabilitation. Circulation. 
2016;133(24):2529-37.
5.  van Domburg RT, Kappetein AP, Bogers AJ. The clinical outcome after coronary bypass surgery: a 30-year 
follow-up study. Eur Heart J. 2009;30(4):453-8.
6.  van Domburg RT, Foley DP, de Feyter PJ, van der Giessen W, van den Brand MJ, Serruys PW. Long-term 
clinical outcome after coronary balloon angioplasty: identification of a population at low risk of recurrent 
events during 17 years of follow-up. Eur Heart J. 2001;22(11):934-41.
7.  Head SJ, Milojevic M, Taggart DP, Puskas JD. Current Practice of State-of-the-Art Surgical Coronary 
Revascularization. Circulation. 2017;136(14):1331-45.
8.  Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial 
revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology 
(ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special 
contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J 
Cardiothorac Surg. 2014;46(4):517-92.
9.  Gao G, Wu Y, Grunkemeier GL, Furnary AP, Starr A. Long-term survival of patients after coronary artery 
bypass graft surgery: comparison of the pre-stent and post-stent eras. Ann Thorac Surg. 2006;82(3):806-
10.
10.  Adelborg K, Horvath-Puho E, Schmidt M, Munch T, Pedersen L, Nielsen PH, et al. Thirty-Year Mortality 
After Coronary Artery Bypass Graft Surgery: A Danish Nationwide Population-Based Cohort Study. Circ 
Cardiovasc Qual Outcomes. 2017;10(5):e002708.
11.  Weintraub WS, Clements SD, Jr., Crisco LV, Guyton RA, Craver JM, Jones EL, et al. Twenty-year survival 
after coronary artery surgery: an institutional perspective from Emory University. Circulation. 
2003;107(9):1271-7.
12.  Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, et al. Ten-Year Follow-Up Survival of 
the Medicine, Angioplasty, or Surgery Study (MASS II). A Randomized Controlled Clinical Trial of 3 
Therapeutic Strategies for Multivessel Coronary Artery Disease. 2010;122(10):949-57.
13. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49(15):1600-6.
14.  Nauffal V, Schwann TA, Yammine MB, El-Hage-Sleiman AK, El Zein MH, Kabour A, et al. Impact of prior 
intracoronary stenting on late outcomes of coronary artery bypass surgery in diabetics with triple-vessel 
disease. J Thorac Cardiovasc Surg. 2015;149(5):1302-9.
15.  Samano N, Geijer H, Liden M, Fremes S, Bodin L, Souza D. The no-touch saphenous vein for coronary 
artery bypass grafting maintains a patency, after 16 years, comparable to the left internal thoracic artery: 
A randomized trial. J Thorac Cardiovasc Surg. 2015;150(4):880-8.
16.  Sousa-Uva M, Head SJ, Milojevic M, Collet JP, Landoni G, Castella M, et al. 2017 EACTS Guidelines on 
perioperative medication in adult cardiac surgery. Eur J Cardiothorac Surg. 2017.
17.  Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, et al. Long-term patency of saphenous vein 
and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department 
of Veterans Affairs Cooperative Study. J Am Coll Cardiol. 2004;44(11):2149-56.
18.  Aldea GS, Bakaeen FG, Pal J, Fremes S, Head SJ, Sabik J, et al. The Society of Thoracic Surgeons Clinical 
Practice Guidelines on Arterial Conduits for Coronary Artery Bypass Grafting. Ann Thorac Surg. 
2016;101(2):801-9.
45
Life-long clinical outcome after the first myocardial revascularization procedures
3
19.  Taggart DP, Altman DG, Gray AM, Lees B, Gerry S, Benedetto U, et al. Randomized Trial of Bilateral 
versus Single Internal-Thoracic-Artery Grafts. New England Journal of Medicine. 2016;375(26):2540-9.
20.  Tabata M, Grab JD, Khalpey Z, Edwards FH, O’Brien SM, Cohn LH, et al. Prevalence and Variability 
of Internal Mammary Artery Graft Use in Contemporary Multivessel Coronary Artery Bypass Graft 
Surgery. Analysis of the Society of Thoracic Surgeons National Cardiac Database. 2009;120(11):935-40.
21.  Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the 
management of acute coronary syndromes in patients presenting without persistent ST-segment 
elevationTask Force for the Management of Acute Coronary Syndromes in Patients Presenting without 
Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 
2016;37(3):267-315.
22.  Yamaji K, Kimura T, Morimoto T, Nakagawa Y, Inoue K, Kuramitsu S, et al. Very Long-Term (15 to 23 
Years) Outcomes of Successful Balloon Angioplasty Compared With Bare Metal Coronary Stenting. 
Journal of the American Heart Association. 2012;1(5).
23.  Investigators B. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 
2007;49(15):1600-6.
24.  Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, et al. Treatment of complex 
coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass 
surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 
2013;43(5):1006-13.
25.  Head SJ, Milojevic M, Daemen J, Ahn J-M, Boersma E, Christiansen EH, et al. Mortality after coronary 
artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery 
disease: a pooled analysis of individual patient data. The Lancet.
26.  Lopes NH, Paulitsch FdS, Gois AF, Pereira AC, Stolf NA, Dallan LO, et al. Impact of number of vessels 
disease on outcome of patients with stable coronary artery disease: 5-year follow-up of the Medical, 
Angioplasty, and bypass Surgery Study (MASS). European Journal of Cardio-Thoracic Surgery. 
2008;33(3):349-54.
27.  Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary 
angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. 
German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med. 1994;331(16):1037-43.
28.  van Domburg RT, Foley DP, de Jaegere PP, de Feyter P, van den Brand M, van der Giessen W, et al. Long 
term outcome after coronary stent implantation: a 10 year single centre experience of 1000 patients. 
Heart (British Cardiac Society). 1999;82 Suppl 2:Ii27-34.
29.  Parasca CA, Head SJ, Milojevic M, Mack MJ, Serruys PW, Morice MC, et al. Incidence, Characteristics, 
Predictors, and Outcomes of Repeat Revascularization After Percutaneous Coronary Intervention 
and Coronary Artery Bypass Grafting: The SYNTAX Trial at 5 Years. JACC Cardiovasc Interv. 
2016;9(24):2493-507.
30.  Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, et al. Trial of everolimus-eluting stents or bypass 
surgery for coronary disease. N Engl J Med. 2015;372(13):1204-12.

Chapter 4
Current Practice of State-of-the-Art Surgical 
Coronary Revascularization
Head SJ, Milojevic M, Taggart DP, Puskas JD.
Circulation. 2017;136:1331-1345.
48
Chapter 4
ABSTRACT
Coronary artery bypass grafting remains one of the most commonly performed 
major surgeries, with well-established symptomatic and prognostic benefits 
in patients with multivessel and left main coronary artery disease. This review 
summarizes current indications, contemporary practice, and outcomes of 
coronary artery bypass grafting. Despite an increasingly higher-risk profile 
of patients, outcomes have significantly improved over time, with significant 
reductions in operative mortality and perioperative complications. Fiveand 10-
year survival rates are ≈85% to 95% and 75%, respectively. A number of technical 
advances could further improve shortand long-term outcomes after coronary 
artery bypass grafting. Developments in off-pump and no-touch procedures; 
epiaortic scanning; conduit selection, including bilateral internal mammary 
artery and radial artery use; intraoperative graft assessment; minimally 
invasive procedures, including robotic-assisted surgery; and hybrid coronary 
revascularization are discussed.
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INTRODUCTION
Coronary artery disease is one of the leading causes of death in Western countries. 
Since the introduction of coronary artery bypass grafting (CABG) in the 1960s 
(1), it has rapidly become one of the most commonly performed major surgical 
procedures (2). Outcomes have significantly improved over time, with declining 
rates of operative mortality and major morbidity, which may be due in part to 
better patient selection, improved surgical techniques, and better alternative 
techniques in patients presenting with cardiogenic shock (eg, mechanical support 
devices) (3). Large multicenter randomized and observational studies have 
reported excellent short-term outcomes (4,5).
Despite the rise in rates of percutaneous coronary intervention (PCI) and the 
technical advances in stent design, CABG remains crucial for patients with 
multivessel coronary disease that is too complex to be treated optimally with 
PCI (6-8). According to data from the Organisation for Economic Cooperation 
and Development, CABG is on average performed at a rate of 44 per 100 000 
individuals (Figure 1) (9).
In this review, we discuss contemporary indications for CABG, practice patterns, 
and outcomes. We also discuss specific surgical techniques and a number of 
technical advances that have received attention over the last decade and could 
potentially improve shortand long-term outcomes after CABG.
CONTEMPORARY INDICATIONS, PRACTICE, AND OUTCOMES
Preoperative Risk Assessment
The choice of percutaneous or surgical revascularization depends on the risk-
tobenefit ratio of procedures and should be decided by a multidisciplinary heart 
team that includes at least an interventional cardiologist and cardiovascular 
surgeon but can be expanded according to the status of the patient with an 
anesthesiologist, nephrologist, geriatrist, etc. (10). To determine which treatment 
strategy should be favored and what the risks of surgical intervention are, 
preoperative risk assessment is crucial. Several risk scores have been established 
to estimate the surgical predicted risk of mortality. The most widely used scores 
are the EuroSCORE (II) and the Society of Thoracic Surgeons’ risk model, with 
the latter also providing a calculated risk of stroke, renal failure, sternal wound 
infection, and length of stay (11,12). Although these models include different 
variables, risk factors can be categorized as follows: (1) demographic variables such 
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as age and sex; (2) previous cardiovascular events, including prior cardiovascular 
surgery or intervention, myocardial infarction, and stroke or transient ischemic 
attack; (3) cardiovascular variables, which include left ventricular function, 
diabetes mellitus, hypertension, arrhythmias, and peripheral vascular disease; 
(4) noncardiovascular variables, including renal failure and chronic obstructive 
pulmonary disease; (5) disease complexity and pathology, that is, the number 
of diseased vessels, degree of valve stenosis and regurgitation, and presence of 
endocarditis; and (6) the hemodynamic status of the patient and the urgency 
of surgery. In studies comparing the Society of Thoracic Surgeons’ score and 
EuroSCORE II models in patients undergoing isolated CABG, the Society of 
Thoracic Surgeons’ score and EuroSCORE II performed similarly (13,14).However, 
despite the comprehensiveness of these models, additional comorbid factors such 
as pulmonary hypertension, liver disease, previous chest radiation, and the frailty 
status of the patient are not included in either model but increase surgical risk and 
may play an important role (15). The degree and complexity of coronary disease 
do not appear to affect shortor long-term outcomes after CABG, as shown in the 
SYNTAX trial (Synergy Between Percutaneous Coronary Intervention With TAXUS 
and Cardiac Surgery). The SYNTAX score quantifies the complexity of coronary 
artery disease by the location and length of lesions, presence of a chronic total 
occlusion, bifurcation or trifurcation lesions, severe lesion calcification, vessel 
tortuosity, and diffuse disease and small vessels, and it has been proved to be 
a predictor of prognosis after PCI but not CABG. It is therefore a robust factor 
to differentiate which patients are candidates for CABG rather than PCI and is 
recommended for use in both the US and European clinical guidelines (16,17). 
In patients in whom the risk-to-benefit ratios of percutaneous and surgical 
revascularization are similar, the patients’ preferences should strongly influence 
the treatment strategy.
The appropriate diagnostic workup of patients before revascularization 
should thus include a full medical history, an ECG, laboratory assessments, 
cardiac echocardiography, and coronary angiography. Although notuniversally 
performed, preoperative carotid ultrasound should be routinely considered to 
detect carotid lesions that are linked to stroke.
Procedural Characteristics of Contemporary CABG
The majority of CABG procedures are performed through a median sternotomy 
with the use of cardiopulmonary bypass so that the heart can be arrested, thereby 
producing ideal conditions to allow a technically less demanding procedure. 
During on-pump surgery, the heart is arrested with cardioplegia, a potassium-
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rich solution to inhibit the depolarization/repolarization cycle of myocardial 
cells, for myocardial preservation. Ischemic preconditioning may further reduce 
myocardial ischemia but has not been shown to reduce clinical outcomes (18).
Off-pump coronary artery bypass (OPCAB) procedures, however, do not require 
cardiopulmonary bypass and cardioplegia because the heart continues to 
beat. It is a technically more demanding procedure but theoretically reduces 
complications of cardiopulmonary bypass related to a systemic inflammatory 
reaction syndrome, microemboli, an increased blood-brain barrier permeability, 
and aortic manipulation for cross-clamping and cannulation to the heart-lung 
machine. An overview of CABG procedures performed in the United States 
showed that the percentage of procedures performed off-pump peaked at 23% in 
2002 but declined to 17% in 2012 (19).
Figure 1. Number of coronary artery bypass graft (CABG) operations per 100 000 inhabitants.
All data are from 2013 except for data from Hungary (2012), Belgium (2012), Australia (2012), Canada 
(2012), Turkey (2012), Chile (2012), the Netherlands (2010), the United States (2010), Iceland (2009), 
Portugal (2009), and Switzerland (2008). Data are from the Organisation for Economic Cooperation 
and Development (OECD) (9).
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The choice of conduits to bypass coronary lesions has been a continuous debate 
since the use of a single internal mammary artery (IMA) graft proved to have 
superior long-term outcomes over saphenous vein grafts. However, despite 3 
guidelines with recommendations for increasing the use of arterial conduits, 
including 1 dedicated guideline from the Society of Thoracic Surgery in 2016 
on conduit selection for CABG (Table 1), rates of multiple arterial grafting with 
IMA grafts and/ or the radial artery remain persistently low. In the United 
States between 2002 and 2005, the rate of bilateral IMA (BIMA) use was only 
4% (21). In contemporary practice, the vast majority of CABG procedures are 
performed with the left IMA (LIMA) anastomosed to the left anterior descending 
artery (LAD) and additional stenoses bypassed with vein grafts to perform 
complete revascularization. However, there is significant variability in how 
CABG procedures are performed in different countries in terms of the use of 
cardiopulmonary bypass, the type of cardioplegia, and which conduits are used 
(22).
Short-Term Complications and Long-Term Prognosis
Complication rates of CABG are typically measured at 30 days and include death, 
stroke, myocardial infarction, re-exploration for bleeding, renal failure requiring 
dialysis, atrial fibrillation, and deep sternal wound infection (eg, mediastinitis; 
Table 2). In most reports of large series of isolated CABG, early mortality rates are 
1% to 2%, and higher mortality is reported for patients at higher risk in emergent 
scenarios or because of multiple comorbidities and advanced age. Although 
outcomes have improved, CABG still carries a considerable risk of morbidity.1 
Neurological complications include stroke in 1% to 3% and delirium in 8% to 50% 
of patients. The rate of myocardial infarction differs significantly among studies 
because of varying definitions, including changes on the ECG or cardiac enzyme 
elevations, but is estimated to occur at a rate of 2% to 4%. About 3% of patients 
with myocardial infarction have clinical hemodynamic instability resulting from 
early graft failure; the majority of patients will be managed by PCI, although 
some patients will require surgical reoperation. Reoperation is required in 2% 
to 4% of patients because of bleeding complications and increases the risk of 
other complications; bleeding can be reduced by blood conservation techniques, 
including cell-saver machines, antifibrinolytics use, and platelet and plasma 
transfusions. Some degree of renal failure is frequent after CABG, but only about 
1% of patients require dialysis. About 15% to 30% of patients have new-onset 
atrial fibrillation that is usually transient. Mediastinitis develops in 0.5% to 3% of 
patients and causes long lengths of stay and recovery time and frequently requires 
sternal debridement or reconstruction. Although concerns about neurocognitive 
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decline after CABG resulting from cardiopulmonary bypass have been raised (23), 
large randomized studies have found preserved neurocognitive function after 
both on-pump or off-pump surgery (24).
Length of stay after isolated CABG and combined CABG and valve procedures 
is ≈7 and 10 days, respectively (25). Patients are limited in their activities during 
the first 6 weeks after CABG because of the general effects of major surgery and 
anesthesia and the sternotomy, which requires time to heal. After discharge, 
cardiac rehabilitation optimizes physical, psychological, and social functioning 
of patients after CABG to increase quality of life (26). Clearly, lifestyle changes, 
including smoking cessation, healthy food choices, and exercising, improve 
long-term prognosis. Moreover, educa-tion on long-term secondary prevention 
compliance is essential. Compliance rates of taking antiplatelet medications, 
β-blockers, statins, and angiotensin-converting enzyme inhibitors after CABG 
are suboptimal, even though optimal medical therapy significantly improves 
long-term outcomes (27). Intense or maximally tolerated statin therapy should 
be prescribed to reach a low-density lipoprotein cholesterol target <70 mg/
dL. β-Blockers should be initiated in patients with a preoperative myocardial 
infarction or reduced left ventricular ejection fraction (<35%). In addition, 
angiotensin-converting enzyme inhibitors should be given to patients with 
reduced left ventricular function (<40%) and a glomerular filtration rate >30 ml/
min per 1.73 meter squared. There is currently no consensus on the routine use of 
dual antiplatelet therapy after CABG.
Results of major adverse cardiac or cerebrovascular events at 5-year follow-up 
from large, contemporary CABG trials show that all-cause mortality at 5 years 
ranges between 5% and 15%, myocardial infarction between 2% and 8%, and stroke 
between 1% and 4%, depending on the population and definitions used (Table 3). 
Repeat revascularization ranges between 2% and 15% and depends on whether it 
is performed for anatomic or ischemic reasons. Historically, survival at 10 years is 
≈75% (35,36) but may prove to be higher in contemporary practice, especially with 
higher use of guideline-directed medical therapy.
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Table 1. Guideline Recommendations for Conduit Use During Coronary Artery Bypass Grafting.
2011 ACCF/AHA (17) 2016 STS (20) 2014 ESC/EACTS (16)
LAD territory “If possible, the LIMA should be used to 
bypass the LAD artery if indicated” (Class I, 
Level of Evidence B)
“The RIMA is probably indicated to 
bypass the LAD artery when the LIMA is 
unavailable or unsuitable as a bypass 
conduit” (Class IIa, Level of Evidence C)
“The IMA should be used to bypass the LAD 
artery when bypass of the LAD is indicated” 
(Class I, Level of Evidence B)
“Arterial grafting with IMA to the LAD 
system is recommended” (Class I, Level of 
Evidence A)
BITA “When anatomically and clinically 
suitable, use of a second IMA to graft the 
left circumflex or right coronary artery 
(when critically stenosed and perfusing 
LV myocardium) is reasonable to improve 
the likelihood of survival and to decrease 
reintervention” (Class IIa, Level of 
Evidence B)
“Use of BIMAs should be considered in 
patients who do not have an excessive risk 
of sternal complications” (Class IIa, Level of 
Evidence B)
“BIMA grafting should be considered in 
patients <70 yr of age” (Class IIa, Level of 
Evidence B)
RA “Use of a RA graft may be reasonable 
when grafting left-sided coronary 
arteries with severe stenosis (>70%) and 
right-sided arteries with critical stenosis 
(≥90%) that perfuse LV myocardium” 
(Class IIb, Level of Evidence B)
“As an adjunct to LIMA to LAD (or in 
patients with inadequate LIMA grafts), 
use of a RA graft is reasonable when 
grafting coronary targets with severe 
stenosis” (Class IIa, Level of Evidence B)
“Use of the RA is recommended only for 
target vessels with high-degree stenosis” 
(Class I, Level of Evidence B)
Gastroepiploic 
artery
No recommendation provided “The RGEA may be considered in 
patients with poor conduit options or 
as an adjunct to more complete arterial 
revascularization” (Class IIb, Level of 
Evidence B)
No recommendation provided
Total arterial 
revascularization
“Complete arterial revascularization may be 
reasonable in patients less than or equal to 
60 yr of age with few or no comorbidities” 
(Class IIb, Level of Evidence C)
“Arterial grafting of the right coronary 
artery may be reasonable when a critical 
(≥90%) stenosis is present” (Class IIb, 
Level of Evidence B)
“As an adjunct to LIMA, a second arterial 
graft (RIMA or RA) should be considered 
in appropriate patients” (Class IIa, Level of 
Evidence B)
“Total arterial revascularization is 
recommended in patients with poor vein 
quality independently of age” (Class I, Level 
of Evidence C)
“Total arterial revascularization 
should be considered in patients with 
reasonable life expectancy” (Class IIa, 
Level of Evidence B)
ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; BIMA, 
bilateral internal mammary artery; BITA, bilateral internal thoracic artery; EACTS, European Association for 
CardioThoracic Surgeons; ESC, European Society of Cardiology; IMA, internal mammary artery; LAD, left 
anterior descending; LIMA, left internal mammary artery; LV, left ventricular; RA, radial artery; RGEA, right 
gastroepiploic artery; RIMA, right internal mammary artery; and STS, Society of Thoracic Surgeons.
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Indications for CABG
CABG is indicated for both relief of symptoms and prolongation of life. Patients 
with stable coronary artery disease in whom medical therapy fails to significantly 
reduce symptoms are generally evaluated for myocardial revascularization. 
Evidence from the latest randomized trials showed that CABG appeared 
particularly beneficial for patients with more severe and complex coronary artery 
disease. Subgroup analyses from the SYNTAX trial showed that the difference 
between CABG and PCI treatment was evident only in those with intermediate 
or high severity of disease as determined by the SYNTAX score (37,38). Diabetic 
patients often have diffusely diseased vessels with progressive atherosclerosis. 
CABG provides a improved long-term prognosis particularly in these patients 
(7). Indeed, clinical guidelines recommend that CABG be performed in patients 
with complex disease, as well as in diabetic patients (16,17). With continuous 
improvements in both CABG and PCI technology, recommendations for which 
revascularization strategy should be preferred for a specific patient continue to 
evolve on the basis of new results from randomized trials and vary significantly 
between different geographical regions.
Whether CABG should be performed in patients with ischemic cardiomyopathy 
has recently been investigated in the STICH trial (Surgical Treatment for Ischemic 
Heart Failure). Among 1212 patients with a left ventricular ejection fraction <35% 
who were randomly assigned to CABG or medical therapy, 10-year outcomes 
favored CABG over medical therapy for all-cause death (58.9% versus 66.1%, 
respectively; P=0.02) and cardiovascular death (40.5% versus 49.3%, respectively; 
P=0.006) (39). The impact of CABG on cardiovascular death remained consistent 
over all ages (40). From these results, an evidence basis for the indication of CABG 
in patients with poor ejection fraction is substantiated.
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Table 2. Incidence, Predictors, and Reductions of Short-Term Complications After Coronary Artery 
Bypass Grafting.
Complication Incidence, % Important Specific Predictors How to Potentially Reduce Its Occurrence
Mortality 1–2 Cardiovascular risk factors
Comorbidities: renal failure, lung disease, neurological 
impairment, etc
Patient status Urgency of procedure
Reduce procedural invasiveness
Adequate patient selection in multidisciplinary heart 
team meetings
Delaying CABG in patients with an acute myocardial 
infarction whenever possible
Increasing the use of mechanical support devices in patients 
with cardiogenic shock
Stroke 1–3 Previous stroke or transient ischemic attack
Peripheral vascular disease, including carotid disease
Preoperative and postoperative de novo atrial fibrillation
Hypertension
Severe atherosclerotic aorta
Off-pump CABG
Clampless/no-touch procedures Epiaortic scanning
Myocardial 
infarction
2–4 Recent myocardial infarction Urgency of procedure
Procedural factors, including the graft configuration, 
number of distal anastomoses, incomplete 
revascularization, and longer cardiopulmonary 
bypass time
Procedural problems related to insufficient myocardial 
protection, air embolism, and anastomoses
Sufficient myocardial protection with cardioplegia and 
thermal regulation
Operative graft flow measurement using TTFM
Re-exploration 
for bleeding
2–4 Body surface area or body mass index 
Immunosuppressive therapy
Preoperative antiplatelet or anticoagulation use Prior 
cardiovascular surgery
Urgency of procedure
Complexity of coronary disease or number of distal 
anastomoses
Preoperative timely discontinuation of antiplatelet or 
anticoagulation therapy
Delaying surgery until the effect of antiplatelets has 
worn off
Platelet function testing for optimal timing of surgery
Perioperative antifibrinolytic agents, platelets, and fresh-
frozen plasma
Delirium 8–50 Older age Cognitive function
Prior cerebrovascular disease Duration of 
cardiopulmonary bypass
Preoperative screening
Avoid postoperative infection
Multicomponent intervention to manage cognitive 
impairment, sleep deprivation, immobility, visual and 
hearing impairment, and dehydration
Renal failure 
requiring dialysis
1 Preoperative renal function Diabetes mellitus
Preoperative status (eg, cardiogenic shock)
Off-pump CABG
Atrial fibrillation 15–30 Peripheral vascular disease Preoperative atrial 
fibrillation Obesity
Medication such as amiodarone or sotalol, 
antiinflammatory corticosteroids, β-blockers, statins, 
antioxidant agents such as N-acetylcysteine, ACE 
inhibitors, and omega-3 fatty acids
Mediastinitis 0.5–3 Obesity
Diabetes mellitus Hypertension
Preoperative renal failure on dialysis Prior 
cardiovascular surgery Duration of cardiopulmonary 
bypass Bilateral IMA use
Re-exploration for bleeding
Preoperative hygiene including preoperative antiseptic 
showers and hair removal
Perioperative antibiotics
Specific patient selection for bilateral IMA use Vancomycin 
paste
Optimal glycemic control
ACE indicates angiotensin-converting enzyme; CABG, coronary artery bypass grafting; IMA, internal mammary 
artery; and TTFM, transit-time flow measurement. Modified from Head et al1 with permission of the publisher. 
© 2013, Oxford University Press.
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When patients are evaluated for revascularization, results from a coronary 
angiogram provide necessary information on which vessels require 
revascularization. Because visual inspection of coronary angiograms can be 
subjective and cannot always estimate the functional significance of a lesion 
to flow, fractional flow reserve (FFR) is frequently used to quantify the degree 
of stenosis in terms of a pressure drop across a coronary lesion. An FFR ≤0.80 
is generally considered to be a significant stenosis (41). Although FFR-guided 
revascularization has been shown to be associated with significantly improved 
outcomes after PCI (42), evidence from studies evaluating FFRguided CABG is 
scarce. Toth and coauthors (43) compared angiographyand FFR-guided CABG 
and reported that FFR-guided CABG was associated with fewer anastomoses and 
a higher rate of off-pump procedures but with comparable rates of the composite 
of death, myocardial infarction, and target vessel revascularization at 3-year 
follow-up in the largest study to date.
CONDUITS
BIMA Use
A large body of clinical and angiographic evidence supports the use of BIMA 
instead of a single IMA graft with additional venous conduits. Particularly in 
younger patients, the benefit of BIMA use is apparent, with the age cutoff estimated 
at 60 to 70 years (44,45). This may be the result of the combination of a longer life 
expectancy of younger patients and diverging survival curves between single IMA 
and BIMA use with longer follow-up. A meta-analysis of studies with a follow-up 
duration of >9 years found that among 15 583 patients enrolled in 9 observational 
studies, survival was significantly improved in patients in whom BIMA grafts 
were used as opposed to a single IMA graft, with a hazard ratio (HR) of 0.79 (95% 
confidence interval (CI), 0.75–0.84) (46). However, some surgeons may be reluctant 
to perform BIMA grafting because of fear of an increased risk of deep sternal wound 
infections; this risk is most apparent in female patients with obesity, diabetes 
mellitus (particularly those with poorly regulated diabetes mellitus), renal failure, 
and chronic obstructive pulmonary disease. To limit the risk of sternal wound 
infections, skeletonized rather than pedicled harvesting of IMA grafts is preferred 
because it maintains sternal vasculature, which significantly reduced the risk of 
sternal wound complications in a recent analysis (47).
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ART (Arterial Revascularization Trial) randomly assigned 3102 patients to BIMA 
or single IMA use and is likely to provide a definitive answer on whether BIMA 
should be performed more routinely. Short-term safety rates were comparable 
for groups with single IMA and BIMA use, with 30-day mortality rates of 1.2% in 
both groups and comparable rates of stroke, myocardial infarction, and repeat 
revascularization, although there was an increased risk for sternal reconstruction 
with BIMA use (5). Recent completion of a 5-year midterm follow-up showed that 
there was no difference between BIMA and single IMA use for the primary end 
point of death (8.7% versus 8.4%, respectively; P=0.77) or in terms of mortality, 
myocardial infarction, and stroke (12.2% versus 12.7%, respectively; P=0.69) (34).
This may be the result of the use of a radial graft in 20% of patients in the single 
IMA group, which could have improved outcomes in that group by providing a 
second arterial conduit. Moreover, rates of adherence to optimal medical therapy 
for secondary prevention were excellent in both groups, perhaps limiting early 
vein graft failure. The study was not powered to detect a difference at 5-year 
follow-up and will continue to 10 years. Indeed, the benefit of BIMA is often seen 
with increased follow-up because vein graft failure accelerates after 5 years.
When CABG with BIMAs is performed, whether to use both arteries in situ or in a 
Y or T configuration remains a matter of debate. A recent randomized controlled 
trial of 304 randomized patients concluded that the primary end point of graft 
patency at 3-year follow-up was comparable for composite grafting and in 
situ grafts, and there were no differences in the rates of all-cause survival and 
myocardial infarction (48). However, composite grafting significantly reduced 
the rate of repeat revascularization over 7-year follow-up, probably because of 
more complete arterial revascularization with composite grafts: 3.2±0.8 distal 
anastomoses were placed versus 2.4±0.5 with in situ grafts (P<0.01).
Radial Artery Use
The radial artery is often used in patients in whom BIMA use is not feasible or 
advised or to augment the number of arterial grafts performed in addition to BIMA 
grafting to accomplish total arterial revascularization. Numerous randomized 
controlled trials have compared graft patency of radial arteries and vein grafts. 
A metaanalysis of 5 trials found that radial artery grafts were associated with 
significantly better graft patency than vein grafts (49) but without reductions in 
all-cause death in underpowered analyses (50,51). Several propensitymatched 
observational studies showed that the radial artery improved long-term survival 
over the use of vein grafts (52,53). The radial artery has furthermore been 
compared with the right IMA (RIMA) in addition to a LIMA to the LAD. In the 
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RAPCO trial (Radial Artery Patency and Clinical Outcomes), a total of 394 patients 
<70 years of age were assigned to receiving a radial artery or free RIMA; at a mean 
follow-up of 5.5 years, the Kaplan-Meier estimates of graft patency were 89.8% 
and 83.2%, respectively (P=0.06), although 10-year follow-up is awaited (54). A 
meta-analysis of 8 propensitymatched analyses including 15374 patients reported 
a significantly better survival with a RIMA graft than with a radial artery, with a 
HR of 0.75 (95% CI, 0.58–0.97; P=0.03) (55). Therefore, it has been proposed that 
the radial artery be used as an alternative to the RIMA in patients with a high risk 
of mediastinitis or to graft the highly stenosed right coronary artery or distal 
circumflex territory.
Recent interest has been directed to determining whether the radial artery as an 
adjunct to BIMA use is superior to additional vein grafts. Benedetto and colleagues 
(56) reported that survival of 275 propensitymatched pairs, after a mean follow-
up of 10.6 years, was comparable between patients receiving a radial artery and 
those receiving a vein graft in addition to BIMA use (P=0.54). Grau and colleagues 
(57), however, reported that, although 15-year survival was comparable between 
BIMA with radial or vein grafting, survival beyond the 10-year follow-up appeared 
to be significantly better with a radial artery. Impressively, Shi and colleagues (58) 
reported that 15-year survival was 82% versus 72% in patients receiving a radial 
versus vein graft as a third conduit (P=0.021) in an analysis of 262 propensity-
matched pairs.
If a radial artery is used, it should be anastomosed only to coronaries with a 
high-grade stenosis (>90%) to avoid competitive flow that may otherwise lead to a 
“string sign” of the conduit. In the RAPS trial (Radial Artery Patency Study; n=440), 
the rate of graft occlusion was 11.8% in patients with 70% to 89% stenosis in the 
native vessel but only 5.9% in patients with ≥90% stenosis (P=0.03) (59).
Saphenous Vein Graft Optimization
In current practice, almost 80% of all bypass conduits are saphenous veins 
because of their ease of harvesting and the lesser technical challenge of vein 
grafting compared with multiple arterial grafting. Although recent studies have 
shown excellent outcomes with vein grafts compared with the RIMA as part of a Y 
configuration with LIMA inflow (60), the major disadvantage of the saphenous vein 
is its tendency for progressive failure during follow-up (61). Despite the higher 
use of optimal medication in recent studies, particularly antiplatelet therapy and 
statins, saphenous vein grafts still show a significant failure rate (62). However, 
vein graft patency could be improved. First, Samano and colleagues (63) have 
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now reported a 16-year follow-up of a no-touch technique for vein graft harvest 
that resulted in significantly better patency than conventional skeletonized vein 
harvesting, which may be the result of reduced intimal hyperplasia and protection 
against distension-induced damage that preserves vessel morphology and nitric 
oxide secreting activity (64). The use of endoscopic vein harvesting to reduce the 
rate of wound infections, wound dehiscence, and overall complications compared 
with open vein harvesting raised concerns about reduced graft patency because 
of the potential for increased damage to the conduit with endoscopic techniques. 
However, 2 large observational studies reported no long-term excess of all-cause 
mortality or myocardial infarction with endoscopic vein harvesting compared 
with open vein harvesting (65,66). Second, exploratory work from the PREVENT 
IV trial (Project of Ex-Vivo Vein Graft Engineering via Transfection) reported that 
storage of vein grafts in a buffered solution provided significantly improved graft 
patency and tended to reduce the rate of adverse clinical outcomes at 5 years 
compared with vein grafts stored in normal saline or blood (67). Although many 
solutions have been developed, large-scale studies are not yet available. Third, 
both Taggart and colleagues (68) and Meirson and colleagues (69) have reported 
that the use of an external stent for saphenous vein grafts significantly reduced 
intimal hyperplasia at the 1-year follow-up, perhaps as a consequence of a lower 
oscillatory shear index that results in less turbulent flow. Larger studies with 
longer follow-up are required to determine whether this translates into improved 
vein graft patency and ultimately improved clinical outcomes.
Intraoperative Graft Assessment
CABG is the only major vascular surgical procedure that is not routinely assessed 
with a “completion angiogram” or other imaging study at the time of surgery. In 
all other vascular surgical procedures, this intraoperative quality assessment is 
considered routine and necessary. Although intraoperative angiography remains 
impractical on a routine basis for CABG except in a hybrid operating room, 
some quantitative and qualitative assessment of graft flow and function may be 
considered in CABG.
Suboptimal rates of graft patency may be potentially related to operative 
technical issues such as anastomotic imprecision, graft kinking, and limited graft 
outflow. Therefore, several methods have been introduced as intraoperative 
graft assessment tools to check for technical issues that could be resolved during 
the operation. Transit-time flow measurement (TTFM) is the most widely used 
technique because of its user-friendliness and comprehensive validation. 
Among studies that applied TTFM during CABG, 2% to 4% of grafts required 
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revision (70,71). Studies that have related TTFM findings to shortand longer-term 
outcomes have been controversial, although the majority of studies found that 
either graft flow or pulsatility index was a predictor of short-term complications, 
as well as death and graft failure during follow-up (71). Although TTFM is valuable 
to identify truly poor and truly good grafts, its value is limited in identifying grafts 
with minor abnormalities that may present false-negative values of pulsatility 
index and flow. As a result, recent studies have suggested that 2 parameters, 
graft flow and anastomotic patency, are required for the complete assessment of 
bypass grafts. TTFM combined with epicardial echocardiography is an approach 
that provides both a functional and an anatomic assessment of bypass grafts. In a 
recent article by Di Giammarco and coauthors (72), the positive predictive value of 
TTFM was increased from 10% to almost 100% if epicardial echocardiography was 
also performed to directly image flow through the graftcoronary anastomosis.
OFF-PUMP AND AORTIC MANIPULATION
Off-Pump Surgery
More than 60 randomized trials have compared offpump with on-pump CABG. 
Several meta-analyses of these trials performed at different time points and with 
different inclusion criteria all come to a uniform conclusion: OPCAB significantly 
reduced short-term rates of stroke and renal failure but did not reduce the 
risk of mortality or myocardial infarction in lowand mixedrisk patients (73,74). 
Specific studies in high-risk patients found a significant reduction in mortality 
with OPCAB compared with on-pump CABG in high-risk patients, although at the 
price of higher rates of repeat revascularization (74,75).
Two of the largest contemporary trials (CORONARY trial (CABG Off or On 
Pump Revascularization Study), n=4752, and GOPCABE trial (German Off 
Pump Coronary Artery Bypass in Elderly Study), n=2539) noted that there were 
comparable 1-year rates of mortality, stroke, myocardial infarction, renal failure 
requiring dialysis, and repeat revascularization, as well as composite end points 
of these events (76). The CORONARY trial recently reported results at the 5-year 
follow-up; there were still no differences in any of the clinical end points, with 
identical survival between the 2 techniques at 5 years (33). Concerns about OPCAB 
procedures are particularly related to the potential for a lower rate of complete 
revascularization and compromised graft patency. Whether there is an impact 
of onor off pump surgery on survival remains highly controversial. In a recent 
single-center analysis of 13 226 patients, 10-year risk-adjusted survival was nearly 
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identical between onand off-pump CABG (72.8% versus 72.1%, respectively; 
P=0.56), as was the freedom from death and reintervention (P=0.23) (77). Routine 
intraoperative TTFM may be of particular value to the OPCAB surgeon to ensure 
optimal graft patency during challenging cases.
One of the fundamental issues with OPCAB remains the experience and 
expertise of the surgeon. The multi-center ROOBY trial (Randomized On/
Off Bypass) reported significantly better outcomes with on-pump CABG but 
was severely criticized because of strikingly asymmetrical experience with on-
pump versus off-pump CABG among the enrolling surgeons (78). In trials that 
required substantial experience of participating surgeons such as CORONARY 
and GOPCABE, outcomes of OPCAB have not been inferior (33,76). A recent 
study found that OPCAB outcomes were best if a surgeon performed >50 OPCAB 
procedures annually (79), although another study suggested that outcomes were 
not dependent on the level of the operator being a trainee or attending (80). It 
has become clear that the experience of not only a specific surgeon but also the 
entire hospital matters in optimizing outcomes with OPCAB (81). For this reason, 
clinical guidelines recommend that OPCAB be performed in high-volume off-
pump centers (16).
Clampless and No-Touch Surgery
One particular potential benefit of OPCAB procedures is the possibility of avoiding 
manipulation of the aorta. However, OPCAB has most commonly been performed 
with the use of a side clamp for proximal anastomoses, which increases the risk of 
hard and soft plaque emboli that could cause neurological events. Some critique has 
been directed to studies comparing OPCAB and onpump CABG for not specifically 
avoiding any manipulation of the aorta by using either proximal anastomosis devices 
or a conduit configuration that still requires a proximal anastomosis. This may explain 
why perioperative stroke reduction with OPCAB has not been more impressive. A 
propensity-matched analysis reported a trend toward a significant reduction in in-
hospital allcause mortality associated with avoiding aortic clamping in addition to a 
significantly lower rate of stroke (82). Indeed, aortic manipulation has been found 
to be associated with postoperative major adverse events, and any reduction of 
aortic manipulation, by clamping only once instead of multiple times, reduces the 
risk of stroke. Therefore, the weight of evidence suggests that the surgical approach 
associated with the lowest risk of perioperative stroke appears to be a no-touch, total 
arterial off-pump CABG (Figure 2); a network metaanalysis of 13 studies and 37720 
patients supports this recommendation by showing significant reductions mortality, 
stroke, and renal failure when this technique is applied (83). Even if on-pump surgery 
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is performed and the aorta is cross-clamped, stroke rates can be reduced by not 
performing multiple clamping or avoiding sidebiting clamp techniques. 
Epiaortic Scanning
Surgeons generally palpate the aorta before cannulating or constructing a proximal 
anastomosis to detect in atherosclerotic burden that is present in >50% of patients 
who undergo CABG. However, aortic palpation has limited sensitivity because of 
the inability to palpate the complete circumference of the aorta and to detect soft 
plaques. Consequently, epiaortic ultrasonography has been recommended to 
detect plaque, and several large retrospective studies of all cardiac surgery 
operations and specifically CABG procedures found that the use of epiaortic 
ultrasound significantly reduced the incidence of stroke (84,85). This reduction in 
stroke is achieved by modifying the surgical technique when significant plaque is 
detected. The need for technique modifications based on epiaortic ultrasonography 
ranges between 4% and 31% (85,86), depending on the type of modification and the 
definitions used. On the basis of these findings, intraoperative epiaortic scanning 
should be considered before aortic manipulation.
Figure 2. Example of a complete arterial no-touch coronary artery bypass graft configuration
Cx indicates circumflex; LAD, left anterior descending; LITA, left internal thoracic artery; PDA, 
posterior descending artery; RA, radial artery; and RITA, right internal thoracic artery.
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REDUCING INVASIVENESS
Minimally Invasive CABG
An alternative approach to a sternotomy for CABG may be to perform minimally 
invasive direct coronary artery bypass (MIDCAB) via a small (5–10 cm) left anterior 
thoracotomy. The LIMA can then be harvested by direct vision or with robotic 
endoscopic techniques. The largest series by Holzhey and colleagues (87) of 
1768 patients undergoing MIDCAB from 1996 to 2009 reported a postoperative 
mortality of 0.8% and a 95.5% graft patency at routine postoperative angiography 
(n=712). Survival at 5 and 10 years was 88.3% and 76.6%, respectively. A number 
of small studies have compared MIDCAB procedures with conventional CABG. 
A recent propensity-matched analysis of 159 pairs showed comparable rates 
of procedural complications and similar lengths of hospital stay after LAD 
revascularization via MIDCAB and sternotomy (88). However, postoperative pain 
is often increased after a MIDCAB approach. Despite this, full recovery after a 
MIDCAB procedure appears to be quicker than after sternotomy, with potential 
improvements in quality of life.
Robotic CABG
In most centers, the term robotic CABG is used to describe a robotic LIMA harvest 
technique, followed by a hand-sewn off-pump LIMA-LAD anastomosis via a 
very small (3–4 cm) left anterior thoracotomy without rib excision or spreading. 
Operative times are generally longer than for CABG procedures through 
sternotomy, but short-term outcomes are comparable (89). A metaanalysis showed 
excellent safety and only a 2.5% rate of conversion to sternotomy (90). Concerns 
about the quality of anastomoses have been raised, but a series of 307 patients 
showed that 95% of LIMA-LAD conduits were patent among 199 patients with an 
angiogram before discharge (91). At longer follow-up, graft patency has been in the 
range of 92% to 97% for LIMA-to-LAD anastomoses through 8 years of follow-up 
(92,93).
The term robotic CABG may also refer to a robotic totally endoscopic CABG 
procedure in which the LIMA is both harvested and anastomosed to the LAD by 
robotic endoscopic techniques. Totally endoscopic CABG procedures have been 
used to treat isolated LAD lesions and multivessel disease. However, in a single-
arm multicenter registry, 13 of 98 patients (13%) with the intention of totally 
endoscopic CABG needed to be excluded intraoperatively because of failed 
femoral cannulation or inadequate working space, emphasizing that appropriate 
patient selection is essential for this very demanding technical procedure (94). 
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Because it is so technically challenging and has a high rate of conversion to 
sternotomy of ≈15% to 20% (90), widespread adoption of totally endoscopic CABG 
procedures awaits the development of easily maneuverable anastomotic devices.
Hybrid Coronary Revascularization
Hybrid coronary revascularization (HCR) consisting of a LIMA-LAD anastomosis 
through (robotic) MIDCAB plus stenting of remaining non-LAD lesions for 
patients with multivessel disease has received much attention in recent years. A 
small randomized trial to assess the safety of the procedure included 200 patients 
who were randomly assigned to undergo either HCR or CABG. There were no 
differences in the rates of death, myocardial infarction, stroke, major bleeding, or 
repeat revascularization at the 1-year follow-up (95). Among centers in the United 
States, overall short-term complication rates were low and comparable to those 
of conventional CABG (96). However, particular benefits include higher patient 
satisfaction and shorter times for patients to return to work. Midterm results over 
the first years of follow-up have been promising, with reports of rates of major 
adverse cardiac or cerebrovascular events and survival comparable to those of 
CABG, although higher rates of repeat revascularization associated with HCR are 
a potential concern (97,98).
Only carefully selected patients are currently considered candidates for HCR, as 
shown by a recent analysis of 198 622 patients treated with CABG in the United 
States between 2011 and 2013, of whom only 0.5% underwent HCR (96). Criteria 
for HCR therefore include a proximal LAD lesion graftable with a MIDCAB or 
robotic MIDCAB procedure; a complexity of residual lesions feasible for PCI, 
for example, intermediate SYNTAX score at most; and no contraindication to 
dual antiplatelet therapy. Because there is currently no substantiated evidence 
from largescale randomized controlled trials to support widespread use of HCR 
as opposed to multiarterial CABG, HCR is currently limited to patients with 
specific indications (Table 4). Moreover, HCR may be technically and logistically 
more demanding than CABG or PCI alone, with the option of PCI before CABG, 
which introduces the issue of preoperative continuation of dual antiplatelet 
therapy; the option of CABG before PCI, with the potential risk of ischemia in 
non-LAD lesions; or the option of simultaneous PCI and CABG, which requires a 
hybrid operating room. The recent National Institutes of Health–funded Hybrid 
Observational Trial by Puskas and colleagues (100) demonstrated a wide variation 
in current practice across a network of 11 premier US cardiac surgical centers 
for patients with hybrid-eligible coronary lesions. There was general agreement 
among cardiologists and surgeons at these sites as to which of 6669 consecutive 
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patients who underwent diagnostic coronary angiography could be considered 
eligible for HCR (n=454, 12.2%). Moreover, among 200 patients who had HCR and 
98 who had multivessel PCI, major adverse cardiac or cerebrovascular events 
were statistically similar through 17.6 months of follow-up, with a nonsignificant 
trend toward more adverse events in the PCI group during the later months of 
follow-up. Thus, equipoise is established for a larger prospective randomized trial 
of HCR versus multivessel PCI in patients with low-SYNTAX-score, hybrid-eligible 
coronary artery disease. Such a trial has been recently funded by the National 
Heart, Lung, and Blood Institute and will begin enrollment in late 2017.
Table 4. Proposed Current Indications for Hybrid Revascularization in Patients With 
Multivessel Disease.
Patients with a low SYNTAX score but an LAD lesion not amenable to PCI
Patients with an indication for CABG requiring complete revascularization but with a contraindication for sternotomy
Patients with a graftable proximal LAD lesion but poor surgical targets in the Cx or RCA that are amenable to PCI
Patients undergoing emergent PCI of a culprit Cx or RCA lesion but with residual disease requiring staged surgical 
revascularization of the LAD
Patients with a porcelain aorta and no ability to achieve complete revascularization without the use of a proximal anastomosis in 
whom off-pump revascularization of the LAD can take place with residual lesions being treated by delayed PCI
Patients with a history of pericarditis in whom non-LAD surgical targets are difficult to identify
Patients requiring a redo sternotomy after a previous noncoronary cardiac operation in whom grafting surgical targets in the Cx 
is high risk for lateral wall dissection
CABG indicates coronary artery bypass grafting; Cx, circumflex; LAD, left anterior descending 
artery; PCI, percutaneous coronary intervention; RCA, right coronary artery; and SYNTAX, Synergy 
Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery.
Adapted from Head and colleagues (99) with permission of the publisher.
In a survey of surgeons in the United States, only 10% were in favor of HCR (101), 
although a more recent survey among 200 cardiologists and surgeons found that 
three quarters of responders (n=90) believed adoption of HCR will expand in the 
next decade (102). Therefore, a heart team should weigh the benefits and risks 
of PCI, CABG, and HCR to decide which treatment is most appropriate for each 
individual patient with multivessel disease (10). With the most recent randomized 
trials and large observational studies of PCI with drug-eluting stents versus 
CABG in multivessel disease showing improved outcomes with CABG,(7,31,37,103) 
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surgeons will be reassured and confident that CABG is effective and offers 
increased longevity. Before HCR becomes a standard procedure at centers around 
the world, surgeons will have to commit to MIDCAB procedures. 
Figure 3. Developments for state-of-the-art coronary artery bypass graft (CABG).
MIDCAB indicates minimally invasive coronary artery bypass; revasc., revascularization; and TTFM, 
transit-time flow measurement.
Conclusions
Although patients referred for CABG bear increasing cardiovascular risk factors 
and comorbidities, actual outcomes have significantly improved over the last 
decades, with low rates of 30-day complications. Although many developments 
in operative techniques and devices have been established to further improve 
both shortand long-term outcomes, adoption rates often remain low. The use 
of multiple arterial conduits remains scarce, mostly because of fear of sternal 
wound complications and the lack of data from randomized trials; the ART trial, 
which is currently completing 10 years of follow-up, will provide necessary and 
long-awaited insights. The weight of data shows similar mortality outcomes with 
onand off-pump surgery among lowand mixed-risk patients; patients at high risk 
of morbidity and mortality with conventional CABG benefit most from OPCAB. 
Minimizing aortic manipulation is directly related to lower rates of stroke after 
CABG, and no-touch OPCAB may provide the lowest stroke risk. Intraoperative 
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Doppler graft assessment should be routine, especially in OPCAB. One of the 
most exciting developments is hybrid revascularization, although evidence for 
widespread use is not currently available and surgical experience with MIDCAB 
procedures is still limited. These and other developments have provided the 
contemporary state-of-the-art CABG procedure (Figure 3).
70
Chapter 4
REFERENCES
1. Head SJ, Kieser TM, Falk V, Huysmans HA, Kappetein AP. Coronary artery bypass grafting: part 1: the 
evolution over the first 50 years. Eur Heart J. 2013;34:2862–2872. doi: 10.1093/eurheartj/eht330.
2. Jha AK, Fisher ES, Li Z, Orav EJ, Epstein AM. Racial trends in the use of major procedures among the 
elderly. N Engl J Med. 2005;353:683–691. doi: 10.1056/NEJMsa050672.
3. ElBardissi AW, Aranki SF, Sheng S, O’Brien SM, Greenberg CC, Gammie JS. Trends in isolated 
coronary artery bypass grafting: an analysis of the Society of Thoracic Surgeons Adult Cardiac 
Surgery Database. J Thorac Cardiovasc Surg. 2012;143:273–281. doi: 10.1016/j.jtcvs.2011.10.029.
4. Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, Straka Z, Piegas LS, Akar 
AR, Jain AR, Noiseux N, Padmanabhan C, Bahamondes JC, Novick RJ, Vaijyanath P, Reddy S, Tao 
L, Olavegogeascoechea PA, Airan B, Sulling TA, Whitlock RP, Ou Y, Ng J, Chrolavicius S, Yusuf S; 
CORONARY Investigators. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl 
J Med. 2012;366:1489–1497. doi: 10.1056/ NEJMoa1200388.
5. Taggart DP, Altman DG, Gray AM, Lees B, Nugara F, Yu LM, Campbell H, Flather M; ART Investigators. 
Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 
1-year results of the Arterial Revascularisation Trial (ART). Eur Heart J. 2010;31:2470– 2481. doi: 
10.1093/eurheartj/ehq318.
6. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, Mack MJ, Holmes DR Jr, 
Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery 
versus percutaneous coronary intervention in patients with three-vessel disease and left main 
coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381:629–
638. doi: 10.1016/S0140-6736(13)60141-5.
7. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, 
Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, 
Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand 
M, Fuster V; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients 
with diabetes. N Engl J Med. 2012;367:2375–2384. doi: 10.1056/NEJMoa1211585.
8. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrié D, Clayton TC, 
Danchin N, Flather M, Hamm CW, Hueb WA, Kähler J, Kelsey SF, King SB, Kosinski AS, Lopes N, 
McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ. Coronary 
artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: 
a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373:1190–
1197. doi: 10.1016/ S0140-6736(09)60552-3.
9. Organisation for Economic Cooperation and Development. Health at a Glance 2015. Paris: OECD 
Publishing; 2015.
10.  Head SJ, Kaul S, Mack MJ, Serruys PW, Taggart DP, Holmes DR Jr, Leon MB, Marco J, Bogers AJ, 
Kappetein AP. The rationale for heart team decisionmaking for patients with stable, complex 
coronary artery disease. Eur Heart J. 2013;34:2510–2518. doi: 10.1093/eurheartj/eht059.
11.  Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, Lockowandt U. EuroSCORE II. 
Eur J Cardiothorac Surg. 2012;41:734–744. doi: 10.1093/ejcts/ezs043.
12.  Shahian DM, O’Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, Shewan 
CM, Dokholyan RS, Peterson ED, Edwards FH, Anderson RP; Society of Thoracic Surgeons Quality 
Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models, part 
1: coronary artery bypass grafting surgery. Ann Thorac Surg. 2009;88:S2–S22.
13.  Osnabrugge RL, Speir AM, Head SJ, Fonner CE, Fonner E, Kappetein AP, Rich JB. Performance of 
EuroSCORE II in a large US database: implications for transcatheter aortic valve implantation. Eur J 
Cardiothorac Surg. 2014;46:400–408. doi: 10.1093/ejcts/ezu033.
71
Current Practice of State-of-the-Art Surgical Coronary Revascularization
4
14.  Wang TK, Li AY, Ramanathan T, Stewart RA, Gamble G, White HD. Comparison of four risk scores 
for contemporary isolated coronary artery bypass grafting. Heart Lung Circ. 2014;23:469–474. doi: 
10.1016/j. hlc.2013.12.001.
15.  Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, 
Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau 
J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB; Valve Academic Research Consortium 
(VARC)-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: 
the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 
2012;42:S45–S60. doi: 10.1093/ejcts/ezs533.
16.  Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, 
Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, 
Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Zamorano 
JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ç, Fagard R, Ferrari 
R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, 
Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, 
Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, 
Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof 
P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber 
S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner HO, Wassmann S, Wendler O, Zamorano 
JL; European Society of Cardiology Committee for Practice Guidelines; EACTS Clinical Guidelines 
Committee; Task Force on Myocardial Revascularization of the European Society of Cardiology 
and the European Association for Cardio-Thoracic Surgery; European Association of Percutaneous 
Cardiovascular Interventions. 2014 ESC/EACTS guidelines on myocardial revascularization: the 
Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and 
the European Association for Cardio-Thoracic Surgery (EACTS): developed with the special 
contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). 
Eur J Cardiothorac Surg. 2014;46:517–592. doi: 10.1093/ejcts/ezu366.
17.  Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka LF, 
Hutter AM Jr, Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, 
Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD. 2011 ACCF/AHA guideline for coronary 
artery bypass graft surgery: a report of the American College of Cardiology Foundation/American 
Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e652–e735. doi: 10.1161/ 
CIR.0b013e31823c074e.
18.  Heusch G, Bøtker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. J Am Coll 
Cardiol. 2015;65:177–195. doi: 10.1016/j. jacc.2014.10.031.
19.  Bakaeen FG, Shroyer AL, Gammie JS, Sabik JF, Cornwell LD, Coselli JS, Rosengart TK, O’Brien SM, 
Wallace A, Shahian DM, Grover FL, Puskas JD. Trends in use of off-pump coronary artery bypass 
grafting: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. J Thorac 
Cardiovasc Surg. 2014;148:856–863, 864.e1. doi: 10.1016/j. jtcvs.2013.12.047.
20.  Aldea GS, Bakaeen FG, Pal J, Fremes S, Head SJ, Sabik J, Rosengart T, Kappetein AP, Thourani VH, 
Firestone S, Mitchell JD; Society of Thoracic Surgeons. The Society of Thoracic Surgeons clinical 
practice guidelines on arterial conduits for coronary artery bypass grafting. Ann Thorac Surg. 
2016;101:801–809. doi: 10.1016/j.athoracsur.2015.09.100.
21.  Tabata M, Grab JD, Khalpey Z, Edwards FH, O’Brien SM, Cohn LH, Bolman RM 3rd. Prevalence 
and variability of internal mammary artery graft use in contemporary multivessel coronary artery 
bypass graft surgery: analysis of the Society of Thoracic Surgeons National Cardiac Database. 
Circulation. 2009;120:935–940. doi: 10.1161/CIRCULATIONAHA.108.832444.
72
Chapter 4
22.  Head SJ, Parasca CA, Mack MJ, Mohr FW, Morice MC, Holmes DR Jr, Feldman TE, Dawkins KD, Colombo 
A, Serruys PW, Kappetein AP; SYNTAX Investigators. Differences in baseline characteristics, practice 
patterns and clinical outcomes in contemporary coronary artery bypass grafting in the United States and 
Europe: insights from the SYNTAX randomized trial and registry. Eur J Cardiothorac Surg. 2015;47:685–695. 
doi: 10.1093/ejcts/ ezu197.
23.  Selnes OA, Gottesman RF, Grega MA, Baumgartner WA, Zeger SL, McKhann GM. Cognitive and 
neurologic outcomes after coronary-artery bypass surgery. N Engl J Med. 2012;366:250–257. doi: 10.1056/
NEJMra1100109.
24.  Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, Straka Z, Piegas LS, Akar AR, Jain AR, 
Noiseux N, Padmanabhan C, Bahamondes JC, Novick RJ, Vaijyanath P, Reddy SK, Tao L, Olavegogeascoechea 
PA, Airan B, Sulling TA, Whitlock RP, Ou Y, Pogue J, Chrolavicius S, Yusuf S; CORONARY Investigators. 
Effects of off-pump and on-pump coronaryartery bypass grafting at 1 year. N Engl J Med. 2013;368:1179–
1188. doi: 10.1056/NEJMoa1301228.
25.  Head SJ, Howell NJ, Osnabrugge RL, Bridgewater B, Keogh BE, Kinsman R, Walton P, Gummert JF, 
Pagano D, Kappetein AP. The European Association for Cardio-Thoracic Surgery (EACTS) database: an 
introduction. Eur J Cardiothorac Surg. 2013;44:e175–e180. doi: 10.1093/ejcts/ezt303.
26.  Niebauer J. Is there a role for cardiac rehabilitation after coronary artery bypass grafting? Treatment after 
coronary artery bypass surgery remains incomplete without rehabilitation. Circulation. 2016;133:2529–
2537. doi: 10.1161/CIRCULATIONAHA.116.021348.
27.  Iqbal J, Zhang YJ, Holmes DR, Morice MC, Mack MJ, Kappetein AP, Feldman T, Stahle E, Escaned J, Banning 
AP, Gunn JP, Colombo A, Steyerberg EW, Mohr FW, Serruys PW. Optimal medical therapy improves 
clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or 
coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention 
With TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up. Circulation. 2015;131:1269–1277. 
doi: 10.1161/CIRCULATIONAHA.114.013042.
28.  Hueb W, Lopes NH, Pereira AC, Hueb AC, Soares PR, Favarato D, Vieira RD, Lima EG, Garzillo CL, Paulitch 
Fda S, César LA, Gersh BJ, Ramires JA. Five-year follow-up of a randomized comparison between off-
pump and on-pump stable multivessel coronary artery bypass grafting: the MASS III Trial. Circulation. 
2010;122(suppl):S48–S52. doi: 10.1161/CIRCULATIONAHA.109.924258.
29.  Ahn JM, Roh JH, Kim YH, Park DW, Yun SC, Lee PH, Chang M, Park HW, Lee SW, Lee CW, Park SW, Choo 
SJ, Chung C, Lee J, Lim DS, Rha SW, Lee SG, Gwon HC, Kim HS, Chae IH, Jang Y, Jeong MH, Tahk SJ, Seung 
KB, Park SJ. Randomized trial of stents versus bypass surgery for left main coronary artery disease: 5-year 
outcomes of the PRECOMBAT Study. J Am Coll Cardiol. 2015;65:2198–2206. doi: 10.1016/j.jacc.2015.03.033.
30.  Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack 
MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Efficacy and safety of edifoligide, 
an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass 
graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294:2446–2454.
31.  Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Choo SJ, Chung CH, 
Lee JW, Cohen DJ, Yeung AC, Hur SH, Seung KB, Ahn TH, Kwon HM, Lim DS, Rha SW, Jeong MH, Lee BK, 
Tresukosol D, Fu GS, Ong TK; BEST Trial Investigators. Trial of everolimus-eluting stents or bypass surgery 
for coronary disease. N Engl J Med. 2015;372:1204–1212. doi: 10.1056/NEJMoa1415447.
32.  Mäkikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, Trovik T, Eskola M, Romppanen H, 
Kellerth T, Ravkilde J, Jensen LO, Kalinauskas G, Linder RB, Pentikainen M, Hervold A, Banning A, Zaman 
A, Cotton J, Eriksen E, Margus S, Sørensen HT, Nielsen PH, Niemelä M, Kervinen K, Lassen JF, Maeng M, 
Oldroyd K, Berg G, Walsh SJ, Hanratty CG, Kumsars I, Stradins P, Steigen TK, Fröbert O, Graham AN, 
Endresen PC, Corbascio M, Kajander O, Trivedi U, Hartikainen J, Anttila V, Hildick-Smith D, Thuesen L, 
Christiansen EH; NOBLE Study Investigators. Percutaneous coronary angioplasty versus coronary artery 
bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, 
open-label, non-inferiority trial. Lancet. 2016;388:2743–2752. doi: 10.1016/S01406736(16)32052-9.
73
Current Practice of State-of-the-Art Surgical Coronary Revascularization
4
33.  Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Straka Z, Piegas LS, Avezum A, Akar AR, Lanas 
Zanetti F, Jain AR, Noiseux N, Padmanabhan C, Bahamondes JC, Novick RJ, Tao L, Olavegogeascoechea PA, 
Airan B, Sulling TA, Whitlock RP, Ou Y, Gao P, Pettit S, Yusuf S; CORONARY Investigators. Five-year 
outcomes after off-pump or on-pump coronary-artery bypass grafting. N Engl J Med. 2016;375:2359–
2368. doi: 10.1056/ NEJMoa1601564.
34.  Taggart DP, Altman DG, Gray AM, Lees B, Gerry S, Benedetto U, Flather M; ART Investigators. 
Randomized trial of bilateral versus single internalthoracic-artery grafts. N Engl J Med. 2016;375:2540–
2549. doi: 10.1056/ NEJMoa1610021.
35.  BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 
2007;49:1600–1606.
36.  Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires 
JA. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized 
controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 
2010;122:949–957. doi: 10.1161/CIRCULATIONAHA.109.911669.
37.  Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, Morice MC, Holmes DR Jr, 
Feldman TE, Ståhle E, Underwood P, Dawkins KD, Kappetein AP, Mohr FW. Coronary artery bypass 
grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year 
follow-up of the SYNTAX trial. Eur Heart J. 2014;35:2821–2830. doi: 10.1093/eurheartj/ehu213.
38.  Morice MC, Serruys PW, Kappetein AP, Feldman TE, Ståhle E, Colombo A, Mack MJ, Holmes DR, Choi 
JW, Ruzyllo W, Religa G, Huang J, Roy K, Dawkins KD, Mohr F. Five-year outcomes in patients with 
left main disease treated with either percutaneous coronary intervention or coronary artery bypass 
grafting in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery 
Trial. Circulation. 2014;129:2388– 2394. doi: 10.1161/CIRCULATIONAHA.113.006689.
39.  Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, 
Petrie MC, Oh JK, She L, Moore VL, DesvigneNickens P, Sopko G, Rouleau JL; STICHES Investigators. 
Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511–
1520. doi: 10.1056/NEJMoa1602001.
40.  Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, Hill JA, Lee KL, Rouleau JL, Prior DL, Ali 
IS, Maddury J, Golba KS, White HD, Carson P, Chrzanowski L, Romanov A, Miller AB, Velazquez EJ; 
STICH Trial Investigators. Ten-year outcomes after coronary artery bypass grafting according to age in 
patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-
up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2016;134:1314–1324. 
doi: 10.1161/CIRCULATIONAHA.116.024800.
41.  Adjedj J, De Bruyne B, Floré V, Di Gioia G, Ferrara A, Pellicano M, Toth GG, Bartunek J, Vanderheyden 
M, Heyndrickx GR, Wijns W, Barbato E. Significance of intermediate values of fractional flow 
reserve in patients with coronary artery disease. Circulation. 2016;133:502–508. doi: 10.1161/ 
CIRCULATIONAHA.115.018747.
42.  De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic N, Mobius-Winckler S, Rioufol G, 
Witt N, Kala P, MacCarthy P, Engström T, Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert 
O, Curzen N, Johnson JB, Limacher A, Nüesch E, Jüni P; FAME 2 Trial Investigators. Fractional flow 
reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014;371:1208–1217. doi: 10.1056/
NEJMoa1408758.
43.  Toth G, De Bruyne B, Casselman F, De Vroey F, Pyxaras S, Di Serafino L, Van Praet F, Van Mieghem 
C, Stockman B, Wijns W, Degrieck I, Barbato E. Fractional flow reserve-guided versus angiography-
guided coronary artery bypass graft surgery. Circulation. 2013;128:1405–1411. doi: 10.1161/ 
CIRCULATIONAHA.113.002740.
44.  Mohammadi S, Dagenais F, Doyle D, Mathieu P, Baillot R, Charbonneau E, Perron J, Voisine P. Age 
cut-off for the loss of benefit from bilateral internal thoracic artery grafting. Eur J Cardiothorac Surg. 
2008;33:977–982. doi: 10.1016/j.ejcts.2008.03.026.
74
Chapter 4
45.  Kieser TM, Lewin AM, Graham MM, Martin BJ, Galbraith PD, Rabi DM, Norris CM, Faris PD, 
Knudtson ML, Ghali WA; APPROACH Investigators. Outcomes associated with bilateral internal 
thoracic artery grafting: the importance of age. Ann Thorac Surg. 2011;92:1269–1275. doi: 10.1016/j.
athoracsur.2011.05.083.
46.  Yi G, Shine B, Rehman SM, Altman DG, Taggart DP. Effect of bilateral internal mammary artery 
grafts on long-term survival: a meta-analysis approach. Circulation. 2014;130:539–545. doi: 10.1161/
CIRCULATIONAHA.113.004255.
47.  Benedetto U, Altman DG, Gerry S, Gray A, Lees B, Pawlaczyk R, Flather M, Taggart DP; Arterial 
Revascularization Trial Investigators. Pedicled and skeletonized single and bilateral internal 
thoracic artery grafts and the incidence of sternal wound complications: insights from the Arterial 
Revascularization Trial. J Thorac Cardiovasc Surg. 2016;152:270–276. doi: 10.1016/j.jtcvs.2016.03.056.
48.  Glineur D, Boodhwani M, Hanet C, de Kerchove L, Navarra E, Astarci P, Noirhomme P, El Khoury 
G. Bilateral internal thoracic artery configuration for coronary artery bypass surgery: a prospective 
randomized trial. Circ Cardiovasc Interv. 2016;9:e003518.
49.  Cao C, Manganas C, Horton M, Bannon P, Munkholm-Larsen S, Ang SC, Yan TD. Angiographic 
outcomes of radial artery versus saphenous vein in coronary artery bypass graft surgery: a meta-
analysis of randomized controlled trials. J Thorac Cardiovasc Surg. 2013;146:255–261. doi: 10.1016/j.
jtcvs.2012.07.014.
50.  Petrovic I, Nezic D, Peric M, Milojevic P, Djokic O, Kosevic D, Tasic N, Djukanovic B, Otasevic P. Radial 
artery vs saphenous vein graft used as the second conduit for surgical myocardial revascularization: 
long-term clinical follow-up. J Cardiothorac Surg. 2015;10:127. doi: 10.1186/s13019015-0331-9.
51.  Collins P, Webb CM, Chong CF, Moat NE; Radial Artery Versus Saphenous Vein Patency (RSVP) Trial 
Investigators. Radial artery versus saphenous vein patency randomized trial: five-year angiographic 
follow-up. Circulation. 2008;117:2859–2864. doi: 10.1161/CIRCULATIONAHA.107.736215.
52.  Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM, Harris LJ, Stelzer P, Cohen B, Hoffman DM. 
Radial artery conduits improve long-term survival after coronary artery bypass grafting. Ann Thorac 
Surg. 2010;90:1165– 1172. doi: 10.1016/j.athoracsur.2010.05.038.
53.  Schwann TA, Engoren M, Bonnell M, Clancy C, Habib RH. Comparison of late coronary artery bypass 
graft survival effects of radial artery versus saphenous vein grafting in male and female patients. Ann 
Thorac Surg. 2012;94:1485–1491. doi: 10.1016/j.athoracsur.2012.05.029.
54.  Hayward PA, Gordon IR, Hare DL, Matalanis G, Horrigan ML, Rosalion A, Buxton BF. Comparable 
patencies of the radial artery and right internal thoracic artery or saphenous vein beyond 5 
years: results from the Radial Artery Patency and Clinical Outcomes trial. J Thorac Cardiovasc Surg. 
2010;139:60–65. doi: 10.1016/j.jtcvs.2009.09.043.
55.  Benedetto U, Gaudino M, Caputo M, Tranbaugh RF, Lau C, Di Franco A, Ng C, Girardi LN, Angelini 
GD. Right internal thoracic artery versus radial artery as the second best arterial conduit: Insights 
from a meta-analysis of propensity-matched data on long-term survival. J Thorac Cardiovasc Surg. 
2016;152:1083–1091.e15.
56.  Benedetto U, Caputo M, Zakkar M, Bryan A, Angelini GD. Are three arteries better than two? Impact 
of using the radial artery in addi tion to bilateral internal thoracic artery grafting on long-term surviv 
al. J Thorac Cardiovasc Surg. 2016;152:862–869.e2. doi: 10.1016/j. jtcvs.2016.04.054.
57.  Grau JB, Kuschner CE, Johnson CK, Ferrari G, Zapolanski A, Brizzio ME, Shaw RE. The effects of 
using a radial artery in patients already receiving bilateral internal mammary arteries during 
coronary bypass grafting: 30day outcomes and 14-year survival in a propensity-matched cohort. Eur 
J Cardiothorac Surg. 2016;49:203–210. doi: 10.1093/ejcts/ezv176.
58.  Shi WY, Tatoulis J, Newcomb AE, Rosalion A, Fuller JA, Buxton BF. Is a third arterial conduit necessary? 
Comparison of the radial artery and saphenous vein in patients receiving bilateral internal thoracic 
arteries for triple vessel coronary disease. Eur J Cardiothorac Surg. 2016;50:53–60. doi: 10.1093/ ejcts/
ezv467.
75
Current Practice of State-of-the-Art Surgical Coronary Revascularization
4
59.  Desai ND, Cohen EA, Naylor CD, Fremes SE; Radial Artery Patency Study Investigators. A randomized 
comparison of radial-artery and saphenousvein coronary bypass grafts. N Engl J Med. 2004;351:2302–
2309. doi: 10.1056/NEJMoa040982.
60.  Kim KB, Hwang HY, Hahn S, Kim JS, Oh SJ. A randomized comparison of the Saphenous Vein Versus 
Right Internal Thoracic Artery as a Y-Composite Graft (SAVE RITA) trial: one-year angiographic 
results and mid-term clinical outcomes. J Thorac Cardiovasc Surg. 2014;148:901–907. doi: 10.1016/j.
jtcvs.2014.03.057.
61.  Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and 
patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 
patients during 25 years. J Am Coll Cardiol. 1996;28:616–626.
62.  Hess CN, Lopes RD, Gibson CM, Hager R, Wojdyla DM, Englum BR, Mack MJ, Califf RM, Kouchoukos 
NT, Peterson ED, Alexander JH. Saphenous vein graft failure after coronary artery bypass surgery: 
insights from PREVENT IV. Circulation. 2014;130:1445–1451.
63.  Samano N, Geijer H, Liden M, Fremes S, Bodin L, Souza D. The no-touch saphenous vein for coronary 
artery bypass grafting maintains a patency, after 16 years, comparable to the left internal thoracic 
artery: a randomized trial. J Thorac Cardiovasc Surg. 2015;150:880–888. doi: 10.1016/j. jtcvs.2015.07.027.
64.  Verma S, Lovren F, Pan Y, Yanagawa B, Deb S, Karkhanis R, Quan A, Teoh H, Feder-Elituv R, Moussa F, 
Souza DS, Fremes SE. Pedicled no-touch saphenous vein graft harvest limits vascular smooth muscle 
cell activation: the PATENT saphenous vein graft study. Eur J Cardiothorac Surg. 2014;45:717–725. doi: 
10.1093/ejcts/ezt560.
65.  Dacey LJ, Braxton JH Jr, Kramer RS, Schmoker JD, Charlesworth DC, Helm RE, Frumiento C, 
Sardella GL, Clough RA, Jones SR, Malenka DJ, Olmstead EM, Ross CS, O’Connor GT, Likosky DS; 
Northern New England Cardiovascular Disease Study Group. Long-term outcomes of endoscopic 
vein harvesting after coronary artery bypass grafting. Circulation. 2011;123:147– 153. doi: 10.1161/
CIRCULATIONAHA.110.960765.
66.  Williams JB, Peterson ED, Brennan JM, Sedrakyan A, Tavris D, Alexander JH, Lopes RD, Dokholyan 
RS, Zhao Y, O’Brien SM, Michler RE, Thourani VH, Edwards FH, Duggirala H, Gross T, Marinac-Dabic 
D, Smith PK. Association between endoscopic vs open vein-graft harvesting and mortality, wound 
complications, and cardiovascular events in patients undergoing CABG surgery. JAMA. 2012;308:475–
484.
67.  Harskamp RE, Alexander JH, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, Gibson 
CM, Califf RM, Kouchoukos NT, Harrington RA, Ferguson TB Jr, Lopes RD. Vein graft preservation 
solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the 
PREVENT IV randomized clinical trial. JAMA Surg. 2014;149:798–805.
68.  Taggart DP, Ben Gal Y, Lees B, Patel N, Webb C, Rehman SM, Desouza A, Yadav R, De Robertis F, 
Dalby M, Banning A, Channon KM, Di Mario C, Orion E. A randomized trial of external stenting for 
saphenous vein grafts in coronary artery bypass grafting. Ann Thorac Surg. 2015;99:2039– 2045. doi: 
10.1016/j.athoracsur.2015.01.060.
69.  Meirson T, Orion E, Di Mario C, Webb C, Patel N, Channon KM, Ben Gal Y, Taggart DP. Flow patterns in 
externally stented saphenous vein grafts and development of intimal hyperplasia. J Thorac Cardiovasc 
Surg. 2015;150:871–878. doi: 10.1016/j.jtcvs.2015.04.061.
70.  Mujanovi E, Kabil E, Bergsland J. Transit time flowmetry in coronary surgery: an important tool in 
graft verification. Bosn J Basic Med Sci. 2007;7:275–278.
71.  Kieser TM, Rose S, Kowalewski R, Belenkie I. Transit-time flow predicts outcomes in coronary artery 
bypass graft patients: a series of 1000 consecutive arterial grafts. Eur J Cardiothorac Surg. 2010;38:155–
162. doi: 10.1016/j.ejcts.2010.01.026.
72.  Di Giammarco G, Canosa C, Foschi M, Rabozzi R, Marinelli D, Masuyama S, Ibrahim BM, Ranalletta 
RA, Penco M, Di Mauro M. Intraoperative graft verification in coronary surgery: increased diagnostic 
accuracy adding high-resolution epicardial ultrasonography to transit-time flow measurement. Eur 
J Cardiothorac Surg. 2014;45:e41–e45. doi: 10.1093/ejcts/ ezt580.
76
Chapter 4
73.  Afilalo J, Rasti M, Ohayon SM, Shimony A, Eisenberg MJ. Off-pump vs. on-pump coronary artery bypass 
surgery: an updated meta-analysis and meta-regression of randomized trials. Eur Heart J. 2012;33:1257–1267. 
doi: 10.1093/eurheartj/ehr307.
74.  Deppe AC, Arbash W, Kuhn EW, Slottosch I, Scherner M, Liakopoulos OJ, Choi YH, Wahlers T. Current 
evidence of coronary artery bypass grafting off-pump versus on-pump: a systematic review with meta-
analysis of over 16,900 patients investigated in randomized controlled trials. Eur J Cardiothorac Surg. 
2016;49:1031–1041. doi: 10.1093/ejcts/ezv268.
75.  Kowalewski M, Pawliszak W, Malvindi PG, Bokszanski MP, Perlinski D, Raffa GM, Kowalkowska ME, 
Zaborowska K, Navarese EP, Kolodziejczak M, Kowalewski J, Tarelli G, Taggart DP, Anisimowicz L. Off-pump 
coronary artery bypass grafting improves short-term outcomes in high-risk patients compared with on-
pump coronary artery bypass grafting: metaanalysis. J Thorac Cardiovasc Surg. 2016;151:60–77.e1. doi: 10.1016/j. 
jtcvs.2015.08.042.
76.  Diegeler A, Börgermann J, Kappert U, Breuer M, Böning A, Ursulescu A, Rastan A, Holzhey D, Treede H, 
Rieß FC, Veeckmann P, Asfoor A, Reents W, Zacher M, Hilker M; GOPCABE Study Group. Off-pump versus 
onpump coronary-artery bypass grafting in elderly patients. N Engl J Med. 2013;368:1189–1198. doi: 10.1056/
NEJMoa1211666.
77.  Kirmani BH, Holmes MV, Muir AD. Long-term survival and freedom from reintervention after off-pump 
coronary artery bypass grafting: a propensity-matched study. Circulation. 2016;134:1209–1220. doi: 10.1161/ 
CIRCULATIONAHA.116.021933.
78.  Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, Lucke JC, Baltz JH, Novitzky D; Veterans 
Affairs Randomized On/Off Bypass (ROOBY) Study Group. On-pump versus off-pump coronary-artery 
bypass surgery. N Engl J Med. 2009;361:1827–1837. doi: 10.1056/ NEJMoa0902905.
79.  Lapar DJ, Mery CM, Kozower BD, Kern JA, Kron IL, Stukenborg GJ, Ailawadi G. The effect of surgeon volume 
on mortality for off-pump coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2012;143:854–863. doi: 
10.1016/j.jtcvs.2011.12.048.
80.  Murzi M, Caputo M, Aresu G, Duggan S, Angelini GD. Training residents in off-pump coronary artery bypass 
surgery: a 14-year experience. J Thorac Cardiovasc Surg. 2012;143:1247–1253. doi: 10.1016/j. jtcvs.2011.09.049.
81.  Konety SH, Rosenthal GE, Vaughan-Sarrazin MS. Surgical volume and outcomes of off-pump coronary 
artery bypass graft surgery: does it matter? J Thorac Cardiovasc Surg. 2009;137:1116–1123.e1.
82.  Börgermann J, Hakim K, Renner A, Parsa A, Aboud A, Becker T, Masshoff M, Zittermann A, Gummert JF, 
Kuss O. Clampless off-pump versus conventional coronary artery revascularization: a propensity score 
analysis of 788 patients. Circulation. 2012;126(suppl 1):S176–S182. doi: 10.1161/ CIRCULATIONAHA.111.084285.
83.  Zhao DF, Edelman JJ, Seco M, Bannon PG, Wilson MK, Byrom MJ, Thourani V, Lamy A, Taggart DP, Puskas 
JD, Vallely MP. Coronary artery bypass grafting with and without manipulation of the ascending aorta: a 
network meta-analysis. J Am Coll Cardiol. 2017;69:924–936. doi: 10.1016/j. jacc.2016.11.071.
84.  Ozatik MA, Göl MK, Fansa I, Uncu H, Küçüker SA, Küçükaksu S, Bayazit M, Sener E, Taşdemir O. Risk factors 
for stroke following coronary artery bypass operations. J Card Surg. 2005;20:52–57. doi: 10.1111/j.08860440.20
05.200384.x.
85.  Rosenberger P, Shernan SK, Löffler M, Shekar PS, Fox JA, Tuli JK, Nowak M, Eltzschig HK. The influence 
of epiaortic ultrasonography on intraoperative surgical management in 6051 cardiac surgical patients. Ann 
Thorac Surg. 2008;85:548–553. doi: 10.1016/j.athoracsur.2007.08.061.
86.  Hangler HB, Nagele G, Danzmayr M, Mueller L, Ruttmann E, Laufer G, Bonatti J. Modification of surgical 
technique for ascending aortic atherosclerosis: impact on stroke reduction in coronary artery bypass 
grafting. J Thorac Cardiovasc Surg. 2003;126:391–400.
87.  Holzhey DM, Cornely JP, Rastan AJ, Davierwala P, Mohr FW. Review of a 13-year single-center experience 
with minimally invasive direct coronary artery bypass as the primary surgical treatment of coronary artery 
disease. Heart Surg Forum. 2012;15:E61–E68. doi: 10.1532/HSF98.20111141.
88.  Raja SG, Benedetto U, Alkizwini E, Gupta S, Amrani M; Harefield Cardiac Outcomes Research Group. 
Propensity score adjusted comparison of MIDCAB versus full sternotomy left anterior descending artery 
revascularization. Innovations (Phila). 2015;10:174–178. doi: 10.1097/IMI.0000000000000162.
77
Current Practice of State-of-the-Art Surgical Coronary Revascularization
4
89.  Halkos ME, Vassiliades TA, Myung RJ, Kilgo P, Thourani VH, Cooper WA, Guyton RA, Lattouf OM, Puskas 
JD. Sternotomy versus nonsternotomy LIMA-LAD grafting for single-vessel disease. Ann Thorac Surg. 
2012;94:1469–1477. doi: 10.1016/j.athoracsur.2012.05.049.
90.  Bonatti J, Schachner T, Bonaros N, Lehr EJ, Zimrin D, Griffith B. Robotically assisted totally endoscopic 
coronary bypass surgery. Circulation. 2011;124:236–244. doi: 10.1161/CIRCULATIONAHA.110.985267.
91.  Halkos ME, Liberman HA, Devireddy C, Walker P, Finn AV, Jaber W, Guyton RA, Puskas JD. Early clinical 
and angiographic outcomes after robotic-assisted coronary artery bypass surgery. J Thorac Cardiovasc Surg. 
2014;147:179–185. doi: 10.1016/j.jtcvs.2013.09.010.
92.  Yang M, Wu Y, Wang G, Xiao C, Zhang H, Gao C. Robotic total arterial off-pump coronary artery bypass 
grafting: seven-year single-center experience and long-term follow-up of graft patency. Ann Thorac Surg. 
2015;100:1367–1373. doi: 10.1016/j.athoracsur.2015.04.054.
93.  Currie ME, Romsa J, Fox SA, Vezina WC, Akincioglu C, Warrington JC, McClure RS, Stitt LW, Menkis AH, 
Boyd WD, Kiaii B. Long-term angiographic follow-up of robotic-assisted coronary artery revascularization. 
Ann Thorac Surg. 2012;93:1426–1431. doi: 10.1016/j. athoracsur.2011.11.031.
94.  Argenziano M, Katz M, Bonatti J, Srivastava S, Murphy D, Poirier R, Loulmet D, Siwek L, Kreaden U, 
Ligon D; TECAB Trial Investigators. Results of the prospective multicenter trial of robotically assisted 
totally endoscopic coronary artery bypass grafting. Ann Thorac Surg. 2006;81:1666–1674. doi: 10.1016/j.
athoracsur.2005.11.007.
95.  Gşsior M, Zembala MO, Tajstra M, Filipiak K, Gierlotka M, Hrapkowicz T, Hawranek M, Poloşski L, 
Zembala M; POL-MIDES (HYBRID) Study Investigators. Hybrid revascularization for multivessel coronary 
artery disease. JACC Cardiovasc Interv. 2014;7:1277–1283. doi: 10.1016/j. jcin.2014.05.025.
96.  Harskamp RE, Brennan JM, Xian Y, Halkos ME, Puskas JD, Thourani VH, Gammie JS, Taylor BS, de Winter 
RJ, Kim S, O’Brien S, Peterson ED, Gaca JG. Practice patterns and clinical outcomes after hybrid coronary 
revascularization in the United States: an analysis from the Society of Thoracic Surgeons Adult Cardiac 
Database. Circulation. 2014;130:872–879. doi: 10.1161/CIRCULATIONAHA.114.009479.
97.  Modrau IS, Holm NR, Mæng M, Bøtker HE, Christiansen EH, Kristensen SD, Lassen JF, Thuesen L, Nielsen 
PH; Hybrid Coronary Revascularization Study Group. One-year clinical and angiographic results of hybrid 
coronary revascularization. J Thorac Cardiovasc Surg. 2015;150:1181–1186. doi: 10.1016/j.jtcvs.2015.08.072.
98.  Rosenblum JM, Harskamp RE, Hoedemaker N, Walker P, Liberman HA, de Winter RJ, Vassiliades TA, 
Puskas JD, Halkos ME. Hybrid coronary revascularization versus coronary artery bypass surgery with 
bilateral or single internal mammary artery grafts. J Thorac Cardiovasc Surg. 2016;151:1081–1089. doi: 
10.1016/j.jtcvs.2015.10.061.
99.  Head SJ, Börgermann J, Osnabrugge RL, Kieser TM, Falk V, Taggart DP, Puskas JD, Gummert JF, Kappetein 
AP. Coronary artery bypass grafting, part 2: optimizing outcomes and future prospects. Eur Heart J. 
2013;34:2873–2886. doi: 10.1093/eurheartj/eht284.
100.  Puskas JD, Halkos ME, DeRose JJ, Bagiella E, Miller MA, Overbey J, Bonatti J, Srinivas VS, Vesely M, Sutter 
F, Lynch J, Kirkwood K, Shapiro TA, Boudoulas KD, Crestanello J, Gehrig T, Smith P, Ragosta M, Hoff SJ, 
Zhao D, Gelijns AC, Szeto WY, Weisz G, Argenziano M, Vassiliades T, Liberman H, Matthai W, Ascheim DD. 
Hybrid coronary revascularization for the treatment of multivessel coronary artery disease: a multicenter 
observational study. J Am Coll Cardiol. 2016;68:356–365. doi: 10.1016/j. jacc.2016.05.032.
101.  D’Ancona G, Vassiliades TA, Boyd WD, Donias HW, Stahl KD, Karamanoukian H. Is hybrid coronary 
revascularization favored by cardiologists or cardiac surgeons? Heart Surg Forum. 2002;5:393–395.
102.  Harskamp RE, Halkos ME, Xian Y, Szerlip MA, Poston RS, Mick SL, Lopes RD, Tijssen JG, de Winter RJ, 
Peterson ED. A nationwide survey on perception, experience, and expectations of hybrid coronary 
revascularization among top-ranked US hospitals. Am Heart J. 2015;169:557–563.e6. doi: 10.1016/j.
ahj.2015.01.003.
103.  Weintraub WS, Grau-Sepulveda MV, Weiss JM, O’Brien SM, Peterson ED, Kolm P, Zhang Z, Klein LW, 
Shaw RE, McKay C, Ritzenthaler LL, Popma JJ, Messenger JC, Shahian DM, Grover FL, Mayer JE, Shewan 
CM, Garratt KN, Moussa ID, Dangas GD, Edwards FH. Comparative effectiveness of revascularization 
strategies. N Engl J Med. 2012;366:1467–1476. doi: 10.1056/NEJMoa1110717.

Chapter 5
Heart Team decision-making and long-term 
outcomes for 1000 consecutive cases of coronary 
artery disease
Domingues CT, Milojevic M, Thuijs DJFM, van Mieghem NM,  
Daemen J, van Domburg RT, Kappetein AP, Head SJ. 
Interact Cardiovasc Thorac Surg. 2019; 28:206-213.
80
Chapter 5
ABSTRACT
OBJECTIVES: The Heart Team has been recommended as standard care for 
patients with coronary artery disease (CAD). However, little is known about the real 
benefits, potential treatment delays and late outcomes of this approach. Our goal 
was to determine the safety and feasibility of multidisciplinary Heart Team decision 
making for patients with CAD.
METHODS: We retrospectively assessed 1000 consecutive cases discussed by 
the Heart Team between November 2010 and January 2012. We assessed (i) time 
intervals between different care steps involving the Heart Team; (ii) the distribution 
of patients according to the complexity of their CAD; and (iii) the 5-year survival as 
estimated from Kaplan–Meier curves.
RESULTS: Of 1000 case discussions, 40 were repeat cases, resulting in 960 unique 
cases. The mean age was 65 years, 73% were men, and 29% had diabetes. Native 
vessel disease was present in 86.4%, of which 69% had simple 1-vessel disease (1VD) 
or 2-vessel disease (2VD), and 31% had complex left main (LM) or 3-vessel disease 
(3VD). The time interval between referral by a community hospital and final 
treatment was less than 6 weeks for 90% of cases. Treatment decisions were delayed 
in 35% of cases due to a need for additional diagnostic information. For simple 
1or 2VD with or without proximal left anterior descending artery involvement, 
treatment was medical therapy in 6% and 12%, respectively; percutaneous coronary 
intervention (PCI) in 88% and 85%, respectively; and coronary artery bypass 
grafting (CABG) in 6% and 3%, respectively. For 3VD disease, treatment was equally 
split between CABG and PCI (46% for both). PCI was preferred for isolated LM or 
LM with 1VD (81% vs CABG 16%), whereas CABG was preferred in LM with 2or 3VD 
(71% vs PCI 19%). The 5-year mortality rate was 16% for 1or 2VD, 17% for 3VD, 3% for 
isolated LM or with 1VD and 27% for LM with 2or 3VD.
CONCLUSIONS: In this single-centre analysis, the Heart Team approach was 
feasible, with decision making and treatment by the Heart Team following within 
a short time after referral. However, the timing of treatment could be further 
optimized if adequate information and imaging were available at the time of the 
Heart Team meeting. The final treatment recommendation by the Heart Team was 
largely in accordance with clinical guidelines.
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INTRODUCTION
Decision making about the most optimal treatment for patients with coronary 
artery disease (CAD) remains a difficult task, particularly since interventional 
cardiologists, clinical cardiologists and cardiac surgeons are increasingly targeting 
the same patient population for medical therapy, percutaneous coronary 
intervention (PCI) and coronary artery bypass grafting (CABG).
Moreover, the focus on patient groups with a higher risk for adverse outcomes 
due to advanced age or comorbidities represents a complex new reality in 
cardiovascular care. These elements have contributed to the need for collaboration 
among different specialists. Over the last decade, since the publication of the 
Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac 
Surgery (SYNTAX) trial, a multidisciplinary Heart Team approach has been 
promoted to provide more patient-centric, evidence-based health care (1).
The Heart Team for CAD established its roots during the conduct of randomized 
trials. Since the SYNTAX trial, the Heart Team approach has become standard in 
trials involving complex cardiac conditions with the aim of ensuring accurate 
patient selection and estimating clinical equipoise between treatments to 
allow randomization (2). Consequently, there is growing awareness that a 
multidisciplinary approach to medicine improves the level of care by avoiding 
individual physician factors (1).
Heart Team decision making has received a Class 1C recommendation in European 
and American guidelines on myocardial revascularization (3, 4). Despite the 
assumed advantages of the Heart Team approach over decision making by the 
individual physician, studies to support this statement are limited. As a result, 
the Heart Team approach has not yet been widely implemented. The reasons for 
this are multifactorial, including, amongst others, that (i) some consider that 
the concept introduces delays in decision making; (ii) meetings held outside the 
tertiary treating hospitals might not be reimbursed by local health care systems; 
and (iii) it remains unclear whether decision making is indeed improved by 
multidisciplinary discussions.
This study evaluates the process of discussing cases by a Heart Team to determine 
(i) the feasibility of having a Heart Team; (ii) the time interval from referral to 
treatment; (iii) treatment choices made by the Heart Team; and (iv) real-world 
long-term results of treatments suggested by the Heart Team. With these data, our 
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goal was to provide additional understanding of Heart Team decision making that 
would further support this approach in other institutions and in future clinical 
guidelines.
METHODS
Study design
This was an observational, retrospective study that included 1000 consecutive 
cases of patients with CAD discussed by the Heart Team at the Thoraxcenter of the 
Erasmus University Medical Center between November 2010 and January 2012. 
Approval from the institutional review board was obtained for this study, and 
patient informed consent was waived.
Heart Team meetings
The Heart Team meeting takes place daily at 8:30 am, with 30 min allocated for 
each meeting. The Heart Team comprises a cardiothoracic surgeon, a clinical 
cardiologist and an interventional cardiologist. In addition, residents of the 
cardiology or cardiothoracic surgery department, researchers and other health 
care professionals attend these meetings regularly, which contributes to gaining 
experience in clinical shared decision making.
At the Heart Team meeting, patients with CAD (with or without concomitant 
valvular disease) potentially requiring coronary revascularization are discussed. 
These cases are referred to the Heart Team meeting by cardiologists from 
community hospitals or cardiologists from our own institution. All patients 
diagnosed with CAD in our institution, regardless of the complexity of the 
coronary lesions, are referred for discussion by the Heart Team, except for those 
patients who undergo an ad hoc PCI procedure. Patients with heart failure, 
complex valve disease or congenital heart disease are referred to other specialized 
multidisciplinary teams for additional discussion.
Patient information provided to the Heart Team is listed in an institutional letter 
(Supplementary Material, Appendix Fig. S1). To ensure that the relevant data are 
available during the meeting and for reasons of time management, this letter 
contains baseline characteristics and risk scores determined prior to the Heart 
Team meeting. During the Heart Team meeting, the coronary angiographic and 
cardiac echocardiographic images are assessed by the Heart Team. The SYNTAX 
score was calculated during the meeting only for a select group of patients 
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with complex CAD to aid the team in making a final treatment decision (1). The 
decisions made by the Heart Team include CABG, PCI, medical therapy, the need 
for additional diagnostic information, or the need for input from a different 
specialty. If additional diagnostic information or input from a different specialty is 
required, the patient may be discussed again in the Heart Team meeting after this 
new information becomes available. The decisions for each case are made jointly 
and are based on the most recent evidence-based treatment recommendations 
available. After a treatment decision is reached, it is registered on the institutional 
letter, and the patient and referring cardiologist are informed about the 
treatment decision and the reasons for that particular decision. The patient’s 
preference is taken into account, and an open, non-autocratic discussion takes 
place. Patient consent is obtained and, when applicable, the patient is scheduled 
for the procedure.
Data collection
All cases discussed in the Heart Team meetings are systematically registered 
in a computerized institutional database. Patients included in this study were 
extracted from the database. Data were extracted by retrospectively reviewing 
the institutional letter, the referring letter from the cardiologist and the 
medical records in our electronic patient information system. In 23 cases, the 
final treatment received by the patient was missing from our electronic patient 
information system, which required us to contact the referring community 
hospital. Information on the vital status of studied patients for up to 5 years was 
obtained either through the hospital records or the Dutch Civil Registry.
Definitions
Patients with a body mass index >30 kg/m2 were considered obese. A creatinine 
level >200 mmol indicated renal impairment. Patients were considered to have 
hypertension or dyslipidaemia if they were receiving medication to treat it. 
Left ventricular function was considered normal if the left ventricular ejection 
fraction (LVEF) was 50–70%, and mild, moderate or severe if the LVEF was 40–49%, 
30–39% or <30%, respectively. Summary scores to estimate the procedural risk (e.g. 
additive EuroSCORE and logistic EuroSCORE) were calculated retrospectively 
from the information on the institutional letter if the score was not already 
available.
The clinical presentation of patients ranged from asymptomatic to recent 
myocardial infarction or out-of-hospital cardiac arrest. These definitions were 
based on European guidelines (3).
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A coronary lesion was considered significant if a >50% stenosis was present in a vessel 
with a diameter of >1.5 mm. Patients were divided into 3 different groups, depending 
on the type of CAD. The first group comprised a mix of patients: (i) patients with 
nonsignificant CAD (the Heart Team found the coronary lesions to be not significant 
after analysing the coronary angiogram); (ii) patients with unclear involvement of 
coronary arteries (e.g. due to insufficient information on the coronary angiographic 
images provided); and (iii) patients with stenosis of the coronary artery from a 
cause other than arteriosclerosis; for example, spasm or malformation. The second 
group comprised patients with native vessel CAD. The third group included patients 
previously treated with CABG who presented with a significant lesion in the saphenous 
vein graft, internal mammary artery, native vessel or a combination of significant 
lesions. The second group of patients (e.g. those with native vessel lesions) was 
further divided into ‘simple’ versus ‘complex’ CAD. The group of simple CAD 
included patients with 1-vessel disease (1VD) or 2-vessel disease (2VD) with and 
without involvement of the proximal left anterior descending (LAD) artery; and 
the group of complex CAD included patients with 3-vessel disease (3VD) or left 
main (LM) disease. The SYNTAX score, if calculated by the Heart Team during the 
meeting, was used only for patients with complex CAD, who were divided into 3 
groups: SYNTAX score 0–22, SYNTAX score 23–32 and SYNTAX score >=33.
Statistical analyses
Discrete variables are reported using percentages and counts of the total 
sample. Continuous variables are presented as mean with standard deviation or 
median with interquartile range (Q1– Q3), where appropriate. Five-year survival 
rates were estimated using Kaplan–Meier methods, and comparisons between 
groups were made using log-rank testing. Subgroup analyses were performed 
for subgroups of patients with LM disease or 3VD and within the group of 
patients with simple coronary disease. A 2 sided P-value of <0.05 was considered 
statistically significant. Analyses were performed using SPSS Statistics version 21.0 
(IBM Corporation, Armonk, NY, USA).
RESULTS
Heart Team meetings
Between November 2010 and January 2012, 1000 cases were discussed and 
297 meetings took place. A mean of 3.36 cases were discussed at each meeting 
(median 3, Q1–Q3 2–4). Forty cases were rediscussed, and treatment was initiated 
only after the second discussion. This process resulted in a total of 960 different 
85
Heart Team decision making and long-term outcomes for 1000 consecutive cases of coronary artery disease
5
case discussions that resulted in a treatment proposed by the Heart Team. Of the 
960 cases, 822 (85.6%) were referred by 22 different community hospitals and 138 
(14.4%) were referred by a cardiologist from our own institution.
Table 1. Baseline clinical characteristics presented to the Heart Team.
Characteristics Patients (n = 960)
Age (years) 65.1 ± 11.0 (960/960)
Male gender 73.0 (701/960)
Comorbid risk factors
Obesity 27.4 (220/960)
Diabetes 29.0 (278/960)
Hypertension 98.2 (943/960)
Dyslipidaemia 90.6 (870/960)
Tobacco use 20.4 (196/960)
Positive family history 30.7 (295/960)
COPD 12.9 (124/960)
Renal impairment 2.1 (94.7/960)
Cardiovascular history
No prior cardiovascular events 63.8 (613/960)
Prior PCI 25.8 (248/960)
1 x PCI
2 x PCI
18.9 (181/960)
4.9 (47/960)
3 x PCI or more 2.1 (20/960)
Prior CABG 8.0 (77/960)
1 x CABG
2 x CABG
7.9 (76/960)
0.1 (1/960)
Prior other cardiac procedure (excluding CABG) 1.1 (11/960)
Prior heart failure 6.1 (59/960)
Peripheral vascular disease 11.1 (107/960)
Recent myocardial infarctiona 24.8 (238/960)
Left ventricular function
Normal 77.3 (742/958)
Mild 12.5 (120/958)
Moderate 5.4 (52/958)
Severe 4.6 (44/958)
Risk scores
Additive EuroSCORE 4.0 ± 3.0 (954/960)
Logistic EuroSCORE 4.6 ± 5.6 (954/960)
Values are shown as mean ± SD (n) or% (n/N).
aOccurred in the last 3 months.
CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; 
PCI, percutaneous coronary intervention; SD, standard deviation.
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Patient population
The mean age of the population was 65.1 ± 11.0 years, and 73% were men (Table 1). 
Diabetes was present in 29% of patients, and 23% of patients had left ventricular 
dysfunction. The mean additive EuroSCORE was 4.0% ± 3.0%, and the logistic 
EuroSCORE was 4.6% ± 5.6%.
The majority of patients presented with stable or unstable CAD, or a recent non-
ST-segment elevation myocardial infarction (Table 2). Group 1 included 53 patients 
(5.5%) in whom the involvement of the coronary artery was not clear at presentation 
to the Heart Team, who had coronary artery spasm or malformation, or who had no 
Table 2. Disease-specific and anatomical characteristics at presentation to the Heart Team.
Characteristics Patients (n = 960)
Presentation
Asymptomatic or atypical symptoms 15.7 (151/960)
Stable angina 35.3 (339/960)
Unstable angina 23.5 (226/960)
NSTEMI 14.2 (137/960)
STEMI 3.2 (31/960)
Congestive heart failure 7.6 (73/960)
Out-of-hospital cardiac arrest 2.0 (20/960)
Coronary artery disease
Undefined or non-significant 5.5 (53/960)
De novo 86.5 (830/960)
Simple 69.4 (576/830)
1VD or 2VD—non-proximal LAD 77.4 (446/576)
1VD or 2VD—proximal LAD 22.6 (130/576)
Complex
3VD only
30.6 (254/830)
64.6 (164/254)
Left main, any 35.4 (90/254)
Left main, isolated or with 1VD 35.6 (32/90)
Left main, with 2VD or 3VD
Previous CABG
64.4 (58/90)
8.0 (77/960)
Bypass graft (SVG or IMA) 48.1 (37/77)
Native vessel 33.8 (26/77)
Both bypass graft and native vessel 18.2 (14/77)
SYNTAX score 23.2 ± 10.4 (156/254)
Low (0-22) 51.9 (81/156)
Intermediate (23-32) 29.5 (46/156)
High >_(33) 18.6 (29/156)
Values are shown as mean ± SD (n) or % (n/N). 1VD, single-vessel disease; 2VD, 2-vessel disease; 3VD, 
3-vessel disease; CABG, coronary artery bypass grafting; IMA, internal mammary artery; LAD, left 
anterior descending; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment 
elevation myocardial infarction; SD, standard deviation; SVG, saphenous vein graft.
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CAD at all (Fig. 1). Group 2 included 830 patients (86.5%) who presented with native 
vessel CAD. Group 3 included 77 patients (8%) with a history of CABG. Among the 
patients with native vessel CAD, the majority of patients presented with simple CAD 
either with or without involvement of the LAD artery (69.4%). The other 30.6% of the 
patients had complex CAD with a mean SYNTAX score of 23.2 ± 10.4.
Time intervals
Patients referred by the cardiologists from Erasmus MC were discussed at the 
meeting held the same day as the referral or the day thereafter and received 
treatment a median of 10 days (Q1– Q3 1–27) after discussion by the Heart Team.
For patients who were referred to the Heart Team from community hospitals, the 
Heart Team meeting took place a median of 2 days (Q1–Q3 1–4) after the referral 
(Fig. 2). It took a median of 16 days (Q1–Q3 4–27) from referral to treatment. In the 
subgroup of cases with simple CAD, it took a median of 16 days (Q1–Q3 4–26) from 
referral to treatment, whereas for complex CAD it took a median of 14 days (Q1–Q3 
5–35). Treatment was performed within 6 weeks of referral in 90.0% of the cases: 
93.2% for simple CAD and 80.2% for complex CAD. Treatment within 2 weeks of 
referral was performed in 48.0% of the cases: 46.5% for simple CAD and 51.4% for 
complex CAD. In only 27 of the 822 externally referred patients (3.3%), the time from 
referral to treatment took more than 3 months, which was explained by the need for 
further evaluation of another cardiac condition in 11 cases (1.3%), a requested delay 
by the patient in another 11 cases (1.3%) and another non-cardiac condition that 
required investigation or treatment before revascularization in 5 cases (0.6%).
Heart Team decisions
The Heart Team requested an additional investigation in more than one-third of the 
case discussions before deciding on a final treatment recommendation (Table 3). 
Invasive cardiac imaging was required in 29.2% of the cases. In 4.3% of the cases, 
it was necessary to perform non-invasive cardiac imaging to assess myocardial 
viability or concomitant valve disease.
The majority of patients in Group 1 received medical therapy. After further 
investigation, 18.8% underwent PCI and 3.7% had CABG (Fig. 3). Of the patients 
in Group 2 who presented with native 1VD or 2VD, PCI was the recommended 
treatment in 84.7% of patients without proximal LAD involvement and in 87.6% 
of patients with proximal LAD involvement, whereas CABG was recommended in 
only 2.6% and 6.1%, respectively. Patients with isolated LM disease or LM plus 1VD 
underwent PCI in 81.2% of cases and CABG in 15.6%. Patients with LM disease and 
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2VD or 3VD underwent PCI in 18.9% of cases and CABG in 70.6%. There was an 
equal split of 45.7% PCI and 45.7% CABG in patients with 3VD without LM disease, 
whereas 8.5% of patients received medical therapy. Patients in Group 3 with a 
previous CABG underwent PCI in 79.2% of cases and received medical therapy in 
19.4%, whereas only 1 redo CABG was performed.
Long-term survival
Twenty-six patients were lost to follow-up during a median time of 4.6 years (Q1–
Q3 4.2–5.0). The 5-year mortality rate of patients with simple native-vessel CAD 
was comparable for 1VD or 2VD with proximal LAD involvement (16.4%) and for 
1VD or 2VD without proximal LAD involvement (15.7%) (P = 0.70) (Fig. 4A). Patients 
with isolated LM or in combination with 1VD showed the lowest mortality rate 
(3.4%), whereas those patients with LM and additional 2VD or 3VD had the highest 
mortality rate (26.9%) after 5 years (Fig. 4B). Patients with 3VD without LM disease 
had a mortality rate of 17.1% after 5 years of follow-up.
Figure 1. Patient flowchart according to clinical presentation. aOne patient was lost to follow-
up. Additional investigation: clinical evaluation (comorbidity evaluation or other specialist opinion), 
non-invasive cardiac imaging (myocardial ischaemia test, dobutamine stress echocardiography, 
magnetic resonance imaging and multislice computed tomography) and invasive cardiac imaging 
(intravascular ultrasound, coronary angiography and coronary angiography with fractional flow 
reserve). CABG, coronary artery bypass grafting; CAD, coronary artery disease; PCI, percutaneous 
coronary intervention.
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Figure 2. Time from referral from community hospitals to the Heart Team discussion and 
treatment. Times represent referral by the community hospital to the Heart Team discussion (A); 
from the Heart Team discussion to final treatment (B); and from referral to final treatment including 
the discussion in the Heart Team meeting (C). The median of time in days and its corresponding 
interquartile range (Q1–Q3).
DISCUSSION
This study includes all of the steps of care of a large group of patients with CAD 
discussed by a real-world Heart Team. By analysing 1000 cases discussed by the 
Heart Team from referral to long-term survival, we found a structured Heart 
Team approach to be feasible and safe in formulating treatment strategies for 
patients with CAD. Heart Team discussions have not been widely implemented 
despite the well-established multidisciplinary approach in other specialties and 
the fact that the need for Heart Team decision making for CAD is emphasized to 
promote transparency in decision making, improve the exchange of knowledge, 
adhere to established guidelines and minimize physician-related bias (5–10). This 
study provides more evidence to support Heart Team decision making.
From a logistical standpoint, our Heart Team meetings are held early in the 
morning to avoid interference with other clinical obligations. This timing also 
allows the treatment recommendations to be performed during the day of the 
meeting, when necessary, limiting further treatment delays. According to the 
2014 European Society of Cardiology/European Association for Cardio-Thoracic 
Surgery (ESC/EACTS) guidelines on myocardial revascularization, PCI or CABG 
should be performed within 6 weeks after angiography for patients with simple 
CAD and within 2 weeks for patients with a high-risk anatomical configuration 
(3), based on adverse events that may occur in patients on the wait list for 
revascularization (11). In this study, revascularization was performed within 6 
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weeks after referral in the majority of patients, and within 2 weeks in 51.4% of 
cases with complex CAD. It is important to acknowledge that even with a Heart 
Team discussion, revascularization can be performed within the recommended 
time intervals and thus can be considered safe.
Table 3. Heart Team recommendations for additional investigations.
Additional investigation request Patients (n = 1000)
Any request 35.3 (353/1000)
Clinical evaluationa 2.4 (24/1000)
Non-invasive cardiac imaging 4.3 (43/1000)
Myocardial ischaemia testb 16.6 (7/43)
Dobutamine stress echocardiography 23.3 (10/43)
Magnetic resonance imaging 32.6 (14/43)
Multislice computed tomography 27.9 (12/43)
Invasive cardiac imaging 29.2 (292/1000)
Intravascular ultrasound 0.3 (1/292)
Coronary angiography 30.1 (88/292) 
Coronary angiography with fractional flow reserve 69.5 (203/292)
Values are shown as % (n/N).
a  Further clinical evaluation when the clinical status of a patient has changed or other non-cardiac 
comorbidities have been diagnosed during the interval between referral and the Heart Team meeting.
b Non-specific request.
In 353 of the cases (35.3%), the Heart Team requested additional diagnostic 
tests before deciding on a specific treatment recommendation. Due to their 
complexity, 40 cases (4%) were rediscussed before a decision could be reached. 
This means that Heart Team decision making can be further optimized by 
providing adequate information and imaging at the time of the meeting so that 
a decision can be reached immediately. Nevertheless, even after assessing the 
patient’s record, reviewing the cardiac images, and carefully considering the risks 
and benefits of revascularization, in 2.4% of cases, there was a need to clinically 
evaluate the patient. This critical look exemplifies how the multidisciplinary 
heart team approach promotes customized, patient-centred care. Furthermore, 
the Heart Team aims to increase agreement among surgeons and cardiologists, 
which enables a more consistent tailor-made final treatment recommendation 
and a bidirectional exchange of information and preferences between 
physicians, patients and their families. Indeed, numerous studies have shown 
that multidisciplinary teams in oncology changed the initial management plan 
because of new insights or newly clarified diagnostic information and improved 
patient satisfaction by providing a shared decisionmaking process (12).
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Figure 4. All-cause death after Heart Team proposed treatment for patients with native vessel 
CAD. (A) An analysis of patients with simple CAD; (B) an analysis of patients with complex CAD. 1VD, 
single-vessel disease; 2VD, 2-vessel disease; 3VD, 3-vessel disease; CAD, coronary artery disease; 
LAD, left anterior descending; LM, left main.
Other studies have explored different aspects of the Heart Team decision making. 
Denvir et al. (13) assessed variations in decisions to revascularize patients with CAD 
between specialists and found that there was a statistically significant poor agreement 
between cardiac clinical specialists in the choice of treatment offered to patients. 
An open discussion appeared to improve agreement by providing more evidence to 
support the Heart Team discussions and thereby improving the decision making. This 
finding has been demonstrated by Sanchez et al. (14), who found that the decision 
to revascularize, as provided by the Heart Team was appropriate according to the 
Appropriate Use Criteria in 99.3% of cases. Importantly, our data add to the existing 
literature on using a Heart Team by showing that the treatment recommendation 
of CABG, PCI or medical therapy as provided by the Heart Team was consistent with 
clinical guideline recommendations (3). Patients with simple native vessel CAD most 
often underwent PCI, whereas patients with more complex diseases increasingly 
underwent CABG. Only 1 patient who presented with angina after previous CABG 
underwent redo CABG; the remaining patients received either medical therapy 
or PCI, which is the recommended strategy in patients with atherosclerotic graft 
disease (3, 4). Several studies found that the Heart Team treatment suggestion was 
implemented in >90% of the cases (15, 16). In cases in which the Heart Team decision 
was not implemented, this was usually due to factors unknown at the time of the 
discussion (15, 16). However, some patients require urgent PCI while awaiting CABG, 
which may cause deviations from the Heart Team suggestion.
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Non-primary PCI without on-site surgical backup is controversial and may lead to 
physician-related bias. Success and failure in the care of patients, especially those 
with multivessel CAD, hinge on communication between surgeons and cardiologists. 
Therefore, clear protocols by national regulatory bodies on which patient should be 
discussed within a Heart Team are warranted. Patients who received revascularization 
without a documented Heart Team decision will only be covered legally if the 
procedure is performed according to national guidelines.
Our analysis provides novel insights into the real-world, long-term survival of 
patients treated according to the Heart Team decisions. In the SYNTAX trial, the 
5-year mortality rate in the randomized cohort of patients with LM or 3VD was 11.4% 
after CABG and 13.9% after PCI. Specifically, patients with 3VD had a mortality rate 
of 9.2% vs 14.6% after CABG and PCI, respectively (17), which is lower than the 17.1% 
mortality rate in our study. However, our real-world cohort also included patients 
who would otherwise not be randomized in the SYNTAX trial; indeed patients in the 
SYNTAX registries had a 5-year mortality rate of 12.6% (CABG Registry) and 30% (PCI 
Registry) (18), respectively. Thus survival of the entire SYNTAX cohort will be higher 
than that of the randomized cohort and more comparable to that of our analysis. 
Moreover, only patients with de novo CAD were included in the SYNTAX trial; 
whereas we included a large percentage of patients with a history of PCI, which may 
increase the risk of death during the follow-up period.
Limitations
This study is retrospective; therefore, several inherent limitations should be 
considered. For example, some information may not have been recorded in 
patient records; for example, information on SYNTAX scores was available for 
only 61.4% (n = 156) of patients with complex disease, so we could not evaluate 
the distribution of patients to different treatment strategies according to SYNTAX 
score tertiles. During the enrolment period of the current study, the calculation 
of the SYNTAX score was not ‘standard point of care’ in our hospital.
Moreover, data are available only on decisions made by the Heart Team, so we 
were unable to assess whether the treatment decisions suggested by the individual 
Heart Team members were changed during the Heart Team discussion. In 
addition, although we included 1000 case discussions, the complexity of disease 
was variable so the groups of patients with specific coronary complexities were 
too small to compare 5-year survival rates with different treatment strategies.
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CONCLUSIONS
The Heart Team approach is feasible and provides transparency for decision 
making. Decision making and treatment by the Heart Team followed within a short 
time after patient referral, suggesting that the Heart Team does not compromise 
maximum waiting times. However, the flow of patients can be further optimized 
if adequate information and imaging files are available at the time of the Heart 
Team meeting. The final treatment recommendation by the Heart Team was 
largely in accordance with clinical guidelines.
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SUPPLEMENTAL MATERIAL
Supplementary figure 1. Heart Team sheet cardiothoracic surgery.
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CAD, coronary artery disease; NYHA, New York Heart Association; ECG, electrocardiogram; 
FEV1, forced expiratory volume in 1 second; RR, Riva-Rocci (bloodpressure); VC, vital capacity; 
Hb, hemoglobine; Ht, hematocrit; Creat, creatinine (measure renal clearance); ESR, erythrocyte 
sedimentation rate; CRP, C-reactive Protein; WBC, white blood count; AST, aspartate 
aminotransferase (liver enzyme); ALT, alanine aminotransferase (liver enzyme); Tromb, 
trombocytes; Rh., rhesus factor; MI, myocardial infarction; AP, angina pectoris; COPD, chronic 
obstructive pulmonary disease; Ex. Art. Path, extra-arterial pathology; CVA, cerebrovascular 
accident, e.g. stroke; CABG, coronary artery bypass grafting; Surg Thor. Aorta, surgery to thoracic 
aorta; LAD, left anterior descending (coronary artery); Diag, diagonal arterial branch of LAD; 
IM, intermediary arterial branch; Cx, circumflex artery; MO, margo obtusis; PLCX, postero-
lateral branch derived from circumflex artery; RCA, right coronary artery; RDP, ramus 
descendens posterior; PLr, postero-lateral branch derived from right coronary artery; LIMA, left 
internal mammarian artery; RIMA, right internal mammarian artery; VCS, superior vena cava; 
VCI, inferior vena cava; RA, right atrium; AP, arteria pulmonalis; pulmonary artery; APS, arteria 
pulmonalis sinistra; left pulmonary artery APD, arteria pulmonalis dextra; right Pulmonary 
artery; LA, left atrium LV, left ventricle; AO, aorta; EF, ejection fraction; CO, cardiac output; 
CI, cardiax index; PVR, pulmonary vascular resistance. 
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ABSTRACT
BACKGROUND: Numerous randomised trials have compared coronary artery bypass 
grafting (CABG) with percutaneous coronary intervention (PCI) for patients with 
coronary artery disease. However, no studies have been powered to detect a difference 
in mortality between the revascularisation strategies.
METHODS: We did a systematic review up to July 19, 2017, to identify randomised 
clinical trials comparing CABG with PCI using stents. Eligible studies included patients 
with multivessel or left main coronary artery disease who did not present with acute 
myocardial infarction, did PCI with stents (bare-metal or drug-eluting), and had more 
than 1 year of follow-up for all-cause mortality. In a collaborative, pooled analysis of 
individual patient data from the identified trials, we estimated all-cause mortality up 
to 5 years using Kaplan-Meier analyses and compared PCI with CABG using a random-
effects Cox proportional-hazards model stratified by trial. Consistency of treatment 
effect was explored in subgroup analyses, with subgroups defined according to baseline 
clinical and anatomical characteristics.
FINDINGS: We included 11 randomised trials involving 11 518 patients selected by heart 
teams who were assigned to PCI (n=5753) or to CABG (n=5765). 976 patients died over 
a mean follow-up of 3.8 years (SD 1.4). Mean Synergy between PCI with Taxus and 
Cardiac Surgery (SYNTAX) score was 26.0 (SD 9.5), with 1798 (22.1%) of 8138 patients 
having a SYNTAX score of 33 or higher. 5 year all-cause mortality was 11.2% after PCI 
and 9.2% after CABG (hazard ratio (HR) 1.20, 95% CI 1.06–1.37; p=0.0038). 5 year all-
cause mortality was significantly different between the interventions in patients with 
multivessel disease (11.5% after PCI vs 8.9% after CABG; HR 1.28, 95% CI 1.09–1.49; 
p=0.0019), including in those with diabetes (15.5% vs 10.0%; 1.48, 1.19–1.84; p=0.0004), 
but not in those without diabetes (8.7% vs 8.0%; 1.08, 0.86–1.36; p=0.49). SYNTAX score 
had a significant effect on the difference between the interventions in multivessel 
disease. 5 year all-cause mortality was similar between the interventions in patients 
with left main disease (10.7% after PCI vs 10.5% after CABG; 1.07, 0.87–1.33; p=0.52), 
regardless of diabetes status and SYNTAX score.
INTERPRETATION: CABG had a mortality benefit over PCI in patients with multivessel 
disease, particularly those with diabetes and higher coronary complexity. No benefit for 
CABG over PCI was seen in patients with left main disease. Longer follow-up is needed 
to better define mortality differences between the revascularisation strategies.
105
Mortality after CABG versus PCI with stenting for CAD
6
INTRODUCTION
Numerous randomised trials (1–3) have compared coronary artery bypass grafting 
(CABG) with percutaneous coronary intervention (PCI) with balloon angioplasty, 
bare-metal stents, or drug-eluting stents for the treatment of multivessel or left main 
coronary artery disease. In 2009, Hlatky and colleagues1 reported the results of a 
pooled analysis of individual patient data from ten randomised trials involving 7812 
patients assigned to CABG or PCI with balloon angioplasty or bare-metal stents. In 
that study, 5 year mortality was 8.4% after CABG and 10.0% after PCI (p=0.12). More 
recent trials (4–10) comparing CABG with PCI with drug-eluting stents have found 
similar mortality for the revascularisation strategies. However, to date, no clinical 
trial has been sufficiently powered to detect a difference in all-cause mortality 
between CABG and PCI using stents.
To overcome this limitation, we did a pooled analysis of individual-patient data from 
randomised trials comparing CABG with PCI using stents to examine the comparative 
effects of these interventions on long-term all-cause mortality in all patients with 
coronary artery disease and separately in patients with multivessel or left main 
disease.
Research in context 
Evidence before this study
We searched MEDLINE, Embase, and the Cochrane Library up to July 19, 2017, to 
identify randomised clinical trials comparing coronary artery bypass grafting (CABG) 
with percutaneous coronary intervention (PCI) using stents. We used the search 
terms “coronary artery bypass grafting”, “percutaneous coronary intervention”, 
“stent”, and “random*”. Studies were included if the patients had multivessel or left 
main coronary artery disease and did not present with acute myocardial infarction, 
PCI was done with bare-metal or drug-eluting stents and not balloon angioplasty, and 
more than 1 years’ follow-up for all-cause mortality was available. We identified 12 
high-quality trials.
One trial found a survival benefit of CABG over PCI with bare-metal stents for 
multivessel disease at 6 years’ follow-up. Another trial found better survival at 5 
years’ follow-up with CABG than with PCI using first-generation drug-eluting stents 
in patients with multivessel disease and diabetes. However, these results have not 
been reproduced in other individual trials with 3–10 years’ follow-up, except in 
underpowered and hypothesis-generating subgroup analyses. Two pooled analyses of 
CABG versus PCI with balloon angioplasty or bare-metal stents for multivessel disease 
106
Chapter 6
found conflicting results, and what the survival differences are between CABG and 
PCI remains largely unclear.
Added value of this study
This study is the largest analysis of patients randomly assigned to PCI using 
stents or to CABG. To our knowledge, this study shows for the first time that 
all-cause mortality is significantly lower with CABG than with PCI in an overall 
randomised population of patients with multivessel or left main coronary artery 
disease. Additionally, the use of individual patient data allowed identification of 
important subgroups that have a survival benefit from CABG. These subgroups 
include patients with multivessel disease and diabetes and those with higher 
coronary lesion complexity (established with the Synergy between PCI with Taxus 
and Cardiac Surgery (SYNTAX) score). Patients with left main disease had similar 
survival with PCI and CABG, regardless of diabetes and SYNTAX score.
Implications of all the available evidence
Some patients have specific indications for PCI or CABG, such as coronary 
complexity too high for PCI or operative risk too high for CABG. In patients with 
estimated clinical equipoise, as determined by heart teams, consideration of disease 
type (multivessel or left main), coronary complexity, and diabetes status is crucial 
because these are important treatment effect modifiers of favourable mortality 
after CABG versus PCI and should affect decisions on coronary revascularisation in 
daily practice. However, longer follow-up of randomised trials is needed to better 
define mortality differences in overall patients and specific subgroups.
METHODS
Study selection and data collection
We searched MEDLINE, Embase, and the Cochrane Library up to July 19, 2017, 
using the search terms “coronary artery bypass grafting”, “percutaneous 
coronary intervention”, “stent”, and “random*”. Two researchers (SJH and MM) 
independently identified randomised trials comparing CABG with PCI in which 
patients had multivessel or left main coronary artery disease and did not present 
with acute myocardial infarction, PCI was done with stents (bare-metal or drug-
eluting) and not balloon angioplasty, and more than 1 year follow-up for all-cause 
mortality was available (appendix). Abstracts from meetings were not considered, 
nor were unpublished trials. Reference lists from potentially relevant articles 
were checked to ensure no studies were missed.
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We contacted the principal investigators of the eligible trials to obtain individual 
patient data for pooled analyses; data were provided in a standardised 
spreadsheet. Data were cross-checked against the publication of the primary 
endpoint and long-term follow-up publications. Several minor inconsistencies 
were resolved through consensus with trial principal investigators. Baseline and 
procedural characteristics of individual trials are presented in the appendix with 
information about missing data for certain characteristics.
We assessed the quality of individual trials using the Cochrane Collaboration’s 
tool for assessing risk of bias (11). Each trial was approved by its local medical 
ethics committee, and all patients provided written informed consent.
Outcomes and follow-up
To allow a consistent definition of follow-up among trials, the duration of 
follow-up was calculated from the day of the procedure. If patients died before 
the procedure, the time from randomisation to death was used to calculate the 
duration of follow-up.
All-cause mortality was the primary endpoint of this study, with analyses planned 
in all patients and separately in patients with multivessel disease or left main 
disease. The multivessel disease group consisted of patients with multivessel 
disease without left main disease, whereas the left main disease group consisted 
of patients with any left main disease, irrespective of the number of diseased 
vessels.
We also planned separate analyses for trials that used bare-metal stents, those that 
used drug-eluting stents, those that used first-generation drug-eluting stents, 
and those that used newer-generation drug-eluting stents. First-generation drug-
eluting stents released paclitaxel or sirolimus. Newer-generation drug-eluting 
stents released everolimus, zotarolimus, or biolimus. The VA CARDS trial(7) 
(Cooperative Studies Program study number 557) was excluded from the separate 
analyses of first-generation and newer-generation drug-eluting stents because a 
mixture of these stents was used.
We prespecified subgroups for analyses according to the baseline characteristics 
sex, age, body-mass index, hypertension, hypercholesterolaemia, diabetes, 
peripheral vascular disease, previous myocardial infarction, leftventricular 
ejection fraction, and core laboratory-assessed Synergy between PCI with Taxus 
and Cardiac Surgery (SYNTAX) score (as a measure of lesion complexity) (12). 
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Post-hoc subgroup analyses were done according to SYNTAX score tertiles in 
the groups of patients with or without diabetes. In all trials, a Clinical Events 
Committee adjudicated the events.
Statistical analysis
A team consisting of three epidemiologists and statisticians (MM, EB, and GP) 
did the statistical analyses. All analyses were done by intention to treat. Baseline, 
procedural, and outcome data for individual patients were pooled. Continuous 
variables are presented as mean (SD) and were compared with t tests; discrete 
data are presented as frequencies and were compared with χ² tests.
We pooled data from all trials to provide unadjusted Kaplan-Meier estimates 
of all-cause mortality at 5 years follow-up and for landmark analyses at 30 days 
and between 31 days and 5 years. Subgroup analyses were done with follow-up 
data at 5 years only. PCI and CABG were compared with random-effects Cox 
proportionalhazards models stratified by trial and with inclusion of a γ frailty 
term to account for heterogeneity between trials. Trial heterogeneity is captured 
in random-intercept frailty terms, which quantify trial-specific deviation from 
the average hazard ratio (HR). Frailties are unobserved factors, distributed as 
γ random variables with a mean of 1 and variance (θ). Hence, the variance of 
the frailty terms represents heterogeneity in baseline risk between trials. The 
significance of the variance parameter was assessed with the likelihood ratio test. 
The proportional hazards assumption in the Cox model for the overall group was 
assessed by visual inspection of the scaled Schoenfeld residuals over a Kaplan-
Meier transform of time, as well as with the corresponding test for the correlation 
of the Schoenfeld residuals with time, and was not violated (p=0.12). Nevertheless, 
visual inspection of the KaplanMeier curves suggested a time-dependent variance 
in the HR of PCI versus CABG and, therefore, models that allowed for a time-
varying HR were also done. For these models, we assumed a single cutoff point, 
allowing the HR to have different values before and after the cutoff. The cutoff 
was selected on the basis of visual inspection of the scaled Schoenfeld residuals. 
Subgroup analyses according to baseline clinical, procedural, and anatomical 
characteristics were also done with the Cox models.
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Table 1: Baseline, procedural, and discharge data of randomised cohorts.
PCI (n=5753) CABG (n=5765) p value
Age (years) 63·6 (9·8; 5753) 63·7 (9·9; 5765) p=0·72
Sex
Female 23·9% (1373/5753) 23·8% (1371/5765) p=0·91
Male 76·1% (4380/5753) 76·2% (4394/5765) p=0·91
Body-mass index >30 kg/m² 28·1% (1548/5506) 28·3% (1558/5511) p=0·82
Current smoker 22·3% (1274/5701) 22·3% (1273/5703) p=0·97
Diabetes 38·5% (2215/5753) 37·7% (2171/5765) p=0·35
Insulin treated 12·9% (545/4234) 11·9% (504/4245) p=0·16
Hypertension 67·6% (3880/5739) 68·1% (3913/5748) p=0·59
Hypercholesterolaemia 69·5% (3982/5726) 67·3% (3862/5735) p=0·0112
Peripheral vascular disease 8·2% (424/5158) 8·5% (440/5164) p=0·58
Carotid artery disease 7·8% (161/2072) 8·1% (168/2074) p=0·69
Previous TIA or CVA 5·4% (218/4052) 6·2% (253/4054) p=0·098
Previous myocardial infarction 28·0% (1438/5138) 27·5% (1417/5156) p=0·57
Left-ventricular ejection fraction
Moderate (30–49%) 15·2% (807/5303) 14·3% (779/5430) p=0·20
Poor (<30%) 0·9% (49/5303) 1·0 (54/5430) p=0·71
Unstable angina pectoris 34·6% (1786/5158) 34·2% (1767/5160) p=0·68
Three-vessel disease* 58·6% (2460/4201) 61·8% (2594/4197) p=0·063
Left main disease 38·8% (2233/5753) 38·9% (2245/5765) p=0·89
SYNTAX score 26·0 (9·3; 4081) 26·0 (9·8; 4057) p=0·91
0–22 37·6% (1533/4081) 39·1% (1585/4057) p=0·16
23–32 41·1% (1677/4081) 38·1% (1545/4057) p=0·0053
≥33 21·3% (871/4081) 22·8% (927/4057) p=0·10
Type of stent used in PCI†
Bare-metal stent 26·6% (1490/5610) .. ..
Drug-eluting stent 73·4% (4120/5610) .. ..
First-generation 39·2% (2199/5610) .. ..
Newer-generation 34·2% (1920/5610) .. ..
Number of stents used in PCI 3·1 (2·0; 4935) .. ..
CABG procedure
Left internal mammary artery .. 96·2% (4574/4753) ..
Bilateral internal mammary artery .. 18·7% (771/4122) ..
Off-pump .. 27·5% (1085/3945) ..
Medication at discharge
Aspirin 97·3% (4487/4612) 95·5% (3814/3994) p<0·0001
Thienopyridine 96·7% (4479/4630) 45·1% (1815/4026) p<0·0001
Dual antiplatelet therapy 95·1% (4384/4612) 44·0% (1759/3994) p<0·0001
Statin 88·1% (3052/3464) 84·0% (2843/3384) p<0·0001
β blocker 79·1% (2741/3464) 76·2% (2557/3356) p=0·0040
ACE inhibitor or ARB 63·7% (2205/3464) 46·9% (1588/3383) p<0·0001
Calcium-channel blocker 27·7% (959/3463) 21·8% (736/3383) p<0·0001
Data are mean (SD; n) or % (n/N). PCI, percutaneous coronary intervention; CABG, coronary artery bypass 
grafting; TIA, transient ischaemic attack; CVA, cerebrovascular attack; SYNTAX, Synergy between PCI with 
Taxus and Cardiac Surgery; ACE, angiotensin-converting enzyme;  ARB, angiotensin II receptor blocker. *Of 
the group of patients with multivessel disease. †Data are only for patients who underwent PCI; the type of 
drug-eluting stent used was not available for one patient enrolled in the VA CARDS trial (7).
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A two-sided p value of less than 0.05 was considered to indicate statistical 
significance; we did not adjust for multiplicity. All statistical analyses were done 
with SPSS software, version 21, or R software, version 3.2.4. Reporting of this 
individual patient-data, pooled analysis concurs with specific PRISMA guidelines 
(13). This study is not registered and no protocol has been published.
Role of the funding source
This study was done without funding, although individual trials were sponsored. 
The decision to submit the manuscript for publication was made by consensus 
among the principal investigators of the individual trials. Sponsors of the 
individual trials were involved in data collection in the trials, but were not 
involved in data analyses, data interpretation, or drafting of this manuscript.
RESULTS
We identified 19 relevant trials in the literature search, of which seven were 
excluded because patients did not have multivessel or left main disease (n=4), 
only 54% of PCI procedures were done with a stent (n=1), or follow-up was only 
available up to 1 year (n=2; appendix). The principal investigators of the remaining 
12 trials (4–10,14–18) were contacted to obtain individual patient data for a pooled 
analysis; one trial (14) involving 105 patients was unable to provide data. All trials 
were considered to be of high quality according to criteria, despite being unable 
to mask investigators and patients to treatment allocation (appendix).
In the 11 trials that provided data, 11 518 patients selected by heart teams were 
randomly assigned to CABG (n=5765) or to PCI (n=5753). PCI was done with bare-
metal stents in 1490 patients in four trials (n=3051), with first-generation drug-
eluting stents in 2199 patients in four trials (n=4498), and with newer-generation 
drugeluting stents in 1920 patients in three trials (n=3969; table 1). CABG was 
done with a left internal mammary artery in 4574 patients in nine trials (n=4753), 
with a bilateral internal mammary artery in 771 patients in seven trials (n=4122), 
and off-pump in 1085 patients in seven trials (n=3945). SYNTAX scores were 
available from six trials and for 8138 patients (CABG: n=4057; PCI: n=4081). The 
mean SYNTAX score was 26.0 (SD 9.5), with 1798 (22.1%) patients having a SYNTAX 
score of 33 or higher. Baseline, procedural, and discharge data for the patients 
are shown in table 1, and data for each trial and treatment crossovers are shown 
in the appendix. 976 patients died during a mean follow-up of 3.8 years (SD 1.4). 
5 year all-cause mortality was 11.2% (539 events) after PCI and 9.2% (437 events) 
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after CABG (HR 1.20, 95% CI 1.06–1.37; p=0.0038; figure 1, table 2). At 30 days’ follow-
up, all-cause mortality was 1.3% (76 events) after PCI and 1.4% (78 events) after CABG 
(0.97, 0.71–1.33; p=0.84). Between 31 days’ and 5 years’ follow-up, allcause mortality 
was 10.0% (463 events) after PCI and 8.0% (359 events) after CABG (1.26, 1.09–1.44; 
p=0.0009). A time-dependent model showed that the risk of mortality was similar 
for PCI and CABG during the first year of follow-up (0∙97, 0∙80–1∙19; p=0.80), but in 
favour of CABG beyond 1 year (1.39, 1.17–1.62; p<0.0001; appendix). The estimate of 
the frailty parameter for heterogeneity was significant (θ=0.39, p<0.0001).
Patients in trials in which drug-eluting stents were used were older, had more 
comorbidities, and were more likely to have diabetes, left main disease, and 
three-vessel disease than patients in trials in which bare-metal stents were used 
(table 3). 5 year all-cause mortality was 8.7% (131 events) after PCI and 8.2% (125 
events) after CABG (HR 1.05, 95% CI 0.82–1.34; p=0.72) in trials that did PCI with 
bare-metal stents (including 3051 patients), and 12.4% (408 events) after PCI and 
10.0% (312 events) after CABG (1.27, 1.09–1.47; p=0.0017) in trials that did PCI with 
drug-eluting stents (including 8467 patients). The type of stent used (bare-metal 
vs drug-eluting) did not interact with the treatment effect (pinteraction=0.53).
Although there were significant differences in clinical and anatomical 
characteristics between the trials using first-generation drug-eluting stents and 
those using newergeneration drug-eluting stents (table 3), the difference in 
5 year mortality between PCI and CABG was consistent when analysing the 
4300 patients in the trials using firstgeneration drug-eluting stents (13.2% 
(254 events) after PCI vs 11.1% (201 events) after CABG; HR 1.21, 95% CI 1.01–1.46; 
p=0.0415) and the 3969 patients in the trials using newer-generation drug-eluting 
stents (10.3% (136 events) after PCI vs 7.9% (106 events) after CABG; 1.27, 0.98–1.64; 
p=0.0658; pinteraction=0.78).
In subgroup analyses, diabetes was the only baseline characteristic with a 
significant treatment interaction (pinteraction=0.0077). In patients with diabetes, 
PCI was associated with higher 5 year all-cause mortality than was CABG (15.7% 
(278 events) vs 10.7% (185 events); HR 1.44, 95% CI 1.20–1.74; p=0.0001), whereas 
mortality did not differ between the interventions in patients without diabetes 
(8.7% (261 events) after PCI vs 8.4% (252 events) after CABG; 1.02, 0.86–1.21; p=0.81; 
table 2, figures 2, 3). Although the interaction was not significant (pinteraction=0.21), 
the mortality benefit of CABG over PCI tended to increase with increasing 
SYNTAX scores (table 2). A similar trend was found in subgroups of patients with 
or without diabetes (appendix).
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Figure 2. Mortality after CABG versus after PCI during 5 years’ follow-up, by subgroup
Kaplan-Meier estimates are from the overall pooled patient population. PCI, percutaneous coronary 
intervention; CABG, coronary artery bypass grafting; HR, hazard ratio; SYNTAX, Synergy between PCI 
with Taxus and Cardiac Surgery.
644 of 7040 patients with multivessel disease assigned to PCI (n=3520) or to 
CABG (n=3520) died during a mean follow-up of 4.1 years (SD 1.4). 5 year all-cause 
mortality in patients with multivessel disease was higher after PCI than after 
CABG (11.5% (365 events) vs 8.9% (279 events); HR 1.28, 95% CI 1.09–1.49; p=0.0019; 
figure 3, table 2). As observed for the overall patient cohort, the mortality 
benefit of CABG over PCI in patients with multivessel disease increased with 
duration of follow-up in time-dependent models (appendix). 5 year all-cause 
mortality was 15.5% (207 events) after PCI versus 10.0% (134 events) after CABG 
in the subgroup of patients with multivessel disease who had diabetes (HR 1.48, 
95% CI 1.19–1.84; p=0.00037), and 8.7% (158 events) after PCI versus 8.0% (145 
events) after CABG in the subgroup of those patients without diabetes (1.08, 
0.86–1.36; p=0.49; pinteraction=0.0453; table 2). The mortality benefit of CABG 
over PCI increased with increasing SYNTAX scores in patients with multivessel 
disease (table 2).
322 of 4478 patients with left main disease assigned to PCI (n=2233) or to CABG 
(n=2245) died during a mean follow-up of 3.4 years (SD 1.4). 5 year all-cause 
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mortality for patients with left main disease was 10.7% (174 events) after PCI and 
10.5% (158 events) after CABG (HR 1.07, 95% CI 0.87–1.33; p=0.52; figure 3, table 2). 
By contrast with the overall cohort and multivessel disease subgroup, a benefit 
for CABG over PCI was not seen with longer follow-up in time-dependent models 
(appendix). Diabetes status did not interact with the treatment effect in patients 
with left main disease (pinteraction=0.13). 5 year all-cause mortality was 16.5% (71 events) 
after PCI versus 13.4% (51 events) after CABG (HR 1.34, 95% CI 0.93–1.91; p=0.11) in 
the subgroup of patients with left main disease who had diabetes, and 8.8% (103 
events) after PCI versus 9.6% (107 events) after CABG (0.94, 0.72–1.23; p=0.65) in 
the subgroup of those patients without diabetes (table 2). Subgroup analyses 
according to SYNTAX score in patients with left main disease showed that mortality 
from PCI and CABG did not differ according to score (table 2).
DISCUSSION
This collaborative analysis of individual patient data from 11 randomised trials is 
the first large-scale study to compare CABG with PCI with stents. We found that 5 
year all-cause mortality was higher after PCI than after CABG in 11 518 patients. 
In subgroup analyses, CABG only had a mortality benefit over PCI in patients 
with multivessel disease and diabetes; no difference was seen in patients with 
multivessel disease without diabetes, nor in patients with left main disease (with 
or without diabetes). Coronary lesion complexity, assessed with the SYNTAX 
score, was an important effect modifier in patients with multivessel disease, but 
did not appear to modify treatment effect in those with left main disease.
The relative benefits of CABG versus PCI with stents in terms of outcomes are 
highly debated, particularly each time stent design is enhanced. Improvements in 
stent design have led to inclusion of higher-risk patients with more complex disease, 
such as three-vessel or left main disease, in randomised trials. This higher-risk profile 
is also reflected in our data, wherein 5 year allcause mortality in both the CABG and 
PCI cohorts was higher in more recent trials with drug-eluting stents than in earlier 
trials with bare-metal stents, but a larger relative benefit of CABG over PCI was most 
likely due to more complex coronary artery disease.
In all of the included trials, both an interventional cardiologist and a cardiac 
surgeon had to assume clinical equipoise between PCI and CABG for patients to 
be randomised. Some patients were not eligible for inclusion in the selected trials 
because of having coronary lesion complexity too severe to be treated with PCI 
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or operative risk deemed too high for CABG (19). The results of this analysis are 
not generalisable to the entire population of patients with coronary artery disease 
that require revascularisation. Therefore, heart team decision making is crucial to 
recommend the best revascularisation strategy for an individual patient (20).
The mortality benefit of CABG over PCI in the overall group was retained over 
a variety of patient baseline characteristics. However, the presence of diabetes 
was an important modifier, as shown in previous analyses.1 The benefit of CABG 
in patients with diabetes might be attributed to more effective revascularisation 
of diffuse, complex coronary disease. This hypothesis is consistent with the 
findings of the subgroup analysis according to SYNTAX score. In the total cohort, 
a step-wise increase in the difference between CABG and PCI was observed with 
increasing SYNTAX scores. Other studies (21) have also identified sex as an effect 
modifier, but we did not find a significant treatment-by-sex interaction for 5 
year mortality. Patients with multivessel disease had lower mortality with CABG 
than with PCI, consistent with the SYNTAX trial that compared CABG with PCI 
using first-generation drug-eluting stents (22,23). The BEST trial (8), in which 
secondgeneration everolimus-eluting stents were used to treat multivessel 
disease, also found that CABG was associated with a lower incidence of major 
adverse cardiac or cerebrovascular events, driven by a reduced incidence of 
myocardial infarction and repeat revascularisation. Large real-world registries 
have applied propensity score matching to compare CABG with PCI using drug-
eluting stents for multivessel disease to find differences in survival with larger sample 
sizes (24,25). The ASCERT study (25), the largest of such analyses, reported an adjusted 
4 year mortality of 16.4% for CABG and 20.8% for PCI with first-generation drug-
eluting stents in a cohort of patients aged 65 years or older; mortality was consistent 
across multiple subgroups. Notably, the survival curves of CABG and PCI in this study 
are similar to those of the ASCERT study: PCI shows a benefit within the first year of 
followup, but a larger benefit is seen with CABG than with PCI with longer follow-up. 
We showed that this reversal of risk resulted in a benefit for CABG over PCI at a mean 
follow-up of 4.1 years, which might become larger with longer follow-up given that 
the HR favoured CABG at later follow-up in time-varying models.
In the SYNTAX trial (26), 5 year mortality was similar for CABG and PCI with paclitaxel-
eluting, first-generation drug-eluting stents in patients with left main disease. Two 
major trials (9,10) have since focused on finding the optimal revascularisation strategy 
for left main disease and have reported conflicting outcomes of CABG versus PCI. The 
EXCEL trial (10) reported that PCI was non-inferior to CABG after 3 years, whereas 
the NOBLE trial (9) did not show noninferiority for PCI versus CABG at 5 years. The 
118
Chapter 6
differences in timing and composition of the primary endpoints make comparing 
these trials difficult and presumably explain the apparent difference in results. 3 year 
individual endpoints in the NOBLE trial were later confirmed to be similar to those in 
the EXCEL trial (27). In our pooled analysis of data for patients with left main disease 
from four different trials, mortality was similar after CABG and PCI at 5 years’ follow-
up. Unlike for patients with multivessel disease, the similarity in mortality in patients 
with left main disease was consistent in a subgroup analysis according to diabetes 
status, although this difference might be due to the smaller sample size in the diabetic 
subgroup of patients with left main disease. Coronary complexity did not affect 
mortality in patients with left main disease, although patients with a high SYNTAX 
score were relatively under-represented because of specific inclusion criteria (eg, 
in the EXCEL trial) and a preference of heart teams for CABG (19). Therefore, the 
degree of complexity should still be considered when proposing a specific treatment 
for individual patients with left main disease. Patients with a complex left main 
lesion and three-vessel disease with a high SYNTAX score might still benefit from 
CABG in terms of mortality, as well as incidence of myocardial infarction and repeat 
revascularisation, whereas patients with a non-complex lesion and one-vessel or 
two-vessel disease might be excellent candidates for PCI. Clinical guidelines have not 
been revised since the release of data from the EXCEL and NOBLE trials. Based on 
existing data of similar mortality with the two interventions, the indication for PCI 
with contemporary drug-eluting stents might be broadened to patients with more 
complex left main disease (eg, intermediate SYNTAX scores). However, given that only 
978 patients with left main disease in our cohort had high SYNTAX scores, additional 
data are required before PCI can be routinely recommended in patients with complex 
left main disease. Longer follow-up is essential to better define differences in survival 
between CABG and PCI, because landmark analyses from the EXCEL trial (10) showed 
that the risk of mortality after CABG and PCI was different according to follow-up 
duration and might show a benefit for CABG with longer follow-up.
The main strength of this study is that we were able to identify clinically relevant 
differences in all-cause mortality between CABG and PCI because of collaboration 
with the principal investigators of 11 high-quality randomised trials. This 
collaboration allowed data to be pooled to provide sufficient power to examine 
an outcome that occurs reasonably infrequently. Indeed, all-cause mortality is 
considered to be the most clinically important and least biased endpoint, which 
is another strength of this analysis. Access to individual patient data facilitated 
analysis of outcomes in important subgroups and construction of Kaplan-Meier 
curves so that temporal associations between the interventions and mortality 
could be examined.
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Nevertheless, this study has several limitations. First, all the included trials 
assumed clinical equipoise between CABG and PCI. These trials had specific 
inclusion and exclusion criteria, and many patients were excluded because CABG 
or PCI was thought to be the preferred revascularisation strategy based on the 
age, risk profile, or coronary complexity of the individual (19). These criteria and 
the selection of patients resulted in only 22.1% of patients having a SYNTAX score 
of 33 or higher. Second, the inclusion and exclusion criteria led to significant 
heterogeneity in the baseline characteristics of patients from different trials, 
as shown by our assessment of frailty. Third, besides mortality, other outcomes 
that affect morbidity and quality of life, such as myocardial infarction, stroke, 
and repeat revascularisation, are important for the patient and should be 
considered by heart teams when deciding on the best revascularisation option 
for each patient. In an era of exponentially growing health-care costs, with a 
need to reduce expenses, the cost-effectiveness of PCI and CABG should also 
be evaluated. Fourth, the mean patient age was about 64 years, and the mean 
follow-up was 3.8 years. In view of the reasonably long life expectancy of patients 
with coronary artery disease, this follow-up is still too short to establish the 
full effect of the revascularisation method on survival, particularly considering 
the diverging or converging Kaplan-Meier curves in specific subgroups. Fifth, 
definitions and reporting of patient characteristics might have slightly differed 
between trials, which could have affected the results of the subgroup analyses and 
meant that we were unable to do a subgroup analysis according to renal function. 
Sixth, we could not include data from the LE MANS trial (14), although it is very 
unlikely that inclusion of these 105 patients with left main disease would have 
substantially altered the results, and thus the outcomes of this study are robust 
with respect to the available evidence.
CONCLUSION
In conclusion, we showed that 5 year mortality was significantly lower after CABG 
than after PCI. In particular, the benefit of CABG over PCI was shown in patients 
with multivessel disease and diabetes, but not in patients with multivessel disease 
without diabetes. Nor was there a benefit for CABG or PCI in patients with left main 
disease. Consideration of coronary lesion complexity is important when choosing the 
appropriate revascularisation strategy. Longer follow-up is needed to better define 
mortality differences between the interventions.
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SUPPLEMENTAL MATERIAL
APPENDIX 1. STUDY SELECTION FLOW-CHART.
1  
APPENDICES 
APPENDIX 1. Study selection flow-chart
Included trials (n=11) - ERACI II (n=450) - ARTS (n=1205) - MASS-II (n=408) - SoS (n=988) - SYNTAX (n=1800) - PRECOMBAT (n=600) - FREEDOM (n=1900) - VA CARDS (n=198) - BEST (n=880) - NOBLE (n=1184) - EXCEL (n=1905)  
Search on July 19, 2017, using keywords “coronary 
artery bypass”, “percutaneous coronary intervention”, 
“stent”, and “random*”  
MEDLINE 
(n=823) Cochrane (n=315) EMBASE (n=709) 
Investigators 
contacted (n=12 trials) 
Excluded trials (n=7) - Non-LM SVD: SIMA trial1, Diegeler et al3, Thiele et al4, Drenth et al5, and Hong et al6 - No 100% stent use: AWESOME trial7 - Only 1-year follow-up: Boudriot et al8, and CARDia trial9  
Excluded trial (n=1) - Unable to provide data: LE MANS trial2 
19 trials 
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APPENDIX 4. INFORMATION ON RANDOMIZATION AND 
ACTUAL TREATMENTS PERFORMED.
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APPENDIX 5. TIME-DEPENDENT MODELS OF PCI VERSUS CABG.
Patient group Time interval
First hazard Second hazard
Frailty term 
(γ)
P for 
heterogeneity
HR 
(95% CI)
Time interval
HR
 (95% CI)
Overall All 0-365 days 0∙97 (0∙80- 1∙19) 365-1825 days 1∙38 (1∙17- 1∙62) 0∙39 <0∙0001
Diabetes 0-280 days 1∙05 (0∙78- 1∙42) 280-1825 days 1∙76 (1∙38- 2∙24) 0∙11 <0∙0001
No diabetes 0-280 days 0∙84 (0∙62-1∙15) 280-1825 days 1∙12 (0∙90-1∙37) 0∙0880 <0∙0001
SYNTAX score 0-22 0-470 days 0∙63 (0∙41-0∙99) 470-1825 days 1∙40 (0∙97-2∙01) 0∙0454 0∙0094
SYNTAX score 23-32 0-470 days 1∙03 (0∙72-1∙46) 280-1825 days 1∙36 (0∙99-1.87) 0∙0657 0∙0031
SYNTAX score ≥33 0-470 days 1∙83 (1∙18-2∙82) 280-1825 days 1∙34 (0∙93-1∙95) 0∙0191 0∙0602
Bare-metal stent 0-730 days 0∙90 (0∙64-1∙27) 730-1825 days 1∙22 (0∙86-1∙73) 0∙16 <0∙0001
Drug-eluting stent 0-500 days 1∙08 (0∙87-1∙34) 500-1825 days 1∙45 (1∙18-1∙77) 0∙36 <0∙0001
First- generation drug-eluting stent 0-730 days 1∙12 (0∙87-1∙45) 730-1825 days 1∙31 (1∙01-1∙73) 0∙23 <0∙0001
Newer- generation drug-eluting stent 0-180 days 0∙68 (0∙43-1∙10) 180-1825 days 1∙65 (1∙21-2∙25) 0∙13 0∙0020
MVD All 0-280 days 0∙99 (0∙76-1∙29) 280-1825 days 1∙46 (1∙20-1∙77) 0∙40 <0∙0001
Diabetes 0-280 days 1∙11 (0∙78-1∙58) 280-1825 days 1∙77 (1∙34-2∙34) 0∙16 <0∙0001
No diabetes 0-370 days 0∙94 (0∙64-1∙40) 370-1825 days 1∙16 (0∙88-1∙53) 0∙090 <0∙0001
SYNTAX score 0-22 0-600 days 0∙65 (0∙37-1∙14) 600-1825 days 1∙78 (1∙05-3∙01) 0∙0935 0∙0140
SYNTAX score 23-32 0-600 days 1∙43 (0∙91-2∙24) 600-1825 days 1∙60 (1∙00-2∙55) 0∙0720 0∙0065
SYNTAX score ≥33 0-600 days 1∙72 (0∙97-3∙04) 600-1825 days 1∙70 (0∙95-3∙01) 0∙0252 0∙0505
LM All 0-730 days 1∙09 (0∙82-1∙44) 730-1825 days 1∙06 (0∙76-1∙48) 0∙0845 <0∙0001
Diabetes 0-730 days 1∙22 (0∙79-1∙86) 730-1825 days 1∙70 (0∙86-3∙35) 0∙0543 0∙0172
No diabetes 0-730 days 0∙98 (0∙67-1∙43) 730-1825 days 0∙90 (0∙61-1∙32) 0∙0604 0∙0027
SYNTAX score 0-22 0-570 days 0∙68 (0∙37-1∙25) 570-1825 days 1∙12 (0∙64-1∙94) <0∙0001 0∙0001
SYNTAX score 23-32 0-570 days 0∙79 (0∙50-1∙25) 570-1825 days 1∙13 (0∙70-1∙90) 0∙0626 0∙0093
SYNTAX score ≥33 0-570  days 1∙70 (0∙96-3∙02) 570-1825 days 1∙16 (0∙67-1∙99) 0∙0222 0∙0647
DM SYNTAX score 0-22 0-730 days 0∙60 (0∙36-0∙99) 730-1825 days 2∙70 (1∙40-5∙21) <0∙0001 0∙0001
SYNTAX score 23-32 0-730 days 1∙30 (0∙90-1∙89) 730-1825 days 1∙35 (0∙78-2∙34) 0∙0159 0∙0713
SYNTAX score ≥33 0-730 days 1∙78 (1∙06-2∙97) 730-1825 days 1∙75 (0∙92-3∙34) <0∙0001 0∙0001
NO DM SYNTAX score 0-22 0-730 days 0∙91 (0∙52-1∙59) 730-1825 days 0∙99 (0∙55- 1∙79) <0∙0001 0∙0193
SYNTAX score 23-32 0-730 days 0∙90 (0∙54-1∙48) 730-1825 days 1∙19 (0∙70-2∙03) 0∙0807 0∙0096
SYNTAX score ≥33 0-730 days 1∙80 (1∙00-3∙23) 730-1825 days 1∙00 (0∙58-1∙73) 0∙0089 0∙0884
Results of time-dependent models provide a hazard ratio for a first time interval and a second interval with the 
duration of this interval being dependent on when the hazard changes, which can be different according to 
the patient cohort, depending on the visual inspection of the Schoenfeld residuals for that particular analysis. 
CI, confidence interval; DM, diabetes mellitus; HR, hazard ratio.
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APPENDIX 6. FIVE-YEAR OUTCOMES WITHIN GROUPS WITH AND 
WITHOUT DIABETES ACCORDING TO SYNTAX SCORE TERTILES.
Diabetes No diabetes
PCI 
(n=1819)
CABG 
(n=1782)
HR (95% CI)
P-value
P for 
interaction
PCI 
(n=2262)
CABG 
(n=2275)
HR (95% CI)
P-value
P for 
interaction
SYNTAX score 0-22 13·0% 
(58/622)
9·8% 
(53/655)
1·09 (0·75-1·58)
P=0·66
Pint=0·25 6·6% 
(47/911)
7·0% 
(47/930)
0·95 (0·63-1·42)
P=0·80
Pint=0·66
SYNTAX score 23-32 15·1% 
(101/814)
12·5% 
(67/723)
1·32 (0·97-1·79)
P=0·0817
9·9% 
(62/863)
9·4% 
(55/822)
1·03 (0·71-1·48)
P=0·88
SYNTAX score ≥33 20·0% 
(63/383)
12·3% 
(38/404)
1·77 (1·18-2·64)
P=0·0056
13·6% 
(54/488)
11·1% 
(45/523)
1·32 (0·89-1·96)
P=0·16
Kaplan-Meier estimates are from the overall pooled patient population. Hazard ratios (HRs) with 
confidence intervals (CIs) are derived from Cox proportional hazards random-effects models stratified 
by trial.
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ABSTRACT
BACKGROUND: There are no data available on specific causes of death from 
randomized trials that have compared coronary artery bypass grafting (CABG) 
with percutaneous coronary intervention (PCI).
OBJECTIVES: The purpose of this study was to investigate specific causes of death, 
and its predictors, after revascularization for complex coronary disease in patients.
METHODS: An independent Clinical Events Committeeconsisting of expert 
physicians who were blinded tothe study treatment subclassified causes of death 
as cardiovascular (cardiac and vascular), noncardiovascular, or undetermined 
according to the trial protocol. Cardiac deaths were classified as sudden cardiac, 
related to myocardial infarction (MI), and other cardiac deaths.
RESULTS: In the randomized cohort, there were 97 deaths after CABG and 123 
deaths after PCI during a 5-year follow-up. After CABG, 49.4% of deaths were 
cardiovascular, with the greatest cause being heart failure, arrhythmia, or other 
causes (24.6%), whereas after PCI, the majority of deaths were cardiovascular 
(67.5%) and as a result of MI (29.3%). The cumulative incidence rates of all-cause 
death were not significantly different between CABG and PCI (11.4% vs. 13.9%, 
respectively; p = 0.10), whereas there were significant differences in terms of 
cardiovascular (5.8% vs. 9.6%, respectively; p = 0.008) and cardiac death (5.3% 
vs. 9.0%, respectively; p = 0.003), which were caused primarily by a reduction 
in MI-related death with CABG compared with PCI (0.4% vs. 4.1%, respectively; 
p <0.0001). Treatment with PCI versus CABG was an independent predictor of 
cardiac death (hazard ratio: 1.55; 95% confidence interval: 1.09 to 2.33; p = 0.045). 
The difference in MI-related death was seen largely in patients with diabetes, 
3-vessel disease, or high SYNTAX (TAXUS Drug-Eluting Stent Versus Coronary 
Artery Bypass Surgery for the Treatment of Narrowed Arteries) trial scores.
CONCLUSIONS: During a 5-year follow-up, CABG in comparison with PCI was 
associated with a significantly reduced rate of MI-related death, which was the 
leading cause of death after PCI. Treatments following PCI should target reducing 
post-revascularization spontaneous MI. Furthermore, secondary preventive 
medication remains essential in reducing events post-revascularization. 
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INTRODUCTION
Coronary artery bypass grafting (CABG) and percutaneous coronary intervention 
(PCI) are both used for myocardial revasculariza-tion in patients with complex 
coronary artery disease (CAD) with an indication for revascularization (1). A 
large number of studies have reported or compared outcomes of CABG and 
PCI as optimum treatment strategies (2), but data are limited on the causes, 
circumstances, and the mechanisms of death after these procedures.
Observational studies have reported causes of death after PCI and CABG (3–5), but 
these results are difficult to interpret because the cause of death may not always 
be clear in retrospect. Therefore, data from randomized trials in which a Clinical 
Events Committee (CEC) adjudicates deaths provide more valuable information. 
Two randomized clinical trials that compared CABG with medical therapy have 
shown that CABG was particularly effective in reducing rates of sudden cardiac 
death (5,6), but no comparisons between PCI and CABG on the specific causes of 
death are available from randomized trials.
Assessment of the cause of death in contemporary practice should help to 
target potential underlying mechanisms of death and further develop effective 
interventions to improve survival after myocardial revascularization. The goal of 
the present study was to investigate the specific cause of death, and its predictors, 
in patients enrolled in the SYNTAX (TAXUS Drug-Eluting Stent Versus Coronary 
Artery Bypass Surgery for the Treatment of Narrowed Arteries) trial, which 
represents a contemporary cohort of patients who underwent CABG or received 
drugeluting stents (DES).
METHODS
Study design, patients, and randomization
The design, methods, and procedural details of the SYNTAX trial have been 
reported previously (7–9). The SYNTAX study was a prospective, multinational, 
randomized trial conducted in 85 centers in the United States and Europe. In 
this study, 1,800 patients with de novo left main (LM) or 3-vessel disease (3VD) 
were randomly assigned to undergo CABG or PCI with first-generation paclitaxel-
eluting stents (Taxus Express, Boston Scientific, Natick, Massachusetts). Based 
on clinical judgment and consensus of a heart team that consisted of a cardiac 
surgeon and interventional cardiologist at each center, patients with anticipated 
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clinical equipoise through CABG and PCI were randomized (CABG, n = 897 and 
PCI, n = 903).
Randomization occurred via a central interactive voice response system in 
random block sizes per site based on the presence or absence of LM disease and 
medically treated diabetes mellitus. Patients suitable for PCI only entered the PCI 
registry (CABG ineligible patients, n = 198), whereas those suitable for CABG only 
entered the CABG registry (PCI ineligible patients, n = 1,077) (10). Within the nested 
registries, all PCI patients and 649 randomly allocated CABG patients underwent 
5-year follow-up. Routine follow-up assessments were performed by clinical visits 
or telephone interviews at 1, 6, and 12 months, and annually thereafter. All the 
clinical endpoints were assessed by the event-adjudication CEC. Data collection 
and quality were monitored systematically by the principal investigators and 
safety monitoring committee. Complete 5-year follow-up (clinical follow-up or 
death) after randomization to CABG and PCI was achieved in 805 (89.7%) and 871 
(96.5%) patients, respectively. Follow-up was complete for 184 patients (95.8%) in 
the PCI registry and for 607 patients (94.3%) in the CABG registry.
The post-procedure medication regimens and the use of secondary-prevention 
therapy according to American College of Cardiology and American Heart 
Association treatment guidelines (11,12) was strongly recommended for all 
patients. Medication use for the randomized cohort was collected at baseline, 
discharge, at 1 and 6 months, and at 1, 3, and 5 years post-allocation. For the 
nested registries, this was collected at baseline and discharge.
This study was done in accordance with the principles of the Declaration of 
Helsinki, and all sitespecific institutional review boards and applicable regulatory 
agencies approved the study protocol before study initiation.
DEFINITIONS. The definitions used for the classifications of adverse events have 
been previously reported elsewhere (9). Mortality data during the course of follow-
up were collected prospectively. Collection started directly after randomization to 
finalizing the 5-year follow-up; therefore, this included post-randomization pre-
procedural deaths, operative deaths, and deaths during follow-up. For each death 
event, standardized electronic case report forms were used by local principal 
investigators to categorize a terminal event in detail. The case report form included 
a structured narrative description of date and location of death, onset of adverse 
events that preceded the fatal outcome, circumstances of death, and description of 
treatments, if initiated. For all deaths, all available information was obtained and 
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forwarded to the independent CEC, including the death certificates, the coroner’s 
report, and other records (hospital discharge summary, pathology, laboratory, 
radiology, and other diagnostic data). The CEC was composed of physicians who were 
experts in cardiology, cardiac surgery, and neurology. Two CEC members reviewed 
all deaths independently in a blinded manner. Disagreements between reviewers 
and principal investigators were discussed and resolved by full CEC consensus.
Because the SYNTAX study began before publication of the Academic Research 
Consortium definition (13), it used specially designed definitions of death. The CEC 
classified deaths into cardiovascular or noncardiovascular, according to the trial 
protocol. Cardiovascular deaths were further classified as cardiac (sudden cardiac 
deaths, myocardial infarction (MI), progressive heart failure, and arrhythmia) 
and cardiac others (which included other cardiac causes, e.g., cardiac tamponade 
and cardiac deaths with insufficient information for definitive classification), 
vascular (stroke, aortic dissection, and pulmonary embolism), and vascular others 
(major hemorrhage, peripheral embolism, and other). Using these classifications, 
the following cardiac subgroups were defined and analyzed: 1) sudden cardiac 
deaths; 2) MI-related deaths; and 3) congestive heart failure (CHF), arrhythmia, 
and all other cardiac deaths, the latter of which were combined together into a 
single subgroup because of the low number of cases in each particular subgroup. 
Noncardiovascular deaths included those resulting from chronic respiratory 
disease, pneumonia, malignancy, diabetes mellitus, and other conditions (which 
included infections, accidents, suicides, trauma-related, chronic disease, and 
others). When a specific cause of death could not be determined from the available 
evidence, the death was classified as undetermined. Every death was attributed to 
one of the specific causes exclusively.
Major adverse events were considered nonfatal if no death occurred within 
30 days of the event, and when it was not possible to establish any association 
between the event and death from the narrative description of death.
During the Heart Team meeting, both the interventional cardiologist and surgeon 
documented which vessels that were >1.5 mm diameter and >50% stenosis needed 
revascularization. In the original trial protocol, incomplete revascularization 
was defined when the actual revascularization did not correlate with this pre-
operative Heart Team statement.
STATISTICAL ANALYSES. All analyses in the randomized cohort were done 
according to the intention-to-treat principle, whereas in the nested registries, 
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outcomes were presented according to the as-treated principle. As previously 
described, no statistical comparisons between the PCI and CABG registries were 
performed (10).
Continuous variables were reported as mean ± SD and compared with the 
Student t test. Binary variables were expressed as counts and/or percentages and 
compared with the chi-square test or Fisher exact test, as appropriate. Five-year 
rates of death were estimated using the Kaplan-Meier method, and comparisons 
between PCI and CABG were done using the log-rank test. For the randomized 
cohort, subgroup analyses were performed for pre-specified groups of patients 
with LM or 3VD and diabetic patients or nondiabetic patients, and post-hoc 
groups according to SYNTAX score tertiles (low 0 to 22, intermediate 23 to 32, and 
high >=33) and completeness of revascularization. The p values for interaction 
were performed using chi-square tests. Cox proportional hazard models for 
specific causes of death during the 5-year follow-up were constructed to provide 
hazard ratios (HRs) associated with PCI versus CABG treatment. The proportional 
hazards assumption of the Cox models was evaluated with Schoenfeld residuals 
(14). There was no evidence of departure from the assumption of proportionality. 
Multivariate analyses were performed using Cox proportional hazard models 
with backward selection of variables to construct a set of independent predictors. 
Variables considered of clinical importance and with a p value <0.15 in univariate 
analysis were considered in the multivariate models (Supplemental Appendix). 
Models were constructed for the overall randomized cohort and CABG and PCI 
randomized groups separately, as well as for the PCI and CABG registry patients 
separately. The performance of the models was tested using receiver-operating 
characteristics curves. A 2-sided p value of <0.05 was considered to be statistically 
significant for all tests. Analyses were performed using SPSS version 20.0 statistical 
software (IBM, Armonk, New York).
RESULTS
CAUSES OF DEATH. During the 5-year follow-up, there were 123 deaths after 
PCI and 97 deaths after CABG in the randomized cohort. Among PCI patients, 
the majority of deaths were cardiovascular (67.5%, n = 83), of which nearly all 
deaths were from cardiac causes (Table 1). The largest cause of cardiovascular 
death after PCI was related to MI (Figure 1A). In the CABG group, cardiovascular 
deaths accounted for 49.4% (n = 48), noncardiovascular deaths for 48.5% (n = 
47), and 2.1% (n = 2) of deaths occurred due to undetermined causes (Table 1). Of 
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cardiovascular death, only a few deaths were from vascular causes. The greatest 
cause of cardiovascular death after CABG was CHF, arrhythmia, or other causes 
(Figure 1A).
In the PCI registry, 22 (38.6%) patients died of cardiovascular causes, and the 
majority of deaths (50.9%, n = 33) were due to noncardiovascular causes (Figure 
1B). Within the CABG registry, cardiovascular deaths represented 36.7% (n = 29) of 
deaths, whereas noncardiovascular deaths occurred in 41.8% (n = 33) of cases. Of 
note, noncardiovascular deaths were most often caused by malignancies. Rates 
of all-cause death at 5-year follow-up were 30.0% (n = 57) in the PCI registry and 
12.6% (n = 79) in the CABG registry (Table 1). Specific causes of death are shown in 
Figure 3.
Table 1. Speciﬁc Causes of Death in the SYNTAX Trial.
Causes of Death PCI CABG HR (95% CI) p Value PCI Registry CABG Registry
Total 123 (13.9) 97 (11.4) 1.23 (0.94–1.60) 0.10 57 (30.0) 79 (12.6)
Cardiovascular death 83 (9.6) 48 (5.8) 1.62 (1.13–2.31) 0.008 22 (12.1) 29 (4.7)
Cardiac 78 (9.0) 43 (5.3) 1.70 (1.17–2.47) 0.003 17 (9.5) 22 (3.6)
Sudden cardiac death 24 (2.8) 15 (1.9) 1.61 (0.83–3.11) 0.16 5 (2.7) 6 (1.0)
Myocardial infarction 36 (4.1) 4 (0.4) 8.43 (2.99–23.67) <0.0001 3 (1.8) 2 (0.3)
Heart failure 7 (0.8) 13 (1.6) 0.50 (0.20–1.26) 0.14 5 (2.7) 6 (1.0)
Arrhythmia 1 (0.1) 1 (0.1) 0.95 (0.06–15.14) 0.97 0 1 (0.2)
Other 10 (1.1) 11 (1.4) 0.85 (0.36–2.01) 0.71 4 (2.2) 6 (1.0)
CHF/cardiac other 18 (2.1) 24 (3.0) 0.67 (0.37–1.24) 0.20 9 (4.8) 14 (2.2)
Vascular 5 (0.6) 5 (0.5) 0.93 (0.27–3.23) 0.91 5 (2.7) 7 (1.1)
CVA 3 (0.3) 3 (0.3) 0.94 (0.19–4.64) 0.94 1 (0.5) 3 (0.5)
Aortic dissection 0 0 – >0.99 0 2 (0.3)
Pulmonary embolism 0 1 (0.1) 0.014 (0–138,818) 0.60 2 (1.1) 0
Other 2 (0.2) 1 (0.1) 1.86 (0.17–20.55) 0.61 2 (1.1) 2 (0.3)
Noncardiovascular death 40 (4.3) 47 (5.6) 0.85 (0.55–1.31) 0.46 29 (14.9) 33 (5.3)
Chronic respiratory disease 0 1 (0.1) 0.015 (0–141,247) 0.61 3 (1.8) 1 (0.2)
Pneumonia 4 (0.4) 3 (0.3) 1.88 (0.34–10.29) 0.46 6 (3.1) 3 (0.5)
Cancer 20 (2.2) 20 (2.4) 1.04 (0.55–1.97) 0.90 8 (4.2) 20 (3.1)
DM 1 (0.1) 0 60.88 (0–595,324) 0.62 0 1 (0.2)
Other 15 (1.6) 23 (2.8) 0.61 (0.32–1.17) 0.14 12 (5.9) 8 (1.3)
Undetermined death 0 2 (0.2) 0.016 (0–1262) 0.47 6 (3.1) 17 (2.6)
Values are number of events (%), unless otherwise indicated.
CABG, coronary artery bypass grafting; CHF, congestive heart failure; CI,  conﬁdence interval; CVA, 
cerebral vascular accident; DM, diabetes mellitus; HR, hazard ratio; PCI, percutaneous coronary 
intervention; SYNTAX, TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the 
Treatment of Narrowed Arteries.
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Figure 1. Causes of Death in the SYNTAX (A) Randomized Cohort and (B) Nested Registries
CABG, coronary artery bypass grafting; CHF, congestive heart failure; MI, myocardial infarction; Other 
Cardiac, arrhythmia and all other cardiac deaths; PCI, percutaneous coronary intervention; SYNTAX, 
TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed 
Arteries.
INCIDENCES OF DEATH. At 5-year follow-up, there was a significant difference 
in favor of CABG in terms of cardiovascular death (p = 0.008), but not of 
noncardiovascular death (p = 0.46) (Figure 2). The difference in cardiovascular 
death was the result of a significantly lower rate of death due to MI (CABG 0.4% 
vs. PCI 4.1%; p < 0.0001), whereas rates of sudden cardiac death or death by CHF 
or arrhythmia were similar. All-cause death rates were not significantly different 
(p = 0.10) (Figure 2).
SUBGROUP ANALYSES. Subgroup analyses revealed that the reduced rates of 
cardiac death after CABG in comparison with PCI were particularly evident in 
patients with diabetes, 3VD, and a high SYNTAX score, although none of the 
interaction tests were significant (Figure 4A). More in-depth subgroup analyses in 
rates of sudden cardiac deaths, MI-related deaths, and CHF and/or other cardiac 
deaths were performed to detect the cause of this difference (Figure 4B). Among 
all patient subgroups, the rate of sudden cardiac death was numerically higher 
after PCI than after CABG, although this failed to reach statistical significance. Only 
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Figure 2. Kaplan-Meier Cumulative Event Curves by Speciﬁc Causes of Deaths in the 
SYNTAX Randomized Cohort. Analyses include Kaplan-Meier estimates of all-cause mortality 
(A); a subdivision in cardiovascular, non-cardiovascular, and unknown cause of mortality (B); 
subdividing cardiovascular mortality in cardiac and vascular mortality (C); and cardiac death 
subdivided into individual components of sudden cardiac mortality (D), MI-related mortality 
(E), and CHF/other cardiac mortality (F). CVD, cardiovascular; Non-CVD, noncardiovascular; UNK, 
unknown/undetermined; other abbreviations as in Figure 1.
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patients with a high SYNTAX score had significantly higher rates of sudden cardiac 
death after PCI versus CABG (HR: 5.09; 95% confidence interval (CI): 1.46 to 17.71; 
p = 0.011). Differences in MI-related deaths were consistently in favor of CABG and 
were particularly prominent in patients with diabetes, 3VD, and higher SYNTAX 
scores. There were no differences between PCI and CABG in terms of deaths due 
to CHF or other cardiac causes, although patients with a lower SYNTAX score did 
appear to have a nonsignificant benefit with PCI (Figure 4B).
Incomplete revascularization with PCI was associated with risk of cardiac deaths 
(HR: 1.89; 95% CI: 1.20 to 2.98; p = 0.006), which was driven by deaths due t o CHF 
and/or other cardiac causes (HR: 5.97; 95% CI: 1.72 to 20.78; p = 0.005) (Figure 
4C). In CABG patients, there was no increased risk in any specific causes of death 
associated with incomplete revascularization (Figure 4C).
Figure 3. The Kaplan-Meier Cumulative Event Curves by Speciﬁc Causes of Deaths in the 
SYNTAX Nested Registries. The Kaplan-Meier cumulative event curves by specific causes of deaths 
in the SYNTAX PCI (A) and CABG (B) nested registries. Abbreviations as in Figures 1 and 2.
PATIENT CHARACTERISTICS AND PREDICTORS OF ALL-CAUSE AND CARDIAC 
DEATH. Randomized trial. Significant baseline and lesion characteristics of 
patients who were alive or dead at 5 years after revascularization are summarized 
in Table 2 (complete results are in the Supplemental Table 1). Patients who died 
after both PCI or CABG had a higher risk profile at baseline than those who were 
still alive; they were older, had a higher presence of co-morbidities (diabetes, 
peripheral vascular disease, chronic obstructive pulmonary disease, carotid 
artery disease, and creatinine >200 mmol/l), which resulted in higher EuroSCORE 
values. Moreover, rates of medically treated diabetes and the mean SYNTAX score 
were significantly higher in patients who died after PCI, but these rates were not 
higher in patients who died after CABG.
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Figure 4. Hazard Ratios of CABG versus PCI Subgroup Analyses. (A) Cardiac cause of deaths within 
subgroups according to diabetes, left main (LM) or 3-vessel disease, and SYNTAX score. (B) Specific causes 
of cardiac deaths within subgroups according to diabetes, LM, or 3-vessel disease, and SYNTAX score. (C) 
Causes of deaths based on revascularization status (incomplete vs. complete) in PCI and CABG groups. 
CI, confidence interval; CR, complete revascularization; HR, hazard ratio; ICR, incomplete revascularization; 
other abbreviations as in Figures 1 and 2.
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In multivariate analysis, PCI versus CABG treatment was not an independent 
predictor of all-cause death. Although, in the overall model, as well as in the 
separate PCI and CABG models, numerous baseline variables, such as older age and 
the presence of comorbidities, were independent predictors (Table 3). Moreover, 
procedural events such as incomplete revascularization, post-procedural 
prescription of medication as secondary prevention, and the occurrence of 
nonfatal adverse events were predictive of all-cause death. In separate models, 
results were largely similar, although incomplete revascularization, medically 
treated diabetes and left ventricular function were only predictors in the PCI 
model and not in the CABG model (Table 3). In contrast, renal failure and chronic 
obstructive pulmonary disease were only predictors in the CABG model.
Table2. Baseline Characteristics of the Patients in the SYNTAX Randomized Cohort Who 
Completed 5-Year Follow-Up.
PCI (n = 871) p Value CABG (n = 805) p Value
Alive 
(n = 748)
Death 
(n = 123)
Alive 
(n = 708)
Death 
(n = 97)
Demographics
Male 581 (77.7) 82 (66.7) 0.008 563 (79.5) 81 (83.5) 0.36
Age, yrs 64.6 ± 9.6 69.7 ± 8.6 <0.0001 64.1 ± 9.5 70.6 ± 8.1 <0.0001
Medically treated diabetes 177 (23.7) 44 (35.8) 0.004 165 (23.3) 29 (29.9) 0.15
Any 112 (15.0) 24 (19.5) 0.20 96 (13.6) 16 (16.5) 0.43
Requiring insulin 65 (8.7) 20 (16.3) 0.009 69 (9.7) 13 (13.4) 0.26
Hypertension 540 (72.7) 98 (81.0) 0.054 534 (75.9) 80 (84.2) 0.07
Peripheral vascular disease 50 (6.7) 26 (21.1) <0.0001 59 (8.3) 25 (25.8) <0.0001
Unstable angina 206 (27.5) 46 (37.4) 0.025 194 (27.4) 26 (26.8) 0.90
Stabile angina 435 (58.2) 61 (49.6) 0.08 430 (60.7) 45 (46.4) 0.007
Creatinine >200 mmol/l 6 (0.8) 4 (3.3) 0.018 8 (1.1) 6 (6.2) <0.0001
Pulmonary hypertension 7 (0.9) 1 (0.8) 0.90 6 (0.8) 3 (3.1) 0.049
Previous MI 217 (29.4) 54 (44.3) 0.001 227 (32.4) 36 (37.9) 0.28
Carotid artery disease 52 (7.0) 17 (13.8) 0.009 50 (7.1) 17 (17.5) <0.0001
Chronic obstructive pulmonary disease 52 (7.0) 16 (13.0) 0.02 57 (8.1) 18 (18.6) 0.001
LVEF
Moderate (30%–49%) 119 (16.3) 34 (28.3) 0.002 119 (17.0) 20 (20.6) 0.37
Poor (<30%) 5 (0.7) 7 (5.8) <0.0001 12 (1.7) 5 (5.2) 0.028
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Baseline anatomical and clinical scores
SYNTAX score 27.9 ± 11.4 32.4 ± 11.3 <0.0001 29.0 ± 11.3 30.6 ± 12.3 0.19
Additive EuroScore 3.2 ± 2.3 5.3 ± 3.0 <0.0001 3.1 ± 2.3 4.9 ± 2.9 <0.0001
Total Parsonnet score 7.9 ± 6.6 12.3 ± 7.7 <0.0001 7.6 ± 6.3 13.1 ± 7.9 <0.0001
Left main disease 301 (40.2) 45 (36.6) 0.44 273 (38.6) 49 (50.5) 0.024
Procedural characteristics
Bypass time (min) — — — 84.8 ± 32.6 93.1 ± 48.1 0.046
No. of grafts — — — 2.8 ± 0.7 2.6 ± 0.8 0.036
No. of distal anastomoses — — — 3.2 ± 0.9 3.0 ± 1.0 0.026
No. of stents implanted 4.6 ± 2.3 5.0 ± 2.2 0.053 — — —
Staged procedure 97 (13.0) 27 (22.0) 0.008 — — —
Incomplete revascularization 317 (42.7) 71 (58.2) 0.001 260 (36.4) 38 (40.9) 0.40
Treatments at baseline
ARB or ACE inhibitor 432 (57.8) 83 (67.5) 0.042 441 (62.3) 73 (75.3) 0.013
Beta-blocker 555 (74.2) 89 (72.4) 0.67 563 (79.5) 64 (66.0) 0.003
Amiodarone 8 (1.1) 4 (3.3) 0.054 5 (0.7) 1 (1.0) 0.73
Cardiac glycoside 5 (0.7) 3 (2.4) 0.056 4 (0.6) 3 (3.1) 0.012
Diuretics 163 (21.8) 46 (37.4) <0.0001 149 (21.0) 31 (32.0) 0.016
Treatments at discharge
Acetylsalicylic acid 641 (86.4) 56 (45.9) <0.0001 593 (83.9) 32 (34.0) <0.0001
Thienopyridine antiplatelet 238 (32.1) 34 (27.9) 0.35 94 (13.3) 2 (2.1) 0.002
ARB or ACE inhibitor 547 (73.1) 44 (35.8) <0.0001 514 (72.6) 35 (36.1) <0.0001
Beta-blocker 572 (76.4) 52 (42.6) <0.0001 529 (74.9) 36 (37.1) <0.0001
Amiodarone 13 (1.7) 7 (5.7) 0.006 15 (2.1) 4 (4.1) 0.22
Statin 631 (85.0) 51 (41.8) <0.0001 610 (86.3) 28 (29.8) <0.0001
Values are n (%) or mean ± SD.
ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme; LVEF, left ventricular 
ejection fraction; MI, myocardial infarction; other abbreviations as in Table 1.
Treatment with PCI versus CABG was an independent predictor of cardiac death 
(HR: 1.55; 95% CI: 1.0 to 2.33; p = 0.045) (Table 4). Furthermore, the independent 
predictors in the overall and PCI models for cardiac death were nearly identical as 
for all-cause death (Table 4). An additional predictor for cardiac events after PCI 
was the SYNTAX score. The CABG model included previous MI and bypass time 
as additional independent predictors, whereas other baseline characteristics no 
longer were predictors.
Table 2. Continued.
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Nested registries. Baseline and procedural characteristics of patients alive at 
the end of follow-up and patients who died during follow-up are reported in the 
Supplemental Table 2. In the multivariate models that predicted all-cause and 
cardiac death, results were relatively similar to the randomized cohort, with a 
number of baseline, procedural, and post-procedural variables as independent 
predictors (Table 5). Of note, in the PCI registry, LM disease and the SYNTAX score 
were predictors.
Table 3. Independent Predictors of All-Cause Mortality in the SYNTAX Randomized Cohort.
HR (95% CI) p Value
SYNTAX randomized cohort
Age (per 5-yr increase) 1.25 (1.15–1.36) <0.0001
Medically treated diabetes 1.36 (1.01–1.84) 0.042
Peripheral vascular disease 2.04 (1.46–2.83) <0.0001
LVEF poor (<30%) 4.47 (2.31–8.66) <0.0001
Previous MI 1.31 (1.01–1.75) 0.044
Incomplete revascularization 1.37 (1.03–1.81) 0.029
Beta-blocker use at discharge 0.66 (0.47–0.93) 0.019
ARB or ACE inhibitor use at discharge 0.49 (0.35–0.69) <0.0001
Acetylsalicylic acid use at discharge 0.47 (0.33–0.67) <0.0001
Statin use at discharge 0.27 (0.19–0.39) <0.0001
Nonfatal CVA during follow-up 2.07 (1.12–2.95) 0.032
Nonfatal MI during follow–up 3.86 (2.69–5.53) <0.0001
PCI group
Age (per 5-yr increase) 1.25 (1.11–1.40) 0.008
Medically treated diabetes 1.66 (1.09–2.53) 0.018
Peripheral vascular disease 2.77 (1.73–4.44) <0.0001
LVEF poor (<30%) 2.26 (1.67–3.07) <0.0001
LVEF moderate (30%–49%) 2.37 (1.54–3.63) <0.0001
Incomplete revascularization 1.73 (1.17–2.58) 0.007
Beta-blocker use at discharge 0.59 (0.37–0.97) 0.036
ARB or ACE inhibitor use at discharge 0.43 (0.27–0.68) <0.0001
Acetylsalicylic acid use at discharge  0.52 (0.32–0.85) 0.008
Statin use at discharge 0.43 (0.27–0.69) 0.001
Nonfatal MI during follow-up 5.49 (3.68–9.14) <0.0001
CABG group
Age (per 5-yr increase) 1.27 (1.09–1.48) 0.002
Peripheral vascular disease 2.01 (1.14–3.54) 0.016
Creatinine blood level >200 mmol/l 4.75 (1.38–16.41) 0.014
Chronic obstructive pulmonary disease 1.92 (1.05–3.48) 0.033
ARB or ACE inhibitor use at discharge 0.52 (0.28–0.94) 0.033
Acetylsalicylic acid use at discharge 0.39 (0.20–0.74)  0.004
Statin use at discharge 0.28 (0.20–0.43) <0.0001
Nonfatal MI during follow-up 3.88 (1.60–9.39) 0.003
C-statistics for the models were: overall, 0.71 (95% CI: 0.68 to 0.75; p < 0.0001); PCI, 0.74 (95% CI: 0.69 
to 0.79; p < 0.0001); CABG, 0.71 (95% CI: 0.65 to 0.76; p < 0.0001). Abbreviations as in Tables 1 to 3.
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Table 4. Independent Predictors of Cardiac Mortality in the SYNTAX Randomized Cohort.
HR (95% CI) p Value
SYNTAX randomized cohort
PCI treatment vs. CABG 1.55 (1.09–2.33) 0.045
Age (per 5-yr increase) 1.16 (1.04–1.31) 0.009
Peripheral vascular disease 2.55 (1.64–3.98) <0.0001
LVEF poor (<30%) 5.08 (1.97–13.12) 0.001
LVEF moderate (30%–49%) 1.76 (1.15–2.69) 0.009
Previous MI 1.69 (1.14–2.50) 0.010
Incomplete revascularization 1.67 (1.13–2.45) 0.010
ARB or ACE inhibitor use at discharge 0.58 (0.37–0.92) 0.020
Acetylsalicylic acid use at discharge 0.54 (0.34–0.86) 0.010
Statins use at discharge 0.25 (0.16–0.41) <0.0001
Nonfatal MI during follow-up 6.16 (3.98–9.53) <0.0001
PCI group
Peripheral vascular disease 2.79 (1.54–5.71) 0.001
LVEF poor (<30%) 1.83 (1.26–3.15) 0.006
LVEF moderate (30%–49%) 3.06 (1.84–5.57) <0.0001
SYNTAX score 1.03 (1.01–1.05) 0.016
Incomplete revascularization 1.83 (1.15–3.24) 0.011
ARB or ACE inhibitor use at discharge 0.48 (0.27–0.81) 0.007
Acetylsalicylic acid use at discharge 0.46 (0.26–0.88) 0.018
Statins use at discharge 0.39 (0.21–0.58) <0.0001
Nonfatal MI during follow-up 6.79 (4.24–10.72) <0.0001
CABG group
Peripheral vascular disease 4.10 (1.88–8.97) <0.0001
Creatinine blood level >200 mmol/l 5.65 (1.19–26.81) 0.029
Prior MI 2.35 (1.14–4.81) 0.020
Bypass time (min) 1.01 (1.00–1.02) 0.009
Acetylsalicylic acid use at discharge  0.37 (0.16–0.83) 0.016
Statins use at discharge 0.29 (0.18–0.44) <0.0001
Nonfatal MI during follow-up 7.25 (2.39–22.02) <0.0001
C-statistics for the models were: overall, 0.72 (95% CI: 0.67 to 0.77; p < 0.0001); PCI, 0.70 (95% CI: 0.64 
to 0.76; p < 0.0001); CABG, 0.75 (95% CI: 0.66 to 0.83; p < 0.0001).
Abbreviations as in Tables 1 to 3.
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Table 5. Independent Predictors of All-Cause and Cardiac Mortality in the SYNTAX Nested 
Registries.
HR (95% CI) p Value
PCI registry
All-cause mortality
Age (per 5-yr increase) 1.44 (1.23–1.68) <0.0001
Chronic obstructive pulmonary disease 1.90 (1.01–3.59) 0.047
LVEF poor (<30%) 3.19 (1.33–7.65) 0.009
Left main disease 2.29 (1.25–4.19) 0.007
Previous MI 1.88 (1.04–3.41) 0.037
Beta-blocker use at discharge 0.52 (0.28–0.96) 0.038
Nonfatal MI during follow-up 2.50 (1.07–5.83) 0.033
Cardiac mortality
Age (per 5-yr increase) 1.53 (1.11–2.09) 0.008
Medically treated diabetes 5.56 (1.40–22.03) 0.015
Creatinine blood level >200 mmol/l 12.18 (1.51–80.44) 0.019
Left main disease 5.66 (1.52–21.10) 0.010
Previous MI 6.65 (1.91–23.15) 0.003
SYNTAX score 1.09 (1.04–1.14) <0.0001
CABG registry
All-cause mortality
Age (per 5-yr increase) 1.21 (1.04–1.41) 0.015
Medically treated diabetes 2.22 (1.34–3.70) 0.002
Chronic obstructive pulmonary disease 3.32 (1.79–6.17) <0.0001
LVEF moderate (30%–49%) 2.24 (1.33–3.78) 0.002
Procedure time (min) 1.01 (1.00–1.02) <0.0001
Acetylsalicylic acid use at discharge 0.41 (0.22–0.76) 0.004
Nonfatal MI during follow-up 2.54 (1.08–5.96) 0.033
Cardiac mortality
LVEF moderate (30%–49%) 4.05 (1.66–9.87) 0.002
Acetylsalicylic acid use at discharge 0.30 (0.18–0.80) 0.009
Nonfatal MI during follow-up 5.29 (1.52–18.41) 0.016
Abbreviations as in Tables 1 to 3.
DISCUSSION
The present study provides crucial perspectives on causes of death within the 
SYNTAX trial at 5-year follow-up (Central Illustration). Our findings indicate 
that treatment with CABG significantly reduces cardiac death compared with 
PCI, which was due exclusively to a lower incidence of MI-related death. 
Particularly in patient groups with 3VD and/or a SYNTAX score >=33, cardiac 
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death was significantly higher after PCI than CABG. Numerous patient baseline 
characteristics were independent predictors of death, although procedural 
characteristics (e.g., incomplete revascularization), the use of specific 
medications, and events during follow-up (e.g., nonfatal MI) also contributed in 
predicting all-cause and cardiac death.
Similarly to previous randomized trials that compared CABG with PCI using bare-
metal stents, long-term rates of all-cause mortality were comparable between 
CABG and PCI (15,16). Despite the inclusion of patients with more complex disease, 
such as LM and 3VD, rates of all-cause death in the SYNTAX trial were comparable 
to that of previous trials. For the patients treated with CABG, this might be the 
result of more refined operative techniques and conduit choices, among others. 
For patients who underwent PCI, factors that might have contributed to lowering 
adverse events during follow-up were the first-time implantation of DES and the 
increased use of dual antiplatelet therapy. In a recent report on trends in long-
term, cause-specific death after PCI, Spoon et al. (17) found that rates of deaths 
were similar from 1991 to 2012, whereas in more recent procedures, deaths 
occurred less often from cardiac causes.
Unfortunately, many previous analyses from randomized trials were limited by 
few specifics on the causes of cardiac deaths. Anecdotal evidence suggested that 
the advantage of CABG over medical therapy was particularly driven by reduced 
rates of sudden cardiac death (5,6,18). A recent analysis of deaths that occurred in 
the STICH (Surgical Treatment for Ischemic Heart Failure) trial showed that CABG 
further reduced rates of fatal MI (18). Comparative analyses regarding causes of 
death between CABG and PCI are restricted to a single observational study of 
approximately 10,000 patients with 140 sudden cardiac deaths, in which there 
was no difference in the rate of sudden cardiac death after CABG versus PCI (19).
In the present analysis, there was a significant difference in rates of cardiac death 
between CABG and PCI. Rates of sudden cardiac death were comparable, but MI-
related deaths were significantly lower after CABG. The majority of deaths among 
patients who underwent PCI were related to MI, which accounted for nearly 50% 
of the total cardiac deaths. In the BARI 2D (Bypass Angioplasty Revascularization 
Investigation 2 Diabetes) trial, the reduction in the composite of death, stroke, 
and MI with CABG versus medical therapy was driven largely by a reduction in MI, 
whereas the PCI versus medical therapy analysis showed similar rates of MI among 
the 2 groups (20). These findings emphasize the importance of MI reduction after 
PCI. Overall, use of the newer-generation DES (21) and default use of fractional 
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flow reserve (22) are considered to reduce the rate of MI and death by reducing 
events of stent thrombosis and restenosis in more contemporary trials. The impact 
of prolonged use and the exact duration of dual antiplatelet therapy on ischemic 
events remain topics of debate (23,24). Nevertheless, de novo lesions in patients 
who previously underwent PCI can progress to cause MI and subsequently death, 
whereas after CABG, the significance of such lesions with an existing patent 
bypass graft is limited. Even with the use of second-generation DES, the rate of 
spontaneous MI continues to be higher after PCI than CABG (25). Moreover, the 
lower rates of MI-related deaths with CABG might result from more complete 
revascularization and subsequently lower areas of ischemic myocardium (6,26). 
These concepts were validated in several studies that demonstrated that CABG 
had more durable protection against MI in patients with extensive CAD (16,27,28).
Because incomplete revascularization with PCI occurs more often in patients 
with highly complex lesions, and specifically chronic total occlusions (26,29), the 
present results emphasize these differences between CABG and PCI in the cardiac 
death subgroup analyses according to SYNTAX score tertiles. In the highest SYNTAX 
score tertiles, patients who underwent PCI had a higher risk of MI-related death 
and sudden cardiac deaths. Patients with complex disease undergoing PCI have a 
continued higher risk of stent thrombosis, which is related to cardiac death (30). 
In patients with complex disease and incomplete revascularization, lesions without 
revascularization have a considerable risk of progressing to acute events, a similar 
finding as in an analysis of the BARI trial that showed that revascularization versus 
no revascularization reduced the rate of sudden cardiac death (6). Moreover, 
progression of disease in patients with complex disease and higher SYNTAX scores 
may be enhanced because of a higher risk profile (e.g., diabetes, hypertension, 
and so on) that furthermore increases the risk of adverse events (31). These 
considerations contributed to the selection of less complex LM disease in the EXCEL 
(Evaluation of the Xience Everolimus-Eluting Stent Versus Coronary Artery Bypass 
Surgery for Effectiveness of Left Main Revascularization) randomized comparison 
between CABG and LM stenting with current generation DES.
In subgroups according to diabetes, the difference between PCI and CABG in 
cardiac death was greater in diabetic patients than in nondiabetic patients, 
whereas the difference in all-cause death was not significant in diabetic patients 
(32). This is notable in the BARI publication (33), but not in the results of the 
recent FREEDOM (Future Revascularization Evaluation in Patients with Diabetes 
Mellitus: Optimal Management of Multivessel Disease) trial, which results 
were in favor of CABG in terms of all-cause death and comparable outcomes in 
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cardiovascular death (34). This may reflect the relatively low number of events 
of cardiac or cardiovascular death and the play of chance that may play a role. 
In other subgroup analyses, the significant increases in cardiac deaths that 
were observed after PCI in patients with 3VD strengthens the finding that these 
patients particularly benefited from CABG (35). Conversely, consistent with other 
studies of patients with LM diseases, cardiac death was not different between PCI 
and CABG (25,36), justifying the hypothesis on which the current EXCEL trial is 
based (NCT01205776).
Multivariate models identified several distinct variables associated with long-term 
all-cause and cardiac death that may aid decisions regarding revascularization 
strategies. In comparison with previously published studies that identified 
predictors of long-term mortality (33,37,38), our results add significantly to the 
current body of evidence. Longterm analyses of all-cause mortality may lose 
accuracy in determining the relevance of myocardial revascularization to the 
occurrence of death, whereas analysis of cardiac death as adjudicated by a CEC 
may provide a more clear distinction between death as a result of comorbidities 
or as the consequence of CAD. Furthermore, the majority of models to predict 
death included only preoperative values. The present analyses also emphasized 
the importance of nonfatal adverse events (stroke and MI) as predictors of future 
fatal events. We identified that a nonfatal stroke was a significant predictor of 
death, which corresponds with the association between stroke and subsequent 
increased risk not only of repeated stroke, but also of the combined risk of stroke 
and MI (39). In addition, a nonfatal MI was associated with an increased risk of 
all-cause and cardiac mortality. This might be the result of progressive heart 
failure because our findings also showed that patients with a moderate or poor 
left ventricular ejection fraction and a history of MI are at an increased risk of MI-
related death. Therefore, prevention of MI after treatment with PCI, but also after 
CABG, is of critical importance for survival. As shown in our multivariate analyses, 
as well as in several other studies, the importance of secondary prevention 
medication is essential in this regard. Iqbal et al. (40) recently showed that the 
impact of secondary prevention medication was even larger than the impact of 
performing PCI or CABG in patients with complex CAD. Guideline-directed 
medical therapy should be a principal strategy for all patients with CAD, as also 
recently shown in an analysis of BARI 2D data (41). This information on predictors 
may be particularly useful for the Heart Team currently when both PCI and CABG 
are excellent treatment options; the Heart Team should not only determine the 
most optimal revascularization strategy, but which strategy might also be useful 
when integrated into the postprocedural phase (7).
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STUDY LIMITATIONS. The present study represents a post-hoc analysis; 
therefore, the results should be regarded as exploratory and hypothesis-
generating. Moreover, a great number of subgroup analyses have been reported, 
so results should be interpreted with caution because some differences may be the 
results of chance (42). Although the SYNTAX trial was an all-comers randomized 
trial, inclusion of patients in a randomized trial is limited to specific inclusion and 
exclusion criteria; therefore, the external validity, which reflects actual patients 
in the real-world, may be suboptimal.
Despite the primarily used SYNTAX trial classifications, the determination of 
cause-specific death could not always be established. This is particularly relevant 
to the subcategories of cardiac death in which absolute precision may not 
always be possible. However, bias was limited by event adjudication by a blinded 
committee of physician experts using previous standardized definitions.
Autopsy was performed in a low number of cases (n = 38, 10.7%); therefore, the 
rate of death related to MI could be underestimated, considering that MI might 
be involved in the process of heart failure and cardiac rupture, as well as sudden 
cardiac death.
We did not have information on post-procedural occurrence of additional co-
morbidities, which could affect the established groups of predictors.
Although medication use was recorded throughout different time points 
during follow-up, there were no data on compliance rates or on reasons for 
discontinuation of medication. Moreover, at later follow-up with longer periods 
between collection of medication data (e.g., 2 years), we were unable to determine 
the exact date of medication discontinuation. Therefore, we could not assess the 
impact of medication use during follow-up on death rates.
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CONCLUSIONS
For patients with complex CAD, CABG compared with PCI did not reduce all-
cause death, but was shown to be associated with a significantly reduced rate of 
cardiac death that was driven primarily by a reduction of death as a consequence 
of MI. This reduction was greatest in patients with diabetes, 3VD, or a SYNTAX 
score >=33. Although PCI is becoming a more acceptable revascularization strategy 
for patients with LM or 3VD, treatments following PCI should target reducing 
post-revascularization spontaneous MI, because this remains the leading cause of 
death after PCI.
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CLINICAL PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: For patients with complex coronary 
disease, CABG was associated with a lower rate of cardiac death after 5 years than 
PCI, and patients who underwent PCI with first-generation DES were at higher 
risk of fatal MI than those managed with CABG. 
TRANSLATIONAL OUTLOOK: Additional randomized studies in patients 
undergoing PCI with newer generation DES should examine predictors of MI-
related death.
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SUPPLEMENTAL MATERIAL
Baseline variables included in univariate analyses to predict death.
In the overall model including both PCI and CABG patients, the following 
variables were added: male gender, age per 5 years, medically treated diabetes, 
hypertension, hyperlipidemia, peripheral vascular disease, unstable angina, 
history of stroke or transient ischemic attack, creatinine blood level >200 
micromol/L, prior myocardial infarction, carotid artery disease, chronic 
obstructive pulmonary disease, poor left ventricular ejection fraction <30%, 
moderate left ventricular ejection fraction 30-49%, left main coronary disease, 
non-fatal stroke during follow-up, non-fatal myocardial infarction during 
follow-up, incomplete revascularization, beta-blocker at discharge, angiotensin 
converting enzyme or angiotensin renin blocker inhibitor medication at 
discharge, calcium channel blockers at discharge, acetylsalicylic acid at discharge, 
thienopyridine at discharge, diuretics medication at discharge, statins at 
discharge, and PCI versus CABG treatment.
Additional variables added in the separate PCI model: SYNTAX score, number of 
stents implanted, total stent length implanted and staged procedure. The variable 
‘PCI versus CABG treatment’ was deleted in this model.
Additional variables added in the separate CABG model: SYNTAX score, 
procedure time, bypass time, number of grafts and number of distal anastomoses. 
The variable ‘PCI versus CABG treatment’ was deleted in this model.
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Supplemental Table 1. Baseline characteristics of the patients in the SYNTAX Randomized 
Cohort who completed 5-year follow-up.
  PCI (n=871) CABG (n=805)
Baseline characteristics
Alive 
(n=748)
Death 
(n=123)
P Value
Alive 
(n=708)
Death 
(n=97)
P Value
Demographics
 Male 581 (77.7) 82 (66.7) 0.008 563 (79.5) 81 (83.5) 0.36
 Age 64.6 ± 9.6 69.7 ± 8.6 <0.0001 64.1 ± 9.5 70.6 ± 8.1 <0.0001
 BMI (kg/m2) 28.2 ± 4.7 27.9 ± 5.3 0.50 27.9 ± 4.5 27.5 ±4.4 0.39
 Waist diameter, cm 85.0 ± 27.3 84.6 ± 26.8 0.88 85.4 ± 27.4 87.4 ± 25.8 0.54
 Medical treated diabetes 177 (23.7) 44 (35.8) 0.004 165 (23.3) 29 (29.9) 0.15
          Any 112 (15.0) 24 (19.5) 0.20 96 (13.6) 16 (16.5) 0.43
          Requiring insulin 65 (8.7) 20 (16.3) 0.009 69 (9.7) 13 (13.4) 0.26
 Hypertension 540 (72.7) 98 (81.0) 0.054 534 (75.9) 80 (84.2) 0.07
 Hyperlipidemia 590 (79.5) 89 (73.0) 0.10 554 (79.0) 69 (71.9) 0.11
 Peripheral vascular disease 50 (6.7) 26 (21.1) <0.0001 59 (8.3) 25 (25.8) <0.0001
 Current smoker 130 (17.4) 25 (20.3) 0.43 151 (21.4) 19 (20.0) 0.75
 Unstable angina 206 (27.5) 46 (37.4) 0.025 194 (27.4) 26 (26.8) 0.90
 Stabile angina 435 (58.2) 61 (49.6) 0.08 430 (60.7) 45 (46.4) 0.007
 History of stroke or TIA 51 (6.8) 11 (8.9) 0.40 61 (8.7) 13 (13.5) 0.12
 Creatinine > 200 micromol/L 6 (0.8) 4 (3.3) 0.018 8 (1.1) 6 (6.2) <0.0001
 Pulmonary hypertension 7 (0.9) 1 (0.8) 0.90 6 (0.8) 3 (3.1) 0.049
 Prior MI 217 (29.4) 54 (44.3) 0.001 227 (32.4) 36 (37.9) 0.28
 Carotid artery disease 52 (7.0) 17 (13.8) 0.009 50 (7.1) 17 (17.5) <0.0001
 Chronic obstructive pulmonary disease 52 (7.0) 16 (13.0) 0.02 57 (8.1) 18 (18.6) 0.001
LVEF            
 Moderate (30%-49%) 119 (16.3) 34 (28.3) 0.002 119 (17.0) 20 (20.6) 0.37
 Poor (<30%) 5 (0.7) 7 (5.8) <0.0001 12 (1.7) 5 (5.2) 0.028
Baseline anatomical and clinical scores      
 SYNTAX Score 27.9 ± 11.4 32.4 ± 11.3 <0.0001 29.0 ± 11.3 30.6 ± 12.3 0.19
 Additive EuroScore 3.2 ± 2.3 5.3 ± 3.0 <0.0001 3.1 ± 2.3 4.9 ± 2.9 <0.0001
 Logistic EuroScore 3.3 ± 4.2 6.3 ± 5.6 <0.0001 3.3 ± 3.3 7.2 ± 8.1 <0.0001
 Total Parsonnet score 7.9 ± 6.6 12.3 ± 7.7 <0.0001 7.6 ± 6.3 13.1 ± 7.9 <0.0001
 Left Main Coronary disease 301 (40.2) 45 (36.6) 0.44 273 (38.6) 49 (50.5) 0.024
 Left arterial dominance 134 (17.9) 24 (19.5) 0.67 107 (15.1) 20 (20.6) 0.16
Procedural characteristics            
 Emergency treatment 9 (1.2) 1 (0.8) 0.71 6 (0.8) 2 (2.1) 0.26
 Procedure time (min) - - - 206.1 ± 59.1 220.9 ± 82.6 0.095
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 Bypass time (min) - - - 84.8 ± 32.6 93.1 ± 48.1 0.046
 Cross clamp time (min) - - - 55.8 ± 37.3 52.8 ± 22.3 0.50
 Off-pump surgery - - - 99 (13.9) 11 (1.8) 0.59
 Complete arterial - - - 143 (20.0) 14 (15.1) 0.25
 Bilateral internal mammary artery use - - - 200 (28.3) 20 (21.7) 0.19
 Number of grafts - - - 2.8 ± 0.7 2.6 ± 0.8 0.036
      Arterial grafts - - - 1.4 ± 0.7 1.3 ± 0.5 0.17
      Venous grafts - - - 1.4 ± 0.9 1.3 ± 0.9 0.76
 Number of distal anastomoses - - - 3.2 ± 0.9 3.0 ± 1.0 0.026
 Number of stents implanted 4.6 ± 2.3 5.0 ± 2.2 0.053 - - -
 Total stent length implanted (mm) 85.1 ± 48.3 91.8 ± 46.4 0.15 - - -
 Long stenting (>100mm) 244 (32.7) 57 (39.2) 0.16 - - -
 Total overlapping stents 0.6 ± 0.6 0.7 ± 0.7 0.29 - - -
 Staged procedure 97 (13.0) 27 (22.0) 0.008 - - -
 Incomplete revascularization 317 (42.7) 71 (58.2) 0.001 260 (36.4) 38 (40.9) 0.40
Treatments at baseline            
 Acetylsalicylic acid 653 (87.3) 105 (85.4) 0.55 571 (80.6) 75 (77.3) 0.44
 Thienopyridine antiplatelet 451 (60.3) 82 (66.7) 0.18 185 (26.1) 22 (22.7) 0.47
 Antiplatelet-other 33 (4.4) 9 (7.3) 0.16 44 (6.2) 5 (5.2) 0.68
 Coumadin derivative 13 (1.7) 3 (2.4) 0.59 15 (2.1) 5 (5.2) 0.07
 ARB or ACE inhibitor 432 (57.8) 83 (67.5) 0.042 441 (62.3) 73 (75.3) 0.013
 β-Blocker 555 (74.2) 89 (72.4) 0.67 563 (79.5) 64 (66.0) 0.003
 Calcium channel blockers 203 (27.1) 35 (28.5) 0.76 177 (25.0) 26 (26.8) 0.70
 Nitrates 269 (36.0) 46 (37.4) 0.76 288 (40.7) 40 (41.2) 0.92
 Amiodarone 8 (1.1) 4 (3.3) 0.054 5 (0.7) 1 (1.0) 0.73
 Statin 563 (75.3) 85 (69.1) 0.15 545 (77.0) 69 (71.7) 0.20
 Cardiac glycoside 5 (0.7) 3 (2.4) 0.056 4 (0.6) 3 (3.1) 0.012
 Diuretics 163 (21.8) 46 (37.4) <0.0001 149 (21.0) 31 (32.0) 0.016
 H2-receptors blockers 78 (10.4) 9 (7.3) 0.29 67 (9.5) 11 (11.3) 0.56
Treatments at discharge            
 Acetylsalicylic acid 641 (86.4) 56 (45.9) <0.0001 593 (83.9) 32 (34.0) <0.0001
 Thienopyridine antiplatelet 238 (32.1) 34 (27.9) 0.35 94 (13.3) 2 (2.1) 0.002
 Antiplatelet-other 33 (4.4) 2 (1.6) 0.16 23 (3.3) 2 (2.1) 0.52
 Coumadin derivative 41 (5.5) 3 (2.5) 0.17 39 (5.5) 4 (4.1) 0.57
 ARB or ACE inhibitor 547 (73.1) 44 (35.8) <0.0001 514 (72.6) 35 (36.1) <0.0001
 β-Blocker 572 (76.4) 52 (42.6) <0.0001 529 (74.9) 36 (37.1) <0.0001
 Calcium channel blockers 188 (25.1) 24 (19.7) 0.19 168 (23.8) 17 (17.5) 0.17
 Nitrates 112 (15.0) 17 (13.9) 0.76 66 (9.3) 8 (8.2) 0.72
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 Amiodarone 13 (1.7) 7 (5.7) 0.006 15 (2.1) 4 (4.1) 0.22
 Statin 631 (85.0) 51 (41.8) <0.0001 610 (86.3) 28 (29.8) <0.0001
 Cardiac glycoside 12 (1.6) 4 (3.3) 0.20 9 (1.3) 2 (2.1) 0.53
 Diuretics 197 (26.3) 25 (20.5) 0.17 210 (29.7) 22 (22.7) 0.15
 H2-receptors blockers 90 (12.0) 11 (9.0) 0.33 77 (10.9) 8 (8.2) 0.42
Values are shown as mean ± SD or n (%). CABG, coronary artery bypass grafting; PCI, percutaneous 
coronary intervention; BMI, body mass index; MI, myocardial infarction; LVEF, left ventricular ejection 
fraction; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme; TIA, transient 
ischemic attack.
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Supplemental Table 2. Baseline characteristics of the patients enrolled in the SYNTAX Registries 
Cohort who completed 5-year follow-up.
PCI (n=184) CABG (n=607)
Baseline characteristics
Alive 
(n=127)
Death 
(n=57)
P Value
Alive 
(n=528)
Death 
(n=79)
P Value
Demographics            
 Male 94 (70.7) 40 (70.2) 0.94 454 (80.4) 66 (83.5) 0.50
 Age 69.0 ± 10.6 76.3 ± 8.4 <0.0001 65.2 ± 9.3 69.2 ± 9.1 <0.0001
 BMI (kg/m2) 27.8 ± 5.3 28.2 ± 5.9 0.70 28.1 ± 4.6 27.4 ± 4.5 0.21
 Waist diameter, cm 88.2 ± 24.3 82.1 ± 34.5 0.24 81.2 ± 30.1 80.0 ± 28.3 0.77
 Medical treated diabetes 43 (32.3) 25 (43.9) 0.13 155 (27.4) 36 (45.6) 0.001
          Any 25 (18.8) 14 (24.6) 0.37 108 (19.1) 22 (27.8) 0.070
          Requiring insulin 18 (13.5) 11 (19.3) 0.11 47 (8.3) 14 (17.7) 0.008
 Hypertension  105 (79.5) 38 (66.7) 0.058 402 (72.3) 63 (81.8) 0.076
 Hyperlipidemia 95 (72.0) 32 (56.1) 0.033 427 (77.5) 53 (68.8) 0.093
 Peripheral vascular disease 19 (14.3) 12 (21.1) 0.25 69 (12.2) 20 (25.3) 0.002
 Current smoker 18 (13.6) 3 (5.6) 0.11 126 (22.4) 14 (18.2) 0.40
 Unstable angina 45 (33.3) 27 (47.4) 0.066 124 (21.9) 15 (19.0) 0.55
 Stabile angina 65 (48.9) 24 (42.1) 0.39 355 (62.8) 50 (63.3) 0.94
 History of stroke or TIA 15 (11.3) 12 (21.1) 0.077 52 (9.3) 9 (11.4) 0.54
 Creatinine > 200 micromol/L 7 (5.3) 4 (7.0) 0.63 10 (1.8) 3 (3.8) 0.23
 Pulmonary hypertension 2 (1.5) 3 (5.3) 0.14 4 (0.7) 3 (3.8) 0.013
 Prior MI 50 (38.2) 25 (45.5) 0.35 182 (33.1) 29 (36.7) 0.52
 Carotid artery disease 13 (9.8) 7 (12.3) 0.61 64 (11.3) 15 (19.0) 0.042
 COPD 18 (13.5) 19 (33.3) 0.002 37 (6.5) 14 (17.7) 0.001
LVEF            
 Moderate (30%-49%) 34 (26.6) 13 (23.6) 0.68 121 (22.2) 29 (36.7) 0.005
 Poor (<30%) 5 (3.9) 6 (10.9) 0.068 20 (3.7) 7 (8.9) 0.034
Baseline anatomical and clinical scores        
 SYNTAX Score 26.1 ± 11.2 31.3 ± 15.2 0.025 34.6 ± 13.4 37.3 ± 13.4 0,09
 Additive EuroScore 5.1 ± 3.0 7.6 ± 3.4 <0.0001 3.6 ± 2.6 4.8 ± 2.6 <0.0001
 Left Main Coronary disease 47 (35.3) 32 (56.1) 0.008 270 (47.8) 36 (45.6) 0.71
 Left arterial dominance 24 (18.0) 12 (21.1) 0.63 79 (14.0) 9 (11.4) 0.53
Procedural characteristics            
 Emergency treatment 4 (3.0) 4 (7.0) 0.29 14 (2.5) 2 (2.5) 0.98
 Procedure time (min) - - - 213.1 ± 58.2 224.7 ± 88.0 0.26
 Bypass time (min) - - - 92.9 ± 32.7 99.6 ± 48.9 0.28
 Cross clamp time (min) - - - 59.3 ± 25.2 61.2 ± 38.8 0.71
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 Off-pump surgery - - - 106 (18.8) 14 (17.7) 0.82
 Complete arterial - - - 63 (11.2) 9 (11.4) 0.95
 Bilateral IMA use - - - 96 (17.1) 8 (10.3) 0.12
 Number of grafts - - - 2.9 ± 0.8 2.7 ± 0.8 0.20
       Arterial grafts - - - 1.3 ± 0.7 1.2 ± 0.6 0.098
       Venous grafts - - - 1.7 ± 1.0 1.6 ± 1.1 0.55
 Number of distal anastomoses - - - 3.5 ± 0.9 3.5 ± 1.0 0.74
 Number of stents implanted 3.2 ± 1.9 3.0 ± 1.6 0.26 - - -
 Total stent length (mm) 61.3 ± 45.1 52.3 ± 30.1 0.059 - - -
 Long stenting (>100mm) 19 (14.4) 4 (7.1) 0.16 - - -
 Total overlapping stents 0.4 ± 0.6 0.4 ± 0.5 0.75 - - -
 Staged procedure 18 (13.3) 7 (12.3) 0.84 - - -
 Incomplete revascularization 84 (63.2) 41 (71.9) 0.24 133 (23.5) 30 (38.0) 0.006
Treatments at baseline            
 Acetylsalicylic acid 107 (80.5) 52 (91.1) 0.065 423 (74.9) 58 (73.4) 0.78
 Thienopyridine antiplatelet 98 (73.7) 40 (70.2) 0.62 94 (16.6) 10 (12.7) 0.37
 Antiplatelet-other 13 (9.8) 5 (8.8) 0.83 48 (8.5) 8 (10.1) 0.63
 Coumadin derivative 7 (5.3) 2 (3.5) 0.60 20 (3.5) 5 (6.3) 0.23
 ARB or ACE inhibitor 78 (58.6) 32 (56.1) 0.75 313 (55.4) 55 (69.6) 0.017
 β-Blocker 95 (71.4) 33 (57.9) 0.068 441 (78.1) 57 (72.2) 0.24
 Calcium channel blockers 37 (27.8) 21 (36.8) 0.22 153 (27.1) 26 (32.9) 0.28
 Nitrates 51 (38.3) 32 (56.1) 0.023 244 (43.2) 39 (49.4) 0.30
 Amiodarone 0 3 (5.3) 0.008 13 (2.3) 3 (3.8) 0.42
 Statin 86 (64.7) 36 (63.2) 0.84 398 (70.4) 53 (67.1) 0.54
 Cardiac glycoside 5 (3.8) 2 (3.5) 0.93 4 (0.7) 2 (2.5) 0.11
 Diuretics 47 (35.3) 28 (49.1) 0.075 128 (22.7) 34 (43.0) <0.0001
 H2-receptors blockers 6 (4.5) 3 (5.3) 0.82 50 (8.8) 7 (8.9) 0.99
Treatments at discharge            
 Acetylsalicylic acid 125 (92.6) 53 (93.0) 0.92 506 (89.6) 63 (79.7) 0.011
 Thienopyridine antiplatelet 124 (91.9) 54 (94.7) 0.48 98 (17.3) 11 (13.9) 0.45
 Antiplatelet-other 8 (5.9) 5 (8.8) 0.47 35 (6.2) 4 (5.1) 0.69
 Coumadin derivative 4 (3.0) 3 (5.3) 0.44 50 (8.8) 12 (15.2) 0.074
 ARB or ACE inhibitor 86 (63.7) 37 (64.9) 0.87 286 (50.6) 35 (44.3) 0.29
 β-Blocker 101 (74.8) 34 (59.6) 0.036 455 (80.5) 56 (70.9) 0.047
 Calcium channel blockers 35 (25.9) 17 (29.8) 0.58 127 (22.5) 14 (17.7) 0.34
 Nitrates 38 (28.1) 22 (38.6) 0.15 84 (14.9) 16 (20.3) 0.22
 Amiodarone 1 (0.7) 4 (7.0) 0.013 70 (12.4) 9 (11.4) 0.80
 Statin 99 (73.3) 39 (68.4) 0.49 388 (68.7) 52 (65.8) 0.61
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 Cardiac glycoside 2 (1.5) 2 (3.5) 0.37 7 (1.2) 2 (2.5) 0.36
 Diuretics 43 (31.9) 26 (45.6) 0.069 227 (40.2) 41 (51.9) 0.048
 H2-receptors blockers 11 (8.1) 6 (10.5) 0.60 112 (19.8) 16 (20.3) 0.93
Values are shown as mean ± SD or n (%). CABG, coronary artery bypass grafting; PCI, percutaneous 
coronary intervention; BMI, body mass index; MI, myocardial infarction; LVEF, left ventricular ejection 
fraction; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme; TIA, transient 
ischemic attack; IMA, internal mammary artery; COPD, chronic obstructive pulmonary disease.
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ABSTRACT
BACKGROUND: Coronary artery bypass grafting (CABG) and percutaneous 
coronary intervention (PCI) are used for coronary revascularization in patients 
with multivessel and left main coronary artery disease. Stroke is among the 
most feared complications of revascularization. Due to its infrequency, studies 
with large numbers of patients are required to detect differences in stroke rates 
between CABG and PCI.
OBJECTIVES: This study sought to compare rates of stroke after CABG and PCI 
and the impact of procedural stroke on long-term mortality.
METHODS: We performed a collaborative individual patient-data pooled analysis 
of 11 randomized clinical trials comparing CABG with PCI using stents; ERACI 
II (Argentine Randomized Study: Coronary Angioplasty With Stenting Versus 
Coronary Bypass Surgery in Patients With Multiple Vessel Disease) (n = 450), 
ARTS (Arterial Revascularization Therapy Study) (n = 1,205), MASS II (Medicine, 
Angioplasty, or Surgery Study) (n = 408), SoS (Stent or Surgery) trial (n = 988), 
SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and 
Cardiac Surgery) trial (n = 1,800), PRECOMBAT (Bypass Surgery Versus Angioplasty 
Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease) 
trial (n = 600), FREEDOM (Comparison of Two Treatments for Multivessel 
Coronary Artery Disease in Individuals With Diabetes) trial (n = 1,900), VA CARDS 
(Coronary Artery Revascularization in Diabetes) (n = 198), BEST (Bypass Surgery 
Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery 
Disease) (n = 880), NOBLE (Percutaneous Coronary Angioplasty Versus Coronary 
Artery Bypass Grafting in Treatment of Unprotected Left Main Stenosis) trial (n = 
1,184), and EXCEL (Evaluation of Xience Versus Coronary Artery Bypass Surgery 
for Effectiveness of Left Main Revascularization) trial (n = 1,905). The 30-day 
and 5-year stroke rates were compared between CABG and PCI using a random 
effects Cox proportional hazards model, stratified by trial. The impact of stroke 
on 5-year mortality was explored.
RESULTS: The analysis included 11,518 patients randomly assigned to PCI 
(n = 5,753) or CABG (n = 5,765) with a mean follow-up of 3.8 ± 1.4 years during 
which a total of 293 strokes occurred. At 30 days, the rate of stroke was 0.4% 
after PCI and 1.1% after CABG (hazard ratio (HR): 0.33; 95% confidence interval 
(CI): 0.20 to 0.53; p < 0.001). At 5-year follow-up, stroke remained significantly 
lower after PCI than after CABG (2.6% vs. 3.2%; HR: 0.77; 95% CI: 0.61 to 0.97; 
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p = 0.027). Rates of stroke between 31 days and 5 years were comparable: 2.2% 
after PCI versus 2.1% after CABG (HR: 1.05; 95% CI: 0.80 to 1.38; p = 0.72). No 
significant interactions between treatment and baseline clinical or angiographic 
variables for the 5-year rate of stroke were present, except for diabetic patients 
(PCI: 2.6% vs. CABG: 4.9%) and nondiabetic patients (PCI: 2.6% vs. CABG: 2.4%) (p 
for interaction = 0.004). Patients who experienced a stroke within 30 days of the 
procedure had significantly higher 5-year mortality versus those without a stroke, 
both after PCI (45.7% vs. 11.1%, p < 0.001) and CABG (41.5% vs. 8.9%, p < 0.001).
CONCLUSIONS: This individual patient-data pooled analysis demonstrates that 
5-year stroke rates are significantly lower after PCI compared with CABG, driven 
by a reduced risk of stroke in the 30-day post-procedural period but a similar 
risk of stroke between 31 days and 5 years. The greater risk of stroke after CABG 
compared with PCI was confined to patients with multivessel disease and diabetes. 
Five-year mortality was markedly higher for patients experiencing a stroke within 
30 days after revascularization. 
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INTRODUCTION
Numerous randomized clinical trials have compared coronary artery bypass 
grafting (CABG) and percutaneous coronary inter-vention (PCI) for treating 
coronary artery disease; first in the era of balloon angioplasty, subsequently 
with the use of bare-metal stents (BMS) (1,2), and most recently with use of drug-
eluting stents (DES) (3). With improving technology and techniques of PCI, trials 
have increasingly focused on more complex patients with multivessel disease 
(MVD), left main (LM) disease, and diabetes.
Several studies have suggested that CABG versus PCI is associated with a significant 
increase of procedural stroke (1), a devastating outcome with substantial mortality, 
morbidity, and reduced quality of life. To date, there is a lack of conclusive evidence 
on the exact incidence and consequences of stroke following either CABG or PCI 
because individual randomized trials lacked sufficient power to detect small 
but meaningful differences between CABG and PCI (4). In a recent collaborative 
analysis of 11 randomized trials of patients with multivessel or LM coronary 
artery disease who were randomly assigned to CABG or PCI, we found significant 
differences in 5-year all-cause mortality in favor of CABG over PCI in patients 
with MVD and diabetes, whereas no differences were seen among patients with 
MVD without diabetes and in those with LM disease (5). Beyond mortality, it is 
important to consider endpoints that significantly impact quality of life, including 
stroke. We therefore performed an analysis from the individual patient data from 
11 randomized clinical trials of CABG versus PCI to compare procedural and long-
term rates of stroke and the impact of stroke on survival.
METHODS
STUDY SELECTION AND DATA COLLECTION. Details of this pooled analysis have 
been previously published (5). In summary, a systematic search was performed on 
July 19, 2017, to identify randomized clinical trials comparing CABG with PCI for the 
treatment of multivessel or LM disease. Studies were selected if: 1) patients were 
randomly assigned to undergo CABG or PCI treatment; 2) patients had multivessel or 
LM disease; 3) patients did not present with an acute myocardial infarction; 4) PCI was 
performed using stents (BMS or DES) and not balloon angioplasty; 5) the occurrence 
of stroke was collected beyond 30 days of follow-up; and 6) >1-year follow-up for 
all-cause mortality was available. The study was performed according to PRISMA 
(Preferred Reporting Items for Systematic Review and MetaAnalyses) guidelines (6).
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Investigators from 11 individual trials provided the data for the current pooled 
analysis: ERACI II (Argentine Randomized Study: Coronary Angioplasty With 
Stenting Versus Coronary Bypass Surgery in Patients With Multiple Vessel Disease) 
(7), ARTS (Arterial Revascularization Therapy Study) (8), MASS II (Medicine, 
Angioplasty, or Surgery Study) (9), SoS (Stent or Surgery) trial (10), SYNTAX 
(Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac 
Surgery) trial (11), PRECOMBAT (Bypass Surgery Versus Angioplasty Using 
SirolimusEluting Stent in Patients With Left Main Coronary Artery Disease) trial 
(12), FREEDOM (Comparison of Two Treatments for Multivessel Coronary Artery 
Disease in Individuals With Diabetes) trial (13), VA CARDS (Coronary Artery 
Revascularization in Diabetes) (14), BEST (Bypass Surgery Versus Everolimus-
Eluting Stent Implantation for Multivessel Coronary Artery Disease) (15), EXCEL 
(Evaluation of Xience Versus Coronary Artery Bypass Surgery for Effectiveness 
of Left Main Revascularization) trial (16), and NOBLE (Percutaneous Coronary 
Angioplasty Versus Coronary Artery Bypass Grafting in Treatment of Unprotected 
Left Main Stenosis) trial (17) (Supplemental Figure 1). Only the data from the 
LE MANS (Study of Unprotected Left Main Stenting Versus Bypass Surgery) trial 
(n = 105) could not be obtained (18). Baseline and procedural characteristics of 
individual trials are presented in Supplemental Table 1. Local medical ethics 
committees approved each trial at the time of study execution. Patients in each of 
the 11 trials provided written informed consent.
OUTCOMES, DEFINITIONS, AND FOLLOW-UP. Follow-up time was calculated 
from the time of the procedure to allow a universal definition of follow-up among 
trials. Follow-up time was calculated from randomization if patients experienced 
a stroke or died before the procedure took place or if patients did not undergo 
revascularization but only received medical treatment. The primary endpoint of 
this study was stroke. A procedural stroke was defined as stroke occurring in the 
first 30 days after the procedure. All trials, except the SoS trial, collected stroke 
during the entire duration of follow-up; the SoS trial collected stroke only up to 1 
year after revascularization (10). Stroke was defined using the criteria applied in 
each study and consisted mainly of: 1) a focal neurological deficit of central origin 
lasting >24 h with or without confirmation with neuroimaging; or 2) a deficit 
lasting >72 h without the need for confirmation with neuroimaging. Secondary 
endpoints of the present study were all-cause mortality after stroke and a 
composite of all-cause mortality or stroke. In all trials, a clinical events committee 
adjudicated the events.
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Patients with MVD were defined as having 2or 3vessel disease without LM disease. 
Patients with LM disease were defined as having LM disease, either isolated or in 
combination with single-vessel disease or MVD.
STATISTICAL ANALYSIS. The main analyses were performed according to the 
intention-to-treat principle. Outcome data were also analyzed on an as-treated basis 
to determine more accurately the impact of the specific procedure on stroke rate. 
Continuous variables are expressed as a mean ± SD and compared using Student’s 
t-tests, and discrete data are presented as frequencies and compared using chi-square 
tests. We pooled the individual patient data from 11 trials to provide descriptive 
statistics and unadjusted Kaplan-Meier curves. Hazard ratios (HR) of CABG versus 
PCI for stroke were estimated using random effects Cox proportional hazards models 
that were stratified by trial, using a gamma frailty term to account for heterogeneity 
among trials. Frailties are unobserved factors, distributed as g random variables 
with a mean of 1 and variance w. Hence, the variance of the frailty terms represents 
heterogeneity in baseline risk among trials. The statistical significance of the variance 
parameter was assessed using the likelihood ratio test. The rate of stroke was 
estimated at 30 days and 5 years, and landmark analyses were performed after 30 days 
follow-up to assess the long-term risk of stroke after CABG versus PCI. Prespecified 
subgroup analyses of 30-day and 5-year stroke rates were performed according to 
baseline clinical and anatomical characteristics and multivessel or LM disease. The p 
values for interaction were calculated in the random effects Cox proportional hazards 
models. Due to a limited number of events in several of the subgroup analyses of 
30-day stroke, no frailty model could be built; in these specific analyses, the HR and 
interaction terms were analyzed through standard Cox proportional hazards models. 
We did not perform interaction analyses on stratification according to LM/MVD, 
because the LM and MVD groups are not mutually exclusive. Moreover, we explored 
the impact of off-pump CABG as opposed to on-pump CABG among trials that 
provided information on the use of cardiopulmonary bypass, the impact of PCI being 
performed with BMS or DES, and the impact of single versus dual antiplatelet therapy 
(DAPT) at hospital discharge on stroke. Multivariable Cox proportional hazards 
models that included baseline and procedural characteristics were constructed to 
predict 30-day and 5year stroke. Variables were included in the multivariable model 
if p < 0.15 at univariable analyses, with the variable CABG versus PCI being forced 
into the model. The impact of stroke within 30 days of the procedure on mortality 
was explored using the Kaplan-Meier method comparing patients with and without 
30-day stroke. The composite rate of all cause mortality or stroke was explored at 30 
days and 5 years in the overall group of patients, and according to status of diabetes, 
SYNTAX score tertiles, and MVD or LM disease. Two-sided p < 0.05 was considered 
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to indicate statistical significance. Statistical analyses were performed using SPSS 
software version 21 (IBM Corporation, Armonk, New York) or R software version 3.2.4 
(Institute for Statistics and Mathematics of Wirtschaftsuniversität, Wien, Austria).
Table 1. Baseline, Procedural, and Discharge Data of Randomized Cohorts.
PCI (n = 5,753) CABG (n = 5,765)
Age, yrs 63.6 ± 9.8 (5,753) 63.7 ± 9.9 (5,765)
Female 23.9 (1,373/5,753) 23.8 (1,371/5,765)
BMI >30 kg/m2 28.1 (1,548/5,506) 28.3 (1,558/5,511)
Smoking, current 22.3 (1,274/5,701) 22.3 (1,273/5,703)
Diabetes 38.5 (2,215/5,753) 37.7 (2,171/5,765)
Insulin treatment 12.9 (545/4,234) 11.9 (504/4,245)
Hypertension 67.6 (3,880/5,739) 68.1 (3,913/5,748)
Hypercholesterolemia 69.5 (3,982/5,726) 67.3 (3,862/5,735)
Peripheral vascular disease 8.2 (424/5,158) 8.5 (440/5,164)
Carotid artery disease 7.8 (161/2,072) 8.1 (168/2,074)
Previous TIA or CVA 5.4 (218/4,052) 6.2 (253/4,054)
Previous MI 28.0 (1,438/5,138) 27.5 (1,417/5,156)
LV dysfunction, <30% 0.9 (49/5,303) 1.0 (54/5,430)
Unstable disease 34.6 (1,786/5,158) 34.2 (1,767/5,160)
3-vessel disease* 58.6 (2,460/4,201) 61.8 (2,594/4,197)
Left main disease 38.8 (2,233/5,753) 38.9 (2,245/5,765)
SYNTAX score 26.0 ± 9.3 (4,081) 26.0 ± 9.8 (4,057)
PCI–DES used† 73.4 (4,120/5,610) —
PCI–number of stents 3.1 ± 2.0 (4,935) —
CABG–LIMA use — 96.2 (4,574/4,753)
CABG–BIMA use — 18.7 (771/4,122)
CABG–off-pump — 27.5 (1,085/3,945)
Aspirin at discharge 97.3 (4,487/4,612) 95.5 (3,814/3,994)
Thienopyridine at discharge 96.7 (4,479/4,630) 45.1 (1,815/4,026)
DAPT at discharge 95.1 (4,384/4,612) 44.0 (1,759/3,994)
Values are mean ± SD (N) or % (n/N). *Of the group of patients with multivessel disease. 
†Data only for patients who were randomized to PCI and indeed underwent PCI. The type of 
stent used was not available for 1 patient enrolled in the VA CARDS trial. BIMA, bilateral 
internal mammary artery; BMI, body mass index; CABG, coronary artery bypass grafting; CVA, 
cerebrovascular accident; DAPT, dual antiplatelet therapy; DES, drugeluting stents; LIMA, left 
internal mammary artery; LV, left ventricular; MI, myocardial infarction; PCI, percutaneous 
coronary intervention; SYNTAX, Synergy Between Percutaneous Coronary Intervention 
With Taxus and Cardiac Surgery; TIA, transitory ischemic attack; VA CARDS, Coronary Artery 
Revascularization in Diabetes.
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ROLE OF THE FUNDING SOURCE. Whereas several of the individual studies were 
funded by industry, this collaborative analysis had no external funding and did not 
involve any of the original study sponsors.
RESULTS
STUDY POPULATION. Eleven trials randomized 11,518 patients; 5,765 patients 
were randomly assigned to CABG and 5,753 to PCI. Of the 5,765 patients assigned 
to CABG, 5,421 underwent CABG (94%), 233 underwent PCI (4%), and 111 
underwent neither procedure (2%). Of the 5,753 patients assigned to PCI, 5,610 
underwent PCI (98%), 101 underwent CABG (2%), and 42 underwent neither 
procedure (1%). In the as-treated analysis, 5,522 patients underwent CABG and 
5,843 patients underwent PCI. Data on crossovers in each study are presented in 
Supplemental Table 2.
Patient enrollment was between 1995 and 2015 (Supplemental Table 1). PCI was 
performed in 4 trials exclusively with BMS (MASS II, ERACI II, SoS, and ARTS; 
n = 1,518 PCI patients), in 3 trials with firstgeneration DES (PRECOMBAT, SYNTAX, 
and FREEDOM; n = 2,156 PCI patients), in 3 trials with second-generation DES 
(BEST, EXCEL, and NOBLE; n = 1,978 PCI patients), and in 1 trial with a mix of stent 
generations (VA CARDS; n = 101 PCI patients).
There were no clinically significant differences in baseline characteristics between 
patients randomly assigned to either CABG or PCI (Table 1). The pooled patient 
population had a mean age of 63.6 ± 9.8 years, and 24% were female. Diabetes was 
present in 38% of patients, with 12% on insulin. LM disease was present in 39% 
of patients. At discharge, antiplatelet therapy was prescribed significantly more 
often after PCI than after CABG (p < 0.001 for all analyses). The mean follow-up 
was 3.8 ± 1.4 years.
FREQUENCY AND PREDICTORS OF STROKE. A total of 293 strokes occurred 
during follow-up. The cumulative stroke rate at 5-year follow-up was 2.6% 
(129 strokes) in patients randomized to PCI and 3.2% (164 strokes) in patients 
randomized to CABG (HR: 0.77; 95% confidence interval (CI): 0.61 to 0.97; p = 
0.027) (Central Illustration, panel A). At 30 days, stroke occurred in 21 patients 
(0.4%) randomized to PCI and 64 patients (1.1%) randomized to CABG (HR: 0.33; 
95% CI: 0.20 to 0.53; p < 0.001) (Central Illustration, panel B). The rate of stroke 
between 31 days up to 5 years was comparable between PCI (2.2%; 108 strokes) 
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and CABG (2.1%; 100 strokes) (HR: 1.05; 95% CI: 0.80 to 1.38; p = 0.72) (Central 
Illustration, panel B). Results were similar in the as-treated analysis. The value 
of the frailty parameter theta (q) for heterogeneity was q = 0.09 (p < 0.001). In 
a multivariable analysis, the only independent predictor of 30-day stroke was 
CABG (HR: 8.33; 95% CI: 1.06 to 62.5; p = 0.043). In multivariable analysis of 5-year 
stroke, CABG was not an independent predictor (HR: 1.43; 95% CI: 0.94 to 2.13; p = 
0.089). In 7 trials that provided data on on-pump or offpump CABG (n = 3,945), 28% 
of patients underwent off-pump CABG surgery. Rates of stroke at 30 days were 0.6% 
(6 of 1,085) after off-pump CABG and 1.4% (40 of 2,860) after on-pump CABG (p = 
0.13), with 5-year rates of 2.9% (25 of 1,085) versus 3.5% (84 of 2,860), respectively (p 
= 0.60). After CABG, 44% of patients were discharged on DAPT. The rate of stroke at 5 
years was comparable between patients on DAPT or single antiplatelet therapy (3.1% 
(48 of 1,759) vs. 3.8% (67 of 2,109), respectively; p = 0.84).
Whether PCI was performed with BMS or DES did not have an impact on the rate 
of stroke at 30 days (0.5% (7 of 1,518) vs. 0.3% (14 of 4,235); p = 0.89) or 5 years (2.6% 
(39 of 1,518) vs. 2.7% (90 of 4,235); p = 0.83). When analyzing BMS and DES trials 
separately, the difference between PCI and CABG in 5-year stroke was similar among 
trials that used exclusively BMS (2.6% vs. 3.2%, respectively; p = 0.39) or DES (2.7% 
vs. 3.3%, respectively; p = 0.038) (p for interaction = 0.78). Only 190 patients were 
discharged on single antiplatelet therapy after PCI, with the rates of stroke at 5 years 
being 2.5% (91 of 4,384) for patients on DAPT and 4.0% (5 of 190) for patients on single 
antiplatelet therapy (p = 0.41).
SUBGROUP ANALYSES. There were no significant interactions between any the 
treatment effects of PCI versus CABG in the rate of stroke at 30 days except for the 
presence of hypercholesterolemia (p for interaction = 0.023) (Figure 1). There were 
no significant interactions between PCI and CABG and baseline characteristics on 
the rate of stroke at 5 years, except for diabetes (Figures 2 and 3). As shown in Figure 
3A, the 5-year rate of stroke was lower in patients with diabetes randomized to PCI 
versus CABG (2.6% (n = 47 of 2,215) vs. 4.9% (n = 86 of 2,171), respectively; HR: 0.52; 
95% CI: 0.37 to 0.75; p < 0.001) but not in patients without diabetes (2.6% (n = 82 of 
3,538) vs. 2.4% (n = 78 of 3,594), respectively; HR: 1.04; 95% CI: 0.77 to 1.42; p = 0.78) (p 
for interaction = 0.004).
In 4,478 randomized patients with LM disease, treatment with PCI compared with 
CABG resulted in a lower rate of stroke at 30 days (0.3% (6 of 2,233) vs. 1.0% (23 of 
2,245), respectively; HR: 0.26; 95% CI: 0.11 to 0.64; p = 0.003), a difference that was 
no longer present at 5 years (2.6% (43 of 2,233) vs. 2.6% (51 of 2,245), respectively; HR: 
177
Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization
8
0.83; 95% CI: 0.55 to 1.24; p = 0.36) (Figure 3B). In 7,040 randomized patients with 
Figure 1. Stroke After PCI Versus CABG at 30 Days in Subgroup Analyses According to 
Baseline and Procedural Characteristics. *Due to the low number of events, the interaction 
term was derived from Cox proportional hazards models and not the random effects Cox 
proportional hazards models that included a frailty term. BMS, bare-metal stents; CI, conﬁdence 
interval; DES, drug-eluting stents; HR, hazard ratio; LVEF, left ventricular ejection fraction; MI, 
myocardial infarction; SYNTAX, Synergy Between Percutaneous Coronary Intervention With 
Taxus and Cardiac Surgery.
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Figure 2. Stroke After PCI Versus CABG During 5-Year Follow-Up in Subgroup Analyses 
According to Baseline and Procedural Characteristics. Abbreviations as in Figure 1.
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MVD, the rate of stroke was significantly lower after PCI than after CABG at 30 days 
(0.4% (15 of 3,520) vs. 1.2% (41 of 3,520), respectively; HR: 0.36; 95% CI: 0.20 to 0.65; 
p < 0.001) and 5 years (2.7% (86 of 3,520) vs. 3.6% (n = 113 of 3,520), respectively; HR: 
0.74; 95% CI: 0.56 to 0.99; p = 0.039).
IMPACT OF STROKE ON MORTALITY. A total of 976 deaths occurred 
during follow-up. Patients who experienced a stroke within 30 days after 
revascularization had significantly higher 5-year mortality compared with 
patients who did not experience a stroke within 30 days after both CABG (41.5% 
(23 of 64) vs. 8.9% (414 of 5,701); p < 0.001) and after PCI (45.7% (9 of 21) vs. 11.1% 
(530 of 5,732), respectively; p < 0.001) (Figure 4).
COMPOSITE ENDPOINT OF ALL-CAUSE MORTALITY OR STROKE. As shown in 
Table 2, the rate of all-cause mortality or stroke at 30 days was 1.6% (91 of 5,753) 
after PCI versus 2.4% (135 of 5,765) after CABG (p = 0.003). The composite of 
all-cause mortality or stroke between 31 days and 5 years was higher after PCI 
compared with CABG (11.6% vs. 9.3%, respectively; HR: 1.26; 95% CI: 1.11 to 1.32; p 
< 0.001). Finally, the overall difference in the composite of all-cause mortality or 
stroke after PCI versus CABG at 5 years did not reach statistical significance (13.0% 
vs. 11.4%, respectively; HR: 1.11; 95% CI: 0.99 to 1.24; p = 0.069).
Although there were no significant interactions, the benefit of CABG over PCI was 
generally seen in patients with diabetes and higher SYNTAX scores. The difference 
between PCI and CABG in rates of the composite of all-cause death or stroke at 30 
days was similar in patients with MVD (1.8% (n = 62) vs. 2.6% (n = 90); HR: 0.68; 95% 
CI: 0.49 to 0.94; p = 0.020) and LM disease (1.3% (n = 29) vs. 2.0% (n = 45); HR: 0.64; 
95% CI: 0.40 to 1.02; p = 0.062).
Between 31 days and 5 years, the rate of the composite of all-cause death or stroke 
after PCI versus CABG was 11.9% (n = 371) versus 9.1% (n = 274) in patients with MVD 
(HR: 1.31; 95% CI: 1.12 to 1.53; p < 0.001) and 11.3% (n = 174) versus 10.2% (n = 147) in 
patients with LM disease (HR: 1.16; 95% CI: 0.93 to 1.44; p = 0.20). At 5 years, there 
was a difference between PCI and CABG in patients with MVD (13.5% (n = 433) vs. 
11.4% (n = 364); HR: 1.16; 95% CI: 1.01 to 1.33; p = 0.041) but not in patients with LM 
disease (12.4% (n = 203) vs. 12.0% (n = 192); HR: 1.02; 95% CI: 0.84 to 1.25; p = 0.81).
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Figure 3. Stroke After PCI Versus CABG During 5-Year Follow-Up of Patients With and 
Without DM, LM, or MVD. Stroke after PCI (percutaneous coronary intervention) versus CABG 
(coronary artery bypass grafting) during 5-year follow-up of patients with and without diabetes 
mellitus (DM) (A) and patients with left main (LM) or multivessel disease (MVD) (B). There was 
significant diabetes-by-treatment interaction (p for interaction = 0.004). No interaction was explored 
for LM and MVD, because these groups are not mutually exclusive. Abbreviations as in Figure 1.
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Figure 4. Mortality After PCI Versus CABG of Patients With and Without Stroke Within 30 Days 
After Revascularization. Solid lines indicate patients who experienced a stroke within the ﬁrst 30 
days of follow-up, and dotted lines indicate patients without a stroke. Follow-up starts at 30 days, 
indicated here as time 0. Abbreviations as in Figures 1 and 3.
DISCUSSION
In this individual patient-data pooled analysis based on 11 randomized clinical 
trials comparing CABG with PCI for multivessel or LM disease, CABG resulted 
in significantly higher rates of 5-year stroke. A higher rate of stroke in the first 
30 days after the procedure drove the difference. Rates of stroke between 31-day 
and 5-year follow-ups were similar between CABG and PCI. The increased 5-year 
risk of stroke with CABG compared with PCI was confined to patients with MVD 
and diabetes. Strokes occurring within 30 days after the procedure were strongly 
associated with increased long-term mortality, with a rate approaching 50% at 5 
years. The composite of allcause mortality or stroke was lower after PCI compared 
with CABG at 30 days, but higher after PCI at 5 years, especially in patients with 
diabetes, MVD, and in those with high SYNTAX scores.
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Periprocedural strokes are more common after CABG, with an absolute 
incremental risk of nearly 0.7% observed in the present large-scale study. The 
mechanisms underlying the increased risk of stroke with surgery are likely 
multifactorial. First, most CABG procedures are performed on-pump with 
cannulation and clamping of the aorta; even if they are performed off-pump, the 
aorta is often manipulated for construction of the proximal anastomosis (19–21). 
Data from cohort studies suggests that limiting, if not completely avoiding, aortic 
manipulation by performing an anaortic off-pump CABG procedure reduces 
stroke rates substantially (22,23). The use of bilateral internal mammary arteries 
avoids the need for proximal anastomoses and side-clamping of the aorta and 
has been associated with lower stroke rates (24). In the current study, the rate of 
bilateral internal mammary arteries use was relatively low. Second, strategies to 
reduce post-operative bleeding that are often required after CABG (but not after 
PCI), such as usage of tranexamic acid, lead to a hypercoagulable state that may 
increase the risk of stroke (25). Third, post-operative atrial fibrillation is frequent 
after CABG and increases the risk of stroke in the early post-operative period 
(26,27). Fourth, periods of hypoperfusion during surgery and early postoperative 
low cardiac output syndrome may impair brain perfusion, leading to ischemia 
and watershed strokes (28). Another hypothesis is that strokes may be lower after 
PCI due to the routine use of DAPT after stent implantation (29). However, in the 
current study, we did not find this to be associated with a lower rate of stroke 
after CABG.
Our landmark analysis demonstrated a low rate of stroke beyond 30 days that 
was similar between CABG and PCI. The need for more repeat revascularizations 
after PCI than after CABG, as shown in these individual trials (30), did not result 
in a higher stroke rate during follow-up after PCI. Moreover, subgroup analyses 
demonstrated no significant heterogeneity according to baseline characteristics, 
with the important exception of diabetes: stroke rates were nearly doubled 
after CABG compared with PCI in patients with diabetes, but nearly identical 
in patients without diabetes (p for interaction = 0.004). This finding should be 
considered hypothesis-generating and requires confirmation in future studies.
Whereas PCI was associated with lower periprocedural rates of stroke compared 
with CABG in patients with MVD and patients with LM disease, the long-term risk 
of stroke was higher after PCI than CABG in those with LM disease. This finding is 
likely the result of inclusion of the NOBLE trial in which long-term rates of strokes 
were inexplicably higher after PCI than after CABG (17), a finding not confirmed 
in any other randomized trial.
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When the endpoints of all-cause mortality and stroke were combined in a 
composite endpoint, there was no significant difference in the 5-year rates of 
death or stroke between PCI and CABG. However, CABG was associated with 
superior outcomes in patients with MVD, diabetes, and higher SYNTAX scores, 
but not in patients with LM disease.
It remains unclear whether there is a difference in the severity of stroke 
occurring after CABG and PCI. In the FREEDOM trial, severely disabling strokes 
accounted for 55% of all strokes after CABG but only 27% of all strokes after PCI 
(13). An indepth analysis of strokes occurring in the SYNTAX trial showed that 
residual defects were present at discharge in 68% of patients after CABG and in 
47% after PCI (31). It is evident that quality of life of patients who experienced a 
stroke is impaired, although no studies have compared quality of life of patients 
experiencing a stroke after CABG or PCI to determine whether the higher rate of 
residual deficits after CABG is translated into significantly lower long-term quality 
of life. We did, however, find that 5-year mortality was markedly higher among 
patients who experienced a 30-day stroke versus those who did not experience a 
stroke, regardless of whether stroke occurred after CABG or PCI.
The present analysis has several strengths. Sharing of trial data among 
investigators is crucial to compare low-frequency outcomes such as stroke and 
to assess safety and efficacy in patient subgroups (32). This collaborative analysis 
from 11 randomized clinical trials had sufficient power to analyze the occurrence 
of stroke after CABG versus PCI. Moreover, the inclusion of patients from 
different geographic areas increases the external validity of our results. All trials 
prospectively enrolled patients and had a clinical events com mittee to adjudicate 
events, confirming the diagnosis of stroke.
STUDY LIMITATIONS. First, techniques for both CABG and PCI have evolved 
during the patient inclusion period that ranged from 1995 to 2015. Although we 
showed consistent stroke rates after PCI with BMS and DES and for off-pump and 
onpump CABG, it is unclear whether other unmea sured factors may have played 
a role. Second, there was some heterogeneity in baseline characteristics between 
trials, with more recent trials enrolling patients with more complex coronary 
artery disease and with a greater frequency of diabetes. Third, several variables 
potentially related to stroke after CABG were not collected in many of the included 
trials (e.g., aortic manipulation, post-operative atrial fibrillation), and therefore 
our multivariable models could not include factors that may have predicted 
periprocedural stroke. Fourth, rates of stroke may have been underestimated 
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because independent neurological evaluation was not routinely performed nor 
required for the diagnosis of stroke. Involvement of a stroke neurologist has been 
shown to increase the number of strokes found after aortic valve procedures and 
is now mandatory in trials of transcatheter and surgical aortic valve replacement 
(33). Fifth, data on the severity of stroke and residual deficits after stroke 
could not be evaluated because only 2 trials collected such data and definitions 
varied. Finally, antiplatelet therapy may reduce the occurrence of stroke, but 
we lacked data of medication regimens during follow-up. Nevertheless, most 
patients receive at least 1 antiplatelet agent after CABG or PCI, which is generally 
considered to be sufficient for stroke prevention.
CONCLUSIONS
In this large-scale, individual patient-data pooled analysis of randomized trials 
including patients with multivessel or LM coronary artery disease who underwent 
coronary revascularization, PCI resulted in significantly lower 30-day and 5-year 
rates of stroke than CABG, with similar rates of stroke between 31 days and 5 
years. The increased 5-year risk of stroke with CABG was confined to patients with 
MVD and diabetes. Five-year mortality was high in patients experiencing a stroke 
within 30 days after both CABG and PCI. The differential risks of stroke after PCI 
and CABG should be considered in the comprehensive assessment of the long-
term risk-benefit ratio of these alternative revascularization options.
CLINICAL PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: In patients 
undergoing coronary revascularization for multivessel or LM disease, rates of 
stroke were lower after PCI than CABG during the first 30 days but comparable 
thereafter during the next 5 years.
TRANSLATIONAL OUTLOOK: More studies are needed on strategies to prevent 
perioperative stroke in patients undergoing CABG surgery.
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Central illustration Stroke After Percutaneous Coronary Intervention Versus Coronary Artery 
Bypass Grafting.
This ﬁgure illustrates the comparison of coronary artery bypass grafting (CABG) and percutaneous 
coronary intervention (PCI) on stroke during 5-year follow-up (A) and in landmark analyses of stroke 
at 30 days and beyond 30 days (B). Hazard ratios (HR) are for PCI versus CABG. CI, conﬁdence interval.
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Supplemental Table 2. Data on cross-overs in each trial. 
Randomized to CABG Randomized to PCI
Actual CABG Actual PCI No Revasc. Actual CABG Actual PCI No Revasc.
ARTS 579 19 7 6 593 1
ERACI-II 209 16 0 3 222 0
MASS-II 198 0 5 6 194 5
VA-CARDS 81 11 5 6 93 2
SoS 487 11 2 7 480 1
FREEDOM 893 18 36 5 939 9
SYNTAX 854 16 27 11 885 7
PRECOMBAT 248 51 1 24 276 0
BEST 382 51 9 19 413 6
NOBLE 567 23 2 7 580 5
EXCEL 923 17 17 7 935 6
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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Supplemental Figure 1. Study selection flow-chart.
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TO THE EDITOR:
Myles et al. found that treatment with tranexamic acid in patients undergoing 
coronary-artery surgery showed benefits over placebo by lowering the risk of 
major hemorrhage or cardiac tamponade leading to reoperation. Tranexamic 
acid was associated with higher rates of seizures than placebo but with similar 
rates of death and thrombotic events at 30 days. The trial was designed to use 
tranexamic acid at a loading dose of 12.5 mg per kilogram, a maintenance 
infusion of 6.5 mg per kilogram per hour, and a dose of 1 mg per kilogram added 
to the cardiopulmonary-bypass priming solution (1). However, a fixed dose of 
100 mg per kilogram was used and was lowered to 50 mg per kilogram after the 
enrollment of 30% of the trial population.
On the basis of other evidence (2), patients who received 50mg per kilogram were 
probablyless effectively treated without evidence of better safety (3). In the trial, 
the low dose of tranexamic acid was not safer than the high dose in terms of the 
risk of seizure (0.7% vs. 0.6%) but was associated with significantly lower efficacy in 
terms of bloodloss (P=0.03 for interaction)and number of units transfused (P=0.02 
for interaction). Moreover, plasma concentrations of tranexamic acid were aimed 
to be effective for 6 to 8 hours, but no target concentrations or intraoperative 
measurements of concentrations are mentioned. For clinicians who want to 
administer tranexamic acid routinely, the trial is unclear about which dose is to 
be used. We believe that the evidence supports a high dose overa low dose.
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ABSTRACT
OBJECTIVES: The study sought to determine the incidence, predictors, 
characteristics, and outcomes of repeat revascularization during 5-year follow-
up of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With 
TAXUS and Cardiac Surgery) trial.
BACKGROUND: Limited in-depth long-term data on repeat revascularization are 
available from randomized trials comparing percutaneous coronary intervention 
(PCI) or coronary artery bypass grafting (CABG).
METHODS: Incidence and timing of repeat revascularization and its relation 
to the long-term composite safety endpoint of death, stroke, and myocardial 
infarction were analyzed in the SYNTAX trial (n = 1,800) using Kaplan-Meier 
analysis.
RESULTS: At 5 years, repeat revascularization occurred more often after initial 
PCI than after initial CABG (25.9% vs. 13.7%, respectively; p < 0.001), and more 
often consisted of multiple repeat revascularizations (9.0% vs. 2.8%, respectively; 
p = 0.022). Significantly more repeat PCI procedures were performed on de novo 
lesions in patients after initial PCI than initial CABG (33.3% vs. 13.4%, respectively; 
p < 0.001). At 5-year follow-up, patients who underwent repeat revascularization 
versus patients not undergoing repeat revascularization had significantly 
higher rates of the composite safety endpoint of death, stroke, and myocardial 
infarction after initial PCI (33.8% vs. 16.6%, respectively; p < 0.001), and a trend 
was found after initial CABG (22.4% vs. 15.8%, respectively; p = 0.07). After 
multivariate adjustment, repeat revascularization was an independent predictor 
of the composite safety endpoint after both initial PCI (hazard ratio (HR): 2.2; 95% 
confidence interval (CI): 1.6 to 3.0; p < 0.001) and initial CABG (HR: 1.8; 95% CI: 1.2 
to 2.9; p = 0.011).
CONCLUSIONS: Repeat revascularization rates are significantly higher after 
initial PCI than after initial CABG for complex coronary disease. Repeat 
revascularization is an independent predictor of death, stroke, and myocardial 
infarction for myocardial revascularization. 
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INTRODUCTION
Repeat revascularization is a controversial endpoint in clinical trials comparing 
percutaneous coronary intervention (PCI) with coronary artery bypass grafting 
(CABG). It is often criticized because of its subjective and biased nature, as the 
underlying incentive to perform repeat revascularization may be different after 
PCI than CABG.
However, repeat revascularization as an outcome can be of great importance 
(1,2). Although it is usually considered an adverse outcome or failure of the initial 
treatment, repeat revascularization is an efficient therapy associated with a 
reduction in morbidity and mortality (3,4). Although its incidence is highly time 
dependent, the need for repeat revascularization also varies greatly depending on 
the studied population (5,6).
Few data beyond early follow-up of repeat revascularization exist and therefore 
it remains largely unclear which patients are at risk for repeat revascularization, 
what current practice regarding repeat revascularization does entail, and what is 
the actual impact of repeat revascularization on short-term and long-term clinical 
outcomes. Particularly, despite the completion of numerous trials comparing PCI 
with CABG, very limited in-depth long-term follow-up data on practice of repeat 
revascularization in randomized trials is available (1,7). Therefore, this study 
aims to provide insights from a randomized trial comparing PCI with CABG into 
the predictors, characteristics, and short-term and 5-year outcomes of repeat 
revascularization in the SYNTAX (Synergy Between Percutaneous Coronary 
Intervention With TAXUS and Cardiac Surgery) trial.
METHODS
STUDY DESIGN. The SYNTAX trial is a randomized, prospective, multicenter trial 
on the basis of an allcomers design that included patients with complex coronary 
artery disease as defined by the presence of unprotected left main or 3-vessel 
disease. Patients (n = 1,800) were randomized on a 1:1 basis by the Heart Team 
consensus to undergo either CABG or PCI with TAXUS Express paclitaxel-eluting 
stents (Boston Scientific, Marlborough, Massachusetts). If considered unsuitable 
for randomization, patients were entered in to 1 of 2 parallel nested registries 
(PCI registry, n = 193; CABG registry, n = 1,077) (8). This study only included 
comparisons between the randomized cohorts of patients. Indications for repeat 
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revascularization were not specified in the original trial protocol and were on the 
basis of local practice at each participating site.
DEFINITIONS. The primary endpoint of the SYNTAX trial was a composite of 
major adverse cardiac or cerebrovascular events that includes all-cause death, 
myocardial infarction (MI), stroke, and repeat revascularization. Because 
the primary interest of this analysis is to investigate repeat revascularization 
and clinical outcomes during follow-up, the individual endpoints of repeat 
revascularization (all, repeat PCI, and repeat CABG) and all-cause mortality were 
evaluated, as well as the composite safety endpoint of all-cause death, MI, and 
stroke. Definitions of these individual components have been previously reported 
(9). An independent Clinical Events Committee, including cardiologists, cardiac 
surgeons, and a neurologist, reviewed all primary clinical endpoints. In addition, 
revascularization was divided into target vessel revascularization (TVR), target 
vessel target lesion revascularization (TLR), revascularization of a de novo lesion 
in a target vessel (remote TVR), revascularization of a de novo lesion in a nontarget 
vessel (NTVR), de novo lesion revascularization (in both target and nontarget 
vessel), and, for patients who had previously undergone CABG, revascularization 
of a bypass graft.
During the Heart Team meeting when patients were assessed for randomization, 
both the interventional cardiologist and surgeon documented which vessels with 
a >1.5 mm diameter and a 50% stenosis needed revascularization. Incomplete 
revascularization was assessed by correlating this pre-operative statement to the 
actual revascularization.
Throughout the manuscript, initial PCI and initial CABG will refer to the 
procedures to which patients were randomized at the start of the SYNTAX trial. 
Repeat PCI and repeat CABG will refer to repeat revascularizations, irrespective 
of what was the initial procedure.
As initial therapy after randomization, a staged revascularization procedure 
was allowed if performed within 72 h after the first procedure and during the 
same hospital stay or within 14 days in patients with renal insufficiency or post-
procedural contrastinduced nephropathy. All staged procedures have been 
adjudicated by the Clinical Events Committee as such.
To determine procedural adverse events of repeat revascularization, the 
following events were counted when occurring during 30 days after repeat 
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revascularization: death, stroke, subsequent repeat revascularization(s) and MI, 
and the corresponding composite endpoint. To evaluate the effect of successful 
repeat revascularization, an additional analysis was performed by not taking into 
account MI events occurring on the same day as the repeat revascularization. 
Furthermore, a comparative analysis between groups of initial PCI and initial 
CABG was performed of elective and urgent repeat revascularizations.
Indications leading to repeat revascularization included stable angina, unstable 
angina, MI, silent ischemia (established by stress testing), and other reasons 
including both periprocedural complications (bleeding, graft failure or stent 
thrombosis, and technique-related adverse events) and evidence of progression 
of disease (not classified as angina).
STATISTICAL METHODS. Continuous variables are given as mean ± SD and 
compared using the Student t test. Discrete variables are expressed as counts and 
percentages, and comparisons between groups were done with the chi-square 
or Fisher exact test, when appropriate. For comparisons across subgroups, the 
Kruskal-Wallis test, the Wilcoxon rank sum test using pairwise comparisons, and 
the chi-square test for comparing proportions (of categorical variables) between 
>2 groups have been used. Bonferroni method was used to adjust p values for 
multiple comparisons. Five-year clinical outcomes were estimated using the 
Kaplan-Meier method, with comparisons made using the log-rank test (overall 
or pairwise as appropriate). To account for the informative censoring in the 
presence of multiple endpoints, competing risks survival analysis was performed 
by means of nonparametric methods using the cumulative incidence competing 
risk method (10–12). Landmark analyses were used to describe the occurrence of 
repeat revascularization in time: early (within 30 days), intermediate (between 30 
days and 1 year), or late (through 1 to 5 years). After careful selection of baseline 
characteristics and periprocedural variables on the basis of clinical judgment 
(Supplemental Appendix), univariable assessment and multiple testing to 
ensure stability, a multivariable model has been fitted. Multivariable predictors 
of repeat revascularization after initial PCI and initial CABG were determined 
using Backward Wald stepwise selection with a significance level of <0.10 for entry 
and exit in a Cox proportional hazards model. Correlations between variables 
were explored with the Pearson correlation coefficient and highly correlated 
variables were not included in the multivariable model. To evaluate the impact of 
repeat revascularization on clinical outcomes, a comparison was made between 
patients with no repeat revascularization versus events that occurred after 
repeat revascularization in patients who did undergo repeat revascularization. 
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Multivariable Cox proportional hazard analyses were used to determine whether 
repeat revascularization was an independent predictor of the composite safety 
endpoint of all-cause death, stroke, and MI (Model 1), while adjusting for 
baseline characteristics and periprocedural variables (Supplemental Appendix). 
A second model was fitted to relate the type of repeat revascularization (repeat 
PCI revascularization and repeat CABG revascularization) with the composite 
safety endpoint, using a stepwise 2-block model (Model 2). A third model was 
fitted to relate target lesion revascularization (restenosis surrogate) and de novo 
lesion revascularization (marker of disease progression) with the composite 
safety endpoint, using a stepwise 2-block model (Model 3). The proportionality 
of hazards assumption was checked using the global proportionality of hazards 
test on the basis of Schoenfeld residuals. There was no departure from the 
proportionality of hazards assumption in the groups of patients with initial 
CABG (predictors of repeat revascularization: chi-square = 9.11, df = 10, p = 0.52; 
predictors of composite safety endpoint: chi-square = 5.35, df = 9, p = 0.80) and 
initial PCI (predictors of repeat revascularization: chi-square = 13.66, df = 9, p = 
0.14; predictors of composite safety endpoint: chi-square = 6.34, df = 8, p = 0.61). 
A 2-sided p value of 0.05 was considered to be statistically significant for all tests. 
All analyses were conducted using SPSS 21.0 (SPSS Inc., Chicago, Illinois) and SAS 
V.9.3 software (SAS Institute, Cary, North Carolina).
RESULTS
INCIDENCE, TIMING, AND TYPE OF REPEAT REVASCULARIZATION. During 
5-year follow-up, 459 repeat revascularization events were registered; 86.2% 
consisting of repeat PCI and 14.8% of repeat CABG revascularization. Rates of 
repeat revascularization at 5 years after initial CABG and initial PCI were 13.7% 
and 25.9%, respectively (p < 0.001). At all time points during follow-up, repeat 
revascularization rates were significantly higher after initial PCI than after initial 
CABG (Figure 1). After initial CABG treatment, almost all repeat CABG procedures 
were performed within 30 days, with other repeat revascularizations thereafter 
consisting almost exclusively of repeat PCI. Conversely, after initial PCI treatment, 
the relative number of subsequent CABG procedures in relation to repeat PCI 
revascularization remained stable over the length of follow-up. Patients after 
initial PCI more often required multiple repeat revascularizations (9.0% vs. 2.8%, 
respectively; p = 0.022) (Figure 2).
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Kaplan-Meier analysis revealed a higher 5-year cumulative incidence of TVR, 
mainly driven by TLR (19.0% after initial PCI vs. 8.4% after initial CABG; p < 0.001), 
but no difference between groups in remote-TVR or NTVR (Figure 3). There 
were no differences in revascularization for de novo lesions between initial PCI 
and initial CABG (4.8% vs. 6.4%, respectively; p = 0.14). The 5-year cumulative 
incidence of stent thrombosis or graft occlusion was similar after initial PCI and 
initial CABG (5.5% and 4.0%, respectively; p = 0.13), as well as the rate of stent 
thrombosis or graft occlusion leading to repeat revascularization (4.1% and 3.2%, 
respectively; p = 0.31).
In a competing risks analysis, the cumulative incidence of repeat revascularization 
was 19.7% after initial PCI and 11.6% after initial CABG (Supplemental Appendix). 
After initial PCI, death and MI as a first event occurred at a rate of 8.1% and 8.2%, 
respectively. After initial CABG, death and MI occurred as a first event at a rate of 
9.2% and 3.7%, respectively.
Although considered as a single index procedure and not as repeat 
revascularization, 13.6% patients in the initial PCI group underwent a planned 
staged revascularization, resulting in a higher number of actual procedures for 
some patients in the initial PCI group.
REASONS FOR REPEAT REVASCULARIZATION. Symptomatic angina pectoris was 
the primary indication for repeat PCI and its occurrence was largely similar among 
patients randomized to initial PCI versus initial CABG (Table 1). The percentage of 
repeat PCI procedures that were TVR were the majority of all repeat PCI procedures 
after both initial PCI and initial CABG (89.6% and 83.0%, respectively; p = 0.125), 
and about one-half of repeat PCIs in both initial PCI and initial CABG groups were 
performed as TLR procedures (55.7% vs. 51.5%, respectively; p = 1.00). Significantly 
more repeat PCIs were performed on de novo lesions in patients randomized to initial 
PCI versus those randomized to initial CABG (33.3% vs. 13.4%, respectively; p < 0.001). 
About 18% of repeat PCIs in patients initially treated with CABG were performed in 
bypass grafts.
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Figure 3. Repeat Revascularization During 5-Year Follow-Up. Cumulative incidence of 
(A) target vessel revascularization, (B) target lesion revascularization, (C) remote target vessel 
revascularization, (D) nontarget vessel revascularization, (E) de novo lesion revascularization, and 
(F) thrombosis or occlusion leading to repeat revascularization.
Abbreviations as in Figure 1.
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Figure 2. Number and Type of Repeat Revascularizations. Proportion of patients requiring repeat 
revascularization after PCI (blue) and CABG (green). Of the entire 1,800 patients, more patients 
after initial PCI than after initial CABG required multiple repeat revascularizations (9.0% vs. 2.8%, 
respectively; p = 0.022). Hashed rectangles represent repeat CABG revascularizations. Abbreviations 
as in Figure 1.
After initial PCI treatment, 54 patients underwent repeat CABG, of which 88.9% 
had symptoms of angina. In about 70% the indication for repeat CABG was stable 
or unstable angina, whereas in only 5.6% this was because of acute MI. At the time of 
repeat CABG during follow-up, 64.8% of patients initially treated with PCI required 
reintervention in 3 vessels (vs. 12.5% after initial CABG; p = 0.021), whereas patients initially 
treated with CABG predominantly required reintervention in 1 vessel at the time of repeat 
CABG (62.5% vs. 18.5% after initial PCI; p = 0.048). Target vessel repeat revascularization 
by repeat CABG was similar in both groups (PCI: 85.9%, CABG: 83.3%; p = 1.00), whereas 
TLR was higher in patients initially treated with PCI. In the initial CABG group, few 
repeat CABG procedures were preceded by symptoms of angina or acute MI, but 4 events 
(50%) were as a result of acute complications within days of the initial CABG procedure 
(hemorrhage or acute graft failure) (Table 1).
BASELINE AND PROCEDURAL CHARACTERISTICS BY REPEAT REVASCULARIZATION. 
In the initial PCI group, patients that required repeat revascularization, compared with 
those who did not, had a significantly higher rate of diabetes, particularly medically 
treated diabetes (34.1% vs. 22.8%, respectively; p < 0.001), and had more complex disease
211
Incidence, Characteristics, Predictors, and Outcomes of Repeat Revascularization After PCI and CABG
10
Ta
b
le
 1
. C
h
ar
ac
te
ri
st
ic
s 
of
 R
ep
ea
t R
ev
as
cu
la
ri
za
ti
on
s 
at
 th
e 
Ti
m
e 
of
 R
ep
ea
t R
ev
as
cu
la
ri
za
ti
on
.
Re
pe
at
 CA
BG
 R
ev
as
cu
la
riz
at
io
n
Al
l R
ep
ea
t P
CI
 R
ev
as
cu
la
riz
at
io
ns
PC
I G
ro
up
 
(n
 =
 5
4 
Pr
oc
ed
ur
es
)
CA
BG
 G
ro
up
(n
 =
 8
 P
ro
ce
du
re
s)
p 
Va
lu
e
PC
I G
ro
up
(n
 =
 2
59
 P
ro
ce
du
re
s)
CA
BG
 G
ro
up
(n
 =
 1
33
 P
ro
ce
du
re
s)
p 
Va
lu
e
Un
ad
ju
st
ed
Ad
ju
st
ed
Un
ad
ju
st
ed
Ad
ju
st
ed
An
gi
na
 sy
m
pt
om
s
Ye
s
88
.9
 (4
8/
54
)
37
.5
 (3
/8
)
0.
00
3
0.
00
9
74
.1
 (1
92
/2
59
)
76
.7
 (1
02
/1
33
)
0.
58
1.
00
No
5.
6 (
3/
54
)
37
.5
 (3
/8
)
0.
02
4
0.
07
2
16
.2
 (4
2/
25
9)
17
.3
 (2
3/
13
3)
0.
79
1.
00
Sil
en
t i
sc
he
m
ia
5.
6 (
3/
54
)
25
.0
 (2
/8
)
0.
12
0.
36
9.
3 (
24
/2
59
)
6.
0 (
8/
13
3)
0.
33
0.
99
In
di
ca
tio
n l
ea
di
ng
 to
 re
va
sc
ul
ar
iza
tio
n
St
ab
le 
an
gi
na
 
42
.6
 (2
3/
54
)
12
.5
 (1
/8
)
0.
14
0.
70
35
.5
 (9
2/
25
9)
40
.6
 (5
4/
13
3)
0.
33
0.
41
3
Un
sta
bl
e a
ng
in
a
27
.8
 (1
5/
54
)
25
.0
 (2
/8
)
1.
00
1.
00
25
.1
 (6
5/
25
9)
21
.8
 (2
9/
13
3)
0.
47
0.
47
Ac
ut
e M
I
5.
6 (
3/
54
)
0 (
0/
8)
1.
00
1.
00
16
.2
 (4
2/
25
9)
9.
8 (
13
/1
33
)
0.
08
0.
20
Sil
en
t i
sc
he
m
ia
5.
6 (
3/
54
)
12
.5
 (1
/8
)
0.
43
1.
00
10
.0
 (2
6/
25
9)
6.
8 
(9
/1
33
)
0.
28
0.
41
3
Ot
he
r
18
.5
 (1
0/
54
)
50
.0
 (4
/8
)
0.
07
0.
35
13
.1
 (3
4/
25
9)
21
.8
 (2
8/
13
3)
0.
04
2
0.
20
Ve
ss
el 
ty
pe
†
Ta
rg
et
 ve
ss
el
85
.9
 (1
22
/1
42
)
83
.3
 (1
0/
12
)
0.
68
1.
00
89
.6
 (3
36
/3
75
)
83
.0
 (1
61
/1
94
)
0.
02
5
0.
12
5
By
pa
ss
 gr
af
t
0 (
0/
14
2)
75
.0
 (9
/1
2)
<
0.
00
1
<
0.
00
1
0.
5 (
2/
37
5)
18
.0
 (3
5/
19
4)
<
0.
00
1
<
0.
00
1
Ta
rg
et
 le
sio
n
64
.1
 (9
1/
14
2)
8.
3 (
1/
12
)
<
0.
00
1
<
0.
00
1
55
.7
 (2
09
/3
75
)
51
.5
 (1
00
/1
94
)
0.
34
1.
00
De
 no
vo
 le
sio
n
21
.8
 (3
1/
14
2)
0 (
0/
12
)
0.
13
0.
65
33
.3
 (1
25
/3
75
)
13
.4
 (2
6/
19
4)
<
0.
00
1
<
0.
00
1
No
nt
ar
ge
t v
es
se
l‡
De
 no
vo
 le
sio
n
14
.1
 (2
0/
14
2)
8.
3 (
1/
12
)
1.
00
1.
00
10
.4
 (3
9/
37
5)
14
.9
 (2
9/
19
4)
0.
11
0.
55
Nu
m
be
r o
f v
es
se
ls 
re
va
sc
ul
ar
ize
d
1
18
.5
 (1
0/
54
)
62
.5
 (5
/8
)
0.
01
6
0.
04
8
45
.9
 (8
4/
18
3)
53
.9
 (5
5/
10
2)
0.
22
0.
66
2
16
.7
 (9
/5
4)
25
.0
 (2
/8
)
0.
62
1.
00
30
.1
 (5
5/
18
3)
24
.5
 (2
5/
10
2)
0.
34
1.
00
3
64
.8
 (3
5/
54
)
12
.5
 (1
/8
)
0.
00
7
0.
02
1
24
.0
 (4
4/
18
3)
21
.6
 (2
2/
10
2)
0.
66
1.
00
Va
lu
es
 a
re
 %
 (n
/N
). 
*B
on
fe
rr
on
i c
or
re
ct
io
n 
m
et
ho
d 
fo
r 
m
ul
tip
le
 c
om
pa
ris
on
s.
 †
Co
ns
id
er
ed
 o
n 
a 
ve
ss
el
 b
as
is
 a
nd
 n
ot
 a
 p
at
ie
nt
 b
as
is
 fo
r 
re
pe
at
 c
or
on
ar
y 
ar
te
ry
 
by
pa
ss
 g
ra
ft
in
g 
(C
A
BG
) (
pe
rc
ut
an
eo
us
 c
or
on
ar
y 
in
te
rv
en
tio
n 
(P
CI
): 
14
2 
ve
ss
el
s 
re
va
sc
ul
ar
iz
ed
 d
ur
in
g 
54
 e
ve
nt
s 
in
 5
4 
pa
tie
nt
s,
 C
A
BG
: 1
2 
ve
ss
el
s 
re
va
sc
ul
ar
iz
ed
 
du
rin
g 
8 
ev
en
ts
 in
 8
 p
at
ie
nt
s)
 a
nd
 a
ll 
re
pe
at
 P
CI
s 
(P
CI
: 3
75
 v
es
se
ls
 re
va
sc
ul
ar
iz
ed
 d
ur
in
g 
25
9 
ev
en
ts
 in
 1
83
 p
at
ie
nt
s,
 C
A
BG
 1
94
 v
es
se
ls
 re
va
sc
ul
ar
iz
ed
 d
ur
in
g 
13
3 
ev
en
ts
 in
 1
02
 p
at
ie
nt
s)
. ‡
A
ll 
de
 n
ov
o 
le
si
on
s.
 M
I, 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n.
212
Chapter 10
as described by the SYNTAX score (26.6 ± vs. 24.7 ± 11.6, respectively; p = 0.023) at the 
time of randomization (Table 2). They had more stents implanted but had a higher rate 
of incomplete revascularization (53.6% vs. 39.9% among patients not requiring repeat 
revascularization; p < 0.001).
In the initial CABG group, patients requiring repeat revascularization were younger, more 
often underwent an emergent index procedure, and had a lower mean logistic European 
System for Cardiac Operative Risk Evaluation score (3.0 ± 2.8 vs. 4.0 ± 4.6, respectively; p = 
0.001) at the time of randomization (Table 2). The complexity of disease was comparable 
between patients requiring repeat revascularization and those who did not, as was the rate 
of incomplete revascularization (36.1% vs. 43.3%, respectively; p = 0.24). The number of 
grafts was similar, but patients who underwent repeat revascularization more frequently 
underwent complete arterial revascularization, particularly with the use of a radial artery.
PREDICTORS OF REPEAT REVASCULARIZATION. Tables with univariable analyses 
are provided in the Supplemental Appendix. In the final multivariable model to predict 
repeat revascularization in the initial PCI group, medically treated diabetes was a 
strong independent predictor of repeat revascularization (hazard ratio (HR): 1.59; 95% 
confidence interval (CI): 1.20 to 2.12; p = 0.001) (Table 3). The complexity of coronary 
disease as described by the SYNTAX score failed to be a predictor, but instead the number 
of overlapping stents (HR: 1.34; 95% CI: 1.09 to 1.64; p = 0.005) and incomplete initial 
revascularization (HR: 1.54; 95% CI: 1.17 to 2.02; p = 0.002) were found to be independent 
predictors of repeat revascularization. Repeat revascularization was also related to lack of 
antiplatelet therapy as medication at discharge.
In the initial CABG group, enrollment in the United States (HR: 1.75; 95% CI: 1.09 to 
2.81; p = 0.020) and off-pump CABG (HR: 1.51; 95% CI: 0.94 to 2.44; p = 0.091) were 
predictors of repeat revascularization (Table 3). The presence of a left coronary 
artery lesion was found protective for repeat revascularization (HR: 0.55; 95% 
CI: 0.32 to 0.94; p = 0.028). Use of statins but lack of acetylsalicylic acid at discharge 
appears to be inversely related to repeat revascularization.
PROCEDURAL EVENTS FOLLOWING REPEAT REVASCULARIZATION. Thirty-
day adverse event rates following any repeat revascularization were higher after 
initial PCI than after initial CABG; the composite endpoint of death, subsequent 
repeat revascularization, and MI occurred in 22.7% and 11.8%, respectively (p = 
0.017) (Table 4). No strokes were registered in the interval of 30-days following 
any repeat revascularization. MI events occurring on the same day as repeat 
revascularization were excluded to assess the impact of successful repeat 
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revascularization on the 30-day adverse event rates. Under these circumstances 
the difference between initial PCI and initial CABG lost statistical significance 
(13.6% vs. 9.1%, respectively; p = 0.23). Differences between initial PCI and initial 
CABG groups were consistent among all repeat revascularization and PCI repeat 
revascularization.
Although 30-day adverse event rates occurring after elective repeat 
revascularization were almost identical between groups, there was a trend toward 
a higher rate of the composite endpoint after urgent repeat revascularization in 
the PCI group (35.8% vs. 22.2% in the CABG group; p = 0.096), mainly driven by the 
MI rate (26.0% vs. 6.7% in the CABG group; p = 0.006).
OUTCOMES AT 5-YEAR FOLLOW-UP. After initial PCI, the composite safety 
endpoint of all-cause death, stroke and MI was significantly higher among 
patients that underwent repeat revascularization as compared to those who did 
not (27.9% vs. 16.6%, respectively; p < 0.001) (Figure 4). After initial CABG there 
was no difference in the composite safety endpoint (14.9% vs. 15.8%, respectively; 
p = 0.62).
Among patients that underwent repeat revascularization, patients that underwent 
initial PCI versus initial CABG had significantly higher rates of the composite of 
death, MI, or subsequent repeat revascularization (57.4% vs. 38.4%, respectively; 
p = 0.003), which was primarily driven by significantly higher rates of subsequent 
repeat revascularization (43.4% vs. 25.3%, respectively; p = 0.012) and MI (19.2% 
vs. 4.8%, respectively; p = 0.001). There was no significant difference in mortality 
in patients who underwent repeat revascularization after initial PCI versus initial 
CABG (20.2% vs. 13.9%, respectively; p = 0.095) (Figure 5A). When considering 
only patients that underwent repeat PCI procedures, not only subsequent repeat 
revascularization and MI, but also 5-year mortality was higher in patients after 
initial PCI (20.6% vs. 11.5% after initial CABG; p = 0.021) (Figure 5B). Conversely, 
the composite safety endpoint was similar after initial PCI and initial CABG in 
patients not undergoing any repeat revascularization (HR: 0.96; 95% CI: 0.74 to 
1.24; p = 0.73). 
Outcome of MI may be masked by the fact that repeat revascularization is 
sometimes performed because of an MI, whereas MI can also occur 
periprocedurally as a result of repeat revascularization. Rates of an MI before 
repeat revascularization were similar after initial PCI and initial CABG (1.7% vs. 1.2%, 
respectively; p = 0.42), as well as rates of MI without any repeat revascularization 
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(3.4% vs. 2.4%, respectively; p = 0.19). Rates of repeat revascularization without 
any MI during 5-year follow-up were significantly higher after initial PCI than 
after initial CABG (19.2% vs. 11.9%, respectively; p < 0.001). In the initial PCI group 
as compared to the initial CABG group, an MI occurred significantly more often 
on the same day as repeat revascularization (3.3% vs. 0.4%, respectively; p < 0.001). 
An MI also occurred significantly more often after repeat revascularization in the 
initial PCI versus initial CABG group (1.0% vs. 0.1%, respectively; p = 0.022).
THE INDEPENDENT IMPACT OF REPEAT REVASCULARIZATION. After 
performing multivariable analyses (Supplemental Appendix), adjustment for 
baseline and periprocedural characteristics identified repeat revascularization 
as an independent predictor of the composite safety endpoint in the initial PCI 
group (HR: 1.65; 95% CI: 1.20 to 2.27; p = 0.002) (Table 5), for both repeat PCI (HR: 
1.67; 95% CI: 1.20 to 2.32; p = 0.002) and repeat CABG (HR: 1.72; 95% CI: 1.02 to 2.88; 
p = 0.041). Target lesion revascularization was also identified as an independent 
predictor of the composite safety endpoint (HR: 1.69; 95% CI: 1.20 to 2.38; 
p = 0.003), but not de novo lesion revascularization (HR: 1.49; 95% CI: 0.80 to 2.79; 
p = 0.21).
In the initial CABG group, repeat revascularization was not a predictor of the 
composite safety endpoint (HR: 0.92; 95% CI: 0.54 to 1.75; p = 0.92). However, 
although repeat PCI after initial CABG was not a predictor (HR: 0.69; 95% CI: 
0.34 to 1.37; p = 0.28), repeat CABG was associated with the composite safety 
endpoint (HR: 3.32; 95% CI: 1.21 to 9.11; p = 0.020). Neither TLR nor de novo lesion 
revascularization were found to be independent predictors of the composite 
safety endpoint (HR: 1.06; 95% CI: 0.50 to 2.22; p = 0.89; and HR: 0.67; 95% CI: 0.27 
to 1.67; p = 0.39, respectively).
Considering not only events occurring after repeat revascularization but also 
before repeat revascularization, the results were similar (Supplemental Appendix).
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Table 2. Baseline and Procedural Characteristics.
PCI Group (n = 903) CABG Group (n = 897)
Repeat 
Revascularization 
Group (n = 220)
No-Repeat 
Revascularization 
Group (n = 683)
p Value Repeat 
Revascularization 
Group (n = 110)
No-Repeat 
Revascularization 
Group (n = 787)
p Value
Clinical characteristics
Age, yrs 64.8 ± 9.2 65.4 ± 9.8 0.45 63.4 ± 9.0 65.2 ± 9.9 0.07
Female 24.5 (54) 23.3 (159) 0.70 18.2 (20) 21. (169) 0.43
Non-White 5.0 (11) 2.3 (16) 0.044 8.2 (9) 3.9 (31) 0.08
Enrolled in the United States 14.1 (31) 13.5 (92) 0.82 22.7 (25) 12.3 (97) 0.003
Risk factors
Family history of CAD 24.5 (52) 26.9 (174) 0.51 29.7 (30) 27.2 (205) 0.60
Hypertension 75.2 (164) 73.6 (499) 0.63 76.9 (83) 77.0 (603) 0.97
Hyperlipidemia 81.6 (177) 77.8 (528) 0.23 80.0 (88) 76.8 (598) 0.45
Medically treated DM 34.1 (75) 22.8 (156) 0.001 25.5 (28) 24.5 (193) 0.83
Insulin 15.9 (35) 7.9 (54) 0.001 13.6 (15) 9.9 (78) 0.23
Noninsulin 20.9 (46) 17.6 (120) 0.27 16.4 (18) 18.4 (145) 0.60
Current smoker 15.9 (35) 19.3 (132) 0.26 20.9 (23) 22.2 (173) 0.76
Previous MI 33.2 (72) 31.5 (213) 0.65 24.5 (27) 35.1 (273) 0.028
Previous CHF 4.6 (10) 3.8 (26) 0.63 7.3 (8) 5.1 (770) 0.34
Unstable angina 31.4 (69) 28.3 (193) 0.38 33.6 (37) 27.2 (214) 0.16
Peripheral artery disease 9.5 (21) 8.9 (61) 0.78 12.7 (14) 10.3 (81) 0.44
Carotid artery disease 10.0 (22) 7.5 (51) 0.23 4.5 (5) 8.9 (70) 0.12
Previous TIA/CVA 6.8 (15) 7.9 (54) 0.59 8.2 (9) 9.3 (72) 0.72
COPD 9.1 (20) 7.5 (51) 0.44 8.2 (9) 9.4 (74) 0.68
Renal impairment 0.5 (1) 1.3 (9) 0.47 0.9 (1) 1.9 (15) 0.71
BMI, kg/m2 28.4 ± 4.8 28.0 ± 4.8 0.39 27.9 ± 4.8 27.9 ± 4.5 0.92
Logistic EuroSCORE 3.5 ± 3.3 3.9 ± 4.9 0.34 3.0 ± 2.8 4.0 ± 4.6 0.001
LVEF <50% 17.8 (38) 20.1 (134) 0.48 14.5 (16) 20.4 (159) 0.15
Coronary complexity
3VD 59.1 (131) 60.9 (416) 0.63 55.5 (61) 62.0 (487) 0.19
Left main 40.9 (90) 39.1 (267) 0.63 44.5 (49) 38.0 (229) 0.19
LCA 89.5 (197) 89.3 (610) 0.92 84.5 (93) 89.6 (704) 0.12
LCxA 89.5 (197) 84.2 (575) 0.05 84.5 (93) 83.6 (657) 0.80
RCA 86.8 (191) 80.5 (550) 0.034 78.2 (86) 81.6 (641) 0.40
No. of lesions 4.5 ± 1.7 4.3 ± 1.8 0.06 4.3 ± 1.9 4.4 ± 1.8 0.65
SYNTAX Score 26.6 ± 10.3 24.7 ± 10.6 0.023 24.5 ± 9.7 24.7 ± 10.0 0.84
216
Chapter 10
Procedural characteristics
Total stents 5.1 ± 2.4 4.5 ± 2.2 0.001
Total stent length 91.7 ± 51 84.7 ± 47 0.07
Total overlapping stents 0.7 ± 0.7 0.6 ± 0.6 0.015
Staged procedure 17.7 (39) 12.6 (86) 0.06
On pump 75.5 (83) 80.2 (631) 0.25
Off pump 20.6 (22) 14.2 (106) 0.09
Arterial conduits 1.5 ± 0.7 1.4 ± 0.6 0.048
Venous conduits 1.2 ± 1.0 1.4 ± 0.9 0.07
Distal anastomoses 3.1 ± 0.9 3.2 ± 0.9 0.28
Grafts per patient 2.7 ± 0.7 2.8 ± 0.7 0.76
LIMA 98.1 (105) 96.7 (722) 0.56
Radial artery 20.6 (22) 13.1 (98) 0.038
BIMA 32.7 (35) 26.9 (201) 0.21
Second arterial graft 43.0 (46) 34.3 (256) 0.08
Complete arterial 28.0 (30) 17.4 (130) 0.008
Incomplete revascularization 53.6 (118) 39.9 (270) <0.001 36.1 (274) 43.3 (388) 0.24
Revascularization priority*†
Elective 92.3 (203) 94.7 (640) 0.57 90.9 (100) 92.5 (703) 1.00
Urgent 5.5 (12) 3.7 (25) 0.78 1.8 (2) 4.1 (31) 1.00
Emergent 2.3 (5) 1.6 (11) 1.00 7.3 (8) 3.4 (26) 0.18
Medication at discharge
ASA 94.1 (207) 97.0 (656) 0.0044 97.3 (107) 87.2 (663) 0.002
Thienopyridine 93.6 (206) 87.8 (661) 0.003 25.5 (28) 18.7 (142) 0.09
Statins 84.5 (186) 87.4 (591) 0.27 70.9 (78) 75.0 (570) 0.36
Values are mean ± SD or % (n). *Elective: scheduled in advance as it does not involve a medical emergency; 
urgent: can wait until the patient is stable; emergent: no choice but immediate intervention.
†Bonferroni correction method for multiple comparisons.
3VD, 3-vessel disease; ASA, acetylsalicylic acid; BIMA, bilateral mammary artery; BMI, body mass index; CAD, 
coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, 
cerebrovascular event(s); DM, diabetes mellitus; EuroSCORE, European System for Cardiac Operative Risk 
Evaluation; IABP, intra-aortic balloon pump; LCA, left coronary artery; LCxA, left circumﬂex artery; LIMA, left 
internal mammary artery; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD, peripheral artery 
disease; RCA, right coronary artery; SYNTAX, Synergy Between Percutaneous Coronary Intervention With TAXUS 
and Cardiac Surgery; TIA, transient ischemic attack; other abbreviations as in Table 1.
Table 2. Continued.
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Figure 4. Clinical Outcomes After PCI and CABG With or Without Repeat Revascularization 
During Follow-Up. Rates of the composite safety endpoint of all-cause death, stroke, and myocardial 
infarction are compared between patients who required (A) any repeat revascularization or (B) only 
repeat PCI revascularization and those who did not require repeat revascularization. Safety endpoint 
was the composite endpoint of all-cause death, stroke, and myocardial infarction (MI). Abbreviations 
as in Figure 1. 
DISCUSSION
The present study is the first in-depth analysis of repeat revascularization from 
any randomized trial comparing CABG with PCI, whose findings are essential in 
understanding the underlying mechanisms of clinical differences between CABG 
and PCI, and provide insights into potential improvements in both surgical and 
interventional treatment. The main findings are that: 1) repeat revascularization 
rates were significantly higher after PCI compared with CABG at early, 
intermediate, and long-term intervals, and more often consisted of multiple 
repeat revascularizations during follow-up; 2) in agreement with available 
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guidelines, repeat revascularizations were most frequently performed by means 
of PCI after both initial PCI and initial CABG (13,14); 3) the consequences of repeat 
revascularization were apparent in the short term and comparable between 
PCI and CABG, whereas long-term rates of all-cause death, stroke, and MI were 
significantly higher after repeat revascularization after initial PCI but not initial 
CABG; and 4) long-term outcomes were comparable among patients not requiring 
repeat revascularization after either initial PCI or initial CABG.
Data from large PCI trials have demonstrated incremental technical advances 
over time, with the latest generation of drug-eluting stents (DES) achieving the 
lowest rates of restenosis, stent thrombosis, and recurrent MI that may all account 
for repeat revascularization (15). In ARTS-I (Arterial Revascularization Therapies 
Study), use of baremetal stents in the PCI group led to a repeat revascularization 
rate of 30.3%, whereas use of DES in the ARTS-II and SYNTAX trial was associated 
with lower repeat revascularization rates (20.3% and 25.9%, respectively) (7,16). 
The current study was performed with first-generation DES and showed that 
repeat revascularization rates were still about twice as high after PCI than after 
CABG during 5-year follow-up. It has been suggested that outcomes would have 
been different had a second-generation DES been used (17). However, the recent 
results from the BEST (Randomized Comparison of Coronary Artery Bypass 
Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients 
with Multivessel Coronary Artery Disease) trial showed that even with the use 
of second-generation everolimus-eluting stents for multivessel disease, CABG 
results were significantly better than PCI at 5-year follow-up due to a reduction in 
repeat revascularization as well as spontaneous MI (18).
In the current study, repeat revascularization after initial PCI consisted mainly 
of TVR and less for de novo lesions. It appears that both progression of disease 
and stent restenosis or thrombosis are more prominent after initial PCI than after 
initial CABG treatment. By placing anastomoses distal to potential future lesions, 
CABG may have a protective effect from repeat revascularization, although it 
does not prevent future lesions (19). The introduction of nextgeneration DES is 
encouraging with reduced rates of stent thrombosis and TVR that may potentially 
mitigate the differences between PCI and CABG (20,21), but their use will not 
eliminate later revascularization for de novo lesions. Assessment of long-term 
results and trials comparing these stents with CABG are required to assess whether 
reductions in TLR are sufficient to provide noninferior outcomes to CABG (22).
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According to our data, reductions in repeat revascularization are translated into 
improved outcomes in clinical endpoints, particularly MI. In the short-term, 
repeat revascularization was associated with increased periprocedural mortality 
and morbidity, which is more prominent after initial PCI than initial CABG 
treatment, likely to be the result of more acute presentation. Therefore, as repeat 
revascularization can also be a life-saving procedure in the setting of an acute MI, 
it is important to mention that by excluding events occurring at the same day of 
Table 5. Predictors of the Composite Safety Endpoint of All-Cause Death, Stroke, and MI.
HR Model 1*
95% CI
p Value HR Model 2†
95% CI
p Value HR Model 3‡
95% CI
p Value
PCI group (n = 903)
Age (yrs) 1.03 1.02–1.05 <0.001 1.03 1.02–1.05 <0.001 1.03 1.02–1.05 <0.001
Previous MI 1.62 1.19–2.20 0.002 1.65 1.22–2.25 0.001 1.64 1.21–2.23 0.002
PAD 2.03 1.35–3.07 0.001 2.05 1.36–3.09 0.001 2.03 1.34–3.08 0.001
Staged procedure 1.83 1.26–2.59 0.002 1.80 1.24–2.61 0.002 1.82 1.25–2.64 0.002
No ASA 2.47 1.43–4.24 0.001 2.45 1.42–4.21 0.001 2.55 1.49–4.37 0.001
No thienopyridine 3.79 2.12–6.77 <0.001 3.63 2.01–6.57 <0.001 3.92 2.20–6.99 <0.001
Statins 0.61 0.41–0.90 0.013 0.60 0.41–0.89 0.012 0.61 0.41–0.91 0.015
All repeat revascularization* 1.65 1.20–2.27 0.002 Not included Not included
PCI repeat revascularization† Not included 1.67 1.20–2.32 0.002 Not included
CABG repeat revascularization† Not included 1.72 1.02–2.88 0.041 Not included
Target lesion revascularization Not included Not included 1.69 1.20–2.38 0.003
De novo lesion revascularization Not included Not included 1.49 0.80–2.79 0.21
CABG group (n = 897)
Age (yrs) 1.07 1.04–1.09 <0.001 1.07 1.04–1.09 <0.001 1.07 1.04–1.09 <0.001
COPD 1.88 1.27–3.29 0.013 1.87 1.17–3.05 0.014 1.82 1.11–2.99 0.017
PAD 2.54 1.34–3.08 <0.001 2.58 1.27–3.06 <0.001 2.51 1.65–3.81 <0.001
Renal impairment 2.63 1.17–6.16 0.023 2.47 1.38–3.16 0.034 2.56 1.12–5.87 0.028
SYNTAX score 1.02 1.00–1.04 0.078 1.02 1.00–1.04 0.10 1.02 1.00–1.03 0.07
No ASA 2.31 1.41–3.30 <0.001 2.29 1.34–3.09 <0.001 2.32 1.52–3.55 <0.001
Statins 0.48 0.36–0.72 <0.001 0.48 0.34–0.69 <0.001 0.47 0.33–0.68 <0.001
All repeat revascularization* 0.92 0.54–1.75 0.92 Not included Not included
PCI repeat revascularization† Not included 0.69 0.34–1.37 0.28 Not included
CABG repeat revascularization† Not included 3.32 1.21–9.11 0.020 Not included
Target lesion revascularization Not included Not included 1.06 0.50–2.22 0.89
De novo lesion revascularization Not included Not included 0.67 0.27–1.67 0.39
*Repeat revascularization (PCI or CABG) is included as separate variable in Model 1. †PCI repeat 
revascularization and CABG repeat revascularization are included as separate variables in Model 2. 
‡Target lesion revascularization and de novo lesion revascularization are included as separate variables 
in Model 3. Bold values indicate variables of repeat revascularization.
PAD, peripheral artery disease; other abbreviations as in Tables 1, 2, and 3.
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repeat revascularization (the majority consisting of MI), the difference between 
initial PCI and CABG was no longer statistically significant, referring only to the 
intrinsic risk of the procedure. In the long-term, repeat revascularization was 
associated with increased rates of the composite safety endpoint, even after 
adjustment for baseline and procedural characteristics. Comparing PCI and 
CABG in the context of comparable rates of all-cause death and competing risks 
with repeat revascularization that are overestimated by Kaplan-Meier methods 
(23), patients undergoing initial PCI were more likely to return for repeat 
revascularization than those who underwent initial CABG, possibly particularly 
the result of preceding MI. As no difference was noted between initial PCI and 
initial CABG among patients who did not undergo repeat revascularization, 
the importance of identifying patients at risk for revascularization must be 
underlined.
In our analyses we were unable to identify a set of baseline clinical variables that 
could identify patients in whom initial PCI offers similar results as initial CABG 
in terms of repeat revascularization and long-term clinical outcomes as a result 
of these interventions. However, we were able to identify patients at highest 
risk for repeat revascularization for whom specific treatment for appropriate 
riskreduction would apply. The complexity of disease was not a predictor, unlike 
findings of other studies (24,25). Nevertheless, incomplete revascularization and 
the number of overlapping stents that are highly correlated to the SYNTAX score 
(26), were independent predictors of repeat revascularization (4). These findings 
underline the need for routine use of fractional flow reserve that has been shown 
to reduce the number of stents used during PCI with subsequent reductions in 
adverse events (27). Furthermore, in alignment with randomized trials evaluating 
post-PCI antiplatelet therapy and current guidelines, we found that nonuse of 
acetylsalicylic acid or thienopyridine predicted repeat revascularization (28,29), 
and medical therapy was also a predictor of worse long-term outcomes (30). 
Paradoxically, patients requiring repeat revascularization after initial CABG had 
less presence of comorbidities and qualified as lower risk at the time of the initial 
procedure (3). Off-pump CABG and enrollment in the United States versus Europe 
were independent predictors of repeat revascularization, most probably due 
to a more proactive approach for repeat revascularization in case of symptoms 
recurrence after initial CABG (31). Whether incomplete revascularization is an 
important factor when performing CABG, remains a matter of debate (32,33). 
Some data suggest that incomplete revascularization has a particular impact on 
the repeat revascularization rate (34), but incomplete revascularization after 
CABG failed to be an independent predictor in the current analysis. Similar to 
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the findings in the PCI group, secondary prevention measures remain critical in 
reducing adverse events, including repeat revascularization (35). Not included 
in multivariable models, but an area in which CABG outcomes can be improved, 
is early post-operative complications (36). Many repeat CABG revascularizations 
were the result of early complications (hemorrhage or acute graft failure) after 
initial CABG, for which intraoperative graft flow measurements may prove 
beneficial, although no consensus has been reached over their use (35–37).
STUDY LIMITATIONS. The present study is a post hoc analysis of the SYNTAX 
trial and the results should therefore be interpreted within the limits of both 
statistical power and clinical relevance. The SYNTAX trial did not primarily 
intend to investigate the practice of repeat revascularization, although repeat 
revascularization was registered as a component of the primary endpoint under 
supervision of the independent Clinical Events Committee and was a standalone 
secondary endpoint. Angiography was not routinely performed and there are no 
available data on the use of fractional flow reserve or functional testing in the 
assessment of lesions.
CONCLUSIONS
Repeat revascularization is not a benign event as patients requiring repeat 
revascularization are at increased risk of both periprocedural and long-term 
events. Predictors of patients at risk for repeat revascularization highlight 
the need for adequate medical treatment as secondary prevention. Although 
procedural risk of repeat revascularization is similar after initial PCI and CABG 
procedure, long-term results show higher rates of clinically meaningful endpoints 
after repeat revascularization in the PCI group, which drove the differences 
favoring CABG over PCI in the more complex patients in the SYNTAX trial overall. 
However, comparison of long-term results of patients who did not undergo repeat 
revascularization revealed similar outcomes between PCI and CABG, suggesting 
that both careful patient selection and improvements in both PCI and CABG 
technology, techniques, and adjunctive therapies will have a favorable impact in 
the future.
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CLINICAL PERSPECTIVES
WHAT IS NEW? Repeat revascularization is a biased clinical outcome from 
randomized trials comparing PCI with CABG with limited in-depth long-term 
follow-up data available. This study therefore aimed to analyze the incidence, 
characteristics, and predictors of repeat revascularization as well as its long-term 
impact on hard clinical events during 5-year follow-up of the SYNTAX trial.
WHAT IS KNOWN? Repeat revascularization occurred more often after PCI than 
after CABG, and more often consisted of multiple repeat revascularizations. 
Significantly more repeat PCI procedures were performed on de novo lesions 
in patients after initial PCI than initial CABG. Repeat revascularization was an 
independent predictor of the composite safety endpoint of death, MI, and stroke 
after both treatment types for complex coronary artery disease.
WHAT IS NEXT? Careful selection of patients, use of novel interventional devices 
and functional assessment, together with aggressive medical therapy, should 
be the main approach in reducing the rate of repeat revascularization and the 
negative impact it has on clinical outcomes.
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SUPPLEMENTAL MATERIAL
APPENDIX 1.
Variables included and excluded in the models to identify independent predictors 
of repeat revascularization.
PCI model:
Variables considered in univariate analysis: age, gender, hypertension, 
hyperlipidemia, unstable angina, history of myocardial infarction, history 
of heart failure, history of TIA/CVA, peripheral vessel disease, carotid artery 
disease, renal impairment, current smoker, medically treated diabetes mellitus, 
insulin-dependent diabetes mellitus, impaired left ventricular ejection fraction, 
SYNTAX Score, staged procedure, incomplete revascularization, total stents, total 
stent length, number of overlapping stents, RCA lesions, LCxA lesion, no ASA at 
discharge, no thienopyridine at discharge, statins at discharge.
Included in multivariate model: age, SYNTAX Score, medically treated diabetes 
mellitus, incomplete revascularization, staged procedure, number of overlapping 
stents, no ASA at discharge, no thienopyridine at discharge, statins at discharge.
Excluded from multivariate model because of high correlates: number of 
lesions, RCA lesion, LCxA lesion, number of stents, insulin-dependent diabetes 
mellitus.
CABG model:
Variables considered in univariate analysis: age, gender, enrolment in the 
United States vs. Europe, hyperlipidemia, hypertension, diabetes mellitus, type 
1 diabetes, type 2 diabetes, medically treated diabetes, insulin treated diabetes, 
non-insulin treated diabetes, diet treatment diabetes, previous myocardial 
infarction, previous congestive heart failure, unstable angina, peripheral 
vascular disease , previous TIA/stroke, renal impairment, SYNTAX Score, number 
of lesions, LM lesion, LCA lesion, RCA lesion, LCxA lesion, off-pump CABG, 
crystalloid cardioplegia, blood cardioplegia, total arterial conduits, total venous 
conduits, left intermal mammary artery use, radial artery use, bilateral internal 
mammary artery use, more than one arterial conduit, complete arterial, distal 
anastomoses, grafts, incomplete revascularization, no ASA at discharge, no 
thienopyridine at discharge, no antiplatelet at discharge, statins at discharge.
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Included in multivariate model: LCA lesion, SYNTAX Score, more than one 
arterial conduit, incomplete revascularization, off-pump CABG, enrolment in the 
US vs. Europe, statins at discharge, no ASA at discharge, previous MI, previous 
CHF. 
Excluded from multivariate model because of high correlates: radial artery use, 
complete arterial.
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APPENDIX 2.
Variables included in the models to adjust for repeat revascularization as 
independent predictors of death, MI and stroke during follow-up.
PCI model: 
Variables considered in univariate analysis: age, gender, hyperlipidemia, 
hypertension, diabetes mellitus, medically treated diabetes, insulin-dependent 
diabetes, previous myocardial infarction, previous congestive heart failure, 
unstable angina, chronic obstructive pulmonary disease, peripheral vascular 
disease, carotid disease, renal impairment, SYNTAX Score, number of lesions, 
staged procedure, number of stents, number of overlapping stents, incomplete 
revascularization, no ASA at discharge, no thienopyridine at discharge, statins at 
discharge.
Included in the multivariate model: age, previous myocardial infarction, 
peripheral vessel disease, staged procedure, incomplete revascularization, no ASA 
at discharge, no thienopyridine at discharge, and statins at discharge.
Excluded from multivariate model because of high correlates: medically treated 
DM, insulin-dependent DM.
CABG model: 
Variables considered in univariate analysis: age, gender, hyperlipidemia, 
hypertension, diabetes mellitus, medically treated diabetes, insulin-dependent 
diabetes, previous myocardial infarction, previous congestive heart failure, 
unstable angina, chronic obstructive pulmonary disease, peripheral vascular 
disease, carotid disease, renal impairment, SYNTAX score, off-pump CABG, 
crystalloid cardioplegia, blood cardioplegia, more 1 arterial conduit, distal 
anastomoses, grafts incomplete revascularization, no ASA at discharge, no 
thienopyridine at discharge, statins at discharge.
Included in the multivariate model:  age, chronic obstructive pulmonary disease, 
peripheral vessel disease, renal impairment, SYNTAX Score, blood cardioplegia, 
no ASA at discharge, statins at discharge. 
Excluded from multivariate model because of high correlates: medically treated 
DM, insulin-dependent DM.
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APPENDIX 3.
Estimates of the cumulative incidence of adverse events after initial PCI (A) and CABG (B) in 
the presence of competing risks. The percentage of patients in each category sums up to 100% at 
all time points during follow-up. Rev, repeat revascularization; MI, myocardial infarction. 
 
160 
 
160 
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APPENDIX 4.
Univariate analysis to identify independent predictors of repeat revascularization in PCI and 
CABG group. 
PCI group (n=903) CABG group (n=897)
Baseline characteristics HR 95% CI p-value Baseline characteristics HR 95% CI p-value
Age 1.00 0.99-1.01 0.82 Age 0.99 0.97-1.01 0.15
Gender, female 1.08 0.80-1.47 0.62  Gender, female 0.86 0.53-1.39 0.54
Hyperlipidemia 1.20 0.85-1.68 0.31 Enrolment in US 2.06 1.32-3.22 0.001
Hypertension 1.11 0.82-1.51 0.51 Hyperlipidemia 1.17 0.73-1.86 0.51
Medically treated DM 1.70 1.29-2.24 <0.001 Hypertension 1.06 0.68-1.66 0.79
Insulin-dependent DM 2.04 1.42-2.92 <0.001 Medically treated DM 1.12 0.73-1.72 0.60
Previous MI 1.09 0.82-1.45 0.54     Insulin treated DM 1.48 0.86-2.56 0.16
Previous CHF 1.16 0.61-2.19 0.65 Previous MI 0.64 0.42-0.99 0.044
Unstable angina 1.18 0.89-1.57 0.25 Previous CHF 1.67 0.82-3.44 0.16
Current smoker 0.85 0.59-1.22 0.38 Unstable angina 1.39 0.94-2.06 0.10
PAD 1.21 0.77-1.90 0.40 PAD 1.47 0.84-2.58 0.18
Renal impairment 0.47 0.07-3.38 0.46 Previous TIA/CVA 0.91 0.46-1.81 0.79
Previous TIA/CVA 0.92 0.55-1.56 0.76 Renal impairment 0.67 0.09-4.79 0.69
Anatomic characteristics Anatomic characteristics
SYNTAX score 1.01 1.00-1.02 0.035 SYNTAX score 1.00 0.98-1.02 0.88
Number of lesions 1.10 1.01-1.18 0.015 LM lesion 1.28 0.88-1.87 0.20
LM lesion 1.03 0.79-1.35 0.81 LCA lesion 0.65 0.39-1.10 0.11
RCA lesion 1.55 1.05-2.30 0.027 RCA lesion 0.85 0.54-1.33 0.47
LCxA lesion 1.62 1.05-2.49 0.029 LCxA lesion 1.09 0.65-1.83 0.75
Procedure characteristics Procedure characteristics
Number of stents 1.10 1.04-1.16 0.001 Off-pump 1.63 1.02-2.60 0.042
Total stents length 1.00 1.00-1.01 0.07 Crystalloid cardioplegia 1.05 0.71-1.57 0.80
Number of overlapping stents 1.31 1.07-1.60 0.008 Blood cardioplegia 0.77 0.53-1.13 0.18
Staged procedure 1.45 1.02-2.05 0.036 Total arterial conduits 1.32 1.01-1.72 0.045
Incomplete revascularization 0.60 0.46-0.78 <0.001 Total venous conduits 0.83 0.67-1.03 0.09
Discharge medication LIMA use 1.73 0.55-5.46 0.35
No ASA 2.45 1.40-4.29 0.002 RA use 1.58 0.99-2.53 0.055
No thienopyridine 4.01 2.33-6.90 <0.001 BIMA use 1.25 0.83-1.87 0.29
No antiplatelet 41.2 16.5-
102.6
<0.001 2nd arterial graft 1.35 0.92-1.98 0.12
Statins 0.73 0.51-1.06 0.10 Complete arterial 1.70 1.11-2.59 0.014
Distal anastomoses 0.88 0.71-1.10 0.26
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Grafts 0.96 0.74-1.26 0.78
Incomplete 
revascularization
1.28 0.87-1.86 0.21
Discharge medication
No ASA 0.24 0.08-0.76 0.015
No thienopyridine 0.69 0.45-1.06 0.09
No antiplatelet 0.46 0.15-1.44 0.18
Statins 0.75 0.50-1.14 0.18
ASA, acetylsalicylic acid; BIMA, bilateral mammary artery; CHF, congestive heart failure; COPD, 
chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DM, Diabetes mellitus; LCA, 
Left coronary artery; LCxA, Left circumflex artery; LM, left main; LIMA, Left internal mammary artery; 
MI, myocardial infarction; PAD, peripheral artery disease; RA, radial artery; RCA, Right coronary artery; 
TIA, transient ischemic attack.
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APPENDIX 5.
Univariate and multivariate analyses to identify independent predictors of adverse events in PCI and CABG 
group, respectively (only events occurring after repeat revascularization).
PCI (n=903)
Univariate analysis
Model 1* Model 2** Model 3***
Baseline 
characteristics 
(Block 1)
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age 1.04 1.02-1.05 <0.001 1.03 1.02-1.05 <0.001 1.03 1.02-1.05 <0.001 1.03 1.02-1.05 <0.001
Gender, female 1.34 0.96-1.86 0.09
Hyperlipidemia 0.81 0.57-1.15 0.23
Hypertension 1.35 0.93-1.95 0.11
Diabetes mellitus 1.31 0.96-1.80 0.09
Medically treated DM 1.32 0.95-1.83 0.09
 Insulin treatment 1.89 1.25-2.85 0.002
Previous MI 1.61 1.19-2.18 0.002 1.62 1.19-2.20 0.002 1.65 1.22-2.25 0.001 1.64 1.21-2.23 0.002
Previous CHF 1.56 0.82-2.96 0.17
Unstable angina 1.45 1.07-1.99 0.018
COPD 1.55 0.96-2.50 0.07
PAD 2.26 1.51-3.39 <0.001 2.03 1.35-3.07 0.001 2.05 1.36-3.09 0.001 2.03 1.34-3.08 0.001
CAD 1.74 1.10-2.75 0.018
Renal impairment 2.66 0.99-7.16 0.054
Anatomic characteristics
SYNTAX Score 1.01 1.00-1.02 0.17
Number of lesions 1.09 1.00-1.19 0.04
Procedure characteristics
Staged procedure 1.79 1.25-2.58 0.002 1.83 1.26-2.59 0.002 1.80 1.24-2.61 0.002 1.82 1.25-2.64 0.002
Number of stents 1.06 1.00-1.13 0.07
Number of overlapping 
stents
1.11 0.88-1.40 0.39
Incomplete 
revascularization
1.45 1.07-1.96 0.015
Discharge medication
No ASA 4.22 2.55-6.96 <0.001 2.47 1.43-4.24 0.001 2.45 1.42-4.21 0.001 2.55 1.49-4.37 0.001
No Thienopyridine 4.27 2.47-7.37 <0.001 3.79 2.12-6.77 <0.001 3.63 2.01-6.57 <0.001 3.92 2.20-6.99 <0.001
Statins 0.56 0.39-0.82 <0.001 0.61 0.41-0.90 0.013 0.60 0.41-0.89 0.012 0.61 0.41-0.91 0.015
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(Block 2)
*Secondary PCI or CABG 1.80 1.32-2.46 <0.001 1.65 1.20-2.27 0.002 Not included Not included
**Secondary PCI 1.74 1.26-2.42 0.001 Not included 1.67 1.20-2.32 0.002 Not included
**Secondary CABG 1.89 1.15-3.12 0.012 Not included 1.72 1.02-2.88 0.041 Not included
***Target lesion (TLR) 1.85 1.32-2.59 <0.001 Not included Not included 1.69 1.20-2.38 0.003
***De novo lesion 1.52 0.83-2.80 0.18 Not included Not included 1.49 0.80-2.79 0.21
CABG (n=897) Univariate analysis Model 1* Model 2** Model 3***
Baseline 
characteristics 
(Block 1)
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age 1.07 1.05-1.10 <0.001 1.07 1.04-1.09 <0.001 1.07 1.04-1.09 <0.001 1.07 1.04-1.09 <0.001
Gender, female 1.07 0.70-1.62 0.76
Hyperlipidemia 0.71 0.49-1.05 0.08
Hypertension 1.72 1.07-2.77 0.026
Diabetes mellitus 1.30 0.90-1.87 0.16
Medically treated DM 1.22 0.83-1.78 0.32
Insulin treatment 1.24 0.73-2.08 0.43
Previous MI 0.88 0.61-1.28 0.50
Previous CHF 2.36 1.32-4.18 0.003
Unstable angina 0.94 0.641.38 0.75
COPD 1.91 1.19-3.07 0.008 1.82 1.11-2.99 0.018 1.81 1.10-2.97 0.019 1.82 1.11-2.99 0.017
PAD 2.85 1.89-4.28 <0.001 2.45 1.61-3.72 <0.001 2.49 1.64-3.78 <0.001 2.51 1.65-3.81 <0.001
CAD 2.08 1.29-3.34 0.003
Renal impairment 4.24 1.98-9.08 <0.001 2.59 1.13-5.96 0.025 2.44 1.06-5.62 0.036 2.56 1.12-5.87 0.028
Anatomic characteristics
SYNTAX Score 1.02 1.01-1.04 0.005 1.02 1.00-1.03 0.068 1.02 1.00-1.03 0.086 1.02 1.00-1.03 0.07
Number of lesions 0.95 0.91-1.11 0.95
Procedure characteristics
Off pump 0.76 0.44-1.33 0.34
Crystalloid cardioplegia 1.31 0.91-1.88 0.14
Blood cardioplegia 0.74 0.53-1.04 0.09
More 1 arterial conduit 1.15 0.36-3.60 0.82
Distal anastomoses 0.83 0.68-1.03 0.09
Grafts 0.80 0.62-1.03 0.09
Incomplete 
revascularization
1.10 0.77-1.57 0.59
Discharge medication
No ASA 2.84 1.90-4.26 <0.001 2.37 1.55-3.63 <0.001 2.34 1.54-3.57 <0.001 2.32 1.52-3.55 <0.001
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No Thienopyridine 1.05 0.68-1.64 0.82
Statins 0.41 0.29-0.58 <0.001 0.48 0.33-0.69 <0.001 0.48 0.33-0.69 <0.001 0.47 0.33-0.68 <0.001
Repeat revascularization (Block 2)
*Secondary PCI or CABG 0.87 0.51-1.49 0.62 1.11 0.63-1.93 0.73 Not included Not included
**Secondary PCI 0.66 0.36-1.22 0.19 Not included 0.83 0.44-1.56 0.56 Not included
**Secondary CABG 2.87 1.06-7.76 0.038 Not included 3.21 1.17-8.76 0.023 Not included
***Target lesion (TLR) 0.75 0.37-1.54 0.44 Not included Not included 1.06 0.50-2.22 0.89
***De novo lesion 0.63 0.26-1.55 0.63 Not included Not included 0.67 0.27-1.67 0.39
ASA, acetylsalicylic acid; BIMA, bilateral mammary artery; CHF, congestive heart failure; CAD, carotid artery 
disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DM, Diabetes mellitus; 
MI, myocardial infarction; PAD, peripheral artery disease; RA, radial artery; RCA, Right coronary artery; 
TIA, transient ischemic attack; TLR, target lesion revascularization.  
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APPENDIX 6.
Univariate and multivariate analyses to identify independent predictors of adverse events in PCI and CABG 
group, respectively (all events occurring during 5-year follow-up).
PCI (n=867) Univariate analysis Model 1* Model 2** Model 3***
Baseline 
characteristics 
(Block 1)
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age 1.04 1.02-1.05 <0.001 1.04 1.02-1.05 <0.001 1.04 1.02-1.05 <0.001 1.04 1.02-1.06 <0.001
Gender, female 1.23 0.89-1.71 0.20
Hyperlipidemia 0.84 0.60-1.18 0.30
Hypertension 1.34 0.94-1.91 0.11
Diabetes mellitus 1.22 0.90-1.67 0.20
Medically treated DM 1.23 0.91-1.72 0.16
 Insulin treatment 1.79 1.20-2.67 0.005
 Non-insulin treatment 0.88 0.60-1.30 0.52
Diet treatment 0.98 0.40-2.39 0.97
Previous MI 1.73 1.30-2.32 <0.001 1.78 1.33-2.39 <0.001 1.84 1.37-2.47 <0.001 1.81 1.35-2.43 <0.001
Previous CHF 1.64 0.89-3.01 0.11
Unstable angina 1.44 1.06-1.94 0.018
COPD 1.71 1.10-2.67 0.018
PAD 2.05 1.37-3.06 <0.001 1.84 1.22-2.76 0.003 1.86 1.24-2.80 0.003 1.84 1.22-2.78 0.004
CAD 1.58 1.00-2.49 0.048
Renal impairment 2.43 0.90-6.53 0.08
Anatomic characteristics
SYNTAX Score 1.01 1.00-1.02 0.13
Number of lesions 1.10 1.02-1.20 0.02
Procedure characteristics
Staged procedure 1.82 1.28-2.58 0.001 1.81 1.26-2.59 0.001 1.76 1.23-2.52 0.002 1.80 1.26-2.57 0.001
Number of stents 1.06 1.00-1.13 0.05
Number of overlapping 
stents
1.17 0.94-1.46 0.16
Incomplete 
revascularization
1.42 1.07-1.90 0.017
Discharge medication
No ASA 4.11 2.52-6.69 <0.001 2.19 1.29-3.72 0.004 2.19 1.29-3.73 0.004 2.35 1.40-3.96 0.001
No Thienopyridine 3.87 2.24-6.68 <0.001 3.23 1.81-5.77 <0.001 3.11 1.72-5.63 <0.001 3.50 1.97-6.22 <0.001
Statins 0.51 0.36-0.72 <0.001 0.52 0.36-0.76 0.001 0.52 0.36-0.75 0.001 0.53 0.37-0.77 0.001
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Repeat 
revascularization 
(Block 2)
*Secondary PCI or CABG 2.23 1.66-3.00 <0.001 2.21 1.63-2.98 <0.001 Not included Not included
**Secondary PCI 2.09 1.54-2.84 <0.001 Not included 2.13 1.56-2.90 <0.001 Not included
**Secondary CABG
2.03 1.28-3.23 0.003 Not included 2.01
1.24-
3.26
0.005 Not included
***Target lesion(TLR) 2.17 1.58-2.98 <0.001 Not included Not included 2.09 1.51-2.88 <0.001
***De novo lesion 
1.69 0.96-2.97 0.07 Not included Not included 1.58
0.88-
2.81
0.12
CABG (n=897) Univariate analysis Model 1* Model 2** Model 3***
Baseline 
characteristics 
(Block 1)
HR 95% CI p-value HR HR HR HR 95% CI p-value HR 95% CI p-value
Age 1.07 1.05-1.09 <0.001 1.06 1.04-1.09 <0.001 1.06 1.04-1.09 <0.001 1.06 1.04-1.08 <0.001
Gender, female 0.92 0.59-1.42 0.70
Hyperlipidemia 0.73 0.50-1.08 0.11
Hypertension 1.67 1.05-2.67 0.031
Diabetes mellitus 1.34 0.93-1.91 0.11
Medically treated DM 1.23 0.84-1.80 0.28
Previous MI 0.88 0.61-1.28 0.51
Previous CHF 2.17 1.20-3.93 0.010
Unstable angina 1.08 0.75-1.57 0.68
COPD 2.02 1.27-3.22 0.003 1.96 1.20-3.23 0.008 1.81 1.10-3.00 0.020 2.08 1.29-3.35 0.003
PAD 2.72 1.81-4.08 <0.001 1.93 1.25-3.00 0.003 1.97 1.27-3.06 0.002 2.13 1.41-3.23 <0.001
CAD 1.77 1.08-2.90 0.025
Renal impairment 3.34 1.47-7.57 0.004 2.74 1.19-6.30 0.017 2.00 0.79-5.03 0.14 2.68 1.17-6.15 0.020
Anatomic 
characteristics
SYNTAX Score 1.02 1.01-1.04 0.006 1.02 1.00-1.03 0.08 1.02 1.00-1.03 0.11 1.02 1.00-1.04 0.034
Number of lesions 0.99 0.91-1.09 0.90
Procedure 
characteristics
Off pump 0.93 0.56-1.54 0.76
Crystalloid cardioplegia 1.30 0.92-1.84 0.14
Blood cardioplegia 0.74 0.53-1.04 0.09 0.67 0.47-0.95 0.025 0.68 0.48-0.96 0.036 0.68 0.48-0.97 0.031
More 1 arterial conduit 0.69 0.48-1.00 0.05
Distal anastomoses 0.87 0.72-1.06 0.18
Grafts 0.80 0.63-1.02 0.07
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Incomplete 
revascularization
1.10 0.78-1.56 0.58
Discharge medication
No ASA 2.63 1.76-3.93 <0.001 1.97 1.26-3.07 0.003 1.87 1.21-2.90 0.005 2.09 1.37-3.20 0.001
No Thienopyridine 1.06 0.68-1.67 0.79
Statins 0.42 0.30-0.60 <0.001 0.52 0.36-0.74 <0.001 0.50 0.35-0.71 <0.001 0.48 0.34-0.69 <0.001
Repeat revascularization (Block 2)
*Secondary PCI or CABG 1.41 0.90-2.21 0.14 1.66 1.03-2.69 0.039 Not included Not included
**Secondary PCI 1.04 0.62-1.73 0.89 Not included 1.09 0.63-1.90 0.75 Not included
**Secondary CABG 8.17 3.80-17.5 <0.001 Not included 6.89 3.11-15.3 <0.001 Not included
***Target lesion(TLR) Not included Not included 1.32 0.69-2.53 0.40
***De novo lesion Not included Not included 1.24 0.62-2.51 0.54
ASA, acetylsalicylic acid; BIMA,  bilateral mammary artery; CHF, congestive heart failure; CAD, carotid artery disease; 
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DM, Diabetes mellitus; MI, myocardial 
infarction; AD, peripheral artery disease; RA, radial artery; RCA, Right coronary artery; TIA, transient ischemic attack; TLR, 
target lesion revascularization.  
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grafting in the SYNTAX trial
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ABSTRACT
AIMS: The goal of the study was to compare long-term outcomes of percutaneous 
coronary intervention (PCI) versus coronary artery bypass grafting (CABG), 
accounting for the clinical impact of individual components in the composite 
endpoints and prioritising these using the win ratio (Rw).
METHODS AND RESULTS: The win ratio was compared with conventional 
methods of analyses (hazard ratio (HR) and relative risk) in the SYNTAX trial 
(n=1,800). For the composite of death/stroke/myocardial infarction (MI), the win 
ratio favoured CABG and was 1.37 (95% CI: 1.10-1.77) for matched analysis, 1.28 
(95% CI: 1.11-1.53) for unmatched analysis, while the conventional HR was 1.29 
(95% CI: 1.11-1.53). The largest number of winners in favour of CABG over PCI were 
based on MI (n=39 vs. n=19, respectively). Death was significantly reduced with 
CABG in matched (Rw=1.39, 95% CI: 1.04-1.86) and unmatched win ratio analyses 
(Rw=1.27, 95% CI: 1.01-1.42) as compared with non-significant conventional 
analysis (HR 1.19, 95% CI: 0.92-1.56). In subgroups, matched win ratio analyses had 
a larger treatment effect in favour of CABG compared with conventional analyses, 
especially in patients with three-vessel disease and intermediate SYNTAX scores, 
while unmatched win ratios had a smaller point estimate, but with narrower 
confidence intervals than matched analyses findings.
CONCLUSIONS: This re-analysis of the SYNTAX trial using the win ratio shows 
that the most important benefit of CABG treatment is the reduction of hard 
clinical endpoints such as mortality and MI. Future trials using this approach 
can expect to maintain similar statistical power with smaller sample sizes, and 
thereby reduce the cost of a trial. 
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INTRODUCTION
Coronary artery bypass grafting (CABG) and percutaneous coronary intervention 
(PCI) have been compared in many randomised clinical trials (1). These trials 
often used composite endpoints to obtain higher event rates and provide more 
statistical power, thus requiring smaller sample sizes, shorter follow-up, or both 
(2,3). However, composite endpoints are often criticised for having an intrinsic 
weakness, combining events with a very different impact on a patient’s quality of 
life or life expectancy. The reporting of composite endpoints in clinical trials also 
has an inherent limitation in that it emphasises each patient’s first event, which is 
often the outcome of lesser clinical importance.
The SYNTAX trial assessed the optimum revascularisation treatment for patients 
with de novo left main (LM) coronary disease and/or three-vessel disease (3VD), by 
randomly assigning patients to either CABG or PCI with a first-generation drug-
eluting stent (DES). The primary endpoint was powered on non-inferiority of PCI 
versus CABG for the endpoint of major adverse cardiac and cerebrovascular events 
(MACCE), which is the composite of all-cause death, stroke, myocardial infarction 
(MI), and repeat revascularisation (4). The difference in MACCE between PCI and 
CABG was largely driven by higher rates of repeat revascularisation with PCI, 
which is thought to be a softer, less important endpoint, while rates of all-cause 
death were not significantly different between CABG and PCI (5,6).
To overcome this weakness of putting the same emphasis on individual 
components with a clinically different impact in the composite endpoint, a 
recent novel approach, the win ratio, has been introduced (7). Based on clinical 
priorities, the win ratio methodology applies a hierarchical weighting to 
individual components in MACCE. This approach is also designed to combat two 
fundamental difficulties that may be present in typical efficacy studies: study 
population heterogeneity and important events that are censored. The method 
uses risk score stratification to select and match pairs with similar risk profiles 
from both treatment groups and provides a more patient-specific interpretation 
of composite endpoints in clinical trials.
The objective of this re-analysis of the SYNTAX trial was to compare PCI with 
CABG using different methods of analysis, accounting for the severity of the 
individual components and prioritising these using the win ratio approach as an 
informative estimate of treatment difference. Moreover, this paper evaluates the 
impact of applying the win ratio on the design of future trials.
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METHODS
Study design
The design and methods of the SYNTAX trial have been reported previously (8). 
In SYNTAX, 1,800 patients with de novo LM or three-vessel coronary artery disease 
were randomly assigned to undergo CABG or PCI with a paclitaxel-eluting stent 
(TAXUS® Express™; Boston Scientific, Marlborough, MA, USA). Patients with 
anticipated clinical revascularisation equipoise through PCI and CABG were 
randomised (CABG n=897, PCI n=903). Five year follow-up was 89.7% for CABG 
and 96.5% for PCI.
This study was carried out in accordance with the principles of the Declaration 
of Helsinki, and registered on the National Institutes of Health website with 
identifier NCT00114972.
Definitions
The primary endpoint of the trial was MACCE, which included all-cause death, 
stroke, MI, or repeat revascularisation (subsequent CABG or PCI) (9). Secondary 
endpoints consisted of: i) a composite safety endpoint of death/stroke/MI, and ii) 
the individual endpoint of all-cause death. Definitions of these endpoints have 
been published elsewhere (8). Medically treated diabetes was defined as treatment 
with oral hypoglycaemic agents or insulin at the time of enrolment.
Statistical analysis
All analyses were carried out according to the intention-to-treat principle. 
Conventional analyses were performed using: i) Cox proportional hazard analyses 
to provide hazard ratios (HRs), and ii) estimates of relative risk (RR) associated 
with PCI versus CABG treatment. The proportional hazards assumption was 
estimated using Schoenfeld’s test and was found to have been met. Relative 
risks were calculated by dividing the Kaplan-Meier estimated rate of an event at 
five years in the PCI group by the event rate in the CABG group. The 95 percent 
confidence interval (CI) for the relative risk was calculated with the use of the 
standard errors from the Kaplan-Meier curve (10). The significance of differences 
in event rates between treatment groups was assessed with the use of the log-rank 
test. Conventional analyses were performed using SPSS software, Version 20.0 
(IBM Corp., Armonk, NY, USA).
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Win ratio analyses were performed for all-cause death, the composite safety 
endpoint of death/stroke/MI, and for the composite of MACCE (7). The hierarchy 
of events within MACCE was as follows: all-cause death, stroke, MI, repeat CABG, 
repeat PCI.
The win ratio can be used in a matched or unmatched fashion, depending on how 
the patients are compared. As recommended, priority was given to a matched 
approach versus an unmatched approach that dilutes the win ratio (7). In the 
matched approach, each patient in the CABG group was matched to a patient in 
the PCI group based on a similar risk of death. A risk score to predict death was 
developed using 18 pre-selected baseline variables that are known to be associated 
with prognosis (Table 1). A receiver operating characteristic (ROC) curve was 
generated to assess the ability of the scoring system model to predict mortality, 
0.71 (95% CI: 0.67-0.75; p<0.0001). From the Cox proportional model’s coefficients, 
a risk score was calculated for each patient in the trial. Patients in the two 
treatment groups formed matched pairs based on their risk profiles and ranks. 
For each pair, the new treatment is a “winner” or “loser” according to who had 
died first (Figure 1). If no deaths occurred, a “winner” or “loser” was designated 
based on who first had a stroke, and so forth using the hierarchy of events. If one 
patient had an event but the follow-up period of the matched patient was shorter 
or if there were pairs without an event, they were considered “tied”. A “winner” 
patient had a more favourable outcome than his matched pair. The “win ratio” is 
the number of winners in the CABG group divided by the number of winners in 
the PCI group (Figure 1). An estimated win ratio >1 indicates a positive outcome of 
the CABG treatment compared to PCI while a win ratio <1 indicates a difference 
between treatment groups in favour of PCI. A corresponding 95% CI and p-values 
were calculated using dedicated statistical methods, as described by Pocock and 
co-authors (7).
Unmatched analyses were performed for subgroups according to diabetes, LM 
disease and SYNTAX score to compare this result with the matched approach. Due 
to the fact of unequal treatment groups in subgroups, some patients had to be 
excluded randomly to provide equal numbers for matching. In smaller subgroups 
within pre-specified subgroups of patients, up to 17% had to be excluded. To 
determine the impact of randomly excluding patients, a repeated analysis was 
performed 10 times to examine whether the obtained results were affected: this 
was performed in the subgroup of patients with LM disease and an intermediate 
SYNTAX score (n=190). The results of the 10 analyses were very different, with the 
win ratio ranging from 0.31-0.50 with p-values ranging from 0.0050-0.1052 for 
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all-cause death, and, respectively, 0.64-0.96 and 0.13-0.90 for MACCE. Therefore, 
only unmatched analyses were performed for the smaller SYNTAX score subgroups 
within subgroups of patients with LM/3VD and diabetes; no patients needed to be 
excluded for the unmatched analyses (11). In the unmatched approach, a CI for the 
win ratio cannot be directly calculated: the bootstrap method with 1,000 samples 
was performed to determine significance and CIs, using R software version 3.2.4 
(Institute for Statistics and Mathematics of WU, Vienna, Austria). A p-value <0.05 
was considered to be statistically significant for all analyses.
While originally the win-ratio code for unmatched analyses was designed for 
composite endpoints that include two components (death and re-hospitalisation), 
in order to analyse the SYNTAX trial data with five endpoints, the statistical code 
was rewritten, tested and validated according to the original statistical software 
provided directly by the authors of the win ratio approach (7), when we requested 
and as they recommended. Now, this code can be used to calculate the win ratio 
with any number of components in the composite endpoint (for the code contact 
e.andrinopoulou@erasmusmc.nl).
Table 1. Pre-selected variables for risk score model.
Variable Hazard ratio p-value*
Age 1.072 <0.001
Male sex 0.900 0.75
Body mass index 1.011 0.48
Current smoker 1.656 0.007
Medically treated diabetes 1.465 0.10
Previous myocardial infarction 1.370 0.030
Previous stroke 1.766 0.50
Previous transient ischaemic attack 0.825 0.80
Carotid artery disease 1.013 0.96
Congestive heart failure 1.166 0.88
Pulmonary hypertension 1.044 0.87
Peripheral vascular disease 2.513 <0.001
Creatinine >200 micromol/L 1.433 0.054
Dialysis 1.414 0.67
Chronic obstructive pulmonary disease 1.689 0.007
Ejection fraction moderate 1.405 0.040
Ejection fraction poor 1.371 0.006
SYNTAX score 1.010 0.093
Emergency treatment 0.707 0.58
*p-value <0.05 is considered as statistically significant.
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Figure 1. A conceptual diagram illustrating possible scenarios for the win ratio method. The 
determination of a “winner” is made using a predefined hierarchical outcome scheme. In the SYNTAX 
trial, mortality is considered the most important outcome followed by stroke, MI, repeat CABG 
revascularisation and repeat PCI revascularisation. The length of each arrow presents the duration 
of patient follow-up. Arrows ending in a solid circle denote either incomplete or shorter duration of 
follow-up.
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RESULTS
Overall cohort
Of the 1,800 patients randomly assigned to PCI or CABG, 880 matched pairs were 
computed based on the risk score.
For the primary outcome of MACCE at five years, 274 patients who underwent 
CABG won versus 170 patients who underwent PCI, corresponding to a matched 
win ratio of 1.61 (95% CI: 1.341.96; p<0.0001) (Table 2, Figure 2). In comparison with 
matched analyses, unmatched analyses tended to have a smaller ratio between 
CABG and PCI (Figure 2).
Figure 2. Win ratio approach vs. conventional analyses for the overall SYNTAX randomised cohort. 
Different colours represent conventional time-to-event hazard ratio analyses (blue), relative risk 
(purple), unmatched win ratio (orange), matched win ratio (red), approaches with 95% CIs. MACCE: 
major adverse cardiac and cerebrovascular events.
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For the composite safety endpoint of death/stroke/MI, the win ratios and the 
conventional result were similar. The matched win ratio for the composite safety 
endpoint of death/stroke/MI was the analysis with the largest relative difference 
between CABG versus PCI in favour of CABG (n=116 vs. n=161, respectively; Rw=1.37, 
95% CI: 1.10-1.77; p=0.006). Out of 578 (65.7%) matched pairs that were tied for 
the composite of death/stroke/MI, 552 pairs did not have an event of death/stroke/
MI during follow-up, and 26 patients were tied because of a different length of 
follow-up (Table 2, Figure 2).
Table 2. The win ratio matched pairs approach, for the overall cohort and subgroups according 
to SYNTAX score terciles.
Matched pairs SYNTAX trial SYNTAX score ≤22 SYNTAX score 23-32 SYNTAX score ≥33
Death on PCI first 111 21 41 52
Death on CABG first 80 21 28 28
Stroke on PCI first 11 3 3 4
Stroke on CABG first 17 8 6 3
MI on PCI first 39 15 14 11
MI on CABG first 19 5 3 8
Repeat CABG on PCI first 24 9 10 9
Repeat CABG on CABG first 2 2 0 0
Repeat PCI on PCI first 89 29 27 29
Repeat PCI on CABG first 52 21 13 16
None of the above 437 137 149 127
Total number of pairs 880 272 294 287
Win ratio for MACCE 1.61 1.38 1.90 1.91
95% CI 1.34, 1.96 0.98, 1.87 1.37, 2.73 1.42, 2.75
Z-score 5.09 1.85 3.92 4.29
p-value 0.0001 0.064 0.0001 0.0001
Win ratio for death/stroke/MI 1.39 1.15 1.57 1.72
95% CI 1.10, 1.77 0.72, 1.83 1.05, 2.43 1.18, 2.62
Z-score 2.74 0.55 2.21 2.82
p-value 0.006 0.58 0.027 0.005
Win ratio for all-cause death 1.39 1.00 1.46 1.86
95% CI 1.04, 1.86 0.54, 1.86 0.92, 2.45 1.20, 3.07
Z-score 2.31 0 1.57 2.81
p-value 0.021 >0.99 0.12 0.005
CABG, coronary artery bypass grafting; CI, confidence interval; MACCE, major adverse cardiac and 
cerebrovascular events; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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Death occurred first after CABG in 80 patients and first after PCI in 111 patients; 
the unmatched win ratio for all-cause death was 1.27 (95% CI: 1.01-1.42) and the 
matched win ratio was 1.39 (95% CI: 1.04-1.86), which was statistically significant 
unlike conventional analyses that resulted in an HR of 1.19 (95% CI: 0.92-1.56) 
(Table 2, Figure 2).
Subgroup analyses 
SYNTAX score
In patients with intermediate and high SYNTAX scores, the matched win ratio for 
MACCE at five years confirmed statistically significant better outcomes with CABG 
(Rw=1.90, 95% CI: 1.37-2.73 and Rw=1.91, 95% CI: 1.42-2.75, respectively) (Figure 3, 
Table 2). Nevertheless, the magnitude of the treatment effect was larger with the 
matched win ratio; even in the group of patients with a low SYNTAX score, there 
was a trend towards a difference.
For the composite endpoint of death/stroke/MI, the matched win ratio increased 
significantly in favour of CABG from low to intermediate to high SYNTAX scores 
(Rw=1.15 vs. Rw=1.57 vs. Rw=1.72) as well as for all-cause death (Rw=1.00 vs. Rw=1.46 
vs. Rw=1.86) (Figure 3, Table 2). However, the treatment effect of PCI versus CABG 
was strongest with the matched win ratio, and particularly for subgroups of 
patients with intermediate SYNTAX scores where there was a clear increase in the 
treatment effect. In comparison with conventional analyses, the findings from the 
unmatched analyses were similar in patients with low and high SYNTAX scores, 
but were stronger in favour of CABG for patients with intermediate SYNTAX 
scores (Figure 3).
LM/3VD
In patients with LM disease, the matched win ratio was not significantly different 
between CABG versus PCI: 1.27 (95% CI: 0.951.67) for MACCE, 1.02 (95% CI: 0.66-
1.59) for the composite safety endpoint of death/stroke/MI, and 1.00 (95% CI: 0.70-
1.44) for all-cause death (Figure 4, Table 3). In contrast, in patients with three-
vessel disease, the matched win ratio for MACCE (Rw=1.92, 95% CI: 1.70-2.19), 
the composite safety endpoint of death/stroke/MI (Rw=2.00, 95% CI: 1.46-2.86), 
and all-cause death (Rw=2.15, 95% CI: 1.46-3.39) were all in favour of CABG. The 
unmatched approach supports the findings derived from conventional analyses 
in patients with LM, while unmatched analyses were stronger in favour of CABG 
among patients with three-vessel disease (Figure 4).
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Figure 3. Win ratio approach vs. conventional analyses by baseline SYNTAX score terciles. MACCE, 
major adverse cardiac and cerebrovascular events.
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When separately analysing SYNTAX score subgroups for MACCE, differences 
between conventional analyses, the unmatched analyses, and matched analyses 
were only minimal (Table 4). Of note, there was no consistency in changes in PCI 
versus CABG treatment effects choosing conventional or any win ratio analyses, 
although CIs appeared smaller when using win ratio analyses.
Table 3. The win ratio matched pairs approach, according to subgroups of left main disease and 
diabetes.
Matched pairs
Diabetes Coronary disease
DM Non-DM 3VD LM
Death on PCI first 38 74 71 42
Death on CABG first 24 57 33 41
Stroke on PCI first 0 7 8 3
Stroke on CABG first 6 11 8 10
MI on PCI first 4 34 25 15
MI on CABG first 2 17 11 9
Repeat CABG on PCI first 8 19 10 8
Repeat CABG on CABG first 0 3 2 1
Repeat PCI on PCI first 72 62 57 35
Repeat PCI on CABG first 13 43 35 20
None of the above 95 336 278 152
Total number of pairs 217 663 538 336
Win ratio for MACCE 1.71 1.50 1.92 1.27
95% CI 1.19, 2.52 1.21, 1.88 1.70, 2.19 0.95, 1.67
Z-score 3.01 3.70 5.45 1.64
p-value 0.003 0.0002 <0.0001 0.10
Win ratio for death/stroke/MI 1.31 1.35 2.01 1.01
95% CI 0.83, 2.13 1.03, 1.81 1.46, 2.86 0.70, 1.44
Z-score 1.17 2.15 4.42 0
p-value 0.24 0.032 <0.0001 >0.99
Win ratio for all-cause death 1.59 1.30 2.15 1.02
95% CI 0.96, 2.70 0.92, 1.86 1.46, 3.39 0.66, 1.59
Z-score 1.82 1.50 4.01 0.11
p-value 0.069 0.13 <0.001 0.91
CABG, coronary artery bypass grafting; CI, confidence interval; DM, medically treated diabetes; LM, 
left main coronary disease; MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial 
infarction; PCI, percutaneous coronary intervention; 3VD, three-vessel disease.
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Diabetes
In diabetic as well as non-diabetic patients, results using matched and unmatched 
win ratio approaches were comparable to those from conventional analyses 
(Figure 4, Table 3). In diabetic patients, MACCE was significantly lower in favour of 
CABG with a matched win ratio of 1.71 (95% CI: 1.19-2.52; p=0.003), while all-cause 
death and the composite of death/stroke/MI were not significantly different 
between CABG and PCI. In non-diabetic patients, results with the matched win 
ratio approach slightly favoured CABG in comparison to conventional analyses, 
although these differences were minimal.
In separate analyses applying the unmatched win ratio approach to SYNTAX score 
terciles, the overall results of diabetics and nondiabetics were consistent with 
conventional analyses (Table 4). There was no consistency in increasing or decreasing 
the treatment effect of PCI versus CABG when using the win ratio approach.
Table 4. Unmatched win ratio approach for MACCE, according to subgroups of SYNTAX score 
within LM/3VD and diabetic subgroups.
SYNTAX score Type of analysis Left main disease Three-vessel disease Diabetes Non-diabetes
0-22 Hazard ratio 0.91 (0.56, 1.47) 1.28 (0.87, 1.90) 1.30 (0.74, 2.28) 1.03 (0.71, 1.47)
Relative risk 0.96 (0.64, 1.44) 1.24 (0.89, 1.73) 1.26 (0.81, 1.97) 1.06 (0.77, 1.45)
Unmatched Rw 0.93 (0.74, 1.89) 1.28 (1.02, 1.63) 1.26 (0.87, 2.58) 1.08 (0.95, 1.21)
23-32 Hazard ratio 0.94 (0.57, 1.55) 1.88 (1.29, 2.72) 1.56 (0.94, 2.64) 1.48 (1.07, 2.06)
Relative risk 1.01 (0.67, 1.52) 1.68 (1.22, 2.31) 1.45 (0.92, 2.30) 1.38 (1.02, 1.85)
Unmatched Rw 0.87 (0.55, 1.20) 1.83 (1.38, 2.87) 1.45 (0.80, 2.11) 1.41 (1.01, 2.11)
≥33 Hazard ratio 1.78 (1.21, 2.63) 2.02 (1.35, 3.03) 2.25 (1.51, 4.30) 1.62 (1.16, 2.25)
Relative risk 1.57 (1.15, 2.14) 1.74 (1.24, 2.44) 2.22 (1.43, 3.45) 1.46 (1.11, 1.91)
Unmatched Rw 1.68 (1.46, 2.27) 2.11 (1.62, 3.03) 2.70 (1.64, 2.89) 1.61 (1.20, 2.12)
Results are displayed as ratios with 95% CI between brackets. Rw, win ratio.
DISCUSSION
The current analysis demonstrates that, by hierarchically prioritising events 
in the composite of MACCE, the treatment effect of CABG versus PCI is larger 
than with conventional analyses. In smaller subgroups of patients, for which 
unmatched win ratio analyses are necessary, differences between the win 
ratio approach and conventional analyses are minimal. These results provide 
additional insights into the SYNTAX trial results and have several important 
implications for future trial conduct.
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PCI versus CABG
The use of composite endpoints in trials is problematic because it may provoke 
controversy regarding their suitability (12). Components are often unreasonably 
combined (12,13), results are difficult to interpret (14-16), and favourable 
outcomes or combinations of outcomes are cherry picked (6,17). The criticism of 
the PCI versus CABG trials is that the superiority of CABG is primarily driven by 
repeat revascularisation which has less of a clinical impact than all-cause death, 
stroke and MI (5). When repeat revascularisation is not part of the composite 
endpoint, there is no statistically significant difference between PCI and CABG in 
many trials. A meta-analysis of four trials comparing PCI with stents versus CABG 
also did not show a difference in rates of death/stroke/MI between CABG and PCI 
(18). However, overall MACCE rates at five years were significantly lower in CABG 
patients as a result of persistently lower repeat revascularisation rates in those 
patients (18).
The win-ratio approach addresses the limitations of softer clinical components in 
a composite endpoint by putting more emphasis on events with greater clinical 
importance. The win-ratio analysis takes into account not only the number of 
events, but also the timing of the event. While there was no statistically significant 
difference in survival at longest follow-up in the SYNTAX study, the Kaplan-
Meier curves showed a continuous higher all-cause mortality rate after PCI. In 
a conventional time-to-event analysis with log-rank testing, this difference is 
not reflected. The win-ratio analysis of the SYNTAX trial shows that the benefit 
of CABG over PCI is evident in terms of both lower MACCE and lower all-cause 
mortality rates (p=0.021). Using the win ratio, this is the first time that a difference 
in all-cause mortality between PCI and CABG has been shown.
In patients with low SYNTAX scores, the win ratio for MACCE was not statistically 
different between treatment groups, but there was a considerable difference 
between the win-ratio and conventional analysis, suggesting that CABG may be 
favourable even in this subgroup of patients with a low SYNTAX score. This can be 
explained by the three times higher MI rates and the necessity for repeat CABG 
revascularisation in the PCI group. However, these findings are hypothesis-
generating, and the preferred revascularisation method in the group with a low 
SYNTAX score remains a matter of debate that will need evaluation in future 
clinical trials.
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Future clinical trial design
The win ratio proves to be an important method for analysing future randomised 
clinical trial data. The unmatched win ratio substantially increases statistical 
power, while the matched win ratio showed an even larger increase in treatment 
effect (19,20). Using the win ratio for sample size calculations may therefore 
reduce the number of patients in a trial, with the obvious advantages of shorter 
enrolment and lower costs. Expanding the number of components and including 
components with a wide range of impact severity will increase event rates and 
reduce the sample size further. While this would be considered inappropriate for 
conventional analyses (21), this is not an issue when applying the win ratio since 
events are prioritised based on their impact severity.
When using the win ratio, however, it is important to alternate between the 
matched and unmatched approaches. Although the matched approach is 
favoured, our subgroup analysis that was performed 10 times suggests that 
exclusion of patients from an analysis in order to produce matched pairs can 
create a selection bias, causing an incorrect estimate of the true treatment effect 
on the outcome of interest. Therefore, it is recommended to use the unmatched 
approach when matching two treatment groups for which a substantial number of 
patients (arbitrarily >10%) should be excluded for matching.
STUDY LIMITATIONS
Applying the win ratio has some limitations. First, there is no clear consensus on 
ranking the severity of the events in MACCE. In this study, we used the weighting 
scheme as proposed by Tong and coauthors (17). In addition, a repeat CABG was 
rated as having more impact than repeat PCI. One may also argue that repeat CABG 
may have more impact than MI, due to its invasiveness and potential complications. 
Secondly, even within a single event, there are different degrees of severity, such 
as major MI with subsequent left ventricular dysfunction versus MI in the smaller 
branches of the coronary arteries, with less impact on a patient’s quality of life and 
prognosis. Likewise, a severe MI may have more consequences than a minor stroke. 
Future validation and verifications of the win ratio should be conducted before it 
becomes widely used in clinical trials. Moreover, the use of TAXUS stents in clinical 
practice was superseded by second-generation DES, which has been shown to 
improve long-term outcomes significantly. Therefore, the presented analyses must 
be considered observational and “hypothesis-generating”.
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It should be acknowledged that a hazard ratio (HR), relative risk (RR) and the win 
ratio (Rw) are different outcome measures, and it is therefore unclear whether 
they can be compared directly.
CONCLUSIONS
The win ratio is a new method to analyse composite endpoints within clinical 
trials. It can be used effectively and provides a stronger estimate of a treatment 
effect than conventional analyses. Furthermore, it can easily be extended to 
analyse composite endpoints with multiple components and with a wider range 
of impact severity, while maintaining integrity. Based on these advantages, future 
trials adopting this approach can expect similar statistical power with smaller 
sample sizes, and lower trial costs.
In case of PCI versus CABG in the SYNTAX trial, this re-analysis bolstered the results 
of the conventional analysis and strengthened the finding in favour of CABG 
treatment for patients with complex coronary disease. This provides evidence 
that hard clinical outcomes in particular (e.g., death and MI) after CABG are less 
frequent as compared with PCI. It is important to emphasise that this analysis 
does not undermine the findings of the original conventional analysis based on 
a traditional pre-specified design; it does, however, more appropriately estimate 
the treatment effect of PCI versus CABG by prioritising hard clinical endpoints 
over softer endpoints.
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IMPACT ON DAILY PRACTICE
This study demonstrates that the win ratio approach can be simply and efficiently 
used to analyse composite outcomes in clinical trials that have combined 
several components with different clinical importance into a single measure. 
The obtained results provide a valuable framework to clinicians for meaningful 
outcome analysis following percutaneous coronary intervention and coronary 
artery bypass grafting. The win ratio has several advantages over conventional 
analyses and may be pre-specified in future trial designs. 
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ABSTRACT
AIMS: The aim of this study was to investigate short-term and five-year follow-
up results from patients randomised to coronary artery bypass grafting (CABG) 
or percutaneous coronary intervention (PCI) with paclitaxel-eluting stents in the 
SYNTAX trial, focusing on patients with chronic kidney disease (CKD).
METHODS AND RESULTS: Baseline glomerular filtration rate estimates (eGFR) 
were available in 1,638 patients (PCI=852 and CABG=786). The Kidney Disease: 
Improving Global Outcomes (KDIGO) threshold was used to define staging of 
CKD. At five years, death was significantly higher in patients with CKD compared 
to patients with normal kidney function after PCI (26.7% vs. 10.8%, p<0.001) 
and CABG (21.2% vs. 10.6%, p=0.005). Comparing PCI with CABG, there was a 
significant interaction according to kidney function for death (pint=0.017) but not 
the composite endpoint of death/stroke/MI (pint=0.070) or MACCE (pint=0.15). In 
patients with CKD, the rate of MACCE was significantly higher after PCI compared 
with CABG (42.1% vs. 31.5%, p=0.019), driven by repeat revascularisation (21.9% vs. 
8.9%, p=0.004) and allcause death (26.7% vs. 21.2%, p=0.14). In patients with CKD 
who also had diabetes, PCI versus CABG was significantly worse in terms of death/
stroke/MI (47.9% vs. 24.4%, p=0.005) and all-cause death (40.9% vs. 17.7%, p=0.004).
CONCLUSIONS: During a five-year follow-up, adverse event rates were 
comparable between PCI and CABG patients with moderate CKD but significantly 
higher compared to the patients with impaired or normal kidney function. The 
negative impact of CKD on long-term outcome following PCI appears to be 
stronger when compared to CABG, especially in the CKD patients with diabetes 
and extensive coronary disease. 
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INTRODUCTION
Chronic kidney disease (CKD) is a worldwide healthcare problem with an 
increasing incidence (1). Despite the magnitude of resources committed to its 
treatment, CKD is one of the leading causes of death in Western countries (2). 
End-stage renal disease, but also the early stages of CKD are found to be strong 
independent predictors of developing coronary artery disease (CAD) with 
subsequently markedly increased rates of cardiovascular events and high mortality 
(3). The high prevalence of diabetes among patients with CKD contributes to the 
progression of renal disease, thereby promoting accelerated atherosclerosis that 
results in diffuse coronary artery calcifications and represents a group at high 
risk of cardiac mortality (4). It remains unclear whether percutaneous coronary 
intervention (PCI) or coronary artery bypass grafting (CABG) should be preferred 
in patients with CKD. According to the 2014 ESC/EACTS guidelines on myocardial 
revascularisation, CABG is preferable over PCI in patients with CKD if the life 
expectancy is more than one year, while PCI is recommended in patients with a 
life expectancy of less than one year. However, the current guidelines are based 
on observational studies with inherent limitations (5,6). A subgroup analysis 
of the ARTS trial provides data from a randomised comparison of CABG with 
PCI using bare metal stents (BMS) in patients with CKD, but these results are 
difficult to interpret in the current DES era (7). Moreover, data on the optimal 
revascularisation strategy in patients with a combined disease burden of CKD and 
diabetes are only available from the FREEDOM trial in which the authors were 
unable to report any differences among diabetic/nondiabetic patients because 
the population consisted only of diabetic patients with CKD, as mentioned in 
their limitations (8).
In the SYNTAX trial, PCI with first-generation paclitaxel-eluting stents was 
compared with CABG for patients with de novo three-vessel and/or left main (LM) 
disease. Unlike previous trials (9), patients with CKD were not routinely excluded 
(10). Therefore, this study presents unique data of patients with CKD by comparing 
five-year outcomes between CABG and PCI along the spectrum of kidney function.
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METHODS
Study design
The SYNTAX trial design and methods have been described previously (10). Briefly, 
SYNTAX was a prospective, multinational, randomised clinical trial in which 1,800 
patients were randomly assigned to undergo PCI with first-generation paclitaxel-
eluting stents (TAXUS™ Express™; Boston Scientific, Marlborough, MA, USA) or 
CABG. Patients were randomly assigned in a 1:1 fashion to undergo PCI (n=903) or 
CABG (n=897).
This study was carried out according to the principles of the Declaration of 
Helsinki. The trial is registered with number NCT00114972 at the ClinicalTrials.
gov website.
Definitions and endpoints
The definitions used for the classification of adverse events have been reported 
previously (10,11). The primary endpoint of the SYNTAX trial was the composite 
rate of major adverse cardiac and cerebrovascular events (MACCE), defined as 
all-cause death, stroke, myocardial infarction (MI), and repeat revascularisation. 
Secondary endpoints in this study included the composite safety endpoint of 
death/stroke/MI and rates of the individual MACCE components.
Estimation of the glomerular filtration rate (eGFR) was used to assess the degree of 
kidney failure. The eGFR was calculated from the baseline serum creatinine level, 
which was available in 1,638 patients (PCI=852, 94.3% and CABG=786, 87.6%). Of the 
remaining 162 (9.0%) patients, the baseline creatinine could not be determined 
(Supplementary Table 1). For each patient, the eGFR was estimated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (12). The Kidney 
Disease: Improving Global Outcomes (KDIGO) threshold was used to define the CKD 
population (13). According to KDIGO classifications, patients were classified according 
to the eGFR: stage 1, patients with a normal kidney function had an eGFR of ≥90 mL/
min per 1.73 m2; stage 2, impaired renal function, defined by an eGFR between 60 
and 89 mL/min per 1.73 m2; and stages 3-5, CKD, defined by an eGFR <60 mL/min per 
1.73 m2. Patients with CKD were further subdivided into stage 3 (eGFR 30-59 mL/min 
per m2), stage 4 (eGFR 15-29 mL/min per 1.73 m2) and stage 5 (chronic dialysis treatment) 
(13). Using these classifications, the following subgroups were defined and analysed in 
the current study: i) normal kidney function (stage 1); ii) impaired kidney function 
(stage 2); and iii) CKD (stages 3, 4 and 5), the latter being pooled together into a single 
group due to the low number of patients in stages 4 and 5 subgroups.
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Statistical analysis
Data are presented using descriptive statistics, as a percentage, count of sample 
size, or mean±standard deviation (SD). Either the Student’s t-test or the Kruskal-
Wallis test was used to compare continuous variables. Differences in discrete 
variables were compared with a χ2 or Fisher’s exact test, where appropriate.
All analyses were based on the intention-to-treat principle. Short-term outcomes 
were defined within 30 days after the procedure. Five-year rates of adverse events 
were estimated using the Kaplan-Meier method, and comparisons between groups 
were made using log-rank tests. P-values for interaction were acquired using a logistic 
regression chi-square test. Cox proportional hazard models were used to calculate 
hazard ratios (HRs) and 95% confidence intervals (CI) with PCI as the reference 
group. The proportionality for Cox models was tested with Schoenfeld residuals and 
confirmed no significant departures from the proportionality assumption. A two-
sided p-value of <0.05 was considered to be statistically significant. Analyses were 
performed using SPSS Statistics, Version 21.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Of the 1,638 patients, only 219 (25.7%) patients randomised to PCI and 209 (26.6%) 
patients randomised to CABG had a normal kidney function (Figure 1). The majority 
of patients had impaired kidney function (PCI=475 (55.8%) and CABG=426 (54.2%)), 
whereas CKD was present in 158 (18.5%) patients randomised to PCI and 151 (19.2%) 
patients randomised to CABG. Among patients with CKD, 24 patients (PCI=13 (8.2%) 
and CABG=11 (7.3%)) had severe CKD (stage 4) and six patients (PCI=3 (1.9%) and 
CABG=3 (2.0%)) were on chronic dialysis (stage 5). Patients without information on 
GFR had similar baseline characteris tics and five-year outcomes to patients with 
information on GFR (Supplementary Table 1).
Patient characteristics
The risk profile of patients was comparable between PCI and CABG in all categories 
of patients (Supplementary Table 2). Patients with CKD (mean eGFR 47.6±10.8 mL/
min/1.73 m2) had a markedly higher risk profile at baseline than patients with normal 
or impaired kidney function, reflecting an overall higher logistic EuroSCORE. There 
were no differences regarding baseline coronary disease complexity as determined 
by the SYNTAX score (Table 1, Supplementary Table 3). However, a subgroup of CKD 
patients with diabetes had a significantly higher SYNTAX score compared to non-
diabetic CKD patients (32.2±12.1 vs. 28.2±11.7, p=0.008).
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Procedural characteristics and discharge medication
Off-pump CABG was performed more often in patients with CKD compared 
to patients with impaired or normal kidney function (22.1% vs. 13.1% vs. 15.8%, 
respectively; p=0.035) (Supplementary Table 4). The use of multiple arterial grafts 
was lower in CKD patients; in particular, bilateral internal mammary arteries 
(BIMA) were used less frequently (18.8% vs. 28.5% vs. 34.2%, respectively; p=0.007). 
The number of distal anastomoses and the completeness of revascularisation did 
not differ between groups.
In the PCI group, there were no differences among the groups in the procedural 
aspect regarding stent use (Supplementary Table 4). However, the rate of complete 
revascularisation was substantially lower in patients with CKD versus those with 
impaired kidney function or normal kidney function (46.2% vs. 60.5% vs. 56.5%, 
respectively; p=0.007), while a comparable number of patients underwent staged 
procedures (14.6% vs. 12.0% vs. 17.4%, respectively; p=0.16). Acetylsalicylic acid was 
prescribed less often in patients with CKD compared to patients with impaired 
kidney function or normal kidney function after PCI (93.0% vs. 96.4% vs. 99.1%, 
respectively; p=0.006) and CABG (83.0% vs. 89.2% vs. 91.7%, respectively; p=0.043) 
(Supplementary Table 4). No differences in the administration of statins and beta-
blockers were found in either treatment group. In general, secondary preventive 
medication was prescribed more often after PCI than after CABG (Supplementary 
Table 2).
Short-term outcomes
Within the PCI and CABG groups, incidences of 30-day adverse events were 
comparable in patients with CKD, impaired kidney function, and normal kidney 
function (Table 1). Comparing outcomes between PCI and CABG in patients 
with CKD, there were no significant differences in rates of MACCE (6.3% vs. 
4.0%, respectively, p=0.34), the composite of death/stroke/MI (5.7% vs. 2.6%, 
respectively, p=0.18), all-cause death (2.5% vs. 0.7%, respectively, p=0.19), or repeat 
revascularisation (1.9% vs. 1.3%, respectively, p=0.68) (Supplementary Table 2).
Five-year outcomes
In separate groups of both PCI and CABG, rates of adverse events were not 
significantly different between patients with normal vs. impaired kidney function, 
while patients with CKD vs. normal kidney function had significantly higher rates 
of MACCE, the composite safety endpoint of death/stroke/MI, and all-cause death 
(Supplementary Table 5). Rates of repeat revascularisation were lower in patients 
with impaired kidney function and CKD.
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Figure 2. Kaplan-Meier cumulative event curves by the status of kidney function in the SYNTAX randomised cohort. 
p-values are from log-rank test. CABG, coronary artery bypass grafting; CKD, chronic kidney disease; eGFR, estimated 
glomerular filtration rate; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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Table 2. Outcomes at 5 years stratified by baseline kidney function.
PCI CABG HR (95% CI) p-value
Normal kidney function n=219 n=209
MACCE 73 (34.9) 56 (29.6) 1.25 (0.88-1.77) 0.21
Death/stroke/MI 40 (18.4) 30 (16.5) 1.24 (0.77-1.99) 0.37
Death, all-cause 21 (10.8) 18 (10.6) 1.06 (0.57-2.00) 0.85
Repeat revascularisation 57 (28.2) 34 (17.6) 1.63 (1.06-2.49) 0.023
Impaired kidney function n=475 n=426
MACCE 174 (37.3) 102 (25.1) 1.60 (1.25-2.04) <0.001
Death/stroke/MI 83 (17.7) 62 (15.3) 1.18 (0.85-1.63) 0.33
Death, all-cause 51 (10.9) 37 (9.3) 1.22 (0.80-1.86) 0.36
Repeat revascularisation 125 (27.7) 53 (13.4) 2.25 (1.63-3.10) <0.001
CKD n=158 n=151
MACCE 66 (42.1) 42 (31.5) 1.58 (1.08-2.33) 0.019
Death/stroke/MI 50 (31.9) 33 (25.5) 1.45 (0.93-2.25) 0.096
Death, all-cause 41 (26.7) 27 (21.2) 1.44 (0.88-2.34) 0.14
Repeat revascularisation 31 (21.9) 12 (8.9) 2.56 (1.31-4.99) 0.004
Values are presented as n/N (%). Data are Kaplan-Meier estimates of adverse events with p-values 
from log-rank test. Treatment-by-kidney status interactions failed to reach statistical significance 
for MACCE (pint=0.15), the composite safety endpoint (pint=0.070), all-cause death (pint=0.017), and 
repeat revascularisation (pint=0.65). CABG, coronary artery bypass grafting; CKD, chronic kidney 
disease; MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial infarction; PCI, 
percutaneous coronary intervention.
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Figure 3. Hazard ratios of PCI versus CABG according to subgroups based on patient characteristics by the 
status of kidney function. Values are Kaplan-Meier event rates at five years with p-values from log-rank test. 
CABG, coronary artery bypass grafting; CAD, carotid artery disease; CKD, chronic kidney disease; eGFR, estimated 
glomerular filtration rate; HR, hazard ratio; LV, left ventricular; MI, myocardial infarction; PCI, percutaneous 
coronary intervention; PVD, peripheral vascular disease.
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Overall, differences between PCI and CABG in rates of adverse events were larger 
in patients with CKD than in other groups (Table 2, Supplementary Table 6, 
Figure 2). There was a significant treatment-by-kidney function interaction 
for all-cause death (pint=0.017), while interactions for MACCE (pint=0.15) or the 
composite endpoint of death/stroke/MI (pint=0.070) did not reach statistical 
significance.
In patients with CKD, the rate of MACCE was significantly higher after PCI than 
after CABG (42.1% vs. 31.5%, respectively; p=0.019) (Table 2, Figure 2). Rates of 
the composite endpoint of death/stroke/MI were 31.9% vs. 25.5%, respectively 
(p=0.096), and for all-cause death 26.7% vs. 21.2%, respectively (p=0.14).
Subgroup analysis
The rates of the composite of death/stroke/MI were significantly lower in patients 
with normal or impaired kidney function compared to CKD patients irrespective 
of the patient’s baseline characteristics (Supplementary Figure 1).
Overall, subgroup analyses among patients with CKD demonstrated a largely 
consistent benefit of CABG over PCI (Figure 3). However, significant interactions 
were found for gender, SYNTAX score and diabetes.
Subgroup analyses according to diabetic status show a persistent increase in 
the difference in adverse events between CABG and PCI with increasing kidney 
failure (from normal kidney function to CKD) (Supplementary Table 7). Among 
CKD groups, nondiabetic patients had comparable rates between PCI and CABG 
regarding the composite of death/stroke/MI (HR 1.04, 95% CI: 0.60-1.80; p=0.89) and 
all-cause death (HR 0.94, 95% CI: 0.511.71; p=0.83) (Figure 4). In contrast, diabetic 
patients assigned to PCI compared to CABG had significantly higher rates of the 
composite of death/stroke/MI (HR 2.82, 95% CI: 1.32-5.99; p=0.005 with pint=0.039) 
and all-cause death (HR 3.39, 95% CI: 1.41-8.13; p=0.004 with pint=0.018) (Figure 4).
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Figure 4. Kaplan-Meier cumulative event curves in patients with chronic kidney disease stratified 
by medically treated diabetes in the SYNTAX randomised cohort. Curves are separated for (A) non-
diabetic patients and (B) medically treated diabetic patients. Treatment-by-diabetes interactions: 
MACCE (pint=0.10), the composite safety endpoint (pint=0.039), all-cause death (pint=0.018) and 
repeat revascularisation (pint=0.39). p-values are from log-rank test. CABG, coronary artery bypass 
grafting; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; MI, 
myocardial infarction; PCI, percutaneous coronary intervention.
278
Chapter 12
DISCUSSION
This five-year analysis of the SYNTAX trial provides unique data on patients with 
and without CKD undergoing revascularisation. Important findings are that: i) 
the treatment plan for patients with versus without CKD differed significantly 
with CABG (e.g., less BIMA and more off-pump) and PCI (e.g., less complete 
revascularisation); ii) patients with CKD suffer from receiving less guideline-
directed secondary prevention; iii) patients with CKD have significantly poorer 
outcomes after both PCI and CABG than patients with normal or impaired kidney 
function; and iv) differences in the five-year adverse event rates between PCI and 
CABG were minimal in patients with a normal kidney function but in favour of 
CABG in patients with CKD, particularly if diabetes was also present. 
There is an increasing focus on patients with CKD because its presence in patients 
who require myocardial revascularisation is growing (14). Data on the comparison 
between PCI with DES and CABG in this patient group are limited to observational 
studies (15,16). In a propensity-matched analysis of 893 pairs of patients with a 
GFR <60 ml/min/1.73 m2, Chan and co-authors reported that three-year MACCE 
and survival were significantly lower after CABG than PCI with DES (15). In 
contrast, in a larger propensity-matched analysis of 2,960 pairs, Bangalore and 
co-authors found CABG to be associated with short-term death, stroke and 
repeat revascularisation with only a benefit over PCI with DES regarding four-
year rates of MI and repeat revascularisation but not death (16). However, in these 
retrospective analyses, adjustment for selection bias is not always possible, and 
many confounding factors may influence the outcomes. Therefore, the results 
of the current randomised comparison add crucial information to the available 
body of evidence.
We found that the impact of kidney function on the long-term outcomes of PCI 
and CABG was significant. Patients with a decreased eGFR between 60 and 90 
mL/min/1.73 m2 had similar rates of hard clinical endpoints of death/stroke/MI 
when compared to patients with normal kidney function after both CABG and 
PCI, irrespective of SYNTAX score group, but with a significantly increased risk of 
repeat revascularisation after PCI. However, patients with CKD had substantially 
higher rates of the composite of death/stroke/ MI and particularly all-cause 
death than patients with normal or impaired kidney function. This calls for more 
dedicated attempts to improve outcomes in this select group. In this regard, CABG 
was performed more often off-pump to prevent cardiopulmonary bypass circuit-
induced adverse effects on renal function. Despite strong evidence supporting 
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its efficacy after CABG or PCI, the prescription of guideline-directed secondary 
prevention in patients with CKD was less than in other patients. A lack of evidence, 
the possibility of dosing errors, a higher incidence of major bleeding, and no clear 
guideline recommendations for patients with CKD lead to uncertainty among 
clinicians about the optimal post-treatment medication strategy. Nevertheless, 
recent publications show that statins significantly reduce cardiovascular events 
and might be associated with a slower progression of kidney damage (17). Also, 
benefits of low-dose aspirin on long-term survival without an excess of major 
bleeding were also noted in patients with CKD (18).
Kidney function was also found to have a significant impact on differences 
between PCI and CABG outcomes. Patients with a normal kidney function had 
similar adverse event rates with PCI vs. CABG except for repeat revascularisation 
that was higher with PCI. In patients with an impaired kidney function, CABG 
also failed to show a benefit regarding the composite of death/stroke/MI or 
all-cause death. However, in patients with CKD, there was a clear benefit of 
CABG over PCI. The difference in MACCE was driven by higher rates of repeat 
revascularisation, but also due to markedly higher rates of the composite of 
death/stroke/MI (absolute difference 6.4%) driven by all-cause death (absolute 
difference 5.5%). This improved survival might be related to the fact that patients 
with CKD have a higher risk of thrombotic events with PCI as a result of different 
complex haemostatic properties, severe atherosclerosis, and a lack of antiplatelet 
treatments.
Interestingly, several subgroups of patients with CKD were at particularly 
increased risk of adverse events after PCI. While the significant interaction for 
SYNTAX score and gender is consistent with the overall results of the SYNTAX 
trial, we found a positive interaction between diabetes and mortality risk of 
PCI relative to CABG that was not found in the overall SYNTAX trial result11. The 
survival advantage of CABG in this context might be due to the high baseline 
complexity of coronary dis ease and aggressive nature of the atherosclerotic 
disease in diabetic patients. In a subgroup analysis of the FREEDOM trial (8), 
patients with an eGFR of 30-59 mL/min/1.73 m2 versus those with an eGFR ≥60 
mL/min/1.73 m2 also had significantly higher rates of MACCE and particularly 
death, similar to the current analy sis. However, the relative difference between 
PCI and CABG was consistent in patients with and without CKD, suggesting that 
the combination of CKD and diabetes does not increase the benefit of CABG over 
PCI, in contrast to the current analysis. Unfortunately, the FREEDOM trial could 
not distinguish between diabetic and non-diabetic patients with CKD as the study 
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included only diabetic patients.
Limitations
Some limitations of the current analysis need to be acknowledged. Analyses 
according to CKD were not predefined in the trial protocol, and the use of TAXUS 
stents in clinical practice was superseded by second-generation DES, which have 
been shown to improve long-term outcomes significantly. Therefore, results 
should be interpreted as observational and hypothesisgenerating. Second, of the 
CKD patients who were analysed, only 10% had severe and end-stage CKD. Thus, 
our findings should be restricted to the patients with stage 3 CKD (eGFR 30-60 
mL/min/1.73 m²) before index revascularisation. Third, despite the primarily 
used CKD-EPI and KDIGO guidelines to define CKD populations that require 
“the presence of kidney damage at least over three months”, estimations of eGFR 
were only based on the creatinine level at hospital admission. Due to a lack of 
laboratory data during the periprocedural time, we were unable to determine 
contrast-induced nephropathy (CIN) and its impact on early and long-term 
outcomes.
CONCLUSIONS
Patients with CKD have an increased risk of adverse events, particularly mortality, 
after both PCI and CABG. Differences in five-year event rates between PCI and 
CABG are shown to have a significant interaction according to kidney function. 
The negative impact of CKD on long-term outcome following PCI appears to be 
stronger when compared to CABG, especially in the CKD patients with diabetes and 
extensive coronary disease. Patients with a normal or impaired kidney function 
may be candidates for PCI based on a similar risk for adverse events between PCI 
and CABG except for more repeat revascularisation. These results should provide 
a more substantiated evidence basis for clinical guideline recommendations for 
patients with CKD. Nevertheless, an adequately powered, dedicated, randomised 
trial is needed to provide the evidence for an optimal treatment strategy for 
patients with CKD who require myocardial revascularisation.
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IMPACT ON DAILY PRACTICE
The present study demonstrates a profound negative impact of baseline 
moderate kidney failure on five-year survival following both PCI and CABG. 
Importantly, patients are suboptimally treated, although the benefit of a more 
intense antithrombotic and lipid-lowering postoperative therapy on the outcome 
is established after surgical and interventional procedures. For treatment 
decision making, the Heart Team should take into consideration kidney failure, 
particularly in the presence of diabetes together with higher anatomic complexity 
as measured by the SYNTAX score.
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SUPPLEMENTAL MATERIAL
Supplementary Table 1. Baseline characteristics and 5-year outcomes between the patients 
with and without baseline glomerular filtration rate estimates.
PCI cohort CABG cohort
eGFR 
(n=852)
No eGFR 
(n=51)
p-value eGFR 
(n=786)
No eGFR 
(n=101)
p-value
Age, years 65.3±9.7 64.8±9.5 0.73 64.9±9.8 65.1±9.5 0.85
Male 654 (76.8) 36 (70.6) 0.31 627 (79.8) 81 (73.0) 0.10
BMI 28.2±4.8 27.3±4.9 0.23 27.9±4.5 28.0±4.7 0.87
Current smoker 157 (18.8) 10 (20.0) 0.83 177 (23.1) 19 (17.9) 0.23
Medically treated diabetes 219 (25.7) 12 (23.5) 0.73 189 (24.0) 32 (28.8) 0.27
Insulin treatment 86 (10.1) 3 (5.9) 0.33 83 (10.6) 10 (9.0) 0.62
Peripheral vascular disease 78 (9.2) 4 (7.8) 0.75 84 (10.7) 11 (9.9) 0.80
COPD 67 (7.9) 4 (7.8) >0.99 70 (8.9) 13 (11.7) 0.34
Hypertension 622 (73.5) 41 (82.0) 0.18 591 (75.7) 95 (86.4) 0.053
Hyperlipidaemia 662 (78.3) 43 (86.0) 0.19 606 (77.9) 80 (72.1) 0.17
Carotid artery disease 67 (7.9) 6 (11.8) 0.32 64 (8.1) 11 (9.9) 0.53
History of CVA or TIA 67 (7.9) 2 (4.0) 0.32 73 (9.4) 8 (7.3) 0.49
Unstable angina 253 (29.7) 9 (17.6) 0.067 227 (28.9) 24 (21.6) 0.11
Previous MI 272 (32.3) 13 (25.5) 0.31 264 (34.0) 36 (32.7) 0.79
Congestive heart failure 34 (4.0) 2 (3.9) 0.97 40 (5.2) 7 (6.4) 0.61
Pulmonary hypertension 8 (0.9) 0 0.49 12 (1.5) 0 0.19
LVEF poor (<30%) 10 (1.2) 2 (3.9) 0.096 19 (2.4) 3 (2.7) 0.86
LVEF moderate (30-49%) 148 (17.4) 12 (23.5) 0.26 134 (17.0) 19 (17.1) 0.99
Logistic EuroSCORE 3.8±4.6 3.4±3.5 0.43 3.8±4.1 4.2±6.2 0.48
Left main, any 337 (39.6) 20 (39.2) 0.96 310 (39.5) 38 (34.2) 0.29
Number of lesions 3.9±1.7 3.9±1.5 0.99 4.0±1.7 4.1±1.9 0.52
Bifurcations, any 612 (72.3) 37 (72.5) 0.97 568 (72.8) 83 (75.5) 0.56
Trifurcations, any 94 (11.1) 2 (3.9) 0.11 86 (11.0) 8 (7.3) 0.23
Total occlusion, any 204 (24.1) 13 (25.5) 0.82 176 (22.6) 22 (20.0) 0.54
SYNTAX score 28.4±11.5 28.3±11.4 0.98 29.3±11.4 27.6±11.0 0.13
5-year outcomes
MACCE 313 (37.5) 19 (41.0) 0.70 200 (27.5) 29 (31.8) 0.41
Death/stroke/MI 173 (20.6) 12 (25.8) 0.45 125 (17.5) 18 (19.4) 0.55
Death, all-cause 113 (13.5) 10 (21.5) 0.13 82 (11.9) 15 (16.5) 0.14
Stroke 19 (2.4) 1 (2.4) 0.98 29 (3.9) 2 (2.1) 0.42
MI 79 (9.7) 4 (9.3) 0.84 29 (3.8) 4 (4.2) 0.88
Repeat revascularisation 213 (26.8) 9 (24.5) 0.46 99 (13.8) 11 (13.5) 0.76
Values are presented as mean±SD or n/N (%). Kaplan-Meier event rates were estimated at 5 years 
with p-values from log-rank test. BMI, body mass index; CABG, coronary artery bypass grafting; 
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; eGFR, estimated 
glomerular filtration rate; LVEF, left ventricular ejection fraction; MACCE, major adverse cardiac and 
cerebrovascular events; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, 
transient ischaemic attack.
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Supplementary Table 2. Baseline characteristics, 30-day outcomes, and discharge therapy 
comparison between PCI and CABG groups of patients defined by kidney function.
Normal kidney function Impaired kidney function CKD
PCI 
(n=219)
CABG 
(n=209)
p-value PCI 
(n=475)
CABG 
(n=426)
p-value PCI 
(n=158)
CABG 
(n=151)
p-value
Age, years 58.8±9.4 59.3±9.9 0.60 66.0±8.7 65.3±8.8 0.25 71.9±7.3 71.6±7.9 0.68
Male 174 (79.5) 173 (82.8) 0.38 372 (78.3) 353 (82.9) 0.086 108 (68.4) 101 (66.9) 0.78
BMI 28.9±5.2 27.5±9.4 0.003 27.8±4.4 28.1±4.5 0.36 28.3±5.3 28.1±4.6 0.70
Current smoker 73 (33.3) 82 (40.2) 0.14 69 (14.5) 77 (18.5) 0.15 15 (9.7) 18 (12.2) 0.49
Medically treated diabetes 46 (21.0) 51 (24.4) 0.40 129 (27.2) 88 (20.7) 0.023 44 (27.8) 50 (33.1) 0.31
Insulin treatment 18 (8.2) 21 (10.0) 0.51 45 (9.5) 39 (9.2) 0.87 23 (14.6) 23 (15.2) 0.87
Peripheral vascular disease 19 (8.7) 13 (6.2) 0.33 38 (8.0) 47 (11.0) 0.12 21 (13.3) 24 (15.9) 0.52
COPD 19 (8.7) 22 (10.5) 0.52 33 (6.9) 33 (7.7) 0.65 15 (9.5) 15 (9.9) 0.90
Hypertension 144 (66.1) 155 (74.9) 0.046 343 (72.8) 308 (72.6) 0.95 135 (86.0) 128 (85.3) 0.87
Hyperlipidaemia 164 (75.2) 166 (79.8) 0.26 376 (79.8) 321 (76.4) 0.22 122 (77.7) 119 (79.3) 0.73
Carotid artery disease 9 (4.1) 10 (4.8) 0.73 39 (8.2) 29 (6.8) 0.43 19 (12.0) 25 (16.6) 0.25
History of CVA or TIA 9 (4.1) 15 (7.2) 0.16 36 (7.6) 39 (9.2) 0.37 22 (14.0) 19 (12.7) 0.73
Unstable angina 69 (31.5) 58 (27.8) 0.39 142 (29.9) 125 (29.3) 0.86 42 (26.6) 44 (29.1) 0.62
Previous MI 74 (34.1) 84 (40.2) 0.19 140 (29.9) 133 (31.6) 0.59 58 (36.9) 47 (32.0) 0.36
Congestive heart failure 3 (1.4) 8 (3.9) 0.10 16 (3.4) 17 (4.1) 0.60 15 (9.6) 15 (10.3) 0.83
Pulmonary hypertension 3 (1.4) 1 (0.5) 0.34 3 (0.6) 4 (0.9) 0.60 2 (1.3) 7 (4.6) 0.078
LVEF poor (<30%) 2 (0.9) 3 (1.4) 0.61 5 (1.1) 8 (1.9) 0.30 3 (1.9) 8 (5.3) 0.11
LVEF moderate (30-49%) 36 (16.4) 41 (19.6) 0.39 74 (15.6) 68 (16.0) 0.87 38 (24.1) 25 (16.6) 0.10
Logistic EuroSCORE 2.7±3.1 2.8±2.9 0.67 3.6±4.7 3.4±3.3 0.58 6.0±5.3 6.3±6.1 0.58
Left main, any 94 (42.9) 87 (41.6) 0.79 176 (37.1) 163 (38.4) 0.69 67 (42.4) 60 (39.7) 0.63
Number of lesions 3.9±1.9 4.0±1.7 0.61 3.9±1.6 3.9±1.6 0.94 4.0±1.6 4.1±1.9 0.61
Bifurcations, any 154 (70.6) 148 (71.5) 0.53 341 (72.2) 313 (73.8) 0.60 117 (75.0) 107 (71.8) 0.53
Trifurcations, any 18 (8.3) 31 (15.0) 0.036 57 (12.1) 47 (11.1) 0.64 19 (12.2) 8 (5.4) 0.036
Total occlusion, any 47 (21.6) 40 (19.3) 0.91 116 (24.6) 96 (22.6) 0.50 41 (26.3) 40 (26.8) 0.91
SYNTAX score 27.4±11.2 28.8±11.7 0.20 28.5±11.3 29.5±11.2 0.17 29.6±12.3 29.3±11.7 0.86
Complete revascularisation 122 (56.5) 124 (61.4) 0.31 282 (60.5) 279 (66.4) 0.068 73 (46.2) 91 (60.7) 0.011
30-day post-treatment outcomes
MACCE 14 (6.4) 12 (5.8) 0.77 24 (5.1) 18 (4.2) 0.56 10 (6.3) 6 (4.0) 0.34
Death/stroke/MI 11 (5.0) 10 (4.8) 0.91 20 (4.2) 17 (4.0) 0.87 9 (5.7) 4 (2.6) 0.18
Death, all-cause 4 (1.8) 2 (1.0) 0.45 8 (1.7) 2 (0.5) 0.083 4 (2.5) 1 (0.7) 0.19
Repeat revascularisation 8 (3.7) 4 (1.9) 0.28 15 (3.2) 5 (1.2) 0.054 3 (1.9) 2 (1.3) 0.68
Medication at discharge
Acetylsalicylic acid 216 (99.1) 189 (91.7) 0.008 456 (96.4) 378 (89.2) <0.001 147 (93.0) 125 (83.3) 0.008
Thienopyridine antiplatelet 214 (98.2) 42 (20.4) <0.001 458 (96.8) 70 (16.5) <0.001 149 (94.3) 27 (18.0) <0.001
ARB or ACE inhibitor 140 (64.2) 102 (49.5) <0.001 324 (68.5) 215 (50.7) <0.001 109 (69.0) 73 (48.7) <0.001
β-blocker 176 (80.7) 160 (77.7) 0.55 388 (82.0) 333 (78.5) 0.19 122 (72.2) 120 (80.0) 0.55
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Calcium channel blockers 36 (16.5) 41 (19.9) <0.001 132 (27.9) 72 (17.0) <0.001 53 (33.5) 24 (16.0) <0.001
Amiodarone 5 (2.3) 23 (11.2) <0.001 3 (0.6) 59 (13.9) <0.001 4 (2.5) 22 (14.7) <0.001
Statins 188 (86.2) 152 (73.8) 0.099 418 (88.4) 322 (75.9) <0.001 132 (83.5) 114 (76.0) 0.099
Values are presented as mean±SD or n/N (%). Kaplan-Meier event rates were estimated at 30 days with 
p-values from log-rank test. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; 
BMI, body mass index; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; COPD, chronic 
obstructive pulmonary disease; CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; 
LVEF, left ventricular ejection fraction; MACCE, major adverse cardiac and cerebrovascular events; MI, 
myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.
Supplementary Table 2. Continued.
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Supplementary Table 6. Outcomes at 5 years stratified by baseline kidney function.
PCI CABG HR (95% CI) p-value
Normal kidney function, n 219 209
MACCE 73 (34.9) 56 (29.6) 1.25 (0.88-1.77) 0.21
Death/stroke/MI 40 (18.4) 30 (16.5) 1.24 (0.77-1.99) 0.37
Death, all-cause 21 (10.8) 18 (10.6) 1.06 (0.57-2.00) 0.85
Cardiac death 15 (6.9) 11 (5.7) 1.24 (0.57-2.71) 0.58
Vascular death 1 (0.5) 1 (0.5) 0.92 (0.12-14.65) 0.95
Non-cardiovascular death 5 (2.5) 6 (2.7) 0.75 (0.23-2.47) 0.64
Stroke 5 (2.4) 7 (3.6) 0.65 (0.21-2.06) 0.46
MI 24 (11.1) 10 (4.9) 2.25 (1.08-4.72) 0.026
Repeat revascularisation 57 (28.2) 34 (17.6) 1.63 (1.06-2.49) 0.023
Impaired kidney function, n 475 426
MACCE 174 (37.3) 102 (25.1) 1.60 (1.25-2.04) <0.001
Death/stroke/MI 83 (17.7) 62 (15.3) 1.18 (0.85-1.63) 0.33
Death, all-cause 51 (10.9) 37 (9.3) 1.22 (0.80-1.86) 0.36
Cardiac death 30 (6.6) 13 (3.2) 2.04 (1.08-3.92) 0.028
Vascular death 4 (0.9) 2 (0.5) 1.76 (0.32-9.64) 0.51
Non-cardiovascular death 17 (3.8) 20 (5.3) 0.75 (0.39-1.43) 0.38
Stroke 8 (1.8) 18 (4.4) 0.39 (0.17-0.89) 0.021
MI 39 (8.6) 13 (3.1) 2.70 (1.44-5.06) 0.001
Repeat revascularisation 125 (27.7) 53 (13.4) 2.25 (1.63-3.10) <0.001
CKD, n 158 151
MACCE 66 (42.1) 42 (31.5) 1.58 (1.08-2.33) 0.019
Death/stroke/MI 50 (31.9) 33 (25.5) 1.45 (0.93-2.25) 0.096
Death, all-cause 41 (26.7) 27 (21.2) 1.44 (0.88-2.34) 0.14
Cardiac death 27 (17.9) 10 (7.4) 2.33 (1.26-4.70) 0.011
Vascular death 1 (0.7) 1 (0.8) 0.92 (0.16-14.71) 0.95
Non-cardiovascular death 13 (9.4) 15 (12.0) 0.82 (0.39-1.72) 0.59
Stroke 6 (4.3) 4 (3.0) 1.40 (0.39-4.95) 0.60
MI 16 (11.1) 6 (4.2) 2.55 (1.03-6.52) 0.042
Repeat revascularisation 31 (21.9) 12 (8.9) 2.56 (1.31-4.99) 0.004
Values are presented as n/N (%). Data are Kaplan-Meier estimates of adverse events. p-values are 
from log-rank test. Treatment-by-kidney status interactions failed to reach statistical significance 
for MACCE (pint=0.15), the composite safety endpoint (pint=0.070), all-cause death (pint=0.017), 
cardiac death (pint=0.009), vascular death (pint=0.89), stroke (pint=0.21), MI (pint=0.96) and repeat 
revascularisation (pint=0.65). CABG: coronary artery bypass grafting; CKD, chronic kidney disease; HR, 
hazard ratio; MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial infarction; 
PCI, percutaneous coronary intervention.
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Supplementary Table 7. Five-year clinical outcomes according to kidney function and diabetes 
status.
Non-diabetic (n=1,230) Diabetic (n=398)
PCI CABG p-value PCI CABG p-value Interaction 
p-value*
Normal kidney function, n 173 158 56 41
MACCE 54 (31.3) 39 (26.0) 0.26 19 (46.8) 17 (40.6)  0.47  0.97
Death/stroke/MI 30 (17.4) 19 (12.7) 0.24 10 (21.8) 11 (28.1) 0.95 0.47
Death, all-cause 14 (8.2) 11 (7.6) 0.80 7 (15.2) 7 (21.1) 0.92 0.95
Repeat revascularisation 43 (25.3) 26 (17.6) 0.085 14 (38.4) 8 (17.7) 0.11 0.55
Impaired kidney function, n 346 338 129 88
MACCE 115 (33.7) 76 (23.3) 0.004 59 (47.0) 26 (32.3) 0.031  0.64
Death/stroke/MI 63 (18.4) 45 (13.7) 0.11 20 (16.0) 17 (21.4) 0.35 0.13
Death, all-cause 34 (9.9) 25 (7.8)  0.30 17 (13.7) 12 (15.6) 0.84 0.48
Repeat revascularisation 75 (22.8) 39 (12.3) <0.001 50 (40.9) 14 (17.7) 0.001 0.25
CKD, n 114 101 44 50
MACCE 43 (38.1) 30 (32.6)  0.31 23 (52.4) 12 (28.6)  0.005 0.10
Death/stroke/MI 29 (25.7) 23 (25.6) 0.89 21 (47.9) 10 (24.4) 0.005 0.039
Death, all-cause 23 (20.5) 20 (22.5) 0.83 18 (40.9) 7 (17.7)  0.004 0.018
Repeat revascularisation 21 (20.2) 9 (10.4) 0.070 10 (26.6)  3 (7.1) 0.015 0.39
*Interaction term for diabetes status by treatment arm.
CABG, coronary artery bypass grafting; CKD, chronic kidney disease; MACCE, major adverse cardiac 
and cerebrovascular events; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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ABSTRACT
BACKGROUND: The randomized EXCEL (Evaluation of XIENCE versus Coronary 
Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial 
reported a similar rate of the 3-year composite primary endpoint of death, 
myocardial infarction (MI), or stroke in patients with left main coronary artery 
disease (LMCAD) and site-assessed low or intermediate SYNTAX scores treated 
with percutaneous coronary intervention (PCI) and coronary artery bypass 
grafting (CABG). Whether these results are consistent in high-risk patients with 
diabetes, who have fared relatively better with CABG in most prior trials, is 
unknown.
OBJECTIVES: In this pre-specified subgroup analysis from the EXCEL trial, the 
authors sought to examine the effect of diabetes in patients with LMCAD treated 
with PCI versus CABG.
METHODS: Patients (N = 1,905) with LMCAD and site-assessed low or intermediate 
CAD complexity (SYNTAX scores <=32) were randomized 1:1 to PCI with 
everolimus-eluting stents versus CABG, stratified by the presence of diabetes. The 
primary endpoint was the rate of a composite of all-cause death, stroke, or MI at 3 
years. Outcomes were examined in patients with (n = 554) and without (n = 1,350) 
diabetes.
RESULTS: The 3-year composite primary endpoint was significantly higher in 
diabetic compared with nondiabetic patients (20.0% vs. 12.9%; p < 0.001). The rate 
of the 3-year primary endpoint was similar after treatment with PCI and CABG in 
diabetic patients (20.7% vs. 19.3%, respectively; hazard ratio: 1.03; 95% confidence 
interval: 0.71 to 1.50; p = 0.87) and nondiabetic patients (12.9% vs. 12.9%, 
respectively; hazard ratio: 0.98; 95% confidence interval: 0.73 to 1.32; p = 0.89). 
All-cause death at 3 years occurred in 13.6% of PCI and 9.0% of CABG patients 
(p = 0.046), although no significant interaction was present between diabetes 
status and treatment for all-cause death (p = 0.22) or other endpoints, including 
the 3-year primary endpoint (p = 0.82) or the major secondary endpoints of 
death, MI, or stroke at 30 days (p = 0.61) or death, MI, stroke, or ischemia-driven 
revascularization at 3 years (p = 0.65).
CONCLUSIONS: In the EXCEL trial, the relative 30-day and 3-year outcomes of PCI with 
everolimus-eluting stents versus CABG were consistent in diabetic and nondiabetic 
patients with LMCAD and site-assessed low or intermediate SYNTAX scores.
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INTRODUCTION
The number of people with diabetes mellitus is increasing, having risen from 108 
million in 1980 to 422 million in 2014 (1). Patients with diabetes are at an increased 
risk for systemic atherosclerosis and advanced coronary artery disease (CAD), 
and diabetes is a predictor of adverse events after both coronary artery bypass 
grafting (CABG) and percutaneous coronary intervention (PCI) (2,3). In patients 
with diabetes and complex anatomic disease, CABG has been associated with lower 
mortality rates compared with PCI (3–5). As a result, CABG has been recommended 
as the standard of care for patients with diabetes and complex CAD including left 
main coronary artery disease (LMCAD) (6); however, in a recent pooled analysis 
of 3 randomized trials (2 of which were performed more than a decade ago), 
patients with diabetes and low or intermediate anatomic complexity as signified by 
a SYNTAX score of <=32 had similar 5-year rates after PCI and CABG of all-cause 
death, cardiac death, and the composite of death, myocardial infarction (MI), or 
stroke (7).
Conversely, patients with high (>=33) SYNTAX scores had significantly higher 
adverse event rates with PCI compared with CABG. Since the performance of 
these trials, both PCI technology and technique, as well as surgical methods and 
outcomes, have continued to improve. The extent to which diabetes thus influences 
outcomes after contemporary revascularization strategies in patients with LMCAD 
is unknown.
The EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for 
Effectiveness of Left Main Revascularization) trial was a large-scale study in 
which selected patients with LMCAD were randomized to PCI with everolimus-
eluting stents (EES) versus CABG (8). Acknowledging the importance of diabetes, 
randomization was stratified by the presence of this variable to ensure a balanced 
baseline in the diabetic and nondiabetic strata. The present report describes the 
prespecified subgroup analysis examining the impact of diabetes on 30-day and 
3-year outcomes after PCI versus CABG in patients with LMCAD.
METHODS
STUDY DESIGN. The protocol, patient eligibility criteria, and methods of the 
EXCEL trial have been reported previously (9). The EXCEL trial was a prospective, 
multinational, unblinded randomized trial in which 1,905 patients with de novo 
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LMCAD and siteassessed SYNTAX scores <=32 in whom equipoise was present for 
transcatheter versus surgical revascularization were randomly (1:1) assigned to 
undergo PCI with cobalt–chromium fluoropolymer-based EES (Abbott Vascular, 
Santa Clara, California) or CABG. Patients were assessed for eligibility at each 
participating site by a heart team that consisted of (at least) an interventional 
cardiologist and a cardiac surgeon (10). Randomization was stratified according 
to the presence of diabetes and site. The trial was approved by the investigational 
review board or ethics committee at each participating center. All patients 
provided written informed consent before enrollment. The trial was funded by 
Abbott Vascular but led by a broad academic group with equal representation of 
interventional cardiologists and cardiac surgeons (8,9). The trial is registered at 
clinicaltrials.gov, identifier NCT01205776.
ENDPOINTS AND DEFINITIONS. The primary endpoint was the 3-year rate of all-
cause mortality, stroke, or MI. Major powered secondary outcomes included this 
endpoint at 30 days and the composite rate of death, stroke, MI, or ischemia-
driven revascularization (IDR) at 3 years. Other secondary endpoints included the 
components of the primary and secondary endpoints as well as revascularization, 
stent thrombosis, symptomatic graft stenosis or occlusion, and a prespecified 
composite of periprocedural major adverse events.
The definitions of these outcome measures have been previously described in 
detail (8,9). In brief, stroke was defined as a focal neurological deficit of central 
origin lasting >24 h, confirmed by a neurologist and imaging. Post-procedure 
MI was defined as the rise within 72 h after PCI or CABG of creatine kinase-
myocardial band (CK-MB) to >10x the upper reference limit (URL), or >5x URL plus 
new pathological Q waves in at least 2 contiguous leads or new persistent non–
rate-related left bundle branch block, or angiographically documented graft or 
native coronary artery occlusion or new severe stenosis with thrombosis and/or 
diminished epicardial flow, or imaging evidence of new loss of viable myocardium 
or new regional wall motion abnormality. Spontaneous MI was defined as the 
occurrence >72 h after PCI or CABG of a rise and fall of cardiac biomarkers (CK-MB 
or troponin) >1x URL plus electrocardiogram changes indicative of new ischemia, 
or development of pathological Q waves in >2 contiguous electrocardiogram 
leads, or angiographically documented graft or native coronary artery occlusion 
or new severe stenosis with thrombosis and/or diminished epicardial flow, or 
imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality. Revascularization events were classified as either ischemia-driven 
or non–ischemia-driven by pre-specified criteria (9). An independent clinical 
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events committee adjudicated all primary and secondary endpoints with source 
document verification.
Patients with diabetes at baseline were categorized according to treatment as: 1) 
insulin-treated (with or without oral hypoglycemic agents); 2) oral hypoglycemic 
agent–treated without insulin; and 3) nonpharmacological therapy only, including 
dietary modification, exercise, and weight reduction. Using this classification, the 
following diabetes subgroups were defined and analyzed in the present study: 1) 
insulin-treated patients with or without oral hypoglycemic agents; and 2) non–
insulin-treated patients (because only a small number of patients were treated 
without medications).
STATISTICAL ANALYSIS. Subgroup analysis according to diabetes status with 
formal interaction testing was pre-specified in the trial protocol, although no 
formal statistical hypothesis was defined a priori. All analyses were performed 
with data from the time of randomization in the intention-to-treat population, 
which included all patients according to the group to which they were randomly 
assigned, regardless of the treatment received. Data are summarized using 
descriptive statistics, presented as proportions (%, count/sample size) or mean ± 
SD. Continuous variables were compared using the Student’s t-test; differences in 
categorical variables were assessed with the chi-square test or Fisher exact test, as 
appropriate. Event rates were based on Kaplan-Meier estimates in time-to-first-
event analyses and were compared by the log-rank test. Multivariable predictors 
of 3-year outcomes were identified using stepwise selection with a significance 
level of <0.10 for entry and exit in a logistic regression model. p Values for 
interaction were generated by logistic regression chi-square test. Analyses 
according to SYNTAX score tertiles (low 0 to 22, intermediate 23 to 32, high >=33) 
were performed using 3-year Kaplan-Meier event estimates. All analyses were 
performed using SAS software, version 9.4 (SAS Institute, Cary, North Carolina).
RESULTS
BASELINE AND PROCEDURAL CHARACTERISTICS. Baseline diabetes status was 
known in 1,904 of 1,905 randomized patients. Diabetes was present in 554 of 1,904 
patients (29.1%); 147 patients were treated with insulin, 358 were treated with oral 
hypoglycemic agents without insulin, and 49 were treated with nonpharmacological 
measures. Patients with diabetes had a significantly greater number of comorbidities 
compared with nondiabetic patients, including hypertension, hyperlipidemia, 
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anemia, renal insufficiency, peripheral vascular disease, congestive heart failure, 
prior stroke, and a higher STS score, although were less likely to be current smokers 
(Table 1). By core laboratory analysis, diabetic patients also had a higher SYNTAX 
score, more frequently had diffuse or small vessel disease, and had a greater number 
of treated lesions.
As shown in Table 2, bilateral internal mammary artery (BIMA) grafting was 
performed significantly less frequently in patients with diabetes compared with 
patients without diabetes (19.6% vs. 32.4%; p < 0.001). Off-pump CABG technique, 
total bypass time, and the number of grafts did not differ between groups. Mean 
PCI duration was significantly longer in diabetic than in nondiabetic patients. There 
were no significant differences between the groups in other PCI procedural aspects. 
At hospital discharge, no differences in the administration of antiplatelet agents, 
statins, and beta-blockers were found between diabetic and nondiabetic patients 
after both PCI and CABG (Table 2). Medication use during follow-up is presented in 
Supplemental Table 1.
THIRTY-DAY OUTCOMES. As shown in Table 3, the 30-day rates of major adverse 
events were not significantly different in diabetic compared with nondiabetic 
patients; however, in both diabetic and nondiabetic patients, the 30-day rate of the 
composite endpoint of death, stroke, or MI was higher after CABG than after PCI. The 
difference in outcome was driven mainly by higher rates of stroke and MI after CABG, 
whereas rates of all-cause death and ischemiadriven revascularization were similar 
between CABG and PCI. Major adverse events were also higher after CABG than PCI 
in both diabetic and nondiabetic patients. Acute renal failure within 30 days occurred 
more commonly in patients with diabetes compared with those without diabetes (2.7% 
vs. 1.1%; p = 0.01), and was more frequent after revascularization with CABG compared 
with PCI both in patients with (4.1% vs. 1.4%; p = 0.005) and without (1.9% vs. 0.3%; 
p = 0.05) diabetes (p
interaction
 = 0.44) (Supplemental Table 2). Among CABG patients, 
sternal wound dehiscence occurred in 0.4% versus 1.2% of diabetic and nondiabetic 
patients, respectively (p = 0.26). Furthermore, sternal dehiscence did not occur 
more often after the use of BIMA compared with the single internal mammary artery 
technique (0% vs. 0.5%; p = 0.68). There were no significant interactions between 
diabetes status and treatment for any of the 30-day study endpoints.
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Table 1. Baseline Characteristics of Patients According to Diabetes Status in the Overall 
Cohort.
No Diabetes 
(n = 1,350)
Diabetes 
(n = 554)
p Value
Age, yrs 65.7 ± 9.7 66.5 ± 9.2 0.17
Male 78.0 (10,53/1,350) 74.0 (410/554) 0.06
Body mass index, kg/m2 28.0 ± 4.5 30.4 ± 5.5 <0.001
Hyperlipidemia treated with medication 65.7 (886/1,348)  80.5 (445/553) <0.001
Hypertension treated with medication 68.2 (921/1,350) 87.5 (485/554) <0.001
Current smoker 23.9 (321/1,343) 17.3 (95/548) 0.002
Prior myocardial infarction 17.1 (229/1,339) 18.4 (101/549) 0.50
Congestive heart failure 5.7 (77/1,345) 8.9 (49/553) 0.01
History of carotid artery disease 7.3 (98/1,345) 10.5% (58/551) 0.02
Prior stroke 3.0 (41/1,349) 5.1 (28/554) 0.03
Prior transient ischemic attack 2.8 (38/1,343) 3.5 (19/550) 0.47
Peripheral vascular disease 7.7 (103/1,344) 14.1 (78/552) <0.001
Chronic kidney disease* 14.5 (191/1,320) 21.3 (117/549) <0.001
Anemia† 20.1 (268/1,334) 36.1 (200/554) <0.001
Recent myocardial infarction, within 7 days 15.1 (203/1,345) 14.3 (79/552) 0.66
Unstable angina without recent myocardial infarction 23.1 (311/1,345) 27.7 (153/552) 0.03
Prior percutaneous coronary intervention 15.3 (206/1,348) 21.7 (120/554) <0.001
Left ventricular ejection fraction, % 57.4 ± 9.1 56.6 ± 9.8 0.19
Society of Thoracic Surgeons score 0.85 ± 0.81 0.96 ± 0.91 0.01
SYNTAX score
Site-assessed 20.5 ± 6.3 20.8 ± 5.9 0.25
0–22 61.8 (833/1,348) 57.1 (316/553) 0.060
23–32 38.2 (515/1,348) 42.9 (237/553) 0.060
>=33 0 (0/1,348) 0 (0/553) —
Core laboratory assessed 26.2 ± 9.4 27.3 ± 9.1 0.02
0–22 37.7 (491/1,302) 31.1 (167/537) 0.007
23–32 38.6 (502/1,302) 43.6 (234/537) 0.047
>=33 23.7 (309/1,302) 25.3 (136/537) 0.47
Coronary anatomy, core laboratory-assessed Left main 
distal bifurcation involvement Number of lesions treated 
per patient
Number of treated non-left main diseased vessels
0
1
2
3
Diffuse disease or small vessels
56.3 (568/1,009)
2.2 ± 0.9
1.5 ± 1.0
18.8 (250/1,328)
32.8 (435/1,328)
31.3 (416/1,328)
17.1 (227/1,328)
4.7 (62/1,321)
62.6 (253/404)
2.3 ± 0.9
1.7 ± 1.0
14.6 (80/549)
27.1 (149/549)
37.2 (204/549)
21.1 (116/549)
9.3 (51/549)
0.03
0.02
<0.001
0.03
0.02
0.01
0.04
<0.001
Values are mean ± SD or % (n/N). *Estimated glomerular ﬁltration rate <60 ml/min. 
†Hemoglobin <12 g/dl in women and <13 g/dl in men.
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Table 2. Procedural Characteristics and Discharge Medications According to Diabetes 
Status and Revascularization Assignment.
CABG (n = 956) PCI (n = 948)
No Diabetes
(n = 688)
Diabetes
(n = 268)
p Value No Diabetes
(n = 662)
Diabetes
(n = 286)
p Value
Procedural characteristics
Assigned procedure performed 97.0 (667/688) 95.5 (256/268) 0.28 98.6 (653/662) 98.6 (282/286) 0.96
Time to procedure, days 6.8 ± 15.1 6.5 ± 11.9 0.69 3.4 ± 5.7 3.0 ± 4.1 0.73
Procedure duration, min 241.9 ± 70.9 246.2 ± 69.2 0.37 80.2 ± 41.8 87.7 ± 41.8 0.005
Off-pump CABG 30.1 (201/667) 27.3 (70/256) 0.40 — — —
Bypass time, min 81.6 ± 42.4 87.4 ± 51.0 0.21 — — —
Any internal mammary artery used 99.1 (658/664) 98.0 (250/255) 0.19 — — —
Both internal mammary arteries used 32.4 (215/664) 19.6 (50/255) <0.001 — — —
No. of grafts 2.5 ± 0.8 2.6 ± 0.8 0.50 — — —
No. of stents implanted — — — 2.4 ± 1.5 2.6 ± 1.5 0.08
Total stent length, mm — — — 48.0 ± 35.4 51.7 ± 36.4 0.09
Distal LMCA bifurcation treated — — — 56.7 (366/645) 58.2 (163/280) 0.68
2-stent approach — — — 33.1 (121/366) 39.3 (64/163) 0.17
Crush or mini-crush — — — 10.3 (12/117) 21.9 (14/64) 0.03
FFR used — — — 9.0 (59/653) 8.9 (25/281) 0.95
IVUS used
Duration of hospital stay, days
—
12.5 ± 9.5
—
13.2 ± 9.9
—
0.66
77.3 (505/653)
5.4 ± 5.3
77.0 (217/282)
5.5 ± 5.1
0.90
0.33
Discharge medications
Aspirin 98.9 (651/658) 98.8 (245/248) >0.99 98.9 (641/648) 99.3 (278/280) 0.73
P2Y12 inhibitor 33.7 (223/661) 30.4 (76/250) 0.34 98.3 (639/650) 97.2 (273/281) 0.25
DAPT 33.4 (221/661) 28.8 (72/250) 0.18 97.4 (633/650) 96.1 (270/281) 0.29
Statin 92.6 (612/661) 92.0 (230/250) 0.77 96.0 (624/650) 97.5 (274/281) 0.25
Beta-blocker 92.7 (613/661) 92.0 (230/250) 0.71 83.1 (540/650) 83.6 (235/281) 0.84
ACE inhibitor or ARB 40.7 (269/661) 46.0 (115/250) 0.15 54.8 (154/281) 57.5 (374/650) 0.44
Values are % (n/N) or mean ± SD. ACE, angiotensin-converting enzyme; ARB, angiotensin 
II receptor blockers; CABG, coronary artery bypass grafting; DAPT, dual antiplatelet therapy; 
FFR, fractional ﬂow reserve; IVUS, intravascular ultrasound; LMCA, left main coronary artery; 
PCI, percutaneous coronary intervention.
3-YEAR OUTCOMES. Clinical outcomes according to diabetes status and 
treatment group are shown in Table 4 and Figure 1. Compared with nondiabetic 
patients, diabetic patients had higher 3-year rates of the composite primary 
endpoint, including higher rates of all-cause death, cardiovascular death, MI, 
and IDR. The rates of the 3-year composite primary endpoint of death, stroke, 
or MI, or the secondary composite endpoint of death, stroke, MI, or IDR were not 
significantly different between CABG and PCI in either of the nondiabetic and 
diabetic cohorts. The 3-year rate of all-cause death was significantly higher after 
PCI compared with CABG in diabetic patients (13.6% vs. 8.0%; p = 0.046), but not 
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in nondiabetic patients (5.5% vs. 5.0%; p = 0.71). IDR rates were lower after CABG 
compared with PCI in both diabetic and nondiabetic patients, whereas graft 
occlusion or stent thrombosis rates were lower after PCI compared with CABG. 
There were no significant interactions between diabetes status and treatment for 
any of the 3-year study endpoints, including mortality.
Table 3. 30-Day Clinical Outcomes According to Diabetes Status and Revascularization 
Assignment.
All (N = 1,904) No Diabetes (n= 1,350) Diabetes (n = 554)
No 
Diabetes 
(n = 1,350)
Diabetes 
(n = 554)
p 
Value
CABG 
(n = 688)
PCI 
(n = 662)
p Value CABG 
(n = 268)
PCI 
(n = 286)
p Value pinteraction
Death, stroke, 
or MI
6.0 (80) 7.5 (41) 0.24 7.2 (49) 4.7 (31) 0.06 9.8 (26) 5.3 (15) 0.05 0.61
Death, stroke, 
MI, or IDR
6.3 (84) 7.6 (42) 0.29 7.8 (53) 4.7 (31) 0.02 10.2 (27) 5.3 (15) 0.03 0.69
Death 0.9 (12) 1.3 (7) 0.46 0.9 (6) 0.9 (6) 0.96 1.5 (4) 1.1 (3) 0.63 0.68
Cardiovascular 0.8 (11) 1.3 (7) 0.36 0.7 (5) 0.9 (6) 0.73 1.5 (4) 1.1 (3) 0.63 0.58
Stroke 0.8 (10) 1.5 (8) 0.15 0.9 (6) 0.6 (4) 0.55 2.3 (6) 0.7 (2) 0.13 0.44
MI 4.9 (66) 5.5 (30) 0.65 6.1 (41) 3.8 (25) 0.06 6.8 (18) 4.2 (12) 0.20 0.98
Periprocedural 4.9 (65) 4.6 (25) 0.77 5.9 (40) 3.8 (25) 0.08 6.1 (16) 3.2 (9) 0.12 0.68
Spontaneous 0.1 (1) 0.9 (5) 0.003 0.1 (1) 0 0.32 0.8 (2) 1.1 (3) 0.72 0.99
All repeat 
revascularization
1.0 (13) 1.3 (7) 0.56 1.3 (9) 0.6 (4) 0.18 1.5 (4) 1.1 (3) 0.63 0.66
IDR 0.9 (12) 1.3 (7) 0.46 1.3 (9) 0.5 (3) 0.09 1.5 (4) 1.1 (3) 0.63 0.48
PCI 0.5 (7) 1.3 (7) 0.09 0.6 (4) 0.5 (3) 0.74 1.5 (4) 1.1 (3) 0.63 0.92
CABG 0.4 (5) 0 0.15 0.7 (5) 0 0.03 0 0 — >0.99
Graft occlusion 
or stent 
thrombosis
0.7 (9) 0.9 (5) 0.59 1.2 (8) 0.2 (1) 0.02 1.1 (3) 0.7 (2) 0.59 0.26
Major adverse 
events*
15.3 (204) 15.1 (83) 0.92 23.1 (156) 7.3 (48) <0.001 23.5 (62) 7.4 (21) <0.001 0.97
Values are % (n) of Kaplan-Meier time-to-ﬁrst event estimates. *The composite rate of death, stroke, 
myocardial infarction, TIMI major or minor bleeding, transfusion >2 U of blood, major arrhythmia 
(supraventricular tachycardia requiring cardioversion, ventricular tachycardia or ﬁbrillation 
requiring treatment, or bradyarrhythmia requiring temporary or permanent pacemaker), ischemia-
driven revascularization, any unplanned surgery or therapeutic radiologic procedure, renal failure 
(serum creatinine increase by >0.5 mg/dl from baseline or need for dialysis), sternal wound 
dehiscence, infection requiring antibiotics, or prolonged intubation (>48 h). IDR, ischemia-driven 
revascularization; MI, myocardial infarction; other abbreviations as in Table 2.
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Figure 1. 3-Year Outcomes of PCI Versus CABG in Diabetic and Nondiabetic Patients.
Kaplan-Meier estimates of the composite endpoint of all-cause death, stroke, or myocardial 
infarction (MI); the composite endpoint of all-cause death, stroke, MI, or ischemia-driven repeat 
revascularization; all-cause death; and IDR in patients with (A to D) and without (E to H) diabetes. 
p Values are by log-rank test. CABG, coronary artery bypass grafting; CI, conﬁdence interval; 
HR, hazard ratio; IDR, ischemia-driven revascularization; PCI, percutaneous coronary intervention.
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IMPACT OF INSULIN TREATMENT. Among diabetic patients, insulin use was 
associated with greater 3year rates of MI and IDR (Supplemental Table 3). The 
rate of the 3-year primary composite endpoint of death, stroke, or MI was similar 
after PCI and CABG in both insulin-treated and non–insulin-treated diabetic 
patients (Figure 2). There were no significant interactions between insulin 
use, revascularization modality, and 3-year outcomes among diabetic patients 
(Supplemental Table 3).
Figure 2. 3-Year Outcomes in Patients with Diabetes Stratiﬁed by Insulin Treatment.Kaplan-Meier 
estimates of the composite endpoint of all-cause death, stroke, or MI among non–insulin-treated (A) 
and insulin-treated (B) patients. The p values are by log-rank test. Abbreviations as in Figure 1.
SYNTAX SCORE SUBGROUPS. Analysis according to site-reported coronary 
complexity showed a stepwise increase in 3-year event rates with intermediate 
compared with low SYNTAX scores in diabetic patients, but similar event rates in 
nondiabetic patients (Figure 3, Supplemental Table 4). In patients with diabetes 
and low SYNTAX scores (0 to 22), no significant 3-year event rate differences were 
observed between CABG and PCI, except for IDR (7.8% vs. 17.0%, respectively; p = 
0.02); however, 3-year mortality was lower after CABG compared with PCI among 
the 237 diabetic patients with intermediate SYNTAX scores (9.6% vs. 19.6%; p = 
0.04). However, the interaction between low versus intermediate site-assessed 
SYNTAX score and revascularization modality for 3-year death in diabetic patients 
was not significant (p = 0.32). Among nondiabetic patients, rates of adverse events 
were not significantly different after PCI and CABG irrespective of SYNTAX 
scores. The results according to core lab adjudication were similar to those from 
the site-reported analysis (Supplemental Table 5, Supplemental Figure 1).
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MULTIVARIABLE ANALYSIS. As shown in Supplemental Tables 6 and 7, diabetes 
was an independent predictor for the composite endpoint of death, stroke, or 
MI after both CABG (hazard ratio (HR): 1.55; 95% confidence interval (CI): 1.04 to 
2.31; p = 0.03) and PCI (HR: 1.53; 95% CI: 1.04 to 2.26; p = 0.03). Diabetes was also an 
independent predictor of stroke after CABG and all-cause death after PCI.
Table 4. 3-Year Clinical Outcomes According to Diabetes Status and Revascularization 
Assignment.
All (N = 1,904) No Diabetes (n = 1,350) Diabetes (n = 554)
No 
Diabetes
(n = 1,350)
Diabetes
(n = 554)
p Value CABG
(n = 688)
PCI
(n = 662)
p Value CABG
(n = 268)
PCI
(n = 286)
p 
Value
p
interaction
Death, stroke, or MI 12.9 (170) 20.0 (109) <0.001 12.9 (86) 12.9 (84) 0.89 19.3 (51) 20.7 (58) 0.87 0.82
Death, stroke, MI, 
or IDR
18.9 (248) 26.1 (142) <0.001 17.5 (116) 20.2 (132) 0.28 22.8 (60) 29.2 (82) 0.17 0.65
Death 5.3 (69) 10.9 (59) <0.001 5.0 (33) 5.5 (36) 0.71 8.0 (21) 13.6 (38) 0.046 0.22
Cardiovascular 3.1 (41) 6.2 (33) 0.002 3.1 (20) 3.2 (21) 0.85 5.4 (14) 7.0 (19) 0.48 0.68
Stroke 2.3 (30) 3.6 (19) 0.11 2.3 (15) 2.3 (15) 0.99 5.1 (13) 2.3 (6) 0.08 0.17
MI 7.3 (96) 10.5 (56) 0.03 7.5 (50) 7.1 (46) 0.73 10.8 (28) 10.3 (28) 0.76 0.99
Periprocedural 5.0 (67) 4.7 (26) 0.80 6.1 (41) 4.0 (26) 0.09 6.1 (16) 3.5 (10) 0.17 0.81
Spontaneous 2.4 (30) 6.4 (33) <0.001 1.6 (10) 3.2 (20) 0.06 5.6 (14) 7.2 (19) 0.50 0.38
All repeat 
revascularizations
9.2 (117) 13.1 (68) 0.01 7.0 (45) 11.3 (72) 0.008 9.1 (23) 16.9 (45) 0.01 0.68
IDR 9.0 (115) 12.9 (67) 0.01 7.0 (45) 11.0 (70) 0.01 8.7 (22) 16.9 (45) 0.008 0.51
PCI 7.6 (97) 11.1 (58) 0.01 6.1 (39) 9.1 (58) 0.04 8.3 (21) 13.8 (37) 0.058 0.77
CABG 2.0 (26) 2.2 (11) 0.89 0.9 (6) 3.1 (20) 0.005 0.4 (1) 3.8 (10) 0.009 0.37
Graft occlusion or 
stent thrombosis
2.6 (34) 4.0 (21) 0.12 4.8 (31) 0.5 (3) <0.001 6.7 (17) 1.5 (4) 0.002 0.32
Values are % (n) of Kaplan-Meier time-to-ﬁrst event estimates. Abbreviations as in Tables 2 and 3.
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Figure 3. 3-Year Outcomes for Diabetic and Nondiabetic Patients According to Anatomic Lesion 
Complexity as Measured by the Site-Assessed SYNTAX Score. Kaplan-Meier estimates of the 
composite endpoint of all-cause death, stroke, or MI; the composite endpoint of all-cause death, 
stroke, MI, or ischemia-driven repeat revascularization (IDR); all-cause death; and IDR in diabetic 
patients (A to D) and nondiabetic patients (E to H). Treatment by SYNTAX score interactions in 
the diabetic and the nondiabetic groups: The composite endpoint of all-cause death, stroke, or MI 
(pint = 0.81 and pint = 0.98); the composite endpoint of all-cause death, stroke, MI, or IDR (pint = 0.87 
and pint = 0.31); all-cause death (pint = 0.32 and pint = 0.40); and IDR (pint = 0.63 and pint = 0.10). 
p Values are by log-rank test. Rates are separated according to the sitereported SYNTAX score 
values, indicating low (0 to 22) and intermediate (23 to 32) anatomic lesion complexity. SYNTAX, 
Synergy Between PCI With TAXUS and Cardiac Surgery; other abbreviations as in Figure 1.
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DISCUSSION
The present pre-specified EXCEL substudy examined the impact of diabetes on 
clinical outcomes after PCI with EES versus CABG in patients with LMCAD and 
site-assessed low or intermediate SYNTAX scores (Central Illustration). Compared 
with nondiabetic patients, diabetic patients with LMCAD were at a nearly 2-fold 
higher risk for all-cause death, stroke, or MI at 3 years. There was no significant 
difference in the 3-year composite primary endpoint of death, stroke, or MI or 
the powered 3-year secondary endpoint of death, stroke, MI, or IDR after PCI 
or CABG either in the diabetic or nondiabetic strata. Thirty-day adverse events 
were significantly less after PCI compared with CABG both in diabetic and 
nondiabetic patients. Conversely, all-cause mortality at 3 years was greater after 
PCI compared with CABG among diabetic patients with higher site-assessed 
SYNTAX scores, although the interaction between site-assessed SYNTAX score 
and revascularization modality for 3-year death in diabetic patients was not 
significant. IDR at 3 years was higher with PCI, whereas graft failure or thrombosis 
rates were higher after CABG, both irrespective of diabetic status.
Our findings confirm that diabetes is a critical determinant of long-term outcomes 
after myocardial revascularization (3,4). Currently, no specific recommendation 
exists concerning the optimal revascularization strategy in diabetic patients with 
LMCAD (6). Given the clinical and anatomic complexity that is frequently present 
in this high-risk subgroup, the selection between CABG and PCI in diabetic 
patients requires careful consideration. Large-registry data show a substantial 
increase in the number of patients with diabetes and LMCAD undergoing PCI 
over the last 20 years, although outcomes data are scarce (11). Before the present 
report, comparative effectiveness data for PCI with drug-eluting stents (DES) 
versus CABG in diabetic patients were limited to small subgroup analyses from 
clinical trials. In a pooled analysis of individual patient data from the PRECOMBAT 
(Bypass Surgery Versus Angioplasty Using SirolimusEluting Stent in Patients With 
Left Main Coronary Artery Disease) and the SYNTAX (Synergy Between PCI With 
TAXUS and Cardiac Surgery) trials, Cavalcante et al. (12) found no difference 
in the occurrence of major adverse events between CABG and PCI with first-
generation DES in LMCAD patients with or without diabetes at 5-year follow-up. 
The present results in which second-generation EES and contemporary CABG 
techniques were evaluated are consistent with these findings and indicate that 
both revascularization strategies result in comparable rates of major adverse 
events at 3 years.
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Although PCI resulted in substantially fewer major adverse events at 30 days in 
both diabetic and nondiabetic patients, an important consideration affecting 
the selection of revascularization procedure is long-term survival. In this regard, 
a large propensity-matched analysis of 4,048 patient-pairs from the New York 
State outcomes registries suggested that the apparent survival benefit of CABG 
over PCI in diabetic patients in the FREEDOM (Comparison of Two Treatments for 
Multivessel Coronary Artery Disease in Individuals With Diabetes) and SYNTAX 
trials (3,4) might be lost when PCI was performed with EES (13); however, registries 
are particularly sensitive to the occurrence of selection bias, and these results must 
be interpreted with caution (14). Among the 554 diabetic patients randomized in 
the EXCEL trial, a significant difference in mortality between CABG and PCI was 
observed in those with higher SYNTAX scores; however, the EXCEL trial was not 
powered for mortality in the entire population, let alone the diabetic subgroup, 
and no interaction was noted between diabetic status, revascularization, and 
3-year mortality. In a recently published pooled analysis of individual randomized 
patient data (15) from the SYNTAX, PRECOMBAT, EXCEL, and NOBLE (PCI vs. 
CABG in the Treatment of Unprotected Left Main Stenosis) trials (8,16–18), there 
was no significant difference in 5-year mortality after treatment of 4,478 patients 
with LMCAD with PCI versus CABG (10.7% vs. 10.5%; HR: 1.07; 95% CI: to 1.33; 
p = 0.52), either in patients with (n = 1,120; HR: 1.34; 95% CI: 0.93 to 1.31) or without 
(n = 3,358; HR: 0.94; 95% CI: 0.72 to 1.23) diabetes. In this analysis, CABG did, 
however, result in superior survival to PCI in diabetic patients with multivessel 
disease (but without LMCA involvement), again suggesting that in general patients 
with diabetes and complex CAD may preferentially benefit by CABG.
Finally, despite the fact that evidence supports the recommendation of increasing 
use of BIMA grafts during CABG in diabetic patients who are at low risk of deep 
sternal wound infection (6,19,20), rates of BIMA usage are still relatively low 
(only 19.6% of diabetic patients in the present trial). No significant differences in 
sternal wound dehiscence were observed in diabetic patients treated with a single 
internal mammary artery versus BIMA in the EXCEL trial. It is also noteworthy that 
adherence rates to guideline-directed medication therapy after CABG have reached 
90% in the EXCEL trial (21) but remain lower than after PCI. Of note, approximately 
onethird of CABG patients were discharged on dual antiplatelet therapy, which, 
although less than after PCI, represents a higher percentage than in some other 
studies. This may reflect appropriate use after CABG in patients presenting with 
acute coronary syndromes, as well as the potential for dual antiplatelet therapy 
to enhance graft patency (22), the topic of several ongoing randomized controlled 
trials (Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis 
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(TARGET), NCT02053909; Effect of Ticagrelor on Saphenous Vein Graft Patency in 
Patients Undergoing Coronary Artery Bypass Grafting Surgery (POPular CABG), 
NCT02352402; Study Comparing Ticagrelor With Aspirin for Prevention of 
Vascular Events in Patients Undergoing CABG (TiCAB), NCT01755520). Optimizing 
guidelinedirected medication therapy after both CABG and PCI is essential for 
patients to derive the most benefits from revascularization.
STUDY LIMITATIONS. Although randomization was stratified by diabetes status, 
and the diabetes subgroup analysis was pre-specified in the EXCEL trial design, the 
present study was not powered to detect a difference in the primary endpoint of 
death, stroke, or MI between PCI and CABG in the diabetic cohort, and secondary 
outcome measures were not adjusted for multiple comparisons. Hence, the results 
of the present study should be interpreted as hypothesisgenerating only, and 
further investigation in dedicated trials of diabetic patients are warranted (23,24). 
In addition, the EXCEL trial enrolled patients with LMCAD and site-assessed 
low or intermediate SYNTAX scores who were eligible to undergo both PCI and 
CABG. Therefore, these findings cannot be extrapolated either to patients with 
unacceptable high surgical risk or patients with coronary anatomy unsuitable for 
PCI. A major focus of diabetes management is optimal glycemic control. Recently, 
the use of gliflozins has been shown to reduce the risk of major cardiovascular 
events in patients with type 2 diabetes (25). Unfortunately, the use of specific oral 
hypoglycemic agents and data on long-term glycemic control were not collected in 
the present study. Finally, follow-up in the EXCEL trial is complete only through 
3 years; longer-term surveillance is necessary to examine whether additional 
differences emerge over time.
CONCLUSIONS
In the large-scale EXCEL trial, among both diabetic and nondiabetic patients with 
LMCAD and siteassessed low-to-intermediate (<=32) SYNTAX scores, PCI using 
EES and CABG resulted in similar rates of the primary composite endpoint of 
death, stroke, or MI at 3-year follow-up, although fewer adverse events at 30 days 
occurred after PCI. For diabetic patients with LMCAD and relatively noncomplex 
coronary anatomy, PCI may be a reasonable approach, whereas CABG should be 
considered for diabetic patients with more complex CAD.
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CLINICAL PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: Patients with 
diabetes mellitus and left main coronary artery disease (LMCAD) undergoing 
myocardial revascularization are at higher risk of mortality and major adverse 
events than those without diabetes. In a randomized trial, there was no difference 
in the 3-year composite endpoint of all-cause death, stroke, or myocardial 
infarction between PCI and CABG, irrespective of baseline diabetes status.
TRANSLATIONAL OUTLOOK: While CABG remains the standard of care for 
diabetic patients with complex CAD, further studies are needed to ascertain the 
characteristics of patients with diabetes who can be appropriately managed by 
percutaneous intervention.
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Central illustration. Impact of Diabetes Mellitus on 3-Year Outcomes After Left Main 
Revascularization. The incidence rates of the primary composite endpoint of death, stroke, or 
MI among diabetic and non-diabetic patients (A) and according to the type of revascularization 
procedure (B) are shown. Over the 3-year follow-up period, PCI with EES compared with CABG was 
associated with similar risk of the primary composite endpoint among both diabetic and nondiabetic 
patients. CABG, coronary artery bypass grafting; CI, conﬁdence interval; DM, diabetes mellitus; EES, 
everolimus-eluting stents; HR, hazard ratio; MI, myocardial infarction; PCI, percutaneous coronary 
intervention.
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SUPPLEMENTAL MATERIAL
Supplemental Table 1. Rates of medication use during the 3-year follow-up period.
CABG (n=956) PCI (n=948) CABG vs. PCI
No diabetes
(n=688)
Diabetes
(n=268)
P-Value
No diabetes
(n=662)
Diabetes
(n=286)
P-Value
P-Value
No Diabetes
P-Value
Diabetes
Aspirin
Discharge 98.9 (651/658) 98.8 (245/248) 0.90 98.9 (641/648) 99.3 (278/280) 0.57 >0.99 0.55
6 months 97.7 (644/659) 96.8 (243/251) 0.44 97.7 (631/646) 97.8 (268/274) 0.93 >0.99 0.48
12 months 96.3 (629/653) 96.4 (239/248) 0.94 95.8 (614/641) 98.9 (264/267) 0.017 0.65 0.059
24 months 95.3 (591/620) 96.2 (229/238) 0.57 94.4 (586/621) 99.2 (243/245) 0.002 0.47 0.027
36 months 95.5 (569/596) 95.3 (224/235) 0.90 92.7 (559/603) 98.7 (230/233) <0.001 0.039 0.032
P2Y12 inhibitor
Discharge 33.7 (223/661) 30.4 (76/250) 0.34 98.3 (639/650) 97.2 (273/281) 0.28 <0.001 <0.001
6 months 27.8 (184/662) 28.3 (72/254) 0.88 97.4 (631/648) 97.1 (267/275) 0.79 <0.001 <0.001
12 months 25.2 (165/656) 26.0 (65/250) 0.80 83.8 (539/643) 84.3 (226/268) 0.85 <0.001 <0.001
24 months 21.8 (136/623) 24.6 (59/240) 0.38 69.2 (431/623) 72.0 (177/246) 0.42 <0.001 <0.001
36 months 21.0 (126/599) 24.9 (59/237) 0.22 65.8 (398/605) 69.2 (162/234) 0.35 <0.001 <0.001
DAPT
Discharge 33.4 (221/661) 28.8 (72/250) 0.18 97.4 (633/650) 96.1 (270/281) 0.28 <0.001 <0.001
6 months 26.7 (177/662) 27.2 (69/254) 0.88 95.4 (618/648) 94.5 (260/275) 0.56 <0.001 <0.001
12 months 23.5 (154/656) 25.2 (63/250) 0.59 80.6 (518/643) 82.8 (222/268) 0.44 <0.001 <0.001
24 months 19.6 (122/623) 23.3 (56/240) 0.23 64.5 (402/623) 70.7 (174/246) 0.08 <0.001 <0.001
36 months 18.7 (112/599) 23.6 (56/237) 0.11 60.5 (366/605) 67.5 (158/234) 0.06 <0.001 <0.001
Statin
Discharge 92.6 (612/661) 92.0 (230/250) 0.76 96.0 (624/650) 97.5 (274/281) 0.25 0.008 0.040
6 months 95.0 (626/659) 93.7 (237/253) 0.44 96.6 (624/646) 97.5 (268/275) 0.47 0.15 0.032
12 months 96.3 (626/650) 94.0 (233/248) 0.13 96.7 (621/642) 97.4 (261/268) 0.58 0.70 0.055
24 months 96.8 (602/622) 93.7 (24/239) 0.039 96.9 (603/622) 97.2 (239/246) 0.82 0.92 0.064
36 months 97.0 (580/598) 93.2 (220/236) 0.012 96.7 (585/605) 97.4 (228/234) 0.60 0.76 0.032
Beta-blocker
Discharge 92.7 (613/661) 92.0 (230/250) 0.72 83.1 (540/650) 83.6 (235/281) 0.85 <0.001 0.003
6 months 94.4 (624/661) 92.9 (234/252) 0.39 84.5 (546/646) 86.1 (236/274) 0.54 <0.001 0.011
12 months 94.5 (620/656) 93.5 (232/248) 0.56 85.2 (546/641) 86.5 (231/267) 0.61 <0.001 0.008
24 months 95.3 (593/622) 93.3 (223/239) 0.24 85.0 (528/621) 86.2 (212/246) 0.65 <0.001 0.010
36 months 94.5 (566/599) 92.8 (219/236) 0.35 85.6 (516/603) 87.6 (205/234) 0.45 <0.001 0.057
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ACEI or ARB
Discharge 40.7 (269/661) 46.0 (115/250) 0.15 57.5 (374/650) 54.8 (154/281) 0.45 <0.001 0.043
6 months 47.9 (311/649) 56.2 (141/251) 0.026 61.3 (396/646) 58.8 (160/272) 0.48 <0.001 0.55
12 months 52.0 (333/641) 60.8 (149/245) 0.019 62.7 (400/638) 61.9 (164/265) 0.82 <0.001 0.80
24 months 53.9 (332/616) 61.3 (146/238) 0.051 64.7 (400/618) 63.9 (156/244) 0.83 <0.001 0.55
36 months 54.6 (325/595) 64.4 (150/233) 0.010 64.4 (389/604) 65.8 (152/231) 0.70 <0.001 0.75
Values  are presented as % (n/N). ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor 
blockers; CABG, coronary artery bypass grafting; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary 
intervention.
Supplemental Table 1. Continued.
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Supplemental Table 2. Incidence and the 30-day outcome of acute renal failure. 
All (n=1904) No Diabetes (n=1350) Diabetes (n=554)
No diabetes 
(n = 1350)
Diabetes 
(n = 554)
P Value
CABG 
(n = 688)
PCI 
(n = 662)
P Value
CABG 
(n = 268)
PCI 
(n = 286)
P Value Pinteraction
Acute Renal 
Failure
1.1 (15) 2.7 (15) 0.01 1.9 (13) 0.3 (2) 0.005 4.1 (11) 1.4 (4) 0.050 0.44
New requirement 
for dialysis
0.6 (8) 1.6% (9) 0.03 0.9 (6) 0.3 (2) 0.29 3.0 (8) 0.4 (1) 0.02 0.41
    Hemodialysis 0.4 (5) 0.9 (5) 0.17 0.6 (4) 0.2 (1) 0.37 1.5 (4) 0.4 (1) 0.20 0.94
    CVVH 0.3 (3) 0.7 (4) 0.24 0.3 (2) 0.3 (2) 1.00 1.5 (4) 0.0 (0) 0.054 0.95
Outcomes in ARF patients
Death, stroke, 
or MI
20.0 (3) 33.0 (5) 0.47 15.4 (2) 50.0 (1) 0.15 45.5 (5) 0.0 (0) 0.13 >0.99
Death, stroke, MI, 
or IDR
20.0 (3) 33.3 (5) 0.46 15.4 (2) 50.0 (1) 0.15 45.5 (5) 0.0 (0) 0.13 >0.99
Death 6.7 (1) 6.7 (1) 0.98 7.7 (1) 0.0 (0) 0.69 9.1 (1) 0.0 (0) 0.55 1.00
Stroke 0.0 (0) 13.9 (2) 0.16 0.0 (0) 0.0 (0) NA 19.2 (2) 0.0 (0) 0.37 >0.99
MI 20.0 (3) 13.3 (2) 0.62 15.4 (2) 50.0 (1) 0.15 18.2 (2) 0.0 (0) 0.38 >0.99
All repeat 
revascularizations
7.1 (1) 13.3 (2) 0.56 8.3 (1) 0.0 (0) 0.68 18.2 (2) 0.0 (0) 0.38 >0.99
  IDR 7.1 (1) 13.3 (2) 0.56 8.3 (1) 0.0 (0) 0.68 18.2 (2) 0.0 (0) 0.38 >0.99
  PCI 7.1 (1) 13.3 (2) 0.56 8.3 (1) 0.0 (0) 0.68 18.2 (2) 0.0 (0) 0.38 >0.99
  CABG 0.0 (0) 0.0 (0) NA 0.0 (0) 0.0 (0) NA 0.0 (0) 0.0 (0) NA NA
Graft occlusion or 
stent thrombosis
7.1 (1) 6.7 (1) >0.99 8.3 (1) 0.0 (0) 0.68 9.1 (1) 0.0 (0) 0.55 1.00
Values are Kaplan-Meier time-to-first event estimates expressed as % (n). CABG, coronary artery bypass 
grafting; IDR, ischemia-driven revascularization; MI, myocardial infarction; PCI, percutaneous coronary 
intervention.
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Supplemental Table 3. Three-Year Clinical Outcomes in Diabetic Patients According to Insulin Treatment and 
Revascularization Assignment.
All Diabetes (n = 554) No Insulin (n = 407) Insulin (n = 147)
No insulin 
(n = 407)
Insulin 
(n = 147)
P Value
CABG 
(n = 194)
PCI 
(n = 213)
P Value
CABG 
(n = 74)
PCI 
(n = 73)
P Value Pinteraction
Death, stroke, or MI 18.4 (74) 24.5 (35) 0.10 18.3 (35) 18.5 (39) 0.92 22.2 (16) 26.9 (19) 0.61 0.63
Death, stroke, MI, or IDR 23.7 (95) 32.8 (47) 0.03 20.9 (40) 26.2 (55) 0.31 27.8 (20) 38.2 (27) 0.29 0.77
Death 11.0 (44) 10.6 (15) 0.92 7.8 (15) 13.8 (29) 0.07 8.4 (6) 13.0 (9) 0.42 0.82
  Cardiovascular 5.6 (22) 7.9 (11) 0.34 5.3 (10) 5.9 (12) 0.82 5.7 (4) 10.2 (7) 0.35 0.52
Stroke 3.4 (13) 4.4 (6) 0.59 4.8 (9) 2.0 (4) 0.12 5.7 (4) 3.2 (2) 0.43 0.83
MI 8.6 (34) 15.8 (22) 0.02 9.1 (17) 8.3 (17) 0.73 15.4 (11) 16.4 (11) 0.95 0.81
   Periprocedural 4.0 (16) 6.9 (10) 0.15 5.2 (10) 2.8 (6) 0.23 8.3 (6) 5.5 (4) 0.56 0.77
   Spontaneous 4.7 (18) 11.1 (15) 0.009 3.9 (7) 5.5 (11) 0.46 10.1 (7) 12.3 (8) 0.78 0.77
All repeat revascularizations 11.2 (43) 18.5 (25) 0.03 7.6 (14) 14.4 (29) 0.04 13.1 (9) 24.3 (16) 0.14 0.92
  IDR 10.9 (42) 18.5 (25) 0.02 7.1 (13) 14.4 (29) 0.02 13.1 (9) 24.3 (16) 0.14 0.81
  PCI 9.9 (38) 14.8 (20) 0.11 7.1 (13) 12.3 (25) 0.09 11.6 (8) 18.3 (12) 0.37 0.77
  CABG 1.6 (6) 3.8 (5) 0.13 0 3.1 (6) 0.02 1.5 (1) 6.1 (4) 0.17 0.99
Graft occlusion or stent 
thrombosis
2.8 (11) 7.3 (10) 0.02 4.9 (9) 1.0 (2) 0.02 11.7 (8) 2.9 (2) 0.053 0.85
Values are Kaplan-Meier time-to-first event estimates expressed as % (n). CABG, coronary artery bypass grafting; 
IDR, ischemia-driven revascularization; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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Supplemental Table 4. Three-Year Clinical Outcomes According to Diabetes Status, Site-
Reported SYNTAX Score, and Revascularization.
SYNTAX Score 0-22 SYNTAX Score 23-32 
CABG PCI P Value CABG PCI P Value
Diabetic cohort (n=160) (n=156) (n=108) (n=129)
  Death, stroke, or MI 17.0 (27) 17.0 (26) 0.88 22.8 (24) 25.0 (32) 0.84
  Death, stroke, MI, or IDR 20.2 (32) 26.2 (40) 0.30 26.6 (28) 32.8 (42) 0.45
  Death 7.0 (11) 8.6 (13) 0.64 9.6 (10) 19.6 (25) 0.04
    Cardiovascular 4.5 (7) 2.7 (4) 0.39 6.8 (7) 12.1 (15) 0.19
  Stroke 5.8 (9) 2.1 (3) 0.09 2.5 (3) 4.0 (4) 0.54
  MI 7.7 (12) 9.5 (14) 0.66 15.5 (16) 11.1 (14) 0.34
   Periprocedural 3.1 (5) 1.3 (2) 0.27 10.5 (11) 6.2 (8) 0.26
   Spontaneous 5.3 (8) 8.2 (12) 0.34 6.1 (6) 5.8 (7) 0.92
  All repeat revascularization 8.5 (13) 17.0 (25) 0.04 10.1 (10) 16.5 (20) 0.17
    IDR 7.8 (12) 17.0 (25) 0.02 10.1 (10) 16.5 (20) 0.17
      PC 7.1 (11) 12.9 (19) 0.12 10.1 (10) 14.8 (18) 0.29
      CABG 0.7 (1) 4.1 (6) 0.053 0 3.4 (4) 0.07
  Graft occlusion or stent 
thrombosis
7.2 (11) 2.0 (3) 0.03 5.9 (6) 0.8 (1) 0.03
Non-diabetic cohort (n=430) (n=403) (n=257) (n=258)
  Death, stroke, or MI 13.2 (55) 13.1 (52) 0.90 12.5 (31) 12.5 (32) 0.96
  Death, stroke, MI, or IDR 17.9 (74) 18.7 (74) 0.85 16.9 (42) 22.7 (58) 0.14
  Death 5.6 (23) 5.3 (21) 0.84 4.1 (10) 5.9 (15) 0.36
    Cardiovascular 3.7 (15) 3.1 (12) 0.62 2.1 (5) 3.5 (9) 0.31
  Stroke 2.3 (9) 2.3 (9) 0.95 2.4 (6) 2.4 (6) 0.96
  MI 7.7 (32) 7.1 (28) 0.72 7.2 (18) 7.1 (18) 0.93
   Periprocedural 6.4 (27) 4.0 (16) 0.13 5.5 (14) 3.9 (10) 0.40
   Spontaneous 1.5 (6) 3.1 (12) 0.14 1.6 (4) 3.2 (8) 0.27
  All repeat revascularization 7.5 (30) 9.3 (36) 0.37 6.2 (15) 14.4 (36) 0.003
    IDR 7.5 (30) 9.1 (35) 0.44 6.2 (15) 14.0 (35) 0.005
      PCI 6.6 (26) 7.8 (30) 0.50 5.4 (13) 11.2 (28) 0.02
      CABG 0.9 (4) 2.9 (11) 0.06 0.8 (2) 3.6 (9) 0.04
  Graft occlusion or stent 
thrombosis
4.7 (19) 0.5 (2) <0.001 5.0 (12) 0.4 (1) 0.002
Values are Kaplan-Meier time-to-event estimates expressed as % (n). CABG, coronary artery bypass 
grafting; IDR, ischemia-driven revascularization; MI, myocardial infarction; PCI, percutaneous 
coronary intervention.
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Supplemental Table 5. Three-Year Clinical Outcomes According to Diabetes Status, Core Lab SYNTAX Score, and 
Revascularization.
SYNTAX score 0-22 SYNTAX Score 23-32 SYNTAX score ≥33 
CABG PCI P Value CABG PCI P Value CABG PCI P Value
Diabetic cohort (n=94) (n=73) (n=99) (n=135) (n=70) (n=66)
  Death, stroke, or MI 16.2 (15) 14.1 (10) 0.69 24.7 (24) 23.0 (31) 0.61 14.5 (10) 20.2 (13) 0.48
  Death, stroke, MI or IDR 21.6 (20) 19.8 (14) 0.72 26.8 (26) 33.4 (45) 0.46 17.4 (12) 27.9 (18) 0.20
  Death 8.7 (8) 5.7 (4) 0.44 9.3 (9) 16.4 (22) 0.14 5.8 (4) 15.8 (10) 0.07
    Cardiovascular 6.6 (6) 1.5 (1) 0.11 4.2 (4) 8.3 (11) 0.22 5.8 (4) 10.0 (6) 0.41
  Stroke 6.6 (6) 1.4 (1) 0.10 4.3 (4) 2.4 (3) 0.43 4.4 (3) 3.4 (2) 0.71
  MI 5.6 (5) 9.9 (7) 0.29 13.6 (13) 10.1 (13) 0.33 11.6 (8) 7.9 (5) 0.45
   Periprocedural 2.2 (2) 4.1 (3) 0.45 7.2 (7) 3.0 (4) 0.14 8.7 (6) 3.0 (2) 0.17
   Spontaneous 3.5 (3) 5.9 (4) 0.48 7.5 (7) 7.2 (9) 0.83 4.5 (3) 6.5 (4) 0.61
  All repeat revascularization 7.9 (7) 11.7 (8) 0.48 10.8 (10) 21.3 (27) 0.06 7.5 (5) 12.8 (8) 0.31
    IDR 7.9 (7) 11.7 (8) 0.48 10.8 (10) 21.3 (27) 0.06 6.1 (4) 12.8 (8) 0.17
      PCI 6.7 (6) 8.8 (6) 0.70 10.8 (10) 18.1 (23) 0.18 6.1 (4) 11.2 (7) 0.27
      CABG 1.2 (1) 2.9 (2) 0.44 0 4.8 (6) 0.04 0 1.6 (1) 0.30
  Graft occlusion or stent thrombosis 5.7 (5) 1.5 (1) 0.16 7.6 (7) 1.6 (2) 0.03 7.4 (5) 0 0.03
Nondiabetic cohort (n=270) (n=221) (n=246) (n=256) (n=146) (n=163)
  Death, stroke, or MI 12.3 (32) 9.2 (20) 0.21 13.4 (32) 14.7 (37) 0.69 14.0 (20) 14.8 (24) 0.89
  Death, stroke, MI, or IDR 18.6 (48) 15.1 (33) 0.23 18.9 (45) 22.7 (57) 0.32 14.0 (20) 24.0 (39) 0.04
  Death 4.7 (12) 3.7 (8) 0.55 5.1 (12) 6.8 (17) 0.44 5.7 (8) 6.2 (10) 0.84
    Cardiovascular 2.4 (6) 1.8 (4) 0.69 3.4 (8) 4.0 (10) 0.73 3.6 (5) 4.4 (7) 0.72
  Stroke 2.0 (5) 1.4 (3) 0.61 2.6 (6) 2.4 (6) 0.91 1.4 (2) 3.8 (6) 0.21
  MI 6.9 (18) 5.1 (11) 0.35 7.5 (18) 8.4 (21) 0.72 9.2 (13) 7.5 (12) 0.58
   Periprocedural 5.6 (15) 0.9 (2) 0.005 5.8 (14) 5.9 (15) 0.91 7.7 (11) 4.3 (7) 0.22
   Spontaneous 1.2 (3) 4.2 (9) 0.05 1.7 (4) 2.5 (6) 0.59 2.2 (3) 3.2 (5) 0.59
  All repeat revascularization 7.6 (19) 9.7 (21) 0.45 8.7 (20) 11.8 (29) 0.25 2.9 (4) 14.1 (22) <0.001
    IDR 7.6 (19) 9.3 (20) 0.56 8.7 (20) 11.4 (28) 0.31 2.9 (4) 14.1 (22) <0.001
      PCI 7.2 (18) 6.5 (14) 0.74 7.1 (16) 10.2 (25) 0.19 2.2 (3) 12.2 (19) 0.001
      CABG 0.4 (1) 3.7 (8) 0.01 1.7 (4) 2.9 (7) 0.42 0.7 (1) 3.2 (5) 0.14
  Graft occlusion or stent thrombosis 4.4 (11) 0.9 (2) 0.02 5.6 (13) 0.4 (1) <0.001 2.9 (4) 0 0.03
Values are Kaplan-Meier time-to-event estimates expressed as % (n); log-rank p-value. CABG, coronary artery bypass 
grafting; IDR, ischemia-driven revascularization; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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Supplemental Table 6. Independent Predictors of Adverse Events in the CABG Cohort.
Hazard Ratio (95% Confidence Interval) P Value
Death, stroke, or MI
  Diabetes versus non-diabetes 1.55 (1.04-2.31) 0.03
  Hypertension treated with medication 1.67 (1.02-2.72) 0.04
Death, stroke, MI, or IDR
  Hyperlipidemia treated with medication 0.66 (0.46-0.94) 0.02
All-cause death
  Current smoker 2.30 (1.11-4.79) 0.03
  Left ventricular ejection fraction (%) 0.96 (0.94-0.99) 0.01
  MI
  Age 0.96 (0.94-0.99) 0.009
  Recent MI 1.84 (1.01-3.37) 0.048
  Hypertension treated with medication 2.19 (1.14-4.18) 0.02
  Hyperlipidemia treated with medication 0.56 (0.33-0.93) 0.03
Stroke
  Diabetes versus non-diabetes 3.38 (1.39-8.24) 0.007
IDR
  Age 0.96 (0.93-0.99) 0.01
  Male 0.55 (0.30-0.99) 0.046
  Hyperlipidemia treated with medication 0.30 (0.17-0.52) <0.001
CABG, coronary artery bypass grafting; IDR, ischemia-driven revascularization; MI, myocardial 
infarction.
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Supplemental Table 7. Independent predictors of adverse events in the PCI cohort.
Hazard Ratio 
(95% Confidence Interval)
P Value
Death, stroke, or MI
  Diabetes versus non-diabetes 1.53 (1.04-2.26) 0.03
  Age 1.03 (1.01-1.06) 0.008
Death, stroke, MI, or IDR
  Age 1.02 (1.00-1.04) 0.03
  SYNTAX score 1.02 (1.00-1.03) 0.048
All-cause death
  Diabetes versus non-diabetes 2.51 (1.46-4.31) <0.001
  Age 1.06 (1.03-1.10) <0.001
MI
  Body mass index 1.06 (1.01-1.11) 0.02
Stroke
  Male sex 0.34 (0.12-0.91) 0.03
  Body mass index 0.87 (0.76-1.00) 0.04
IDR
  None identified — —
IDR, ischemia-driven revascularization; MI, myocardial infarction; PCI, percutaneous coronary 
intervention.
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Supplemental Figure 1. Three-Year Outcomes for Diabetic and Nondiabetic Patients According 
to Anatomic Lesion Complexity as Measured by the Core Laboratory-Assessed SYNTAX Score.
Kaplan-Meier estimates of the composite endpoint of all-cause death, stroke, or myocardial 
infarction (MI); the composite endpoint of all-cause death, stroke, MI, or ischemia-driven repeat 
revascularization (IDR); all-cause death; and IDR in diabetic patients (A-D) and non-diabetic 
patients (E-H). Treatment by SYNTAX score interactions in the diabetic and the non-diabetic groups: 
The composite endpoint of all-cause death, stroke, or MI (Pint=0.64 and Pint=0.47); the composite 
endpoint of all-cause death, stroke, MI, or IDR (Pint=0.48 and Pint=0.056); all-cause death (Pint=0.20 
and Pint=0.64); and IDR (Pint=0.82 and Pint=0.058). P values are from log-rank test. Rates are separated 
according to the site-reported SYNTAX score values, indicating low (0–22), intermediate (23–32), and 
high (≥33) anatomic lesion complexity. CABG, coronary artery bypass grafting; PCI, percutaneous 
coronary intervention.
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countries enrolled in the SYNTAX trial: 5-year results 
between percutaneous coronary intervention and 
coronary artery bypass grafting
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ABSTRACT
OBJECTIVES: To examine differences among participating countries in baseline 
characteristics, clinical practice, medication strategies and outcomes of patients 
randomized to coronary artery bypass grafting and percutaneous coronary 
intervention in the SYNTAX trial.
METHODS: In SYNTAX, centres in 18 different countries enrolled 1800 patients, of 
which 8 countries enrolled >_80 patients, what was projected to be a large enough 
sample size to be included in the analysis. Baseline characteristics, practice patterns 
and clinical outcomes were compared between the USA (n = 245), the UK (n = 267), 
Italy (n = 197), France (n = 208), Germany (n = 179), Netherlands (n = 148), Belgium 
(n = 91) and Hungary (n = 83). The remaining patients from other participating 
countries were pooled together (n = 382).
RESULTS: Five-year results demonstrated significantly different outcomes between 
countries. After adjustment, percutaneous coronary intervention patients in France 
had lower rates of major adverse cardiac and cerebrovascular events (hazard ratio 
(HR) = 0.60, 95% confidence interval (CI) 0.37–0.98), while the incidence of repeat 
revascularization was higher in Hungary (HR = 1.89, 95% CI 1.14–3.42). Coronary 
artery bypass grafting showed the lowest rate of repeat revascularization in the 
UK (HR = 0.32, 95% CI 0.12–0.85). There were numerous differences in the risk 
profile of patients between participating countries, as well as marked differences in 
surgical practice across countries in the use of blood cardioplegia (range 3.1–89.0%; 
P < 0.001), bilateral internal mammary artery usage (range 7.8–68.2%; P < 0.001) 
and off-pump procedures (range 3.9–44.4%; P < 0.001). Variation was also found 
for percutaneous coronary intervention in the number of implanted stents (range 
4.0 ± 2.3 to 6.1 ± 2.6; P < 0.001) as well as for the entire stents length (range 69.0 ± 45.1 
to 124.1 ± 60.9; P < 0.001). Remarkable differences were observed in the prescription 
of post-coronary artery bypass grafting medication in terms of acetylsalicylic acid 
(range 79.6–95.0%; P = 0.004), thienopyridine (6.8–31.1%; P < 0.001) and statins 
(41.3–89.1%; P < 0.001).
CONCLUSIONS: Patient characteristics and clinical patterns are significantly 
different between countries, resulting in significantly different 5-year outcomes. This 
article presents specific data that can further improve outcomes in each country.
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INTRODUCTION
In order to expedite recruitment, there is a growing trend to involve centres from 
many different countries in large randomized clinical trials. As a consequence, 
participants can be enrolled more rapidly, the time span of trials is reduced, costs 
are less and the external validity of trial results is larger (1, 2). However, internal 
consistency may also be affected by differences in baseline characteristics, medical 
practice patterns and outcomes within participating countries or sites. Several 
recent reports have addressed the fundamental difficult issues of generalizability 
and cross-geographical clinical variations (1–3). Results from the PLATO trial 
suggested a significant treatment interaction of ticagrelor among patients with 
acute coronary syndromes enrolled in the USA or outside the USA, which was the 
result of differences in aspirin maintenance dose (4). Other studies have reported 
significant differences in baseline characteristics, practice patterns and clinical 
outcomes in subgroup analyses stratified according to site enrolment volume (5) 
and geographic region (6) among different clinical scenarios.
Findings from subgroup analyses may allow for a better understanding of risk–
benefit ratios, can alter treatment recommendations and improve prognosis (7). 
In addition, these findings may identify areas in which practice varies between 
countries and may therefore generate awareness among outliers to improve patient 
care.
Coronary artery bypass surgery (CABG) and percutaneous coronary intervention 
(PCI) are both options for myocardial revascularization. Although many studies 
have been performed to aid decision-making of PCI versus CABG (8–10), no such 
data on geographic enrolment within a randomized controlled trial exists to date. 
We, therefore, evaluated differences in baseline characteristics, practice patterns 
and outcomes among countries that enrolled patients in the SYNTAX trial.
METHODS
Study design
The SYNTAX trial design has been described elsewhere (11). Briefly, it was an all-
comers population of patients with de novo left main (LM) or 3-vessel disease, who 
were randomized to PCI with paclitaxel-eluting stents (n = 903) or CABG (n = 897) 
or went into nested PCI (n = 198) or CABG (n = 1077) registries (12). This analysis 
encompasses the randomized cohorts only.
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Only those countries that had enrolled 80 or more patients in the randomized 
trial were analysed; this was the case in (i) the USA (n = 245; 13.6%), (ii) the UK 
(n = 267; 14.8%), (iii) Italy (n = 197; 10.9%), (iv) Germany (n = 179; 9.9%), (v) France 
(n = 208; 11.6%), (vi) the Netherlands (n = 148; 8.2%), (vii) Belgium (n = 91; 5.1%) and 
(viii) Hungary (n = 83; 4.6%). Patients from the remaining countries were pooled 
together in 1 group (Poland (n = 66; 3.7%), Sweden (n = 54; 3.0%), Spain (n = 53; 2.9%), 
Austria (n = 52; 2.9%), Czech Republic (n = 40; 2.2%), Latvia (n = 40; 2.2%), Denmark 
(n = 32; 1.8%), Finland (n = 24; 1.3%), Portugal (n = 13; 0.7%) and Norway (n = 8; 0.4%)), 
as recommended by Pocock et al (1). This study therefore consists of 9 groups of 
patients. Analyses of differences between countries were not pre-specified in this 
study. Therefore, the results of these subgroup analyses should be interpreted as 
‘hypothesis generating’ only.
The institutional review board of all participating sites approved the protocol, 
which is consistent with the International Conference on Harmonisation 
Guidance for Industry E6 Good Clinical Practice, the Declaration of Helsinki and 
all local regulations. Written consent was obtained from all participating patients 
before enrolment. The trial is registered on the National Institute of Health 
website with identifier NCT00114972.
End-points and definitions
The primary end-point of this study was the composite rate of major adverse 
cardiac or cerebrovascular events (MACCE) at 5 years, which included all-cause 
death, stroke, myocardial infarction (MI) and repeat revascularization. Secondary 
end-points consisted of the composite safety end-point of all-cause death, stroke 
and MI as well as the individual component of repeat revascularization. Specific 
definitions of these end-points have been reported previously (11). All end-points 
were adjudicated by an independent Clinical Events Committee that included a 
cardiac surgeon, a cardiologist and a neurologist.
Statistical analyses
Analyses were based on the intention-to-treat principle. Data are presented using 
descriptive statistics, as percentage, count of sample size or mean ± standard 
deviation. The Kruskal–Wallis test was used to compare continuous variables. 
Differences in discrete variables were compared by means of v2 or Fisher’s exact 
test, where appropriate. Time-to-event unadjusted and adjusted Kaplan–Meier 
estimates with log-rank testing were used to compare clinical outcomes after PCI 
and CABG among different countries. Hazard ratios (HRs) and corresponding 95% 
confidence intervals (CI) for the primary end-point and the secondary end-points 
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were calculated relative to using Cox proportional hazards model. Treatment-
by-country interactions were explored using chi-squared test. Outcomes were 
adjusted for a combination of preand intraoperative variables that were deemed 
clinically important and significantly different between countries or believed 
to be clinically relevant (Supplementary Material, Appendix). Schoenfeld 
residuals were used and showed no significant departure from the proportional 
hazards assumption. A 2-sided P-value of <0.05 was considered to be statistically 
significant. Analyses were performed using SPSS Statistics version 21.0 (IBM 
Corporation, Armonk, NY, USA).
Table 1. Participating countries in the SYNTAX randomized cohort.
Country Hospitals PCI patients CABG patients Total no. of 
patients (%)
Completeness of 
follow-up (%)
Austria 2 28) 24 52 (2.9) 44/52 (84)
Belgium 4 44 47 91 (5.1) 83/91 (91)
Czech Republic 1) 20 20 40 (2.3) 40/40 (100)
Denmark 1 17 15 32 (1.8) 30/32 (93)
Finland 1 12 12 24 (1.3) 24/24 (100)
France 6 103 105 208 (11.6) 201/208 (96)
Germany 8 86 93 179 (9.9) 161/179 (89)
Hungary 3 44 39 83 (4.6) 75/83 (90)
Italy 7 101 96 197 (10.9) 187/197 (94)
Latvia 1 20 20 40 (2.3) 37/40 (92)
Netherlands 6 74 74 148 (8.2) 137/148 (92)
Norway 1) 4 4 8 (0.4) 8/8 (100)
Poland 3 33 33 66 (3.7) 62/66 (93)
Portugal 1 6 7 13 (0.7) 12/13 (92)
Spain 4 27 26 53 (2.9) 48/53 (90)
Sweden 3 26 28 54 (3.0) 52/54 (96)
United Kingdom 8 135 132 267 (14.8) 255/267 (95)
United States 22 123 122 245 (13.6) 220/245 (89)
TOTAL 82 903 897 1800 (100.0) 1676/1800 (93)
Values are present as N (%) or n/N (%).
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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Table 2. Baseline characteristics of patients within countries.
USA 
(n = 245)
UK 
(n = 267) 
IT 
(n = 197)
GE 
(n = 179)
FR 
(n = 208)
NL 
(n = 148)
BE 
(n = 91)
HU 
(n = 83) 
Other 
(n = 382)
Age 65.1 ± 10.3 65.4 ± 9.3 66.5 ± 9.1 66.6 ± 9.7 65.9 ± 10.7 64.6 ± 9.1 63.4 ± 10.9 59.0 ± 8.6 64.9 ± 9.1
Male 160 (65.3) 214 (80.1) 158 (80.2) 135 (75.4) 173 (83.2) 117 (79.1) 72 (79.1) 57 (68.7) 312 (81.7)
BMI 30.3 ± 6.2 27.7 ± 4.5 6.7 ± 3.6 227.9 ± 4.1 27.1 ± 4.7 28.1 ± 4.2 27.1 ± 4.0 29.5 ± 4.2 27.7 ± 4.3
Medically treated 
diabetes
78 (31.8) 48 (18.0) 60 (30.5) 54 (30.2) 51 (24.5) 32 (21.6) 16 (17.6) 28 (33.7) 85 (22.3)
Hypertension 208 (85.9) 187 (70.8) 157 (80.1) 161 (89.9) 140 (68.0) 95 (65.5) 53 (59.6) 79 (95.2) 269 (70.6)
Hyperlipidaemia 194 (79.5) 249 (93.6) 137 (69.5) 132 (73.7) 155 (75.2) 113 (76.9) 65 (72.2) 60 (76.9) 286 (75.7)
Carotid artery 
disease
28 (11.4) 8 (3.0) 31 (15.7) 22 (12.3) 14 (6.7) 5 (3.4) 5 (5.5) 8 (9.6) 27 (7.1)
Unstable angina 79 (32.2) 65 (24.3) 83 (42.1) 47 (26.3) 78 (37.5) 25 (16.9) 23 (25.3) 14 (16.9) 99 (25.9)
Previous MI 57 (23.3) 117 (44.3) 66 (33.5) 48 (28.4) 47 (22.6) 53 (36.1) 23 (25.8) 29 (34.9) 145 (38.4)
Congestive heart 
failure
19 (7.8) 8 (3.0) 6 (3.0) 7 (4.2) 4 (1.9) 3 (2.1) 1 (1.1) 5 (6.1) 30 (7.9)
Logistic 
EuroSCORE
4.5 ± 4.6 3.5 ± 2.3 4.8 ± 5.1 4.4 ± 5.8 3.9 ± 3.7 3.2 ± 3.4 3.7 ± 8.5 2.5 ± 3.0 3.3 ± 3.4
Number of lesions 3.6 ± 1.8 3.7 ± 1.6 4.4 ± 1.7 4.3 ± 1.7 3.9 ± 1.6 3.7 ± 1.3 3.9 ± 1.5 4.7 ± 1.8 4.0 ± 1.7
Left main, any 138 (56.3) 109 (40.8) 66 (33.5) 70 (39.3) 88 (42.3) 45 (30.4) 29 (31.9) 29 (34.9) 131 (34.3)
Left main + 2 
vessel disease
49 (20.0) 40 (15.0) 18 (9.1) 19 (10.6) 32 (15.4) 7 (4.7) 9 (9.9) 6 (7.2) 38 (9.9)
Three-vessel 
disease only
107 (43.7) 158 (59.2) 131 (66.5) 108 (60.7) 120 (57.7)  103 (69.6) 62 (68.1) 54 (65.1) 251 (65.7)
SYNTAX score 25.7 ± 11.7 28.8 ± 10.3 31.4 ± 11.3 29.7 ± 10.8 30.5 ± 12.6 26.9 ± 10.7 26.9 ± 11.3 24.5 ± 11.4 29.9 ± 11.2
P < 0.001 for all comparison between groups. Values are shown as mean ± SD or n/N (%).
USA, United States of America; UK, United Kingdom; IT, Italy; GE, Germany; FR, France; NL, Netherlands; BE, 
Belgium; HU, Hungary; Other, Poland, Sweden, Spain, Czech Republic, Latvia, Denmark, Finland, Portugal and 
Norway; BMI, body mass index; MI, myocardial infarction.
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Table 3. Procedural characteristics in PCI randomized cohort.
USA 
(n = 123) 
UK 
(n = 135)
 IT 
(n = 101)
GE 
(n = 86) 
FR
(n = 103)
NL 
(n = 74)
BE 
(n = 44) 
HU 
(n = 44)
Other
(n = 193)
Procedure duration 90.1 ± 42.7 98.1 ± 33.3 123.7 ± 47.1 89.1 ± 40.9 87.6 ± 40.7 106.4 ± 58.2 88.5 ± 31.1 95.9 ± 36.6 121.2 ± 50.8
Total overlapping stent 0.5 ± 0.6 0.9 ± 0.6 0.7 ± 0.6 0.6 ± 0.6 0.4 ± 0.6 0.7 ± 0.7 0.4 ± 0.5 0.9 ± 0.8 0.5 ± 0.6
Bi-/trifurcation lesions 
treated
63 (51.2) 87 (64.4) 63 (62.4) 57 (66.3) 78 (75.7) 45 (60.8) 36 (81.8) 34 (77.3) 140 (72.5)
Left anterior descending 
artery stent treated
62 (50.4) 100 (74.1) 50 (49.5) 58 (67.4) 62 (60.2) 37 (50.0) 20 (45.5) 32 (72.7) 103 (53.4)
Stents implanted 4.0 ± 2.3 4.4 ± 1.9 5.1 ± 2.2 5.1 ± 2.3 4.2 ± 2.1 4.9 ± 2.4 4.2 ± 1.9 6.1 ± 2.6 4.7 ± 2.3
Total length implanted 69.0 ± 45.1 83.8 ± 41.5 101.6 ± 49.3 89.0 ± 44.9 75.3 ± 41.4 96.7 ± 55.7 83.0 ± 42.9 124.1 ± 60.9 84.4 ± 45.9
Long stenting 
(>100 mm)
25 (21.2) 43 (23.0) 46 (45.5) 30 (35.3) 23 (22.8) 29 (42.6) 12 (28.6) 24 (58.5) 62 (33.0)
SYNTAX score 24.9 ± 11.4 28.7 ± 10.2 29.7 ± 11.8 29.7 ± 11.6 30.4 ± 13.2 27.4 ± 10.4 26.3 ± 10.7 22.3 ± 10.6 30.3 ± 10.9
Logistic EuroSCORE 4.5 ± 4.6 3.8 ± 3.5 4.2 ± 4.7 4.1 ± 4.0 4.0 ± 3.8 3.3 ± 3.7 4.4 ± 12.0 3.1 ± 3.9 3.0 ± 2.5
P < 0.001 for all comparison between groups. Abbreviations as in Table 2. Values are shown as mean 
± SD or n/N (%).
RESULTS
Baseline characteristics
Of the 1800 patients enrolled in the SYNTAX trial, complete follow-up data were 
obtained for 1676 patients (93.1%). Completeness of follow-up was comparable 
between groups of countries (P = 0.084) (Table 1). The risk profile of patients varied 
significantly among countries (Table 2, complete results are in Supplementary 
Material, Table S1). Patients in Hungary were the youngest, had the highest number 
of patients with medically treated hypertension and medically treated diabetes, 
while perioperative risk expressed by the logistic EuroSCORE was the lowest. In 
contrast, patients from the USA and Italy were at greater operative risk according 
to the logistic EuroSCORE. Patients in the UK had the highest rates of prior MI and 
therefore more frequent pretreatment left ventricular dysfunction. The SYNTAX 
score was substantially lower in Hungary, while more patients in the USA had LM 
disease (Table 2).
Procedural characteristics
Several differences were noted in PCI characteristics (Table 3, complete results are 
in Supplementary Material, Table S2). Particularly in Hungary a larger number of 
stents were implanted, a higher stent length, and more patients had >100 mm stents. 
There were no significant differences in the rates of complete revascularization. 
Patients in the USA received the lowest total length of implanted stents. Remarkably, 
patients in Germany more often underwent staged procedures compared with 
patients in Italy and France.
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Differences in CABG procedural characteristics are listed in Table 4 and Fig. 1 
(complete results are in Supplementary Material, Table S3). First of all, the necessity 
for emergent treatment was significantly higher in Hungary compared with the 
other groups. Secondly, the procedure, bypass and cross-clamp times showed 
significant variations. Thirdly, in the Netherlands, less grafts were used than in other 
countries, but the number of distal anastomoses was the highest, indicating that 
more jump grafts were used compared with other countries. When comparing type 
of conduits, the use of an arterial graft to the left anterior descending artery, as well 
as the rate of complete arterial grafting, were lowest in Hungary. In France, the use 
of arterial grafts was highest, resulting in the highest rate of complete arterial 
grafting. In Belgium, the rate of bilateral internal mammary artery (IMA) use was 
highest, but the rate of complete arterial grafting was lower because of the use of 
additional venous grafts.
Medication at discharge
There were only marginal differences across groups in prescribing antiplatelet 
treatment after PCI; the prescription of thienopyridine and dual antiplatelet therapy 
was lowest in the Netherlands. There were, however, significant differences 
in the prescription of statins, beta-blockers and antihypertensive medication 
(Supplementary Material, Table S4).
After CABG, there were differences in the prescription of all secondary prevention 
medications (Supplementary Material, Table S4). In the Netherlands and Germany, 
the prescription of antiplatelet therapy was lowest, but the prescription of 
Coumadin derivates was higher. Thienopyridines were prescribed at the highest 
rate in the USA, as was the prescription of dual antiplatelet therapy.
Five-year outcomes
For the entire cohort, the 5-year unadjusted Kaplan–Meier estimates of MACCE 
were lowest in the group of other countries (28.0%) and highest in Germany 
(39.4%, log-rank for all groups P = 0.076) (Fig. 2A). Also, the unadjusted rate of the 
composite safety end-point of death/stroke/MI was highest in Germany (26.4%) 
but lowest in Hungary (12.9%) (log-rank for all groups P = 0.096) (Fig. 2B). Repeat 
revascularization was lowest in the UK (14.1%) and highest in Hungary (31.6%), with 
significant differences across groups (P = 0.008) (Fig. 2C).
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Figure 1. A graphical display showing differences among investigating countries in use percentage 
of arterial conduits (A) and a number of implanted grafts (B). USA, United States of America; UK, 
United Kingdom; IT, Italy; GE, Germany; FR, France; NL, Netherlands; BE, Belgium; HU, Hungary; 
Other, Poland, Sweden, Spain, Czech Republic, Latvia, Denmark, Finland, Portugal and Norway; 
LIMA, left internal mammary artery; BIMA, bilateral internal mammary artery; LAD, left anterior 
descending artery.
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Figure 2. The Kaplan–Meier cumulative event curves by investigating countries in the SYNTAX trial for MACCE (A), 
the composite safety end-point of death/stroke/MI (B) and repeat revascularization (C). Abbreviations as in Fig. 1. 
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MACCE, major adverse cardiac and 
cerebrovascular events; MI, myocardial infarction.
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After PCI, patients in France had the lowest unadjusted event rates of MACCE 
(28.9%), the composite safety end-point of death/stroke/MI (13.7%) and rate of 
repeat revascularization (20.3%), while these rates were highest in Hungary (50.4, 
18.2 and 44.9%, respectively) and Germany (46.8, 29.2 and 29%, respectively; Fig. 
3A and C). After adjustment for baseline and procedural characteristics and with 
the USA as reference, patients in France had a lower risk of MACCE (HR = 0.60, 
95% CI 0.37–0.98) and for the composite safety end-point of death/stroke/MI (HR 
= 0.45, 95% CI 0.22–0.89), while patients enrolled in Hungary had a higher risk of 
repeat revascularization (HR = 1.89, 95% CI 1.14–3.42) ( Supplementary Material, 
Table S5).
After CABG, rates of unadjusted MACCE were lowest in Hungary and highest in 
France (15.3% vs 34.6%), with significant differences among the 9 groups studied 
(log-rank for all; P = 0.026; Fig. 3B). Differences in the unadjusted rates of repeat 
revascularization just failed to reach statistical significance (P = 0.07; Fig. 3D and 
F). After adjustment for baseline and procedural characteristics and with the 
USA as reference, patients enrolled in Germany had a higher adjusted risk for 
the composite of death/stroke/MI (HR = 2.38, 95% CI 1.03–5.67), and in the UK, 
patients had a lower adjusted risk of repeated revascularization (HR = 0.32, 95% CI 
0.12– 0.85; Supplementary Material, Table S5).
The PCI versus CABG treatment effect did not show a significant interaction 
among countries for the end-point of MACCE (Fig. 4A) or the composite safety 
end-point of death/stroke/MI (Fig. 4B). For repeat revascularization, there was a 
significant treatment-bycountries interaction (P for interaction = 0.045) (Fig. 4C).
DISCUSSION
This study demonstrates important differences in the baseline characteristics, 
clinical practice, medication regimens and outcomes among patients undergoing 
revascularization in the different countries involved in the SYNTAX trial. 
Comorbidities and hence the logistic EuroSCORE differed between countries, there 
was a major variation in the complexity of coronary disease according to SYNTAX 
score, and there was a significant difference in 5-year outcomes between countries.
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Geographical variations in patient characteristics and the impact on outcome have 
recently been reported in cardiovascular trials like the EVEREST and ASTRONAUT 
trial (4, 13–15). The current analysis is unique, as for the first time, it estimates the 
impact of the difference in patient characteristics and clinical practice on outcomes 
after PCI and CABG in specific countries. The number of patients with clinically 
relevant comorbidities was highest in the USA and Italy, while patients from 
countries with lower enrolment (Hungary and the pooled group of other (small) 
countries) had less comorbidities. In concordance with other studies, countries 
with low recruiting centres tended to enrol lower risk patients (5).
PCI-treated patients in Hungary were the youngest and had the lowest SYNTAX 
score, while the number of implanted stents was higher, less optimal use of 
secondary prevention medication and they experienced significantly more 
repeated revascularizations. These findings may therefore confirm the importance 
of functional assessment of coronary lesions as opposed to anatomical assessment 
and the use of secondary prevention. Despite recommendations provided in 
the SYNTAX trial protocols, differences in prescription of secondary prevention 
medications are notable and could have had a negative impact on the outcome. Lack 
of optimal therapy and correlation with long-term mortality has been reported 
in previous studies (16, 17). Antiplatelet agents and statins were more often used 
after PCI than after CABG. Preventive medications to maintain stent patency after 
PCI were rigorously prescribed by cardiologists, whereas usefulness of secondary 
prevention was probably underestimated after CABG (18). These findings provide 
an opportunity for quality improvement in discharge medication after CABG in 
several countries but also remind and encourage cardiologists, intensivists and 
cardiac surgeons to start with secondary prevention as soon as possible and to 
discharge patients with optimal therapies, since there is a possibility that primary 
care doctors who will follow-up these patients will not initiate treatment.
Substantial differences were noted in surgical techniques across countries. Despite 
clear recommendations of more arterial grafting in guidelines (19, 20), the published 
rates of arterial grafting are still relatively low (21). Differences in the use of the left 
and/or right IMAs, total arterial revascularization, the number of grafts, myocardial 
protection and the use of off-pump procedures are likely to be influenced by 
surgical training rather than the risk profile of the patient. It is remarkable that a 
procedure that is performed with such a high rate since its introduction more than 
50 years ago remains far away from being standardized globally. Despite evidence of 
a survival benefit in favour of the use of 2 IMAs over the use of a single IMA graft (22), 
their use in the USA, the UK and Hungary was disappointingly low. On the other 
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Figure 3. A graphical display of 5-year outcomes of CABG and PCI cohorts by investigating 
countries in the SYNTAX trial for MACCE (A and B), the composite safety end-point of 
death/stroke/MI (C and D) and repeat revascularization (E and F). Abbreviations as in Fig. 1. Values 
are Kaplan–Meier rates with P-values from log-rank test.
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Figure 4. A graphical display of 5-year outcomes between investigating countries for MACCE (A), the 
composite safety end-point of death/stroke/MI (B) and repeat revascularization (C). Treatment-by-
country interaction failed to reach statistical significance for MACCE (Pint = 0.12) and the composite 
safety end-point (Pint = 0.38), but there is significant interaction for repeat revascularization 
(Pint = 0.045). Abbreviations as in Fig. 1. Values are Kaplan–Meier rates with P-values from log-rank test. HR, 
hazard ratio.
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hand, in the majority of the patients who underwent CABG in Belgium and France, 
2 IMAs graft were used. In this regard, it is important to consider the absence of 
a midterm benefit on clinical outcomes from 2 IMAs over single IMA graft in the 
recent 5-year findings from the Arterial Revascularization Trial (23), although the 
benefits of 2 IMA grafts increase with the duration of follow-up, which formed the 
basis for the current Arterial Revascularization Trial with 10-year follow-up.
After adjustment for baseline clinical patterns, PCI-treated patients in France had 
a significantly lower MACCE rate and CABG patients in Germany had a higher 
incidence of the composite of death, stroke and MI. It remains unclear whether 
any unmeasured confounding may play a role or whether these findings indeed 
represent higher risks of adverse events in specific countries. Furthermore, a 
large difference in repeat revascularization among countries persisted, even after 
adjustment. It is notable that the Netherlands and the UK cohorts had the lowest 
rates of repeated revascularization, whereas other countries (USA, Hungary and 
Italy) had a higher incidence of repeat revascularization (24).
In order to reduce the difference in outcome between different institutions and 
countries, future trials should include standardized protocols for techniques and 
treatment strategies. Rigorous training and monitoring to improve adherence 
to these protocols will be key to improving the quality of a trial. Moreover, the 
design of the SYNTAX trial did not ensure balanced allocation within participating 
countries, which may have had an impact on trial outcomes. Stratifying enrolment 
per country will strengthen the external validation of trial results.
Study limitations
Since the SYNTAX trial was designed to test the difference between PCI and CABG 
and not differences among countries, this post hoc analysis should be interpreted 
as hypothesis generating. However, exploration of clinical patterns by countries 
provides a better insight of the trial in order to investigate a possible geographical 
heterogeneity (1). These analyses were restricted to specific countries based on the 
number of included patients and adverse events during 5-year of follow-up. Pooling 
data from countries with few participants into 1 group might be somewhat arbitrary 
and heterogeneity within this subgroup is likely (1). Unmeasured factors such as the 
medical care delivery system, disease awareness on a population-based scale and 
patient culture might also play an important role beyond clinical and procedural 
characteristics (25). In addition, another bias might be a lower threshold for repeat 
revascularization that may influence the results (15, 26).
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CONCLUSIONS
Baseline characteristics, clinical practice, secondary prevention medication regimens 
and outcomes were different across countries in the SYNTAX trial. These data can 
be used to improve treatment strategies to reduce adverse events after myocardial 
revascularization in specific countries. It points to the fact that, in strategy trials 
like SYNTAX, the results are relevant to a definable group of patients in a particular 
clinical setting. Standardization of treatment strategies may help to improve the 
external validity of trial results and improve recommendation in guidelines.
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SUPPLEMENTAL MATERIAL
Appendix 1. Baseline variables included in univariate analyses to predict 
MACCE, the composite safety endpoint of death/stroke/myocardial infarction 
and repeat revascularization.
In the Cox proportional model, the following variables were added: male 
gender, age, body mass index, medically treated diabetes, peripheral vascular 
disease, creatinine blood level > 200 micromol/L, medically treated hypertension, 
medically treated hyperlipidemia, carotid artery disease, unstable angina, 
prior myocardial infarction, congestive heart failure, pulmonary hypertension, 
moderate left ventricular ejection fraction 30-49%, left main disease, number 
of lesion (determined by Core lab), SYNTAX score, PCI versus CABG, incomplete 
revascularization, enrolment in the United States of America, enrolment in the 
United Kingdom, enrolment in Italy, enrolment in Germany, enrolment in 
France, enrolment in the Netherlands, enrolment in Belgium, enrolment in 
Hungary and enrolment in group of other countries (Austria, Poland, Sweden, 
Latvia, Denmark, Czech Republic, Finland, Spain, Portugal and Norway).
Additional variables added in the separate PCI model: number of stents 
implanted, total stent length implanted, staged procedure, LAD treated, the 
number of overlapping stents and bi/trifurcation treated. The variable ‘PCI versus 
CABG treatment’ was deleted in this model.
Additional variables added in the separate CABG model: procedure time, bypass 
time, off-pump procedure, left internal mammary artery use, bilateral internal 
mammary artery use, complete arterial revascularization, the number of grafts 
and number of distal anastomoses. The variable ‘PCI versus CABG treatment’ was 
deleted in this model.
345
Influence of practice patterns on outcome among countries enrolled in the SYNTAX trial 
Supplemental Table 1. Baseline characteristics of patients within countries.
USA
(245)
UK
(267)
IT
(197)
GE
(179)
FR
(208)
NL
(148)
BE
(91)
HU
(83)
Other
(382) P-Value
Age 65.1±10.3 65.4±9.3 66.5±9.1 66.6±9.7 65.9±10.7 64.6±9.1 63.4±10.9 59.0±8.6 64.9±9.1 <0.001
Male 160 (65.3) 214 (80.1) 158 (80.2) 135 (75.4) 173 (83.2) 117 (79.1) 72 (79.1) 57 (68.7) 312 (81.7) <0.001
BMI 30.3±6.2 27.7±4.5 26.7±3.6 27.9±4.1 27.1±4.7 28.1±4.2 27.1±4.0 29.5±4.2 27.7±4.3 <0.001
Current smoker 58 (24.6) 46 (17.4) 32 (16.9) 29 (16.7) 42 (20.4) 32 (22.4) 21 (23.1) 17 (20.7) 86 (23.0) 0.33
Medical Treated Diabetes 78 (31.8) 48 (18.0) 60 (30.5) 54 (30.2) 51 (24.5) 32 (21.6) 16 (17.6) 28 (33.7) 85 (22.3) <0.001
      Insulin requiring 34 (13.9) 21 (7.9) 25 (12.7) 21 (11.7) 16 (7.7) 16 (10.8) 5 (5.5) 11 (13.3) 33 (8.6) 0.125
Peripheral vascular disease 32 (13.1) 15 (5.6) 23 (11.7) 15 (8.4) 27 (13.0) 14 (9.5) 6 (6.6) 6 (7.2) 39 (10.2) 0.095
COPD 25 (10.2) 20 (7.5) 19 (9.6) 12 (6.7) 12 (5.8) 19 (12.8) 7 (7.7) 5 (6.0) 35 (9.2) 0.36
Creatinine >200 μmol/l 7 (2.9) 1 (0.4) 4 (2.0) 5 (2.8) 0 0 0 1 (1.2) 8 (2.1) 0.041
Hypertension 208 (85.9) 187 (70.8) 157 (80.1) 161 (89.9) 140 (68.0) 95 (65.5) 53 (59.6) 79 (95.2) 269 (70.6) <0.001
Hyperlipidemia 194 (79.5) 249 (93.6) 137 (69.5) 132 (73.7) 155 (75.2) 113 (76.9) 65 (72.2) 60 (76.9) 286 (75.7) <0.001
Carotid artery disease 28 (11.4) 8 (3.0) 31 (15.7) 22 (12.3) 14 (6.7) 5 (3.4) 5 (5.5) 8 (9.6) 27 (7.1) <0.001
History of CVA or TIA 29 (12.0) 23 (8.6) 19 (9.7) 8 (4.5) 14 (6.7) 13 (8.8) 4 (4.4) 8 (9.8) 32 (8.5) 0.21
Unstable angina 79 (32.2) 65 (24.3) 83 (42.1) 47 (26.3) 78 (37.5) 25 (16.9) 23 (25.3) 14 (16.9) 99 (25.9) <0.001
Previous MI 57 (23.3) 117 (44.3) 66 (33.5) 48 (28.4) 47 (22.6) 53 (36.1) 23 (25.8) 29 (34.9) 145 (38.4) <0.001
Congestive heart failure 19 (7.8) 8 (3.0) 6 (3.0) 7 (4.2) 4 (1.9) 3 (2.1) 1 (1.1) 5 (6.1) 30 (7.9) <0.001
Pulmonary hypertension 4 (1.6) 1 (0.4) 6 (3.0) 2 (1.1) 0 3 (2.0) 1 (1.1) 0 3 (0.8) 0.099
LVEF poor (<30%) 5 (2.0) 7 (2.6) 6 (3.0) 7 (3.9) 1 (0.5) 3 (2.0) 0 1 (1.2) 4 (1.0) 0.16
LVEF moderate (30-49%) 43 (17.6) 60 (22.5) 38 (19.3) 33 (18.4) 26 (12.5) 29 (19.6) 6 (6.6) 17 (20.5) 61 (16.0) 0.022
Logistic EuroSCORE 4.5±4.6 3.5±2.3 4.8±5.1 4.4±5.8 3.9±3.7 3.2±3.4 3.7±8.5 2.5±3.0 3.3±3.4 <0.001
Number of lesion 3.6±1.8 3.7±1.6 4.4±1.7 4.3±1.7 3.9±1.6 3.7±1.3 3.9±1.5 4.7±1.8 4.0±1.7 <0.001
Left main, any 138 (56.3) 109 (40.8) 66 (33.5) 70 (39.3) 88 (42.3) 45 (30.4) 29 (31.9) 29 (34.9) 131 (34.3) <0.001
LM+ 1 vessel 28 (11.4) 24 (9.0) 10 (5.1) 15 (8.4) 12 (5.8) 11 (7.4) 6 (6.6) 2 (2.4) 30 (7.9) 0.15
LM+ 2 vessel 49 (20.0) 40 (15.0) 18 (9.1) 19 (10.6) 32 (15.4) 7 (4.7) 9 (9.9) 6 (7.2) 38 (9.9) <0.001
LM+ 3 vessel 37 (15.1) 33 (12.4) 32 (16.2) 28 (15.6) 37 (17.8) 21 (14.2) 11 (12.1) 20 (24.1) 39 (10.2) 0.043
Three-vessel disease only 107 (43.7) 158 (59.2) 131 (66.5) 108 (60.7) 120 (57.7) 103 (69.6) 62 (68.1) 54 (65.1) 251 (65.7) <0.001
Total occlusion 46 (19.0) 58 (22.0) 48 (24.4) 44 (24.9) 57 (27.5) 34 (23.1) 20 (22.0) 20 (24.4) 88 (23.2) 0.72
Bifurcation, any 156 (64.5) 192 (72.7) 149 (75.6) 135 (76.3) 153 (73.9) 105 (71.4) 59 (64.8) 53 (64.6) 298 (78.4) 0.004
Trifurcation, any 15 (6.2) 33 (12.5) 24 (12.2) 21 (11.9) 23 (11.1) 11 (7.5) 6 (6.6) 7 (8.5) 50 (13.2) 0.12
SYNTAX score 25.7±11.7 28.8±10.3 31.4±11.3 29.7±10.8 30.5±12.6 26.9±10.7 26.9±11.3 24.5±11.4 29.9±11.2 <0.001
USA, The United States of America; UK, The United Kingdom; IT, Italy; GE. Germany; FR, France; NL, The Netherlands; BE, 
Belgium; HU, Hungary; Other, Poland and Sweden and Spain and Czech Republic and Latvia and Denmark and Finland and 
Portugal and Norway. BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; 
TIA, transit ischemic attack, MI, myocardial infarction; LVEF, left ventricular ejection fraction. Values are shown as mean ± 
SD or n/N (%).
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Supplemental Table 6. Multivariable predictors of adverse events in the overall cohort.
HR (95% CI) P-Value
  MACCE
          PCI treatment vs. CABG 1.32 (1.11-1.57) 0.002
          Age (per 5-yr increase) 1.10 (1.05-1.15) <0.001
          Medical treated diabetes 1.22 (1.01-1.47) 0.037
          Peripheral vascular disease 1.98 (1.55-2.53) <0.001
          Unstable angina 1.24 (1.03-1.49) 0.020
          Pulmonary hypertension 2.08 (1.14-3.80) 0.017
          SYNTAX score (per 3 score increase) 1.03 (1.01-1.05) 0.009
          Enrolment in France 0.71 (0.54-0.93) 0.012
          Enrolment in group of other countries 0.66 (0.52-0.82) 0.001
  Composite safety endpoint of death/stroke/MI
          Age 1.05 (1.03-1.06) <0.001
          Previous MI 1.33 (1.05-1.68) 0.016
          SYNTAX score (per 3 score increase) 1.04 (1.01-1.07) 0.007
          Enrolment in France 0.65 (0.45-0.95) 0.026
          Enrolment in group of other countries 0.65 (0.48-0.87) 0.004
  Repeat revascularization
          PCI treatment vs. CABG 1.78 (1.41-2.25) <0.001
          Medical treated diabetes 1.33 (1.05-1.69) 0.019
          Peripheral vascular disease 1.49 (1.04-2.17) 0.028
          Enrolment in the USA 1.65 (1.22-2.22) 0.001
          Enrolment in Italy 1.59 (1.14-2.21) 0.006
          Enrolment in Hungary 1.63 (1.06-2.51) 0.027
Abbreviations as in supplemental Table 1.
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Supplemental Table 7. Multivariable predictors of adverse events in the PCI group.
HR (95% CI) P-Value
  MACCE
          Age (per 5-yr increase) 1.08 (1.02-1.14) 0.012
          Medical treated diabetes 1.46 (1.15-1.86) 0.002
          Peripheral vascular disease 1.47 (1.03-2.09) 0.032
          Unstable angina 1.40 (1.11-1.78) 0.005
          Enrolment in France 0.57 (0.38-0.84) 0.005
          Incomplete Revascularization 1.32 (1.06-1.64) 0.015
          No. of implanted stents 1.26 (1.12-1.41) <0.001
          Bi/Trifurcation treated, any 1.30 (1.02-1.65) 0.036
  Composite safety endpoint of death/stroke/MI
          Age (per 5-yr increase) 1.19 (1.10-1.29) <0.001
          Peripheral vascular disease 2.12 (1.42-3.18) <0.001
          Previous MI 1.67 (1.24-2.24) 0.001
          SYNTAX score (per 3 score increase) 1.06 (1.02-1.10) 0.001
          Enrolment in France 0.52 (0.30-0.90) 0.020
  Repeat revascularization
         Medical treated diabetes 1.69 (1.27-2.25) <0.001
         Pulmonary hypertension 3.53 (1.45-8.62) 0.005
         Left main disease 1.45 (1.09-1.94) 0.012
         Enrolment in Hungary 1.83 (1.07-3.10) 0.026
         Incomplete revascularization 1.49 (1.13-1.95) 0.004
         No. of implanted stents 1.33 (1.16-1.53) <0.001
Abbreviations as in supplemental Table 1.
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Supplemental Table 8. Multivariable predictors of adverse events in the CABG group.
HR (95% CI) P-Value
  MACCE
          Age (per 5-yr increase) 1.10 (1.02-1.20) 0.024
          Peripheral vascular disease 2.25 (1.50-3.37) <0.001
          Previous MI 1.37 (2.02-1.03) 0.048
          No. of distal anastomoses 0.79 (0.65-0.96) 0.018
  Composite safety endpoint of death/stroke/MI
          Age (per 5-yr increase) 1.38 (1.22-1.57) <0.001
          Peripheral vascular disease 2.08 (1.27-3.41) 0.004
          Medically treated hypertension 1.77 (1.02-3.09) 0.043
          No. of implanted grafts 0.70 (0.51-0.95) 0.022
  Repeat revascularization
          Age (per 5-yr increase) 1.12 (1.01-1.26) 0.031
          Left main disease 1.69 (1.06-2.68) 0.028
          Enrolment in the UK 0.42 (0.19-0.92) 0.030
Abbreviations as in supplemental Table 1.
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ABSTRACT
BACKGROUND: Despite the well-established benefits of secondary cardiovascular 
prevention, the importance of concurrent medical therapy in clinical trials of 
coronary revascularization is often overlooked.
OBJECTIVES: The goal of this study was to assess compliance with guideline-
directed medical therapy (GDMT) in clinical trials and its potential impact on the 
comparison between percutaneous coronary intervention (PCI) and coronary 
artery bypass grafting (CABG).
METHODS: The Cochrane Central Register of Controlled Trials and MEDLINE 
were searched from 2005 to August 2017. Clinical trial registries and reference lists 
of relevant studies were also searched. Randomized controlled trials comparing 
PCI with drug-eluting stents versus CABG and reporting medical therapy after 
revascularization were included. The study outcome was compliance with 
GDMT, defined as the following: 1) any antiplatelet agent plus beta-blocker plus 
statin (GDMT1); and 2) any antiplatelet agent plus beta-blocker plus statin plus 
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (GDMT2). 
Data collection and analysis were performed according to the methodological 
recommendations of The Cochrane Collaboration.
RESULTS: From a total of 439 references, 5 trials were included based on our 
inclusion and exclusion criteria. Overall, compliance with GDMT1 was low and 
decreased over time from 67% at 1 year to 53% at 5 years. Compliance with GDMT2 
was even lower and decreased from 40% at 1 year to 38% at 5 years. Compliance 
with both GDMT1 and GDMT2 was higher in PCI than in CABG at all time points. 
Meta-regression suggested an association between lower use of GDMT1 and 
adverse clinical outcomes in PCI versus CABG at 5 years.
CONCLUSIONS: Compliance with GDMT in contemporary clinical trials remains 
suboptimal and is significantly lower after CABG than after PCI, which may influence 
the comparison of clinical trial endpoints between those study groups.
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INTRODUCTION
Guideline-directed medical therapy (GDMT) is recommended by evidence-based 
guidelines for all patients with coronary artery disease (CAD). In addition to 
being considered the first line of treatment for patients with stable CAD, GDMT as 
secondary prevention after coronary revascularization with either percutaneous 
coronary intervention (PCI) or coronary artery bypass grafting (CABG) (1,2) is 
associated with a significant reduction in mortality and myocardial infarction 
(MI) risk (3). Moreover, GDMT alone may achieve a greater reduction in mortality 
than the choice of revascularization strategy (4).
However, currently available evidence suggests that compliance with GDMT 
remains poor after coronary revascularization, particularly after CABG (5–8) and 
in patients with comorbidities such as chronic renal disease. This poor compliance 
further increases patients’ already higher risk of adverse outcomes (9). Moreover, 
randomized controlled trials (RCTs) of coronary revascularization, which are the 
primary source of evidence to guide contemporary clinical practice, often provide 
scant information regarding concurrent medical treatment (10). Therefore, 
whether the poor compliance with GDMT reported in population-based studies 
is also reflected in clinical trials and to what extent different compliance rates 
influence clinical outcomes between PCI and CABG remain unknown. The aims 
of the present study were as follows: 1) to analyze compliance with GDMT in 
landmark clinical trials of coronary revascularization; 2) to compare compliance 
with GDMT in PCI versus CABG; and 3) to assess its potential association with 
clinical trial outcomes. 
METHODS
STUDY DESIGN. We performed a systematic review and meta-analysis according 
to recommendations of the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses statement (11) and The Cochrane Collaboration (12).
SEARCH STRATEGY. The Cochrane Central Register of Controlled Trials in 
the Cochrane Library and MEDLINE in PubMed were searched from 2005 to 
August 2017. This search was complemented by handsearching reference lists of 
relevant studies and clinical trial registries (August 2017). We did not apply limits 
by publication language, status, or date. Further details on search strategies are 
described in the protocol and the Supplemental Appendix.
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SELECTION CRITERIA. RCTs comparing PCI with drug-eluting stents versus 
CABG in patients with CAD were included in the study. (Inclusion and exclusion 
criteria are specified in the Supplemental Appendix.)
DEFINITION OF OUTCOMES. GDMT was defined in 2 different categories: 
1) GDMT1, a combination of any antiplatelet agent, beta-blocker, and statin; 
and GDMT2, a combination of any antiplatelet agent, beta-blocker, statin, and 
angiotensin-converting enzyme (ACE) inhibitor and/or angiotensin receptor 
blocker (ARB).
STUDY SELECTION AND DATA COLLECTION. Two review authors independently 
screened all identified references according to pre-defined inclusion criteria. Full-
text articles of those references were retrieved and reviewed for final inclusion 
according to prespecified inclusion and exclusion criteria. Disagreements were 
resolved by consensus.
Authors of the included trials were invited to provide individual patient data 
for the main classes of GDMT: aspirin, adenosine diphosphate P2Y
12
receptor 
inhibitor, beta-blocker, statin, and ACE inhibitor and/or ARB. Data regarding 
clinical outcomes were obtained from published trial reports. One author 
collated outcome data into a master database and performed quality assessment, 
with a second author verifying its accuracy.
Compliance rates were calculated for individual drug classes and GDMT1 and 
GDMT2 as the number of patients prescribed each drug divided by the total 
number of patients with follow-up at each specific time point. Analysis was 
performed for patients undergoing PCI and CABG by computing compliance 
rates for each group. We used the absolute risk reduction as the effect measure, 
and differences in compliance rates and clinical outcomes were calculated by 
subtracting those of CABG from those of PCI. The time points selected for analysis 
were as follows: discharge, 1 year, 3 years, and 5 years.
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RISK OF BIAS ASSESSMENT. Risk of bias of individual studies was assessed 
according to the recommendations of The Cochrane Collaboration (12), taking 
into account the following items: 1) random sequence generation (selection 
bias); 2) allocation concealment (selection bias); 3) blinding of participants and 
personnel (performance bias); 4) blinding of outcome assessment (detection bias); 
5) incomplete outcome data addressed (attrition bias); andselective reporting 
(reporting bias).
STATISTICAL ANALYSIS AND EVIDENCE SYNTHESIS. Meta-analysis was 
conducted to assess the pooled compliance with GDMT in all the trials and to 
compare intervention groups (PCI vs. CABG). Outcomes and effect measures were 
reported as untransformed proportion and risk difference with 95% confidence 
intervals, respectively. The overall meta-analytical effect size was estimated by 
using the random effects model and the restricted maximum likelihood method. 
Chi-square Q statistics and I2 statistics were used to assess heterogeneity. Meta-
regression with a random effects model was performed to assess the impact of 
compliance with GDMT on clinical outcomes at 5 years. Overall trial data (and 
not individual patient data) were used, and only trials with 5-year follow-up 
were included in meta-regression. All statistical analyses were performed using 
the software Open MetaAnalyst (13). A p value <0.05 was considered statistically 
significant for all analyses.
RESULTS
STUDY SELECTION. The study search strategy yielded 749 references, of which 
395 were excluded after screening. A total of 46 papers were reviewed, and 18 
RCTs ultimately met the inclusion criteria. However, after reviewing the full 
papers, only 5 were included for analysis (Supplemental Figure 1).
Thirteen RCTs were excluded:
• MASS II (Medicine, Angioplasty, or Surgery Study) trial (14) and BARI 2D (Bypass 
Angioplasty Revascularization Investigation 2 Diabetes) trial (15) compared 
medical therapy versus revascularization with either PCI or CABG;
• VA CARDS (Coronary Artery Revascularization in Diabetes trial) (16) had serious 
methodological limitations (recruitment was stopped after enrolling only 25% 
of the intended sample size);
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• SIMA (Stenting versus Internal Mammary Artery grafting) trial (17), BARI 
(Bypass Angioplasty Revascularization Investigation trial) (18), LE MANS (Left 
Main Coronary Artery Stenting trial) (19), SoS (Stent or Surgery trial) (20), 
ERACI II (Argentine Randomized Study: Coronary Angioplasty With Stenting 
Versus Coronary Bypass Surgery Trial) (21), and CARDia (Coronary Artery 
Revascularization in Diabetes) trial (22) used bare-metal stents;
• The MICASA (Myocardial Injury Following Coronary Artery Surgery 
Versus Angioplasty) trial (23) and NOBLE (Nordic-Baltic-British Left Main 
Revascularization Study) (24) did not collect data regarding medical therapy; 
and Two other trials were excluded because they did not collect data regarding 
medical therapy during follow-up (25,26).
Therefore, the following trials were included in the final analysis:
• SYNTAX (Synergy Between Percutaneous Coronary Intervention With TAXUS 
and Cardiac Surgery) trial (27);
• FREEDOM (Future Revascularization Evaluation in Patients with Diabetes 
Mellitus: Optimal Management of Multivessel Disease) trial (28);
• PRECOMBAT (Premier of Randomized Comparison of Bypass Surgery versus 
Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary 
Artery Disease) trial (29);
• BEST (Randomized Comparison of Coronary Artery Bypass Surgery and 
Everolimus-Eluting Stent Implantation in the Treatment of Patients with 
Multivessel Coronary Artery Disease) trial (30); and
• EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for 
Effectiveness of Left Main Revascularization) trial (31).
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Figure 1. Compliance With GDMT1, Deﬁned as Any Antiplatelet Agent þ Beta-Blocker þ Statin, in All 
Clinical Trials Over Time. Proportion of compliance calculated as number of patients prescribed guideline-
directed medical therapy (GDMT) 1 divided by the total number of patients at each time point. BEST, Randomized 
Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment 
of Patients with Multivessel Coronary Artery Disease trial; CI, conﬁdence interval; EXCEL, Evaluation of XIENCE 
versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization trial; FREEDOM, Future 
Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease 
trial; PRECOMBAT, Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-
Eluting Stent in Patients with Left Main Coronary Artery Disease trial; SYNTAX, Synergy Between Percutaneous 
Coronary Intervention With TAXUS and Cardiac Surgery trial.
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Figure 2. Compliance With GDMT2, Deﬁned as Any Antiplatelet Agent þ Beta-Blocker þ Statin þ ACE Inhibitor or 
ARB, in All Clinical Trials Over Time. Proportion of compliance calculated as number of patients prescribed GDMT2 
divided by the total number of patients at each time point. ACE, angiotensin-converting enzyme; ARB, angiotensin 
receptor blocker; other abbreviations as in Figure 1.
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An additional 2 surgical trials (CORONARY (CABG Off or On Pump 
Revascularization Study) (32) and ART (Arterial Revascularisation Trial) (33)) 
were added due to their relevance in the field of coronary revascularization and 
the availability of data on medical therapy. These trials were analyzed separately 
because they did not compare PCI versus CABG (Supplemental Figures 2 and 3, 
Supplemental Table 1).
STUDY CHARACTERISTICS. The 6 studies included in this review were all 
large, multicenter RCTs that compared PCI versus CABG in patients undergoing 
revascularization for complex CAD (Table 1). All those studies were considered 
landmark trials that provide the evidence basis for contemporary practice of 
coronary revascularization.
RISK OF BIAS WITHIN STUDIES. All the studies included in this review were 
RCTs of high methodological quality (Supplemental Table 2).
OVERALL COMPLIANCE WITH GDMT. Figures 1 and 2 illustrate compliance 
to GDMT1 and GDMT2, respectively, over time in all the trials. Data regarding 
individual drug classes are available in Supplemental Table 3. There was 
substantial variability between studies in both GDMT1 and GDMT2, as noted by 
the high I2 values at each time point.
COMPLIANCE WITH GDMT IN PCI VERSUS CABG GROUPS. The Central 
Illustration and Figure 3 illustrate the difference between PCI and CABG in the 
proportion of compliance with GDMT1 and GDMT2, respectively, over time. 
For all studies except EXCEL with GDMT1, compliance was higher with PCI than 
with CABG. Data regarding individual drug classes are provided in Supplemental 
Table 4.
COMPLIANCE WITH GDMT AND CLINICAL OUTCOMES. Figure 4 
illustrates the inverse association between the difference in compliance with 
GDMT1 at 5 years and the difference in clinical outcomes (all-cause mortality, MI, 
and a composite endpoint of all-cause mortality, MI, and stroke) for clinical trials 
with 5-year follow-up. As compliance with GDMT increased in the PCI group 
relative to the CABG group, the better outcomes of CABG became less evident. 
There was no difference in clinical outcomes when compliance for PCI exceeded 
that of CABG by approximately 8%.
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Data for all other trials and time points are available in Supplemental Table 5. 
There was no apparent association between compliance with GDMT2 and clinical 
outcomes.
DISCUSSION
Despite the compelling benefits demonstrated by GDMT as secondary prevention 
after coronary revascularization, compliance remains low even in the tightly 
controlled environment of clinical trials. Furthermore, in our study, compliance 
with GDMT was higher in patients undergoing PCI compared with patients 
undergoing CABG, which may skew the comparison of clinical endpoints between 
those revascularization strategies.
OVERALL COMPLIANCE WITH GDMT. Overall compliance with aspirin and 
statins was high and reasonably stable over time, but there was some variation 
among trials, with compliance rates ranging from 75% to 95%. Some of the 
lack of compliance with aspirin may be related to intolerance to aspirin and/
or concurrent use of anticoagulation therapy. Nonetheless, compliance with 
at least 1 antiplatelet agent was close to 100% in most trials throughout follow-
up. Although aspirin intolerance or hypersensitivity can affect up to 10% of the 
population, there are currently rapid desensitization protocols that can be used 
in patients requiring dual antiplatelet therapy (34). Conversely, prevention of 
aspirin resistance has justified consideration of high-dose aspirin (325 mg daily) 
instead of low-dose aspirin (81 mg daily), but its benefits remain uncertain (35).
The differences in the use of adenosine diphosphate P2Y
12
-receptor inhibitors 
may be related to whether dual antiplatelet therapy was used and for how long 
after revascularization. Considering the controversy regarding dual antiplatelet 
therapy after coronary revascularization (36–38), the significant differences 
between trials are not unexpected, particularly when considering surgical trials 
(CORONARY and ART). Although dual antiplatelet therapy is recommended 
after PCI, its benefit after CABG remains uncertain and is only recommended in 
specific circumstances (e.g., off-pump surgery) (35).
Compliance with beta-blockers and ACE inhibitors/ ARBs was lower and more 
variable, ranging from 43% to 80% and 28% to 79%, respectively. These findings 
are in keeping with previous reports from real-world registries (3). One possible 
explanation is the fact that although the efficacy of antiplatelet agents and statins 
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Figure 3. Compliance With GDMT2, Deﬁned as Any Antiplatelet Agent þ Beta-Blocker þ Statin þ ACE 
Inhibitor or ARB, for PCI and CABG. Difference in compliance calculated by subtracting proportion of 
compliance in coronary artery bypass grafting (CABG) from proportion of compliance in percutaneous 
coronary intervention (PCI). Abbreviations as in Figures 1 and 2.
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Figure 4. Meta-Regression Relating Compliance With GDMT1 (Any Antiplatelet Agent þ Beta-
Blocker þ Statin) at 5 Years and Clinical Trial Outcomes at 5 Years. (A) Mortality, (B) myocardial 
infarction (MI), and (C) a composite of death, MI, and stroke. Only 3 trials were included (SYNTAX, 
FREEDOM, and BEST) because the others did not report 5-year outcomes. The x-axis represents the 
difference in compliance with GDMT1 between PCI and CABG; the y-axis represents the difference in 
clinical outcomes between PCI and CABG. As the difference in compliance favoring PCI widens, the 
superiority of CABG in terms of clinical outcomes decreases. The p value is for comparison between PCI 
and CABG. The size of the circles reﬂects the weight of the study. Abbreviations as in Figures 1 and 3.
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in reducing cardiovascular events after coronary revascularization has long been 
recognized (1,39,40), the advantages of other drug classes have been established 
more recently (41) and may vary according to comorbidities and risk factors. 
Indeed, ACE inhibitors/ARBs are not routinely recommended after CABG unless 
in the presence of hypertension, diabetes, left ventricular systolic dysfunction, 
and chronic kidney disease (35,41), due to a potential increase in postoperative 
complications (42). In addition, controversies regarding the adverse effects of 
beta-blockers and statins may influence prescribing decisions (43–45).
Variability between trials was also found regarding compliance with GDMT1 
and GDMT2. Although there was significant heterogeneity, even the highest 
compliance rates were unsatisfactory, as <40% of the patients were taking all 
the guideline-recommended drugs at 1 year. Furthermore, there was a modest 
decline in compliance over time. Although this outcome has been documented 
in the real world, more stable compliance was expected in this study due to the 
stricter follow-up required by clinical trial protocols (46).
The underuse of GDMT, particularly after CABG (8), is likely multifactorial. It may 
be related to underestimation of the importance of GDMT and the misconception 
that the value of maintaining GDMT is reduced once diseased coronary arteries 
have been mechanically revascularized with either PCI or CABG (47–49). In 
keeping with this, medical therapy is often neglected in coronary revascularization 
trials and hence poorly reported or not even collected at all, as happened in the 
recent NOBLE trial (24). On the contrary, GDMT compliance seemed higher in 
patients undergoing PCI than in those treated without revascularization (50,51), 
likely because hospital admission, often precipitated by an acute coronary 
event, provided an opportunity to reconsider prescription of cardioprotective 
medication. The conflicting evidence currently available calls for further studies 
to elucidate the factors related to GDMT noncompliance.
Irrespective of the underlying reasons, poor compliance with medical therapy 
that has demonstrated compelling benefits for secondary prevention in landmark 
clinical trials is a matter of concern. Considering that clinical trials operate within 
a strictly controlled environment and include a highly selected population of 
patients, drug compliance would be expected to be optimal. Furthermore, clinical 
trials provide the evidence to support current clinical practice and emphasize 
ideal standards. Therefore, optimizing compliance to GDMT is paramount to 
improve compliance and outcomes in everyday practice.
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COMPARISON OF COMPLIANCE BETWEEN PCI AND CABG. Compliance with 
GDMT was consistently lower for patients undergoing CABG compared with 
PCI. The difference was particularly marked for P2Y
12
receptor inhibitors, as dual 
antiplatelet therapy is formally recommended in the guidelines after PCI (41). 
In contrast, aspirin and statins were identically used in both groups, and beta-
blockers were more common in the CABG group in the EXCEL trial, perhaps due 
to their potential utility in preventing or treating post-operative atrial fibrillation 
(52).
Compliance with GDMT1 and GDMT2 was also better in the PCI group compared 
with the CABG group, with a difference close to 10% at 1 year for GDMT2. The 
underlying reasons are difficult to identify. The common although erroneous 
assumption that more complete revascularization after CABG obviates the need 
for further medical therapy cannot be overlooked. Medical therapy, particularly 
antiplatelet agents (53) and statins (54), reduces platelet activation, endothelial 
dysfunction, oxidative stress, and inflammation, which have all been associated 
with the development and progression of atherosclerosis (55–57), which is itself 
the primary mechanism leading to graft failure, particularly in venous grafts 
(58). Conversely, the lower compliance with ACE inhibitors/ARBs may be based 
on evidence suggesting that these drugs have no impact on midterm mortality or 
recurrent ischemia after CABG (59). Concerns about the detrimental effect of ACE 
inhibitors/ARBs on renal function and hyperkalemia in the post-operative period 
further compound the lower compliance with these drugs. However, this theory 
remains highly controversial (42,60,61), and the benefit of these drugs after the 
first 3 months has been compellingly demonstrated (62–64).
Another potential explanation for the low overall compliance with GDMT and 
the variability observed between individual trials is the high cost of medicines. 
Cost-effectiveness analyses support this possibility and imply that providing 
full coverage for secondary prevention therapy may save lives and decrease 
consumption of health care resources (65,66). Cardiovascular drugs are not easily 
affordable in many countries, particularly in South America and Southeast Asia. 
Therefore, in trials in which standard medication was not provided by the study 
team, the low compliance rates may reflect patients’ inability to access expensive 
drugs. Although we could not analyze compliance rates stratified according 
to country, the hypothesis that the high price of cardiovascular medication 
significantly limits compliance in clinical trials deserves further investigation.
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INFLUENCE OF GDMT ON CLINICAL TRIAL OUTCOMES. Our data suggest that 
there is a correlation between the difference in compliance rates and clinical 
outcomes when comparing PCI and CABG at 5 years. The better outcomes 
achieved with CABG versus PCI became less obvious as the compliance with GDMT 
increased in PCI versus CABG. Therefore, if compliance rates were identical in 
both groups, the superiority of CABG for major clinical endpoints might have 
been even more marked, as part of the benefit of PCI might be explained by better 
compliance with GDMT. However, because the population of patients included in 
each trial was different, the influence of confounding factors cannot be excluded. 
In addition, the correlation between GDMT1 and clinical outcomes was not 
corroborated by a similar correlation with GDMT2. Nevertheless, the importance 
of this hypothesis deserves consideration. Although some might argue that the 
varying profiles of medical therapy in PCI and CABG is part of the difference in 
the “strategies” of PCI and CABG, a fair and accurate comparison between PCI 
and CABG cannot be appreciated unless medical therapies are equalized with 
both approaches. Other than for dual antiplatelet therapy, single antiplatelet 
treatment, beta-blockers, and statins seem advantageous irrespective of the 
revascularization strategy.
STUDY LIMITATIONS. In this study, medication prescription was considered as a 
surrogate for medication adherence, which may have resulted in overestimating 
true compliance rates. Medication nonadherence is a well-recognized issue 
in cardiovascular disease and may be responsible for approximately 125,000 
preventable deaths every year as only about one-half of the patients consistently 
take prescribed medications (67). In addition, in this study, it was impossible to 
assess whether treatment doses were appropriate and to ascertain the reasons 
for noncompliance because this factor was not tracked in any of the randomized 
trials. Finally, the meta-regression relating compliance to subsequent outcomes 
was based on only 3 studies and compliance data at one point in time, adding 
imprecision to the results. We did not have access to individual patient-level data 
in the present analysis, which would have been superior to meta-regression in 
linking compliance with outcomes.
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CONCLUSIONS
Although GDMT is crucial for patients to derive the most benefit from coronary 
revascularization, compliance was low even in landmark randomized clinical 
trials. Moreover, drug compliance was consistently lower in the CABG group 
compared with the PCI group, and this difference may have influenced the 
differences in major clinical outcomes between groups. Further research is 
warranted to delineate the extent to which different rates of compliance with 
GDMT after PCI compared with CABG influence the relative shortand longterm 
outcomes with these revascularization modalities.
The potential consequences of poor compliance with GDMT on long-term 
clinical outcomes are substantial. Therefore, a pressing need exists to develop 
effective strategies to improve compliance with lifesaving drugs. Clinical trials 
have an important role to play by serving as an example of ensuring outstanding 
compliance with GDMT.
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CLINICAL PERSPECTIVES
COMPETENCY IN PRACTICE-BASED LEARNING AND IMPROVEMENT: 
Compliance with GDMT in contemporary clinical trials is suboptimal and lower in 
trials of patients undergoing CABG than in those investigating PCI.
TRANSLATIONAL OUTLOOK: More concerted efforts are needed to improve 
compliance with GDMT among patients participating in clinical trials of 
coronary revascularization and to understand the impact of compliance on the 
comparative outcomes of patients undergoing percutaneous or surgical coronary 
revascularization.
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SUPPLEMENTAL MATERIAL
Protocol
Objectives
• To analyse compliance with GDMT in landmark clinical trials of coronary 
revascularisation;
• To compare adherence to GDMT in PCI versus CABG;
• To assess its potential association with clinical trial outcomes.
Methods
Study question
• Population – patients undergoing coronary artery revascularisation
• Intervention – percutaneous coronary intervention
• Comparison – coronary artery bypass surgery
• Outcome – compliance with GDMT
Eligibility criteria
• Randomised controlled trials;
• Including patients with complex coronary artery disease;
• Comparing percutaneous coronary intervention and coronary artery bypass 
surgery;
• Reporting compliance with the different drug classes recommended by 
guidelines as secondary cardiovascular prevention;
Exclusion criteria
• PCI performed using bare metal stents (BMS), because they have been replaced 
by DES which are now standard practice and routinely used unless there are 
specific contraindications; trials in which BMS were commonly used are 
now considered ‘historical’ as they do not influence contemporary coronary 
revascularisation;
• Minimally-invasive CABG;
• Comparison of medical therapy versus early revascularisation as this would have 
a significant interference with our outcome of interest which is compliance with 
medical therapy after coronary revascularisation. We considered that medical 
therapy could not be simultaneously intervention and outcome;
• When institutions published duplicate studies with accumulating numbers of 
patients or increased lengths of follow-up, only the most complete reports will 
be included for quantitative assessment at each time interval;
• No exclusion criteria based on language of publication will be used.
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Information sources
• Bibliographic databases
  √ Medline or PubMed
  √ The Cochrane Central Register of Controlled Trials (CENTRAL)
• Clinical trials registries
• Grey literature databases (conference abstracts)
• Reference lists in other reviews and guidelines
• Contact with authors
Search strategy
Query definition
• PubMed/Medline
(((“Angioplasty, Balloon, Coronary”(MeSH Terms) OR “Percutaneous Coronary 
Intervention”(MeSH Terms)) AND (“Coronary Artery Bypass”(MeSH Terms) OR 
“Coronary Disease/surgery”(MeSH Terms) OR “Coronary Vessels/surgery”(MeSH 
Terms) OR “Myocardial Infarction/surgery”(MeSH Terms))) AND (“randomized 
controlled trial”(Publication Type) AND random*(tiab) AND trial(tiab))) AND 
(“2005”(PDAT) : “3000”(PDAT))
• CENTRAL
#1  MeSH descriptor: (Angioplasty, Balloon, Coronary) explode all trees 
3747
#2  MeSH descriptor: (Percutaneous Coronary Intervention) explode all trees 
5100
#3  MeSH descriptor: (Coronary Artery Bypass) explode all trees 5556
#4  MeSH descriptor: (Coronary Disease) explode all trees and with qualifier(s): 
(Surgery - SU) 1855
#5  MeSH descriptor: (Coronary Vessels) explode all trees and with qualifier(s): 
(Surgery - SU) 208
#6  MeSH descriptor: (Myocardial Infarction) explode all trees and with 
qualifier(s): (Surgery - SU) 538
#7  randomized controlled trial:pt  (Word variations have been searched) 
426390
#8  random*:ti,ab,kw  (Word variations have been searched) 620177
#9  trial:ti,ab,kw  (Word variations have been searched) 561361
#10  (#1 or #2) and (#3 or #4 or #5 or #6) and (#7 and #8 and #9) Publication Year from 
2005  416
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Study records
• Data management – database will be created in Excel with documentation of 
reason for exclusion
• Selection process – screening of titles and abstracts by two independent 
reviewers; eligibility assessment of full-text manuscripts by two independent 
reviewers; disagreements will be resolved by consensus.
• Data collection process – one investigators will collect data and a second 
investigator will confirm its accuracy against trial reports. Investigators of the 
original studies will be contacted to obtain missing data.
Risk of bias in individual studies
One investigator will perform quality assessment using specific criteria for RCT as 
recommended by Cochrane.
Supplemental Figure 1. PRISMA flow chart
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Supplemental Table 1. Data for CORONARY and ART trials. 
Trial Date Site Study 
period
Population Number 
patients
Interventions Primary 
endpoint
Follow-
up
Primary 
endpoint 
outcome (%)
p-value
CORONARY 2016 79 centres 
in 19 
countries
2006-
2011
Patients 
undergoing 
isolated CABG 
surgery
4752 ONCABG vs 
OPCABG  
(1:1 ratio)
All-cause 
death, 
nonfatal 
stroke, 
nonfatal 
myocardial 
infarction, 
or new 
renal failure 
requiring 
dialysis
5 years 23.1 
(off-
pump)
23.6
(on-
pump)
0.72
ART 2016 28 centres 
in seven 
countries
2004-
2007
Patients 
undergoing 
isolated CABG 
surgery
3102 BIMA vs SIMA 
grafting (1:1 
ratio)
All-cause 
death, 
myocardial 
infarction, 
or stroke
5 years 12.2 
(SIMA)
12.7 
(BIMA)
0.69
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Supplemental Table 2. Quality assessment.
Trials SYNTAX 
(1)
FREEDOM (2) PRECOMBAT 
(3)
BEST
(4)
EXCEL 
(5)
CORONARY 
(6) 
ART 
(7)
Random sequence 
generation 
(selection bias) 
Low risk
Patients were 
randomly 
allocated
Low risk
Patients were 
randomly 
allocated
Low risk
Patients were 
randomly 
allocated
Low risk
Patients were 
randomly 
allocated
Low risk
Patients were 
randomly 
allocated
Low risk
Patients were 
randomly 
allocated
Low risk
Patients were 
randomly 
allocated
Allocation 
concealment 
(selection bias) 
Low risk
Central 
allocation 
service using 
Interactive 
Voice Response 
System
Low risk
Allocation done 
using permuted 
blocks with 
dynamic 
balancing 
within each 
study centre
Low risk
Central 
allocation using 
an interactive 
Web-based 
response 
system
Low risk
Central 
allocation 
service using an 
interactive Web-
response system 
with random 
block sizes and 
stratification by 
centre
Low risk
Central 
allocation 
service using 
Interactive 
Voice 
Response 
System or 
Web-based 
system
Low risk
Central 
allocation 
service using a 
24-hour auto- 
mated voice-
activated 
telephone 
randomisation 
service
Low risk
Central 
allocation via 
telephone 
call; sequence 
generated 
with randomly 
varying block 
sizes and 
stratified by 
centre
Blinding of 
participants 
and personnel 
(performance 
bias) 
Low risk
No blinding, 
but the review 
authors judge 
that the 
outcome was 
not likely to be 
influenced by 
lack of blinding
Low risk
No blinding, 
but the review 
authors judge 
that the 
outcome was 
not likely to be 
influenced by 
lack of blinding
Low risk
No blinding, 
but the review 
authors judge 
that the 
outcome was 
not likely to be 
influenced by 
lack of blinding
Low risk
No blinding, 
but the review 
authors judge 
that the 
outcome was 
not likely to be 
influenced by 
lack of blinding
Low risk
No blinding, 
but the review 
authors judge 
that the 
outcome was 
not likely to 
be influenced 
by lack of 
blinding
Low risk
No blinding, 
but the review 
authors judge 
that the 
outcome was 
not likely to 
be influenced 
by lack of 
blinding
Low risk
No blinding, 
but the review 
authors judge 
that the 
outcome was 
not likely to 
be influenced 
by lack of 
blinding
Blinding of 
outcome 
assessment 
(detection bias)
Low risk
No blinding 
of outcome 
assessment, 
but the review 
authors 
judge that 
the outcome 
measurement 
was not 
likely to be 
influenced by 
lack of blinding
Low risk
No blinding 
of outcome 
assessment, 
but the review 
authors 
judge that 
the outcome 
measurement 
was not 
likely to be 
influenced by 
lack of blinding
Low risk
No blinding 
of outcome 
assessment, 
but the review 
authors 
judge that 
the outcome 
measurement 
was not 
likely to be 
influenced by 
lack of blinding
Low risk
No blinding 
of outcome 
assessment, 
but the review 
authors 
judge that 
the outcome 
measurement 
was not likely to 
be influenced by 
lack of blinding
Low risk
No blinding 
of outcome 
assessment, 
but the review 
authors 
judge that 
the outcome 
measurement 
was not 
likely to be 
influenced 
by lack of 
blinding
Low risk
No blinding 
of outcome 
assessment, 
but the review 
authors 
judge that 
the outcome 
measurement 
was not 
likely to be 
influenced 
by lack of 
blinding
Low risk
No blinding 
of outcome 
assessment, 
but the review 
authors 
judge that 
the outcome 
measurement 
was not 
likely to be 
influenced 
by lack of 
blinding
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Incomplete 
outcome data 
addressed 
(attrition bias)
Low risk
Minimal loss 
of follow-up 
and missing 
outcome data 
balanced in 
numbers across 
intervention 
groups; 
intention-to-
treat analysis
Low risk
Minimal loss 
of follow-up 
and missing 
outcome data 
balanced in 
numbers across 
intervention 
groups; 
intention-to-
treat analysis
Low risk
Minimal loss 
of follow-up 
and missing 
outcome data 
balanced in 
numbers across 
intervention 
groups; 
intention-to-
treat analysis
Low risk
Minimal loss 
of follow-up 
and missing 
outcome data 
balanced in 
numbers across 
intervention 
groups; 
intention-to-
treat analysis
Low risk
Minimal loss 
of follow-up 
and missing 
outcome data 
balanced 
in numbers 
across 
intervention 
groups; 
intention-to-
treat analysis
Low risk
Minimal loss 
of follow-up 
and missing 
outcome data 
balanced 
in numbers 
across 
intervention 
groups; 
intention-to-
treat analysis
Low risk
Minimal loss 
of follow-up 
and missing 
outcome data 
balanced 
in numbers 
across 
intervention 
groups; 
intention-to-
treat analysis
Selective 
reporting 
(reporting bias) 
Low risk
The study 
protocol is 
available 
and all of 
the study’s 
prespecified 
(primary and 
secondary) 
outcomes that 
are of interest 
in the review 
have been 
reported in the 
prespecified 
way
Low risk
The study 
protocol is 
available 
and all of 
the study’s 
prespecified 
(primary and 
secondary) 
outcomes that 
are of interest 
in the review 
have been 
reported in the 
prespecified 
way
Low risk
The study 
protocol is 
available 
and all of 
the study’s 
prespecified 
(primary and 
secondary) 
outcomes that 
are of interest 
in the review 
have been 
reported in the 
prespecified 
way
Low risk
The study 
protocol is 
available and 
all of the study’s 
prespecified 
(primary and 
secondary) 
outcomes that 
are of interest in 
the review have 
been reported in 
the prespecified 
way
Low risk
The study 
protocol is 
available 
and all of 
the study’s 
prespecified 
(primary and 
secondary) 
outcomes that 
are of interest 
in the review 
have been 
reported in the 
prespecified 
way
Low risk
The study 
protocol is 
available 
and all of 
the study’s 
prespecified 
(primary and 
secondary) 
outcomes that 
are of interest 
in the review 
have been 
reported in the 
prespecified 
way
Low risk
The study 
protocol is 
available 
and all of 
the study’s 
prespecified 
(primary and 
secondary) 
outcomes 
that are of 
interest in the 
review have 
been reported 
in the 
prespecified 
way
Other bias The study 
appears to be 
free of other 
sources of bias
The study 
appears to be 
free of other 
sources of bias
The study 
appears to be 
free of other 
sources of bias
The study 
appears to be 
free of other 
sources of bias
The study 
appears to be 
free of other 
sources of bias
The study 
appears to be 
free of other 
sources of bias
The study 
appears to be 
free of other 
sources of bias
Supplemental Table 2. Continued.
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Supplemental Figure 2. Compliance with guideline-directed medical therapy 1 (GDMT1), defined as 
any antiplatelet agent + beta-blocker + statin, in all clinical trials over time. Proportion of compliance 
calculated as number of patients prescribed GDMT divided by the total number of patients at each 
time point.
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Supplemental Figure 3. Compliance with guideline-directed medical therapy 2 (GDMT2), defined 
as any antiplatelet agent + beta-blocker + statin + angiotensin-converting inhibitor or angiotensin 
receptor blocker, in all clinical trials over time. Proportion of compliance calculated as number of 
patients prescribed GDMT divided by the total number of patients at each time point.
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Supplemental Table 3. Results.
v
389
Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials
15
390
Chapter 15
Supplemental Table 4. Results.
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Supplemental Table 5. Results.
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Chapter 16
Clinical guidelines on perioperative medication in 
adult cardiac surgery
Based on:
2017 EACTS Guidelines on perioperative medication in adult 
cardiac surgery
Sousa-Uva M, Head SJ, Milojevic M, Collet JP, Landoni G, Castella 
M, Dunning J, Gudbjartsson T, Linker NJ, Sandoval E, Thielmann M, 
Jeppsson, Landmesser U.
2017 EACTS/EACTA Guidelines on patient blood management in 
adult cardiac surgery
Pagano D, Milojevic M, Meesters MI, Benedetto U, Bolliger D, von 
Heymann C, Jeppsson A, Koster A, Osnabrugge RL, Ranucci M, Ravn 
HB, Vonk ABA, Wahba A, Boer C.
Eur J Cardiothorac Surg. 2018;53:5-33.
Eur J Cardiothorac Surg. 2018;53:79-111.
J Cardiothorac Vasc Anesth. 2018;32:88-120.
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INTRODUCTION
Clinical guidelines are issued for areas where there is substantial evidence to 
support strong recommendations, usually derived from randomised clinical trials 
or large registries. Quality criteria for developing Clinical Guidelines require 
transparency on how they are formulated. The methodology manual for the 
EACTS clinical guidelines was issued to standardise the development process of 
evidence-based documents (1). Adult cardiac surgery is an essential therapeutic 
approach to reduce mortality and morbidity in appropriately defined patients. 
The outcome depends on the management of underlying conditions, and medical 
treatment is key in the optimal perioperative and long-term success of the cardiac 
surgery. Several studies have suggested that patients after coronary artery bypass 
grafting (CABG) benefit the most from risk-factor modifying strategies (2-6).
Medical therapy impacts on adult cardiac surgery at three distinct phases: 
preoperatively, intraoperatively and postoperatively (7). Preoperatively, drugs 
might need to be introduced or interrupted to decrease the odds of procedural 
complications. Intraoperatively, glycaemia control and prophylactic antibiotics 
are essential to reducing the risk of infectious complications. Postoperatively, 
restarting or initiating medication to prevent ischaemic events, prevent 
arrhythmias, and manage cardiovascular risk factors and heart failure is required 
to impact the long-term prognosis in a positive way, especially if they are included 
in a formal program of cardiac rehabilitation (8).
Cardiac surgery is always a major life event that is associated with increased 
disease awareness and represents a unique opportunity to introduce optimised 
medical therapy and stress the importance of lifestyle modifications, compliance 
with medication and lifelong follow-up. Surgical patients are often sub-optimally 
treated (9, 10) although the benefit of a more intense postoperative patient-based 
medication therapy on the outcome is established after cardiac surgery (10, 11).
The surgical community may be somewhat under-informed (12), although 
previous guidelines on specific drugs have been published (13-15). Therefore 
EACTS Clinical Guideline Committee has found that there is a need to produce an 
updated guideline focusing on the main pharmacological classes involved in the 
perioperative treatment and prevention of adverse events in patients undergoing 
adult cardiac surgery. Excluded are medications used for the treatment of surgery 
complications, such as graft vasospasm after CABG, perioperative ischemia, 
myocardial infarction (MI), low cardiac output syndrome (LCOS), renal failure, 
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arrhythmias except for atrial fibrillation (AF), pneumonia, wound infection, and 
neurological complications. The rationale behind excluding these topics from 
the final document is the fact that is comprehensively covered in other relevant 
clinical guidelines (16-22), or these surgical complications will be enclosed in 
the upcoming expert document. The following central illustration summarises 
what is new and what is essential in these guidelines according to a class of 
recommendation.
Central illustration with the main recommendations.
aAt least 2 days before surgery in patients with normal renal function and 3-4 
days before surgery in dabigatran-treated patients with impaired renal function. 
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; ASA, 
acetylsalicylic acid; BB, beta-blockers; CABG, coronary artery bypass grafting; LDL, low-density 
lipoprotein cholesterol; LVEF, left ventricular ejection fraction: NOAC, non-vitamin K antagonist oral 
anticoagulant; POAF, new onset atrial fibrillation.
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ANTITHROMBOTIC MANAGEMENT
Antithrombotic treatment with anticoagulants and platelet inhibitors reduces the 
risk for thromboembolic complications but may increase the risk of intraoperative 
and postoperative bleeding complications. An individual assessment of the risk 
of thromboembolism and bleeding based on the medication, patient condition 
(elective, urgent or emergent), imaging results and planned surgical intervention 
is recommended within the Heart Team conference. 
Acetylsalicylic acid
Acetylsalicylic acid (ASA) is one of the cornerstones for the treatment of acute and 
chronic cardiovascular disease. Secondary prevention with ASA has been shown 
to reduce mortality, MI and cerebrovascular events in different subsets of patients 
with occlusive cardiovascular disease (23), but increases the risk of bleeding 
complications.
Discontinuation before surgery
A meta-analysis of 13 trials with 2,399 CABG patients comparing preoperative ASA 
administration versus no treatment or treatment with a placebo (24) showed that 
treatment with ASA reduced the risk of perioperative MI (odds ratio (OR) 0.56; 
95% confidence interval (CI) 0.33–0.96) but without mortality reduction (OR 1.16; 
95% CI 0.42–3.22). Postoperative bleeding, red cell transfusions and surgical re-
exploration were increased with ASA. However, the included studies were of low 
methodological quality.  
A recent large randomised controlled trial (RCT) compared the administration of 
ASA (100 mg) on the day of surgery versus the use of a placebo in CABG patients 
(25) and demonstrated no significant effect of ASA-treatment on thrombotic and 
bleeding perioperative events. However, included patients were only eligible if 
not using ASA preoperatively or stopped ASA at least four days before surgery. 
Therefore, a strategy of discontinuation vs. continuation was not evaluated. 
Another RCT on pre-treatment demonstrated that a larger preoperative ASA dose 
(300 mg) was associated with increased postoperative bleeding but a lower rate 
of major cardiovascular events at a 53-month follow-up (26). Similarly, a small 
RCT reported that ASA pre-treated patients (300 mg) had significantly more 
postoperative bleeding (+25%), and this effect was more pronounced (+137%) in 
carriers of the glycoprotein IIIa allele PlA2 (27). Similar results were presented 
in a previous meta-analysis (28), where less bleeding was reported in patients 
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receiving <325 mg ASA daily. Of note, stopping ASA 5 days before surgery and 
replacing it with low molecular weight heparin (LMWH) increases the risk of 
bleeding complication, and therefore, should be abandoned (29).
In summary, the continuation of ASA is associated with more blood loss but less 
ischemic events during and after CABG surgery. Recent data suggest that the 
inhibiting effect of ASA on platelet aggregability is clearly susceptible to platelet 
transfusion (30, 31), which also argues for the continuation of ASA in CABG 
patients undergoing elective or urgent surgery. However, in patients who refuse 
blood transfusions, undergo non-coronary cardiac surgery or those at high risk 
of re-exploration for bleeding—such as complex and redo operations, severe 
renal insufficiency, haematological disease and hereditary platelet function 
deficiencies —ASA should be stopped at least five days before surgery (32). The 
increased risk of bleeding complications if ASA and other antithrombotic drugs 
are not discontinued must be weighed against the potentially increased risk for 
thrombotic complications during the preoperative cessation period.
Restart after surgery
In a large prospective observational trial (33), patients who restarted ASA within 
48 hours of CABG had a mortality rate of 1.3% as compared with a rate of 4.0% 
among those who did not receive ASA during this period (P<0.001). ASA therapy 
was associated with a 48% reduction in the incidence of MI (P<0.001), a 50% 
reduction in the incidence of stroke (P=0.01), a 74% reduction in the incidence of 
renal failure (P<0.001), and a 62% reduction in the incidence of bowel infarction 
(P=0.01). A systematic review of seven studies shows that administration of ASA 
within six hours of CABG surgery is associated with improved graft patency 
without increased incidence of bleeding complications (34). Therefore, ASA 
should be given to all CABG patients as soon as there is no concern over bleeding.
P2Y12 inhibitors
Dual antiplatelet therapy (DAPT) with ASA and P2Y12-receptor inhibitors 
(clopidogrel, ticagrelor, prasugrel) (Table 1) reduces the risk of thrombotic 
complications in patients with acute coronary syndrome (ACS) compared to 
treatment with ASA only (35-37), especially if they undergo percutaneous coronary 
intervention (PCI). The risk of thrombotic complications is further reduced if one 
of the more potent third-generation P2Y12 inhibitors (ticagrelor or prasugrel) is 
used instead of clopidogrel (36, 37), at the expense of increased spontaneous and 
surgical bleeding complications (36, 38).
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Table 1. P2Y12 inhibitors.
Clopidogrel Prasugrel Ticagrelor Cangrelor
Bioavailability 50% 80% 36% 100%
Half life (active metabolite) 1-2 hours 2-15 hours 7-9 hours 3-6 minutes
Binding reversibility Irreversible Irreversible Reversible Reversible
Onset of action 2-6 hours 30 min 30 min 2 min
Frequency of administration Once-daily Once daily twice-daily Intravenous infusion
Duration of effect 3-10 days 7-10 days 3-5 days 1-2 hours
Antidote No No No No
Discontinuation before non-acute surgery At least 5 days At least 7 days At least 3 days 1 hour
Discontinuation before surgery 
Continuing DAPT until surgery increases the risk of bleeding, transfusions and 
re-exploration for bleeding, as shown in RCTs (39, 41), observational studies 
(42, 43) and meta-analyses (44, 45). It is, therefore, recommended that P2Y12-
receptor inhibitors be discontinued before elective surgery whenever possible 
(7, 46). Alternatively, elective operations may be postponed until the DAPT 
treatment period is completed. In urgent cases—most often in patients with ACS—
the risk of thromboembolic episodes (stent thrombosis, MI) while waiting for 
the effect of the P2Y12-receptor inhibitors to cease must be weighed against the 
risk of perioperative bleeding complications. In extreme high-risk patients for 
thrombotic events, e.g. recent stent implantation (47), bridging therapy may be 
considered (7, 46), or surgery may be performed without discontinuation of P2Y12 
inhibitors. If bridging is warranted, GPIIb/IIIa inhibitors may be used. However, 
cangrelor, a new reversible intravenous P2Y12 inhibitor with ultrashort half-
life has demonstrated a high rate of maintenance of platelet inhibition and no 
excessive perioperative bleeding complications (48, 49). However, cangrelor is 
not yet labelled for bridging.
Safe discontinuation intervals differ according to pharmacodynamics and 
pharmacokinetic profile of each P2Y12-receptor inhibitor (46). When P2Y12-
receptor inhibitors are discontinued, ASA therapy should be continued until 
surgery. Discontinuation of clopidogrel five days of more before CABG did not 
increase the risk of bleeding complications (39). A longer time interval (7 days) is 
recommended for prasugrel due to a longer offset of platelet inhibition (50) and 
a higher incidence of CABG-related bleeding complications in comparison with 
clopidogrel (41). In patients treated with ticagrelor, discontinuation three to four 
days, as opposed to five days or more before CABG surgery, is not associated with 
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a higher incidence of bleeding complications (OR 0.93; 95% CI 0.53-1.64, P=0.80) 
(42). This has been confirmed in multiple studies (43, 51). It is unlikely that the 
optimal discontinuation period before surgery of any of the P2Y12 inhibitors will 
ever be tested in an RCT with clinically relevant endpoints.
Platelet function testing
Besides the variances in platelet inhibitory effect between different P2Y12 
inhibitors, there is also a significant individual variation in the magnitude and 
duration of the antiplatelet effect (52-54). Residual platelet reactivity is a marker 
of both ischemic and bleeding events (55), but platelet function testing to adjust 
P2Y12 inhibition does not improve clinical outcome in low and high-risk patients 
(56, 57). Platelet function testing (PFT) may optimise the timing for surgical 
procedures especially in patients in whom the time since discontinuation is 
unclear (e.g. in unconscious or confused patients) or treatment compliance is 
unclear.
Bedside PFT has been suggested as an option to guide interruption of therapy 
rather than an arbitrarily specified period (7, 46). Preoperative ADP-mediated 
platelet aggregation predicts CABG-related bleeding complications in both 
clopidogrel (58, 61) and ticagrelor (54) treated ACS patients. A strategy based 
on preoperative PFT to determine the timing of CABG in clopidogrel-treated 
patients led to 50% shorter waiting time as compared to an arbitrary time-based 
discontinuation strategy (62). PFT in ACS patients eligible for CABG appears as a 
valuable approach to refine the timing of surgery. No RCT or observational study 
has compared perioperative bleeding complications between a fixed versus a PFT-
based time delay from discontinuation to surgery. Furthermore, cut-off levels of 
P2Y12 inhibition to predict perioperative bleedings are not available for all PFT 
devices.
Restart after surgery
Current guidelines recommend DAPT for all ACS patients independently of 
revascularisation treatment (7, 46). This also applies to CABG patients or other 
non-coronary cardiac surgery. Furthermore, DAPT after CABG has been associated 
with reduced all-cause mortality (63, 64) and a better vein graft patency (OR 0.59; 
95% CI 0.43–0.82) (64), although this evidence is conflicting. Potential benefits of 
DAPT after CABG are offset by an increased risk of bleeding complications. 
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The magnitude of benefit appears to be more pronounced in ACS over stable 
angina and with more potent P2Y12 inhibitors versus clopidogrel (63, 65), resulted 
in a reduction of mortality over 50% (40, 41). It is recommended to restart DAPT 
after CABG as soon as considered safe in patients with ACS. There is currently no 
evidence to support starting routine DAPT after CABG in patients not receiving 
DAPT preoperatively, although starting DAPT may be considered in patients with 
a higher ischemic risk due to a coronary endarterectomy or off-pump surgery.
The optimal timing should be as soon as deemed safe. In high ischemic risk 
patients, P2Y12-inhibitors should be restarted within 48 hours after surgery while 
it may be considered safe to postpone after three to four days when ischemic risk 
is low (e.g. stent implantation >1 month ago or ACS without stenting).
Glycoprotein IIb/IIIa inhibitors
GPIIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) are today almost 
exclusively used in conjunction with PCI, but may also be used for bridging high-
risk patients on oral P2Y12 inhibitors to surgery (7, 46, 66). The optimal time 
delay for discontinuation before surgery is mainly based on pharmacokinetic 
assumptions. Platelet function recovery is obtained within 24–48 hours of 
abciximab discontinuation, and up to 4–8 hours after eptifibatide and tirofiban 
discontinuation (67). However, the pooled analysis of patients from the EPILOG 
and EPISTENT trials show no difference between patients treated with abciximab 
and placebo in term of a major blood loss (88% vs. 79%, P=0.27) when the study 
treatment was stopped within 6 hours before surgical incision (68). In addition, 
other clinical studies suggesting that cessation 4h hours before surgery is 
sufficient for all GPIIB/IIIA inhibitors, including abciximab (66, 69). 
PREOPERATIVE ANTICOAGULATION AND BRIDGING
In vitamin K antagonists (VKA)-treated patients (Table 2) (70, 71), VKAs should be 
stopped five days before planned elective surgery to achieve target international 
normalised ratio (INR) below 1.5 on the day of surgery. In non-vitamin K 
antagonist oral anticoagulants (NOACs)-treated patients undergoing elective 
surgery, NOACs should be discontinued before surgery with various time intervals 
according to renal function and type of drugs. In patients on direct factor Xa 
inhibitors (apixaban, edoxaban, rivaroxaban), treatment should be stopped ≥2 
days before surgery (72). In dabigatran-treated patients with creatinine clearance 
<50mL/min/1.73 m2, NOAC should be stopped ≥4 days before surgery.
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Table 2.  Vitamin K antagonists.
Molecule Acenocoumarol Coumadine
(Warfarin) 
Fluindione Phenprocoumone
Half life 10 hours 35–80 hours 30–40 hours 3–4 days
Steady state 2–3 days 3–6 days 3–4 days 6 days
Initial dose 4mg 5mg 20mg 6mg
Duration of effect 2–4 days 4–5 days 2–3 days 4–5 days
The decision to bridge oral anticoagulation with unfractionated heparin (UFH) 
or LMWH depends on the ischaemic risk of underlying diseases. Preoperative 
bridging imposes a risk of perioperative bleeding, and therefore not all patients 
on anticoagulation undergoing cardiac surgery should be bridged (73). Therefore, 
bridging oral anticoagulation is recommended in patients with mechanical 
prosthetic heart valves, valvular AF (moderate-to-severe mitral stenosis), AF 
with a CHA
2
DS
2
-VASc score >4 or with a recent acute thrombotic event within the 
previous four weeks defined as ischemic stroke, ACS or pulmonary embolism 
(PE). Bridging should also be considered in patients with left ventricular apex 
thrombus, antithrombin 3, proteins C and S deficiency.
Bridging should be initiated according to the outline in Figure 1. UFH is the only 
approved bridging method although evidence is not randomised. Studies show 
that patients receiving preoperative UFH versus LMWH had less postoperative 
re-exploration for bleeding after cardiac surgery (74). However, UFH can only be 
administered in a hospital, while LMWH does not require hospital admission and 
continuous IV infusion. Therefore, LMWH is more practical and user-friendly 
and should be considered as an alternative for bridging with dose adjustment 
according to weight and renal function and if possible with monitoring of anti-Xa 
activity with a target of 0.5–1.0 U/mL. The option of bridging with fondaparinux 
is not recommended due to an extended half-life (17-21 hours) and the lack of 
an adequate antidote, although it may have a role in patients with a history of 
heparin-induced thrombocytopenia (75).
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Figure 1. Management of oral anticoagulation in patients with an indication for preoperative 
bridging. INR, international normalised ratio; LMWH, low molecular weight heparin; UFH, 
unfractionated heparin; VKA, vitamin K antagonists; NOAC, non-vitamin K antagonist oral 
anticoagulant.
 aBridging with UFH/LMWH should start when INR values are below specific therapeutic ranges.
bDiscontinuation should be prolonged to >72 hours if creatinine clearance is 50–79 ml/min/1.73 m2, 
or ≥96 hours if creatinine clearance is <50 ml/min/1.73 m2. 
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There is no adequate evidence to support substantiated time intervals for stopping 
preoperative bridging with UFH and LMWH. Based on the pharmacokinetics of 
UFH, it is recommended that administration be discontinued at least 6 hours 
preoperatively. Discontinuation of LMWH should occur >12 hours preoperatively, 
as suggested by studies reporting high plasma concentrations if it is given twice 
daily (76). 
Table 3. Different types of direct oral anticoagulant agents.
Apixaban Dabigatran 
Etexilate
Edoxaban Rivaroxaban
Target Factor Xa Thrombin Factor Xa Factor Xa
Bioavailability 51–85% 6–8% 60% 80%
Tmax  3 hours 2 hours 1–3 hours 2–4 hours
Half-life 9–14 hours 14–17 hours 5–11 hours 9–13 hours
Frequency of administration Twice-daily Once- or twice-daily Once-daily Once- or twice-daily
Renal excretion   25% 80% 36–45% 66% (half inactive)
Antidote Andexanet alfa Idarucizumab Andexanet alfa Andexanet alfa
Discontinuation before non-acute surgery At least 48h At least 48-96 
hoursa
At least 48h At least 48h
aDiscontinuation ≥48 hours if creatinine clearance is >80 ml/min/1.73 m2, discontinuation >72 hours 
if creatinine clearance is 50–79 ml/min/1.73 m2, and discontinuation ≥96 hours if creatinine clearance 
is <50 ml/min/1.73 m2. 
In the case of an urgent procedure, surgery should ideally be delayed. For the 
emergency surgical procedure, the benefit associated with surgery performed 
with a short delay should be balanced with the risk of major haemorrhage. 
When VKAs cannot be stopped for an appropriate time, prothrombin complex 
concentrate (PCC) (25 IU FIX kg) should be given with an additional administration 
of 5  mg of vitamin K1 (intravenous, subcutaneous or oral) (77). In the situation 
of patients taking NOACs (Table 3), it is requested that the timing between the 
last intake and the procedure be checked and the treatment concentration be 
assessed using specific diluted thrombin times (Haemoclot®) for dabigatran 
and anti-factor-Xa assays for the FXa inhibitors. The plasma concentration 
of NOACs should be considered the best way to assess the residual activity of 
the drug and estimate the bleeding risk (78). For dabigatran and rivaroxaban, 
surgery may be safely performed if the plasma concentration is below 30 ng/ml, 
while with higher concentrations surgery should be delayed for 12 hours (if the 
concentration is 30–200 ng/ml) or 24 hours (if the concentration is 200–400 ng/
ml). If plasma concentrations are too high and surgery cannot be postponed, the 
off-label therapeutic use of both non-activated PCC (20–50 U/kg) and activated 
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PCC (FEIBA®, 30 to 50 U/kg) may be considered (79). Although FEIBA® and its high 
potential to overshoot thrombin generation might be more efficient in the case 
of life-threatening bleeding, this benefit should be balanced against an increased 
risk of thrombosis (80). Target concentration ranges from studies on apixaban/
edoxaban are lacking. Idarucizumab has recently been approved for reversing 
the effect of dabigatran based on the Reversal Effects of Idarucizumab on Active 
Dabigatran (REVERSE-AD) trial, which demonstrated complete reversal of the 
anticoagulant effects within minutes (81). No outcome data are available and 
treatment duration, as well as monitoring, is still to be established (81). The effect 
of andexanet alfa in reversing the effect of FXa inhibitors has shown promising 
results, although clinical data are currently unavailable (82, 83).
POSTOPERTIVE ANTITHROMBOTIC AND BRIDGING
Heart valve replacement or repair increases the risk of thromboembolic 
complications, requiring the need for antithrombotic therapy. Scientific evidence 
for the best antithrombotic strategy and duration is scarce (84), resulting in a low 
level of evidence for most recommendations (16).
Mechanical prostheses
Patients undergoing mechanical valve implantations require lifelong treatment 
with VKA guided by INR (Figure 2, Table 2) (85, 86). Anticoagulant treatment with 
UFH and VKA is started on the first postoperative day and is maintained until 
INR is in the therapeutic range. However, special attention of the coagulation 
status and potential bleeding events is required. In the case of bleeding disorders, 
VKAs should be restarted whenever deemed safe and preferably within 48 
hours. Of note, similarly to preoperative bridging, UFH administered by the IV 
route remains the only approved bridging treatment after the implantation of 
mechanical heart valve prostheses (87), although it has never been evaluated 
in a randomised trial. Off-label bridging with subcutaneous LMWH is widely 
implemented in hospital protocols due to its logistic and cost advantages over 
UFH. However, prospective open label non-randomised studies have shown 
subcutaneous enoxaparin to be suitable for a much higher proportion of patients 
within the target anticoagulation range, as compared to UFH, and provide similar 
or better safety. It should, therefore, be considered as an alternative bridging 
strategy to UFH (88, 89). Once the INR is in the adequate target range, bridging 
should be discontinued. 
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The INR target in patients with mechanical prostheses depends on certain patient 
characteristics (e.g. previous thrombosis, AF) and the prosthesis thrombogenicity 
and implantation site (e.g. aortic, mitral or tricuspid) (16). A median target INR 
of 2.5 (range 2.0–3.0) is consistently recommended for aortic prostheses without 
additional risk factors for thromboembolism (16, 90), while higher targets are 
recommended in patients with risk factors (e.g. AF, venous thromboembolism, 
hypercoagulable state, left ventricular ejection fraction (LVEF) <35%) and/or 
mitral and tricuspid prostheses (median target INR >3.0). Of interest in patients 
with mechanical heart valves, the time in the therapeutic range is better 
associated with safety than the target INR range (91), supporting the use of INR 
self-management (92-94). 
The Randomized, phase II study to Evaluate the Safety and pharmacokinetics 
of Oral Dabigatran in patients after heart valve Replacement (RE-ALIGN) trial 
investigated whether dabigatran versus VKAs was safe and effective in patients 
with mechanical heart valves (95). The trial was prematurely stopped because 
of an increased risk of both thromboembolic complications and major bleeding 
with dabigatran. Therefore, NOACs currently have no role in any patient with 
mechanical heart prostheses.
In patients with concomitant atherosclerotic disease, the addition of low-dose 
(75–100 mg) ASA to VKAs may be considered, although the evidence is limited. 
Furthermore, a low dose of ASA may also be added if thromboembolism occurs 
despite an adequate INR. However, combined antithrombotic therapy is 
associated with significant increase in the bleeding risk, which carries an ominous 
prognosis (96). Therefore, it should be reserved for very high thromboembolic 
risk settings like patients with a mechanical valve and an absolute indication for 
DAPT (e.g. recent stent implantation or ACS), a short period (1 month) of triple 
therapy comprising VKA, low-dose ASA and clopidogrel may be considered (16), 
followed by interruption of either ASA or clopidogrel. Ticagrelor and prasugrel 
are not recommended in a triple therapy setting due to the safety hazard (16).
Bioprostheses
The optimal anticoagulation early after implantation of an aortic bioprosthesis 
surgery remains controversial. Either anticoagulation with VKA or single 
antiplatelet therapy (SAPT) with ASA during the first three months should be 
considered. A large study from the US Society of Thoracic Surgeons (STS) Adult 
Cardiac Surgery Database found comparable rates of death, embolic events and 
bleeding in patients treated with ASA alone or VKAs alone for three months after 
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bioprosthetic aortic valve replacement, while combined ASA and VKA therapy 
reduced death and embolic events but significantly increased bleeding (97). A 
Danish registry study showed a higher incidence of thromboembolic events 
and cardiovascular mortality in patients discontinuing warfarin during the first 
six postoperative months (98), although this cannot be directly translated into 
an increased risk if warfarin treatment is not initiated. A recent small RCT of 
370 patients found that three-month warfarin versus ASA therapy significantly 
increased major bleeding while not reducing death or thromboembolic events 
(99). There are no data on continuing lifelong ASA after an initial three months 
of treatment in patients with surgical bioprostheses who do not have any other 
indication for ASA.
Three months of treatment with VKA is recommended in all patients with a 
bioprosthesis implanted in the mitral or tricuspid position.
Valve repair
It is recommended to consider oral anticoagulation with VKA during the first 
three months after valve-sparing aortic root surgery, and after mitral and 
tricuspid repair, although strong evidence is lacking. As for other indications, the 
risk of thromboembolic and bleeding complications must be taken into account 
when the antithrombotic treatment is planned.
Transchateter aortic-valve implantation 
The decision for (dual) antiplatelet therapy or oral anticoagulation after TAVI 
is complicated due to multiple factors associated with i) a prothrombotic 
environment after valve implantation, ii) combined TAVI and stent implantation 
in 30% of patients, and iii) an elderly patient population that frequently bears 
comorbidities and frailty characteristics and should be considered at high risk 
of bleeding. DAPT remains the most widely used antithrombotic strategy after 
TAVI, being used in >60% of patients, while VKAs are used in <20% of patients 
(100). However, subclinical valve thrombosis is another challenging issue as it 
may occur soon after TAVI with antiplatelet treatment and may only be reversed 
after exposure to oral anticoagulant (OAC) therapy (101). Indeed, recent evidence 
demonstrates that VKA alone versus VKA plus ASA produced comparable rates of 
thromboembolic events and mortality while reducing bleeding events (102). Which 
antithrombotic regimen (e.g. antiplatelet, VKA or NOAC) is most appropriate 
after TAVI is currently being tested in several ongoing trials (NCT02247128, 
NCT02556203, NCT02664649). For the moment, there is a consensus that DAPT 
should be used soon after TAVI when there is no indication for OACs.
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Patients who are receiving preoperative anticoagulation
In patients undergoing any cardiac surgery with a preoperative indication for 
OACs other than heart valve replacement or repair, the preoperative regimen of 
VKAs or NOACs should be reinitiated after surgery. Patients with a preoperative 
indication for bridging should also receive postoperative bridging, following 
the same scheme as for mechanical prosthetic heart valves shown in Figure 1. As 
opposed to VKAs, restarting NOACs after surgery should be done more cautiously 
due to the more immediate antithrombotic effects and the increased risk of 
bleeding (95).
ATRIAL FIBRILLATION
Preoperative prophylaxis
The most common arrhythmia in the postoperative period of cardiac surgery 
is AF, and it is associated with longer hospital stay, stroke rate, and mortality 
(103-105). It is also a predictor of AF occurrence years after surgery (105). Since 
the previous comprehensive version of the guidelines on the prevention and 
management of de novo atrial fibrillation after cardiac (106), numerous studies 
have addressed the safety and efficacy of medication to prevent postoperative AF 
(POAF) (17). Treatment with beta-blockers has been shown to reduce POAF (103, 
107). Therefore, patients who are already taking beta-blockers should remain on 
treatment before and after surgery. Patients without beta-blockers may derive 
some benefit with a lower incidence of POAF when starting beta-blockers 2–3 
days before surgery (if tolerated), and carefully up-titrated according to blood 
pressure and heart rate (108). Amiodarone six days preoperatively and six days 
postoperatively has been shown to be more effective than beta-blockers, but it 
is associated with more acute and long-term complications (107, 109). It may be 
considered in patients who are unable to tolerate beta-blockers. Studies suggest 
that both magnesium and fish oil may prevent POAF, but RCTs have shown 
conflicting evidence (110-112). Therefore, a clear recommendation for their use 
cannot be provided at the moment. There is currently no evidence from clinical 
trials to support the use of colchicine, steroids or statins to prevent POAF. 
Management of postoperative atrial fibrillation 
In hemodynamically unstable patients because of POAF, cardioversion and 
antiarrhythmic drugs to restore sinus rhythm are recommended. Amiodarone or 
vernakalant are both effective for restoring sinus rhythm after POAF (113, 114). 
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Historically, in haemodynamically stable patients, rhythm control of POAF 
has been the norm due to the assumption that the restoration/maintenance of 
sinus rhythm would be a superior strategy to rate control. More recent evidence 
has shown that, in asymptomatic or minimally symptomatic patients, there is 
no benefit to adopting a rhythm control strategy, even with amiodarone (115). 
However, 25% of patients in the rate control group crossed over to the rhythm 
control group and vice versa, limiting the ability of the trial to show a significant 
benefit of one strategy over the other. Therefore, in asymptomatic or minimally 
symptomatic patients, a rhythm control strategy should be the preferred strategy, 
while rate control may also be an option. For rate control, beta-blockers or 
diltiazem/verapamil (if beta-blockers are contraindicated) are preferred over 
digoxin (17, 116). The choice of drug depends on patient characteristics, including 
haemodynamics and LVEF. A combination of beta-blockers and digoxin may be 
required.
Prevention of thromboembolism in postoperative atrial fibrillation 
Anticoagulation therapy is necessary for postoperative cardiac surgery 
patients who develop AF to avoid early stroke and mortality (117). OAC reduces 
postoperative mortality in patients discharged with POAF. Nevertheless, there is 
no clear evidence on when to start anticoagulation, and the decision has to be 
made based upon balancing bleeding and thromboembolic risk. Starting early 
with a therapeutic dosage of UFH or LMWH should be considered within 12 to 
48 hours after surgery. OAC should commence 48 hours after and maintained 
for at least four weeks according to the CHA
2
DS
2
-VASc score (17, 118). Most of the 
evidence for anticoagulation of POAF has been obtained with VKAs. For patients 
with mechanical valve prostheses or moderate-to-severe mitral stenosis, VKAs 
are highly recommended (17). There is evidence supporting a greater benefit of 
NOACs over VKA in non-valvular POAF, including a bioprosthetic valve (119, 120).
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS) 
INHIBITORS
There are four classes of drugs that may be used to inhibit the renin-angiotensin 
system (RAAS): 1) angiotensin-converting enzyme inhibitors (ACEIs); 2) 
angiotensin II receptor blockers (ARBs); 3) aldosterone receptor antagonists; 
and 4) direct renin inhibitors (DRI). RAAS-blockers are mainly used to treat 
hypertension and heart failure, but may also protect against the development 
of nephropathy through their inherent properties, which are not only directly 
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related to their effects on lowering blood pressure (121, 122). Nevertheless, the use 
of RAAS blockers in some patients is fraught with controversy (122-125). The role 
of newly developed DRIs in the settings of cardiac surgical patients is uncertain, 
and data are currently lacking.
Preoperative discontinuation 
It has been debated whether ACEIs should be discontinued before CABG (122, 
123,126). The Ischemia Management with Accupril Post Bypass Graft via Inhibition 
of the Converting Enzyme (IMAGINE) study did not show any benefit of quinapril 
administration within seven days of surgery or placebo, with greater morbidity and 
mortality observed at three months in the quinapril group (127). However, the exact 
timing of the discontinuation and re-institution of the drug is poorly defined (124, 
127). RAAS inhibitors, including the ARBs and ACEIs, can also increase the risk of 
perioperative hypotension (128) and vasodilatory shock (129), causing decreased 
systemic vascular resistance (SVR) (124). Therefore, the use of inotropes and 
vasopressors is increased and their time on ventilators and in the intensive care unit 
(ICU) is extended (123, 130). For these reasons, there is a consensus on discontinuing 
RAAS-blockers before cardiac surgery (Table 4) (122, 123, 126). In patients with 
preoperatively uncontrolled hypertension, long-acting ACEIs and ARBs may be 
switched to short-acting ACEIs. Additionally, sacubitril/valsartan-treated patients 
should have the same preoperative assessment like other patients treated with 
the RAAS inhibitors. There are currently no data on whether aldosterone receptor 
antagonists should be stopped or continued until surgery. 
Table 4. Different types of Renin-Angiotensin-Aldosterone System Inhibitors.
  Captopril Enalapril Lisinopril Ramipril Losartan Valsartan
Mechanism of Action ACEI ACEI ACEI ACEI ARB ARB
Half-lifea 2 hours 35-38 hours 12 hours 13-17 hours 6-9 hours 6-9 hours
Frequency of administration Twice- or 
thrice daily
Once- or 
twice-daily
Once daily Once- or 
twice-daily
Once- or 
twice-daily
Once- or 
twice-daily
Maximum dose 450 mg/day 40 mg/day 40 mg/day 20 mg/day 100 mg/day 320 mg/day
Renal excretion   95% 61% 100% 60% 4% 13%
Discontinuation before non-
acute surgery
12 hours 24 hours 24 hours 24 hours 24 hours 24 hours
aincluding half-life of its pharmacologically active metabolite. ACEI, angiotensin-converting enzyme 
inhibitor; ARB, angiotensin II receptor blocker.
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Postoperative use
The ideal blood pressure goal following CABG is not well studied, but a pressure 
of less than 140/90 mmHg has been suggested to be optimal (131, 132). Therapy of 
postoperative hypertension frequently involves beta-blockers, as they also reduce 
the risk of AF/flutter and improve the clinical outcomes of patients with heart 
failure and reduced LVEF (133). ACEIs, however, should also be considered, often 
in addition to beta-blockers in patients with postoperative hypertension and/or 
a reduced LVEF (124, 131, 132). Furthermore, treatment with sacubitril/valsartan 
is recommended in patients who remain symptomatic with chronic heart failure 
(NYHA > II) and who have a reduced LVEF (< 40%) as a replacement for an ACEI 
to further reduce the risk of mortality and readmission (19). ARB can be used 
as an alternative blood pressure therapy in patients with reduced LVEF that 
are intolerant to ACEIs (134,135), but should rather not be used concomitantly 
to ACEIs due to increased rates of hypotension, hyperkalaemia and impaired 
kidney function, especially if aldosterone antagonists are also used (136). For 
other patients without hypertension or a reduced LVEF, the routine use of ACEIs 
is not indicated, as it may potentially lead to more adverse events (127, 137). The 
occurrence of LCOS in the early postoperative phase may result in a prolonged 
ICU stay, and a need for inotropes or vasopressors support, which is associated 
with ischaemia and renal complications (138).
After the early postoperative phase, RAAS-blockers have protective effects in 
CABG-patients with reduced LVEF and impaired kidney function (124), mainly 
for long-term prevention of adverse events (139). In addition to ACEIs and ARBs, 
aldosterone receptor antagonists may also benefit patients with chronic heart 
failure or a reduced LVEF. This benefit was shown in the Randomised Aldactone 
Evaluation Study (RALES) trial, where aldactone reduced overall mortality, 
heart failure symptoms and readmission due to heart failure (140). Eplerenone, 
another aldosterone antagonist, was subsequently shown, in the Eplerenone in 
Mild Patients Hospitalisation and Survival Study in Heart Failure (EMPHASIS-HF), 
to reduce the risk of death and heart failure rehospitalisation in patients with an 
LVEF <35% and NYHA-class II (141). Aldosterone antagonists can be used together 
with beta-blockers and ACEIs in patients following CABG but should be limited 
to patients with reduced LVEF and NYHA-class II–IV heart failure symptoms (141-
143). They should, however, be avoided in patients with kidney failure (eGFR <30 
ml/min/1.73 m2) or hyperkalaemia (>5.0 mEG/L) (143).
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BETA-BLOCKERS
Preoperative beta-blockers 
Current evidence recommends that patients should continue beta-blockers 
before elective and non-elective cardiac surgery (144-146), as doing so results in 
a consistent survival benefit plus a reduction in arrhythmic events in the early 
postoperative period (147). However, the effectiveness of catecholamine in the 
early postoperative period may be limited by concurrent treatment with beta-
blockers until day of surgery (148). Therefore, it may be cumbersome to control 
patients with preoperative long-acting agents, and it should, therefore, be 
considered to switch to short-acting agents to limit adverse events. 
The question of whether to initiate a beta-blocker in the preoperative 
or postoperative period is less clear (149), and such a decision should be 
individualised, involving weighing of the risks and benefits. As discussed in the 
chapter on AF, initiating beta-blockers preoperatively may be considered for 
the prevention of POAF. Whether beta-blockers prevent perioperative MI and 
mortality is a controversial topic. Studies have shown that beta-blockers are 
particularly beneficial in patients with a recent MI (150). Indeed, it is suggested 
that the benefit of beta-blockers before CABG to prevent MI and death is limited 
to patients with recent MI only (151). There is conflicting evidence on whether 
preoperative beta-blockers are beneficial in patients with reduced LVEF but 
without a recent MI (152). However, if beta-blockers are initiated preoperatively, 
careful up-titration of short-acting agents, according to blood pressure and heart 
rate, starting several days before surgery is recommended.
Postoperative beta-blockers
In addition to a preoperative beta-blockade in patients with reduced LVEF, 
continuing beta-blockers during the early postoperative phase has also been 
shown to significantly reduce 30-day mortality following CABG (153). Strong 
evidence suggests that beta-blockers reduce mortality in patients with recent MI 
or reduced LVEF (<35%) (154, 155). Therefore, it is crucial that beta-blockers are 
continued upon discharge for long-term secondary prevention in patients with 
a recent MI or reduced LVEF (156-158). Approved beta-blockers are metoprolol 
succinate, bisoprolol, nebivolol and carvedilol (19).
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DYSLIPIDAEMIA
Statins
Preoperative statin therapy
Observational studies and small RCTs have suggested that initiation of preoperative 
statin therapy before cardiac surgery reduced mortality, POAF and acute kidney 
injury (AKI) (159,160). However, in the Statin Therapy in Cardiac Surgery (STICS) 
trial that randomised 1,922 patients undergoing elective cardiac surgery, the 
initiation of rosuvastatin therapy (20 mg/day) before cardiac surgery did not 
prevent perioperative myocardial damage or reduce the risk of POAF (161). AKI 
was significantly more common among patients who received rosuvastatin than 
among those who received a placebo (161). In another trial of patients undergoing 
cardiac surgery, high-dose initiation of atorvastatin on the day before surgery 
and continuing perioperatively compared with placebo did show a significantly 
higher rate of AKI in patients with chronic kidney disease (162). The trial was later 
prematurely terminated on the grounds of futility (163). In summary, these recent 
data do not support the preoperative initiation of statin therapy in statin-naïve 
patients undergoing cardiac surgery. No data are available on whether patients 
already taking statins should continue or discontinue therapy preoperatively, 
although in common practice statins are continued perioperatively.
Postoperative use
Intense or maximally tolerated statin therapy is recommended with a low-density 
lipoprotein cholesterol (LDL-C) target of <70 m/dl (1.8 mmol/L) or >50% LDL-C 
reduction in patients with CAD. In the Treating to New Targets (TNT) trial, which 
included >4,000 randomised patients, intense LDL-C lowering (to a mean of 79 
mg/dl (2.05 mmol/L)), with atorvastatin 80 mg/day in patients with previous 
CABG, reduced major cardiovascular events by 27% and the need for repeat 
revascularisation by 30%, as compared with less intensive cholesterol lowering to 
a mean of 101 mg/dl (2.61 mmol/L) with atorvastatin 10 mg/day (164). In patients 
with statin intolerance during follow-up, the European Atherosclerosis Society 
has recently developed a scheme for statin re-exposure (165). 
Non-statin lipid lowering agents  
In patients after CABG surgery in whom the LDL-C target <70 mg/dl (1.8 mmol/L) 
is not reached despite an intense or maximally tolerated statin dose, the addition 
of a cholesterol absorption inhibitor, ezetimibe, should be considered. In a recent 
analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International 
Trial (IMPROVE-IT) study, it was observed that patients with a prior experience 
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of CABG surgery who received ezetimibe plus a statin versus a statin alone had a 
substantial reduction in cardiovascular events during a six-year median follow-
up (6).
Although no direct evidence of proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitor use after cardiac surgery exists, the circumstantial evidence 
provides enough facts for its beneficial effects as well after CABG surgery (166). 
Patients in whom the LDL-C target <70 mg/dl (1.8 mmol/L) is not reached despite 
an intense or maximally tolerated statin and ezetimibe dose, the recently 
developed PCSK9 inhibitors have been shown to reduce cardiovascular events 
during follow-up in patients at high cardiovascular risk (167, 168). Therefore, the 
addition of PCSK9 inhibitors should be considered in selected patients.
A meta-analysis of 18 RCTs and 45.058 patients showed that fibrates, agonists 
of peroxisome proliferator-activated receptor-alfa, could reduce major 
cardiovascular events predominantly by prevention of coronary events, but with 
no impact on mortality (169). However, in recent studies, no additional benefit 
of fibrate treatment on top of statin therapy has been demonstrated (170). Bile 
acid sequestrants (cholestyramine, colestipol, colesevelam) reduce LDL-C by 18-
25% and may be used in combination with statins (20). However, gastrointestinal 
adverse events and drug interactions limit their use.
ULCER PREVENTION AND STEROIDS
Ulcer prevention
Based on older studies, the incidence of upper gastrointestinal ulceration and 
bleeding is around 1% after cardiac surgery and is associated with significant 
morbidity and mortality (30–40%) (171). However, patients undergoing 
contemporary cardiac surgery are aggressively treated with antithrombotic 
medication, and the incidence may, therefore, be underestimated. The impact of 
gastrointestinal ulcers and bleeding may be larger due to higher comorbidities 
and more potent antithrombotic medication.
Studies have shown that patients continue to have gastrointestinal complications 
despite intraoperative H2 antagonist therapy and that more robust prophylaxis 
is required (172). A summary of the available evidence concluded that a proton-
pump inhibitor (PPI), but not H2 (histamine) antagonist, reduced gastrointestinal 
complications (173). Indeed, the largest randomised trial of 210 patients 
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undergoing cardiac surgery randomly assigned patients to Teprenone, Ranitidine 
or Rabeprazole, and found that patients treated with a PPI (Rabeprazole) had a 
significantly lower rate of active ulcers of 4.3% compared to 21.4% and 28.6% in the 
patients treated with the H2 antagonist (Ranitidine) and the mucosal protector 
(Teprenone) respectively (174). Therefore, prophylaxis with a PPI should be 
considered, even though there is a concern that routine prophylaxis may increase 
the incidence of postoperative pneumonia (175). However, there is conflicting 
evidence to support this statement (176).
Steroids
The use of cardiopulmonary bypass (CPB) initiates a systemic inflammatory 
response, which is associated with adverse clinical outcomes such as respiratory 
failure, bleeding, adverse neurological function and multiple organ failure (177). 
Steroids attenuate this systemic inflammatory response, and thus theoretically 
there is a potential benefit of steroids for patients undergoing cardiac surgery 
with CPB, although steroids may also increase the risk of infective complications 
and MI.
A meta-analysis of 44 RCTs (n=3205) looking at the use of steroids in patients 
undergoing on-pump CABG showed that steroids reduced POAF, postoperative 
bleeding, and the duration of ICU stay but failed to show a reduction in mortality 
(178). Steroids did not increase the rate of MI or infective complications. On the 
basis of this analysis, the Steroids in Cardiac Surgery (SIRS) trial was conducted 
(179). In the trial, 7,507 patients with a EuroSCORE >5 who underwent cardiac 
surgery with CPB were randomised between methylprednisolone or placebo, 
showing no difference in the risk of 30-day mortality (4% vs. 5%, respectively) or 
the risk of mortality and major morbidity (24% vs. 24%, respectively). Although 
there was no difference in the rate of infections or delirium, there was a safety 
concern due to significantly higher rates of myocardial injury. The Dexamethasone 
for Cardiac Surgery (DECS) trial randomised nearly 4,500 patients undergoing 
cardiac surgery with CPB and confirmed that no benefit was found with steroids 
over placebo in the composite of mortality, MI, stroke, renal failure or respiratory 
failure (180).
In summary, the routine use of prophylactic steroids is not indicated for patients 
undergoing cardiac surgery. However, a subgroup analysis of the DECS trial 
demonstrated an interaction according to age, suggesting that patients younger 
than 65 years may have a benefit of the preoperative use of steroids (181). Indeed, 
younger patients generally have a more pronounced inflammatory response than 
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elderly patients, and therefore suppression of this effect with steroids could have 
a potential benefit. Patients on chronic steroid therapy should receive their usual 
preoperative dose of steroids on the day of surgery. Additional perioperative 
stress-dose steroids for these patients is reasonable, but not evidence-based 
medicine (182).
ANTIBIOTIC PROPHYLAXIS
Perioperative infections following cardiac surgery, including surgical site 
infections (SSIs), bloodstream infections, pneumonia and C. difficile colitis, 
dramatically affect survival, are the cause of prolonged hospitalisation or 
readmission, and significantly increase costs (183). Moreover, these major 
infections are of particular importance since they have a relatively high prevalence 
of nearly 5% in total cardio-surgical population (184).
Surgical antibiotic prophylaxis (SAP) before cardiac surgery is recommended 
to decrease the incidence of major infections. In addition to intravenous SAP 
administration, the gentamicin-collagen sponge has been developed to keep a 
high concentration of the agents in the local tissues surrounding postoperative 
wounds. The results from a recent meta-analysis showed significant risk 
reduction of sternal wound infection after implantation of gentamicin-collagen 
sponges (185). However, the heterogeneity among studies was large and powerful 
studies to confirm the benefit of additional local intervention in certain patient 
populations are warranted.
Dosing of surgical antibiotic prophylaxis
Rates of infection after cardiac surgery are lower in patients with higher (versus 
lower) antibiotic serum concentrations at the time of starting CPB, as well as 
at the end of surgery (186, 187). To date, because of its safety, effectiveness, and 
user-friendliness, SAP in cardiac surgery is routinely based on standardised 
doses rather than weight-based doses, which avoid the need for individual 
patient calculations and therefore clearly reduce the risk of dosing errors (Table 
5). Nevertheless, based on limited evidence that exists for optimal dosing in 
obese patients (188, 189), the dose of cephalosporin should not routinely exceed 
the usual adult dose. For patients with renal failure, dosing should be adjusted 
according to the creatinine clearance. 
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Duration of surgical antibiotic prophylaxis
Repeat intraoperative dosing is recommended to ensure adequate serum and 
tissue concentrations if the duration of the procedure exceeds two half-lives of 
the antibiotic agent or when there is excessive intraoperative blood loss. Indeed, 
a randomised trial of 838 patients comparing a single-dose versus a 24-hour 
multiple-dose cefazolin regimen in patients undergoing cardiac surgery reported 
higher SSI rates with the single-dose regimen (190). A recent meta-analysis of 
12 RCTs with 7,893 patients showed that SAP administered ≥24 versus <24 hours 
significantly reduced the risk of SSI by 38% (95% CI 13–69%, P=0.002) and the risk 
of deep sternal wound infections by 68% (95% CI 12–153%, P=0.01) (191). Other 
studies have failed to show the benefit of prolonging SAP to >48 hours (192, 193), 
while this does increase the risk of acquired antibiotic resistance compared 
with shorter prophylaxis (194-196). Therefore, based on current evidence, the 
optimal length of SAP in adult cardiac surgery is 24 hours and should not exceed 
48 hours. Whether intermittent or continuous antibiotic administration should 
be preferred remains unclear, although some evidence suggests that continuous 
infusion may reduce postoperative infectious complications (197). For a strategy 
of intermittent administration, the exact timing of redosing depends on the half-
life time of the antibiotic agent that is used. It should, furthermore, be adjusted 
for a prolonged antibiotic half-life time in patients with renal failure (198-201). 
Moreover, repeating SAP shortly after initiation of CPB has recently been shown 
to ensure adequate drug levels (201).
Choice of surgical antibiotic prophylaxis
The majority of pathogenic organisms isolated from patients with SSIs after 
cardiac surgery are gram-positive bacteria, which are followed by gram-negative 
bacteria. Only a minority of other bacteria, anaerobes, fungi and parasites have 
been identified (202, 203). 
Particularly due to rising numbers of methicillin-resistant Staphylococcus aureus 
(MRSA) infections among patients undergoing cardiac surgery, the importance 
of eradicating intranasal Staphylococcus aureus colonisation is stressed. There 
is clear evidence from large RCT that intranasal mupirocin twice daily for four 
days prior to cardiac surgery significantly reduces SSIs in patients known to be 
colonised with Staphylococcus aureus (204, 205). However, for patients in whom 
the status of colonisation is unknown, testing for colonisation well in advance 
of cardiac surgery should be considered to allow the appropriate preoperative 
duration of mupirocin eradication treatment in colonised patients. Although this 
introduces logistical difficulties and has cost implications, such a strategy should 
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be preferred over routine mupirocin treatment in patients with an unknown 
colonisation status.
Table 5. Half-life time of the most used antibiotics for SAPa.
Antibiotic Agent Half-life time
Ampicilline 60 minutes
Ampicilline/Sulbactam 60 minutes
Amoxicilline 60 minutes
Amoxicilline/Clavulanate 60 minutes
Cefazolin 94 minutes
Cefotaxime 60 minutes
Cefotiam 45 minutes
Ceftriaxone 7–8 hours
Cefuroxime 70 minutes
Ciprofloxacin 3-5 hours
Clindamycin 2.5 hours
Gentamicin 1.5–2 hours
Imipenem 60 minutes
Levofloxacin 7–8 hours
Meropenem 60 minutes
Metronidazole 7 hours
Piperacillin 60 minutes
Piperacillin/Tazobactam 45 minutes
Tobramycin 1.5–2 hours
Vancomycin 6 hours
aRepeat intraoperative dosing if the duration of the procedure exceeds two half-lives of the 
antibiotic agent or when there is excessive intraoperative blood loss or hemodilution. SAP, surgical 
antibiotic prophylaxis.  
For systemic antibiotic prophylaxis, numerous studies have clearly shown that 
antibiotic prophylaxis with first- and second-generation cephalosporins can 
effectively reduce the incidence of SSI and postoperative infectious complications 
in patients undergoing cardiac surgery (Table 6) (206-208), even though a meta-
analysis showed that second-generation cephalosporins might be superior in 
reducing SSIs (209). In patients with a ß-lactam-allergy who cannot tolerate 
cephalosporins, Clindamycin or Vancomycin is sufficient for gram-positive 
coverage (210-213). However, up to 15% of hospitalised patients reported allergy to 
penicillin, but after a formal allergy evaluation, between 90-99% of these patients 
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are found to be able to safely underwent penicillin treatments (214). Importantly 
these patients are more likely to be treated with vancomycin, clindamycin and 
quinolones with the increased risk of developed drug-resistant infections such 
as vancomycin-resistant Enterococcus and Clostridium difficile (215), leading 
to increased mortality, morbidity and prolonged hospital stays. Therefore, 
implementation of hospital protocols, including preoperative skin testing may be 
effective therapeutic tools to reduce the rates of intra-hospital infections, lower 
costs of antibiotics and improve the patient’s outcome (214, 216).
In patients colonised with MRSA in whom cephalosporins are insufficient, the 
administration of Vancomycin is recommended (217-219). 
Table 6. Recommendations for the choice of SAP.
Type of procedure Recommended 
agents
Alternative agents in patients 
with ß-lactam allergy
Strength of evidence
CABG Cefazolin, cefuroxime Clindamycin, Vancomycin A
Cardiac device implantation 
(e.g. pacemaker)
Cefazolin, cefuroxime Clindamycin, Vancomycin A
Ventricular assist devices Cefazolin, cefuroxime Clindamycin, Vancomycin C
Heart, lung, heart-lung transplantation Cefazolin Clindamycin, Vancomycin A
CABG, coronary artery bypass grafting; SAP, surgical antibiotic prophylaxis.  
Anaesthesia and postoperative analgesia
Anaesthetic agents and techniques might impact clinically relevant postoperative 
outcomes through pharmacological organ protective mechanisms (220, 221) 
and by blunting the stress response (222). Halogenated anaesthetics (Isoflurane, 
Desflurane and Sevoflurane) are commonly used anaesthetic drugs with 
hypnotic, analgesic and muscle-relaxant properties. On top of this, halogenated 
anaesthetics versus total intravenous anaesthetics result in additional organ 
protection and improvements in clinically relevant endpoints after CABG, 
including reduction of mortality and perioperative MI (220, 221, 223-228).
Postoperative pain following cardiac surgery still occurs frequently, both in the 
ICU and in the general ward (229). It is often underdiagnosed and undertreated, 
especially in patients who are unable to self-report pain, and an overall more 
than half of the operated patients report pain as the most traumatic experience of 
their postoperative stay (230, 231). General recommendations for pain assessment 
developed for general surgery and the ICU are also indicated in cardiac surgery 
patients. Adequate pain relief is associated with improved outcomes through a 
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better respiratory function (e.g. an effective cough), early mobilisation, delirium, 
and a reduction of cardiovascular complications, which lead to a reduced ICU 
stay and lower associated costs. Poorly treated pain can have long-term sequelae, 
which negatively impacts the quality of life and increases healthcare-related costs 
(232, 233).
Regional anaesthesia for perioperative pain control 
Locoregional techniques (epidural, intrathecal analgesics, paravertebral block, 
intercostal nerve block, wound infiltration) provide excellent postoperative 
pain control with different documented impacts on clinically relevant outcomes 
(234-238). 
Epidural analgesia started before surgery, and following published guidelines 
for epidural catheter positioning and removal (233), is also associated with a 
possible mortality reduction (222) and a low risk of epidural hematoma (239). 
Intrathecal (‘Spinal’) administration of morphine has been demonstrated to 
reduce postoperative opioid consumption and may be an alternative to epidural 
analgesia, as it is associated with reduced risk of epidural hematoma (234, 240). 
Administration of intrathecal clonidine, in addition to morphine, may provide 
additional benefits in terms of pain control and mechanical ventilation (MV) 
duration, but it may also increase the risk of hypotension (235, 236, 241).
The paravertebral block is another alternative to neuraxial techniques. Compared 
with epidural analgesia, the paravertebral block showed a similar analgesic 
efficacy and a lower incidence of minor complications in patients undergoing 
thoracotomy (242). However, evidence in cardiac surgery patients is very limited. 
In patients undergoing median sternotomy, the bilateral paravertebral block 
should be performed. Although this approach appears safe and is probably 
associated with fewer complications compared to epidural analgesia, it requires 
further investigation (243).
Infiltration of local anaesthetics along the sternal wound may also be effective in 
reducing postoperative opioid consumption (244). However, continuous infusion 
through a parasternal catheter has been associated with increased risk of sternal 
wound infection (245). A single injection may be effective but requires further 
investigation (246).
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Postoperative pain assessment 
Routine assessment of pain and its severity improves pain management, both 
in the ICU and on the ward, and allows the verification of the effectiveness of 
analgesic medications. It permits the monitoring of the response to therapy and 
detection of complications and side effects. Multimodal analgesia (e.g. analgesia 
through different techniques or drugs acting on different pathways) is more 
effective than analgesia, relying on a single technique in the overall surgical 
population, and there is no reason to doubt that this also applies to the cardiac 
surgical setting (233).
Several analgesic techniques and drug classes are currently available. Intravenous 
opioids are currently considered ‘standard of care’ in the management of 
significant postoperative pain in the ICU after cardiac surgery. In cooperative 
patients, patient-controlled analgesia (PCA) is superior to nurse-controlled 
analgesia regarding pain control (247). Several opioids are available, with no clear 
evidence of the superiority of one over the others. A possible exception might be 
remifentanil, which has shown cardioprotective effects (248) and superiority in 
pain control (249, 250). Use of paracetamol (acetaminophen) is safe and reduces 
opioid consumption (251-254), making it the best agent to manage postoperative 
pain after an opioid-based cardiac anaesthesia and in combination with 
postoperative opioids. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are still used in cardiac surgery 
(255) in spite of worsening of renal function in some patients. The concomitant 
administration of other NSAIDs can theoretically diminish the antiplatelet effects 
of low-dose aspirin, increasing the risk of thromboembolic effects (heart attacks 
and strokes) (256-261). Nevertheless, RCTs and meta-analyses have shown that 
the use of low-dose NSAIDs in selected patients at low risk of adverse events is 
effective in reducing pain and opioid consumption and may shorten mechanical 
ventilation time and ICU stay (262-266). A single propensity-matched study 
suggested a possible reduction in mortality associated with ketorolac use (267). 
Therefore, their use as a second-line agent in patients without contraindications 
may be considered. On the contrary, RCTs showed that selective cyclooxygenase-2 
(COX-2) inhibitors are associated with an increase in adverse cardiovascular 
events and should, therefore, not be routinely administered (268, 269). Analgesic 
adjuvants can reduce postoperative pain if given preoperatively (gabapentine or 
pregabalin) or postoperatively (ketamine) (235, 270-272).
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Blood glucose management
Hyperglycaemia affects over 40% of patients after cardiac surgery, due to stress 
and the use of inotropes (184). Controlled studies show that patients with diabetes 
mellitus (DM) have increased morbidity and mortality after cardiac surgery (273). 
Perioperative hyperglycaemia, per se, even in non-DM patients, is associated with 
negative outcomes after cardiac surgery. Moreover, roughly 20–30% of cardiac 
surgery patients have pre-existing DM (274). DM is associated with endothelial 
and platelet dysfunction, leading to prothrombotic states, adverse vascular 
events and increased infection risk. The prevalence of unrecognised DM and 
pre-DM in patients undergoing cardiac surgery contributes heavily to high blood 
glucose concentrations (BGC) in the perioperative period (274). Small increases in 
perioperative BGC are associated with significant increases in hospital mortality 
and morbidity (274, 275). Therefore, preoperative documentation of the diagnosis 
of diabetes and its type should be a universal practice. Patients undergoing adult 
cardiac surgery should have a fast glucose measurement at hospital admission 
and if >120 mg/dl (6.6 mmol/L) be determined to have haemoglobin A1c (HbA1c). 
Preoperative and post-ICU glucose management have no solid scientific evidence 
and are based on expert opinion. ICU data are controversial and should be 
interpreted cautiously. However, there is randomised evidence that perioperative 
BGC control reduces the risk of mortality and adverse events in cardiac surgery 
(276-278). There is also evidence that blood glucose control should be started 
before the operation and not deferred until after surgery. The overall adequacy 
of BGC monitoring in the weeks before surgery, as reflected by preoperative 
HbA1c, is associated with a several perioperative complications including 
mortality, stroke, renal failure, sternal wound infections, prolonged ICU stays 
and readmission (279).
Perioperative hyperglycaemia is probably a marker of illness severity rather 
than a cause of poor outcomes (280). Indeed, the degree of hyperglycaemia is 
related to the level of activation of the stress response. While mild to moderate 
stress hyperglycaemia is protective, it is likely that severe stress hyperglycaemia 
may be deleterious. However, the blood glucose threshold above which stress 
hyperglycaemia becomes harmful is still unknown. Many observational studies 
have been carried out to find the most reliable approach to blood glucose levels, 
and a U-shaped association between mean blood glucose levels and mortality was 
found, with the lowest mortality observed for the 125–160 mg/dl range (281).
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Importantly, evidence points towards an increased risk of hypoglycaemic events 
with aggressive glycaemic control and suggests that moderate control can achieve 
clinically relevant improvements (282-285). The GLUCO-CABG Trial showed that 
intensive insulin therapy to target glucose of 100 and 140 mg/dL in the ICU did 
not significantly reduce perioperative complications compared with the target 
glucose of 141 and 180 mg/dL after CABG (286). Moreover, the Normoglycemia 
in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation 
(NICE-SUGAR) trial showed that blood glucose control below 108 mg/dL was 
associated with a significant increase in all-cause mortality in ICU patients, 
including both surgical and non-surgical patients (287). Observational studies 
suggest that, particularly in patients with insulin-treated DM, glucose levels 
below the recommended threshold of 180 mg/dl are associated with increased 
complications. In patients without DM and non-insulin dependent DM, higher 
blood glucose levels were associated with more complications than lower blood 
glucose levels (288, 289). Whether or not differential glucose thresholds should be 
stratified according to previous diabetic status requires further large prospective 
randomised studies. 
There is high variability in methods of and indications for insulin therapy, 
management of non-insulin agents and blood glucose monitoring among 
glucose management guidelines issued by several professional organisations 
due to controversial findings and the lack of high-quality studies (290). A 
multidisciplinary ‘diabetes team’ should be in charge of continuous IV insulin 
infusion protocols, treatment algorithms for the transition to subcutaneous 
insulin after discharge from the ICU, nutritional requirements and the 
reintroduction of oral anti-diabetics, using hospitalisation as a ‘window of 
opportunity’ for patient education, treatment selection and dose adjustment 
(Figure 3). 
Before hospital discharge, the patients with a diagnosis of DM or pre-DM should 
have an endocrinology consultation and dietary counselling. Post discharge, 
plasma glucose and HbA1c levels should be followed up regularly, with appropriate 
adjustments made in insulin and oral hypoglycaemic therapies with the aim of 
keeping HbA1c <7%.
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Figure 3. A recommended bottom-to-top stepwise strategy to implement perioperative blood 
glucose control (modified from Preiser et al. (282)).
428
Chapter 16
REFERENCES
1. Sousa-Uva M, Head SJ, Thielmann M, Cardillo G, Benedetto U, Czerny M, et al. Methodology 
manual for European Association for Cardio-Thoracic Surgery (EACTS) clinical guidelines. Eur J 
Cardiothorac Surg. 2015;48(6):809-16.
2. Kulik A, Desai NR, Shrank WH, Antman EM, Glynn RJ, Levin R, et al. Full prescription coverage 
versus usual prescription coverage after coronary artery bypass graft surgery: analysis from the 
post-myocardial infarction free Rx event and economic evaluation (FREEE) randomized trial. 
Circulation. 2013;128(11 Suppl 1):S219-25.
3. Zhang H, Yuan X, Zhang H, Chen S, Zhao Y, Hua K, et al. Efficacy of Chronic ş-Blocker Therapy 
for Secondary Prevention on Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery. 
Circulation. 2015;131:2194-2201.
4. Milojevic M, Head SJ, Parasca CA, Serruys PW, Mohr FW, Morice MC, et al. Causes of Death Following 
PCI Versus CABG in Complex CAD: 5-Year Follow-Up of SYNTAX. J Am Coll Cardiol. 2016;67(1):42-
55.
5. Hlatky MA, Solomon MD, Shilane D, Leong TK, Brindis R, Go AS. Use of medications for secondary 
prevention after coronary bypass surgery compared with percutaneous coronary intervention. J 
Am Coll Cardiol. 2013;61(3):295-301.
6. Eisen A, Cannon CP, Blazing MA, Bohula EA, Park JG, Murphy SA, et al. The benefit of adding 
ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute 
coronary syndrome in the IMPROVE-IT trial. Eur Heart J. 2016;37(48):3576-84.
7. Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on 
myocardial revascularization: The Task Force on Myocardial Revascularization of the European 
Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery 
(EACTS). Developed with the special contribution of the European Association of Percutaneous 
Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517-92.
8. Niebauer J. Is There a Role for Cardiac Rehabilitation After Coronary Artery Bypass Grafting? 
Treatment After Coronary Artery Bypass Surgery Remains Incomplete Without Rehabilitation. 
Circulation. 2016;133(24):2529-37.
9. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Coronary artery bypass 
graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and 
left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 
2013;381(9867):629-38.
10. Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, et al. Trial of everolimus-eluting stents or bypass 
surgery for coronary disease. N Engl J Med. 2015;372(13):1204-12.
11. Iqbal J, Zhang YJ, Holmes DR, Morice MC, Mack MJ, Kappetein AP, et al. Optimal medical therapy 
improves clinical outcomes in patients undergoing revascularization with percutaneous coronary 
intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous 
Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up. 
Circulation. 2015;131(14):1269-77.
12. Milojevic M, Head SJ, Mack MJ, Mohr FW, Morice MC, Dawkins KD, et al. Influence of practice 
patterns on outcome among countries enrolled in the SYNTAX trial: 5-year results between 
percutaneous coronary intervention and coronary artery bypass grafting. Eur J Cardiothorac Surg. 
2017:52(3):445-453.
13. Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, et al. Guideline on antiplatelet 
and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008;34(1):73-92.
14. Lazar HL, McDonnell M, Chipkin SR, Furnary AP, Engelman RM, Sadhu AR, et al. The Society of 
Thoracic Surgeons practice guideline series: Blood glucose management during adult cardiac 
surgery. Ann Thorac Surg. 2009;87(2):663-9.
429
Clinical guidelines on perioperative medication in adult cardiac surgery 
16
15. Kulik A, Ruel M, Jneid H, Ferguson TB, Hiratzka LF, Ikonomidis JS, et al. Secondary prevention after 
coronary artery bypass graft surgery: a scientific statement from the American Heart Association. 
Circulation. 2015;131(10):927-64.
16. Falk V, Baumgartner H, Bax JJ, De Bonis M, Hamm C, Holm PJ et al. ESC/EACTS. Guidelines for the 
management of valvular heart disease. Eur J Cardiothorac Surg. 2017:52(4):616-664
17. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the 
management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 
2016;50(5):e1-e88.
18. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC 
Guidelines for the management of patients with ventricular arrhythmias and the prevention of 
sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias 
and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). 
Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 
2015;36(41):2793-867.
19. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for 
the diagnosis and treatment of acute and chronic heart failureThe Task Force for the diagnosis and 
treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed 
with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart 
Journal. 2016;37(27):2129-200.
20. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS 
Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37(39):2999-3058.
21. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the 
management of acute coronary syndromes in patients presenting without persistent ST-segment 
elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting 
without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart 
J. 2016;37(3):267-315.
22. Pagano D, Milojevic M, Meesters MI, Benedetto U, Bolliger D, von Heymann C, Jeppsson A, Koster A, 
Osnabrugge RL, Ranucci M, Ravn HB, Vonk ABA, Wahba A, Boer C. 2017 EACTS/EACTA Guidelines 
on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg. 2018;53:79-111.
23. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet 
therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj. 
2002;324(7329):71-86.
24. Hastings S, Myles P, McIlroy D. Aspirin and coronary artery surgery: a systematic review and meta-
analysis. Br J Anaesth. 2015;115(3):376-85.
25. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al. Stopping vs. Continuing Aspirin 
before Coronary Artery Surgery. N Engl J Med. 2016;374(8):728-37.
26. Deja MA, Kargul T, Domaradzki W, Stacel T, Mazur W, Wojakowski W, et al. Effects of preoperative 
aspirin in coronary artery bypass grafting: a double-blind, placebo-controlled, randomized trial. J 
Thorac Cardiovasc Surg. 2012;144(1):204-9.
27. Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W, Dropinski J, et al. Prediction of the 
excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of 
aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg. 2005;130(3):791-6.
28. Sun JC, Whitlock R, Cheng J, Eikelboom JW, Thabane L, Crowther MA, et al. The effect of pre-
operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary 
artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J. 
2008;29(8):1057-71.
29. Nenna A, Spadaccio C, Prestipino F, Lusini M, Sutherland FW, Beattie GW, et al. Effect of Preoperative 
Aspirin Replacement with Enoxaparin in Patients Undergoing Primary Isolated On-Pump Coronary 
Artery Bypass Grafting. Am J Cardiol. 2016;117(4):563-70.
430
Chapter 16
30. Hansson EC, Shams Hakimi C, Astrom-Olsson K, Hesse C, Wallen H, Dellborg M, et al. Effects of ex 
vivo platelet supplementation on platelet aggregability in blood samples from patients treated with 
acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth. 2014;112(3):570-5.
31. Martin AC, Berndt C, Calmette L, Philip I, Decouture B, Gaussem P, et al. The effectiveness of platelet 
supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: An in-vitro 
study. Eur J Anaesthesiol. 2016;33(5):361-7.
32. Zisman E, Erport A, Kohanovsky E, Ballagulah M, Cassel A, Quitt M, et al. Platelet function recovery 
after cessation of aspirin: preliminary study of volunteers and surgical patients. Eur J Anaesthesiol. 
2010;27(7):617-23.
33. Mangano DT, Multicenter Study of Perioperative Ischemia Research G. Aspirin and mortality from 
coronary bypass surgery. N Engl J Med. 2002;347(17):1309-17.
34. Musleh G, Dunning J. Does aspirin 6 h after coronary artery bypass grafting optimise graft patency? 
Interact Cardiovasc Thorac Surg. 2003;2(4):413-5.
35. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition 
to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 
2001;345(7):494-502.
36. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel 
in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57.
37. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus 
clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15.
38. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, et al. Bleeding complications with the 
P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes 
(PLATO) trial. Eur Heart J. 2011;32(23):2933-44.
39. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of 
clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute 
coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) 
Trial. Circulation. 2004;110(10):1202-8.
40. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, et al. Ticagrelor versus clopidogrel in 
patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the 
PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57(6):672-84.
41. Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ, et al. Mortality benefit with 
prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data 
analysis. J Am Coll Cardiol. 2012;60(5):388-96.
42. Hansson EC, Jideus L, Aberg B, Bjursten H, Dreifaldt M, Holmgren A, et al. Coronary artery bypass 
grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide 
study. Eur Heart J. 2016;37(2):189-97.
43. Tomsic A, Schotborgh MA, Manshanden JS, Li WW, de Mol BA. Coronary artery bypass grafting-related 
bleeding complications in patients treated with dual antiplatelet treatment. Eur J Cardiothorac Surg. 
2016;50(5):849-56.
44. Pickard AS, Becker RC, Schumock GT, Frye CB. Clopidogrel-associated bleeding and related complications 
in patients undergoing coronary artery bypass grafting. Pharmacotherapy. 2008;28(3):376-92.
45. Purkayastha S, Athanasiou T, Malinovski V, Tekkis P, Foale R, Casula R, et al. Does clopidogrel affect 
outcome after coronary artery bypass grafting? A meta-analysis. Heart. 2006;92(4):531-2.
46. Ferraris VA, Saha SP, Oestreich JH, Song HK, Rosengart T, Reece TB, et al. 2012 update to the Society of 
Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac 
operations. Ann Thorac Surg. 2012;94(5):1761-81.
47. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, 
Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN. 2017 
ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration 
with EACTS.Update on DAPT in Coronary artery Disease. 2017. Eur Heart J. 2018;39(3):213-260. 
431
Clinical guidelines on perioperative medication in adult cardiac surgery 
16
48. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, et al. Bridging antiplatelet 
therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. Jama. 
2012;307(3):265-74.
49. Qamar A, Bhatt DL. Current status of data on cangrelor. Pharmacol Ther. 2016;159:102-9.
50. Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential 
consequences for clinical use. Eur Heart J. 2009;30(16):1964-77.
51. Gherli R, Mariscalco G, Dalen M, Onorati F, Perrotti A, Chocron S, et al. Safety of Preoperative Use of 
Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary 
Syndromes Undergoing Coronary Artery Bypass Grafting. JAMA Cardiol. 2016;1(8):921-8.
52. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind 
assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel 
in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 
2009;120(25):2577-85.
53. Storey RF, Bliden KP, Ecob R, Karunakaran A, Butler K, Wei C, et al. Earlier recovery of platelet 
function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients 
with high antiplatelet responses. J Thromb Haemost. 2011;9(9):1730-7.
54. Malm CJ, Hansson EC, Akesson J, Andersson M, Hesse C, Shams Hakimi C, et al. Preoperative 
platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac 
surgery patients: a prospective observational study. Br J Anaesth. 2016;117(3):309-15.
55. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, et al. Bleeding and stent thrombosis 
on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification 
after percutaneous coronary intervention. Eur Heart J. 2015;36(27):1762-71.
56. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust 
antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100-9.
57. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, et al. Platelet function 
monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome 
(ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 
2016;388(10055):2015-22.
58. Kwak YL, Kim JC, Choi YS, Yoo KJ, Song Y, Shim JK. Clopidogrel responsiveness regardless of the 
discontinuation date predicts increased blood loss and transfusion requirement after off-pump 
coronary artery bypass graft surgery. J Am Coll Cardiol. 2010;56(24):1994-2002.
59. Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D, et al. Multiple electrode whole-
blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac 
Surg. 2011;91(1):123-9.
60. Ranucci M, Colella D, Baryshnikova E, Di Dedda U, Surgical, Clinical Outcome Research G. Effect of 
preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J 
Anaesth. 2014;113(6):970-6.
61. Mahla E, Prueller F, Farzi S, Pregartner G, Raggam RB, Beran E, et al. Does Platelet Reactivity Predict 
Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet 
Therapy? Ann Thorac Surg. 2016;102(6):2010-7.
62. Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ, et al. Platelet function measurement-
based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary 
artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-
associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv. 2012;5(2):261-9.
63. Verma S, Goodman SG, Mehta SR, Latter DA, Ruel M, Gupta M, et al. Should dual antiplatelet therapy be 
used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled 
trials. BMC Surg. 2015;15:112.
64. Deo SV, Dunlay SM, Shah IK, Altarabsheh SE, Erwin PJ, Boilson BA, et al. Dual anti-platelet therapy after 
coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card 
Surg. 2013;28(2):109-16.
432
Chapter 16
65. van Diepen S, Fuster V, Verma S, Hamza TH, Siami FS, Goodman SG, et al. Dual Antiplatelet Therapy 
Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM 
Insights. J Am Coll Cardiol. 2017;69(2):119-27.
66. Savonitto S, D’Urbano M, Caracciolo M, Barlocco F, Mariani G, Nichelatti M, et al. Urgent surgery in 
patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet 
therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth. 2010;104(3):285-91.
67. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, 
effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic 
Therapy. Chest. 2004;126(3 Suppl):234S-64S.
68. Lincoff AM, LeNarz LA, Despotis GJ, Smith PK, Booth JE, Raymond RE, et al. Abciximab and bleeding 
during coronary surgery: results from the EPILOG and EPISTENT trialsşşA complete list of the 
principal investigators and study coordinators of the EPILOG (Evaluation in PTCA to Improve Long-
term Outcome with abciximab GP IIb/IIIa blockade) Study Group and the EPISTENT (Evaluation of 
Platelet IIb/IIIa Inhibition in STENTing) Study Group can be found in the Appendices. The Annals of 
Thoracic Surgery. 2000;70(2):516-26.
69. De Carlo M, Maselli D, Cortese B, Ciabatti N, Gistri R, Levantino M, et al. Emergency coronary artery 
bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor 
inhibitors. Int J Cardiol. 2008;123(3):229-33.
70. Faraoni D, Levy JH, Albaladejo P, Samama CM, Groupe d’Interet en Hemostase P. Updates in the 
perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit 
Care. 2015;19:203.
71. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart 
Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients 
with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507.
72. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or defibrillator surgery 
without interruption of anticoagulation. N Engl J Med. 2013;368(22):2084-93.
73. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative Bridging 
Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015;373(9):823-33.
74. Jones HU, Muhlestein JB, Jones KW, Bair TL, Lavasani F, Sohrevardi M, et al. Preoperative use of 
enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for 
postoperative bleeding after open-heart surgery in patients who present with an acute coronary 
syndrome: clinical investigation and reports. Circulation. 2002;106(12 Suppl 1):I19-22.
75. Gellatly RM, Leet A, Brown KE. Fondaparinux: an effective bridging strategy in heparin-induced 
thrombocytopenia and mechanical circulatory support. J Heart Lung Transplant. 2014;33(1):118.
76. O’Donnell MJ, Kearon C, Johnson J, Robinson M, Zondag M, Turpie I, et al. Brief communication: 
Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary 
interruption of warfarin. Ann Intern Med. 2007;146(3):184-7.
77. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, 
et al. Management of severe perioperative bleeding: guidelines from the European Society of 
Anaesthesiology. Eur J Anaesthesiol. 2013;30(6):270-382.
78. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, et al. Management of major 
bleeding complications and emergency surgery in patients on long-term treatment with direct oral 
anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative 
haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis. 2013;106(6-7):382-93.
79. Levy JH, Spyropoulos AC, Samama CM, Douketis J. Direct oral anticoagulants: new drugs and new 
concepts. JACC Cardiovasc Interv. 2014;7(12):1333-51.
80. Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex 
concentrates (PCCs): what is the evidence? Thromb Haemost. 2014;111(2):189-98.
81. Pollack CV, Jr., Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for 
Dabigatran Reversal. N Engl J Med. 2015;373(6):511-20.
433
Clinical guidelines on perioperative medication in adult cardiac surgery 
16
82. Connolly SJ, Milling TJ, Jr., Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet Alfa 
for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016;375(12):1131-41.
83. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet Alfa for the 
Reversal of Factor Xa Inhibitor Activity. New England Journal of Medicine. 2015;373(25):2413-24.
84. Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared 
with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-
analysis of randomized trials. Arch Intern Med. 2007;167(2):117-24.
85. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients 
with mechanical heart valve prostheses. Circulation. 1994;89(2):635-41.
86. Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, et al. Warfarin versus dipyridamole-aspirin 
and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a 
prospective randomized clinical trial. Circulation. 1985;72(5):1059-63.
87. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines 
on the management of valvular heart disease (version 2012): the Joint Task Force on the Management 
of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association 
for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012;42(4):S1-44.
88. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J. Experience with 
enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart. 
2003;89(5):527-30.
89. Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A. Low-molecular-weight heparin as a bridging 
anticoagulant early after mechanical heart valve replacement. Circulation. 2006;113(4):564-9.
90. Iung B, Rodes-Cabau J. The optimal management of anti-thrombotic therapy after valve 
replacement: certainties and uncertainties. Eur Heart J. 2014;35(42):2942-9.
91. Grzymala-Lubanski B, Svensson PJ, Renlund H, Jeppsson A, Själander A. Warfarin treatment quality 
and prognosis in patients with mechanical heart valve prosthesis. Heart. 2016.
92. Heneghan C, Ward A, Perera R, Self-Monitoring Trialist C, Bankhead C, Fuller A, et al. Self-
monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. 
Lancet. 2012;379(9813):322-34.
93. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, et al. Self-monitoring 
and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2016;7:CD003839.
94. Head SJ, Celik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur 
Heart J. 2017.
95. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran 
versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206-14.
96. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, et al. Risk of bleeding 
with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial 
fibrillation. Arch Intern Med. 2010;170(16):1433-41.
97. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS, et al. Early anticoagulation 
of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult 
Cardiac Surgery National Database. J Am Coll Cardiol. 2012;60(11):971-7.
98. Merie C, Kober L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J, et al. Association of 
warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, 
thromboembolic complications, and bleeding. Jama. 2012;308(20):2118-25.
99. Rafiq S, Steinbrüchel DA, Lilleør NB, Møller CH, Lund JT, Thiis JJ, et al. Antithrombotic therapy after 
bioprosthetic aortic valve implantation: Warfarin versus aspirin, a randomized controlled trial. 
Thrombosis Research. 2016;150:104-10.
100. Nombela-Franco L, Webb JG, de Jaegere PP, Toggweiler S, Nuis RJ, Dager AE, et al. Timing, predictive 
factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing 
transcatheter aortic valve implantation. Circulation. 2012;126(25):3041-53.
434
Chapter 16
101. Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, de Backer O, et al. Possible Subclinical 
Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med. 2015;373(21):2015-24.
102. Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ, Nombela-Franco L, Cheema A, Kefer J, et al. 
Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation 
Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2016;9(16):1706-17.
103. Steinberg BA, Zhao Y, He X, Hernandez AF, Fullerton DA, Thomas KL, et al. Management of 
postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing 
cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation 
Registry. Clin Cardiol. 2014;37(1):7-13.
104. Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P, et al. Atrial fibrillation after 
isolated coronary surgery affects late survival. Circulation. 2008;118(16):1612-8.
105. Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients undergoing 
aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled 
cardiovascular mortality. Eur J Cardiothorac Surg. 2010;37(6):1353-9.
106. Dunning J, Treasure T, Versteegh M, Nashef SA, Audit E, Guidelines C. Guidelines on the prevention 
and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac 
Surg. 2006;30(6):852-72.
107. Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, et al. Interventions for preventing 
post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 
2013(1):CD003611.
108. Sear JW, Foex P. Recommendations on perioperative beta-blockers: differing guidelines: so what 
should the clinician do? Br J Anaesth. 2010;104(3):273-5.
109. Chatterjee S, Sardar P, Mukherjee D, Lichstein E, Aikat S. Timing and route of amiodarone for 
prevention of postoperative atrial fibrillation after cardiac surgery: a network regression meta-
analysis. Pacing Clin Electrophysiol. 2013;36(8):1017-23.
110. Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V, Gottskalksson G, et al. Does 
treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? 
Europace. 2010;12(3):356-63.
111. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, et al. N-3 Fatty acids for the 
prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. 
J Am Coll Cardiol. 2005;45(10):1723-8.
112. Miller S, Crystal E, Garfinkle M, Lau C, Lashevsky I, Connolly SJ. Effects of magnesium on atrial 
fibrillation after cardiac surgery: a meta-analysis. Heart. 2005;91(5):618-23.
113. Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: a systematic 
review. Scand Cardiovasc J Suppl. 2013;47(1):2-10.
114. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, et al. Vernakalant hydrochloride 
for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, 
placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2(6):652-9.
115. Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, et al. Rate Control versus 
Rhythm Control for Atrial Fibrillation after Cardiac Surgery. N Engl J Med. 2016;374(20):1911-21.
116. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-
analysis of the literature. European Heart Journal. 2015;36(28):1831-8.
117. Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, et al. Perioperative atrial 
fibrillation and the long-term risk of ischemic stroke. Jama. 2014;312(6):616-22.
118. Anderson E, Dyke C, Levy JH. Anticoagulation strategies for the management of postoperative atrial 
fibrillation. Clin Lab Med. 2014;34(3):537-61.
119. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus 
warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104.
120. Seeger J, Gonska B, Rodewald C, Rottbauer W, Wöhrle J. Apixaban in Patients With Atrial Fibrillation 
After Transfemoral Aortic Valve Replacement. JACC: Cardiovascular Interventions. 2017;10(1):66-74.
435
Clinical guidelines on perioperative medication in adult cardiac surgery 
16
121. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition 
on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-62.
122. Bhatia M, Arora H, Kumar PA. Pro: ACE Inhibitors Should Be Continued Perioperatively and Prior to 
Cardiovascular Operations. J Cardiothorac Vasc Anesth. 2016;30(3):816-9.
123. Disque A, Neelankavil J. Con: ACE Inhibitors Should Be Stopped Prior to Cardiovascular Surgery. J 
Cardiothorac Vasc Anesth. 2016;30(3):820-2.
124. Mangieri A. Renin-angiotensin system blockers in cardiac surgery. J Crit Care. 2015;30(3):613-8.
125. Zou Z, Yuan HB, Yang B, Xu F, Chen XY, Liu GJ, et al. Perioperative angiotensin-converting enzyme 
inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in 
adults. Cochrane Database Syst Rev. 2016(1):CD009210.
126. Bertrand M, Godet G, Meersschaert K, Brun L, Salcedo E, Coriat P. Should the angiotensin II 
antagonists be discontinued before surgery? Anesth Analg. 2001;92(1):26-30.
127. Rouleau JL, Warnica WJ, Baillot R, Block PJ, Chocron S, Johnstone D, et al. Effects of angiotensin-
converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. 
Circulation. 2008;117(1):24-31.
128. Zhang Y, Ma L. Effect of preoperative angiotensin-converting enzyme inhibitor on the outcome of 
coronary artery bypass graft surgery. Eur J Cardiothorac Surg. 2015;47(5):788-95.
129. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD, et al. Management of 
vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel 
pressor agent. J Thorac Cardiovasc Surg. 1998;116(6):973-80.
130. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after 
cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg. 2000;15(5):347-
53.
131. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 
evidence-based guideline for the management of high blood pressure in adults: report from the 
panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311(5):507-20.
132. Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension 
practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359-66.
133. Crystal E, Garfinkle MS, Connolly SS, Ginger TT, Sleik K, Yusuf SS. Interventions for preventing 
post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 
2004(4):CD003611.
134. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, 
or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. 
N Engl J Med. 2003;349(20):1893-906.
135. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan 
in patients with chronic heart failure and reduced left-ventricular systolic function taking 
angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-
71.
136. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan 
on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. 
Lancet. 2003;362(9386):759-66.
137. Oosterga M, Voors AA, Pinto YM, Buikema H, Grandjean JG, Kingma JH, et al. Effects of quinapril 
on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on 
Vascular Ace and Determinants of Ischemia. Am J Cardiol. 2001;87(5):542-6.
138. Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R, et al. Preoperative use of angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for 
acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol. 2008;3(5):1266-73.
139. Savarese G, Costanzo P, Cleland JGF, Vassallo E, Ruggiero D, Rosano G, et al. A Meta-Analysis 
Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers 
in Patients Without Heart Failure. Journal of the American College of Cardiology. 2013;61(2):131-42.
436
Chapter 16
140. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on 
morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation 
Study Investigators. N Engl J Med. 1999;341(10):709-17.
141. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients 
with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
142. Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS. Combining neuroendocrine inhibitors in 
heart failure: reflections on safety and efficacy. Am J Med. 2007;120(12):1090 e1-8.
143. Pitt B, Pedro Ferreira J, Zannad F. Mineralocorticoid receptor antagonists in patients with heart 
failure: current experience and future perspectives. European Heart Journal - Cardiovascular 
Pharmacotherapy. 2017;3(1):48-57.
144. Chan AY, McAlister FA, Norris CM, Johnstone D, Bakal JA, Ross DB, et al. Effect of beta-blocker use 
on outcomes after discharge in patients who underwent cardiac surgery. J Thorac Cardiovasc Surg. 
2010;140(1):182-7, 7 e1.
145. ten Broecke PW, De Hert SG, Mertens E, Adriaensen HF. Effect of preoperative beta-blockade on 
perioperative mortality in coronary surgery. Br J Anaesth. 2003;90(1):27-31.
146. Daumerie G, Fleisher LA. Perioperative beta-blocker and statin therapy. Curr Opin Anaesthesiol. 
2008;21(1):60-5.
147. Blessberger H, Kammler J, Steinwender C. Perioperative use of beta-blockers in cardiac and 
noncardiac surgery. Jama. 2015;313(20):2070-1.
148. Carl M, Alms A, Braun J, Dongas A, Erb J, Goetz A, et al. S3 guidelines for intensive care in cardiac 
surgery patients: hemodynamic monitoring and cardiocirculary system. Ger Med Sci. 2010;8.
149. Sjoland H, Caidahl K, Lurje L, Hjalmarson A, Herlitz J. Metoprolol treatment for two years after 
coronary bypass grafting: effects on exercise capacity and signs of myocardial ischaemia. Br Heart 
J. 1995;74(3):235-41.
150. Puymirat E, Riant E, Aissoui N, Soria A, Ducrocq G, Coste P, et al. ş blockers and mortality after 
myocardial infarction in patients without heart failure: multicentre prospective cohort study. Bmj. 
2016;354.
151. Booij HG, Damman K, Warnica JW, Rouleau JL, van Gilst WH, Westenbrink BD. beta-blocker Therapy 
is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass 
Graft Surgery: Insights from the IMAGINE Trial. Cardiovasc Drugs Ther. 2015;29(3):277-85.
152. Brinkman W, Herbert MA, O’Brien S, Filardo G, Prince S, Dewey T, et al. Preoperative beta-blocker 
use in coronary artery bypass grafting surgery: national database analysis. JAMA Intern Med. 
2014;174(8):1320-7.
153. Lin T, Hasaniya NW, Krider S, Razzouk A, Wang N, Chiong JR. Mortality reduction with beta-blockers 
in ischemic cardiomyopathy patients undergoing coronary artery bypass grafting. Congest Heart 
Fail. 2010;16(4):170-4.
154. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-
13.
155. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-
analysis. Ann Intern Med. 2001;134(7):550-60.
156. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular 
dysfunction: the CAPRICORN randomised trial. The Lancet.357(9266):1385-90.
157. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention 
Trial in-Congestive Heart Failure (MERIT-HF). The Lancet.353(9169):2001-7.
158. Chatterjee S, Biondi-Zoccai G, Abbate A, D’Ascenzo F, Castagno D, Van Tassell B, et al. Benefits of ş 
blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ : 
British Medical Journal. 2013;346.
159. Mannacio VA, Iorio D, De Amicis V, Di Lello F, Musumeci F. Effect of rosuvastatin pretreatment 
on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg. 
2008;136(6):1541-8.
437
Clinical guidelines on perioperative medication in adult cardiac surgery 
16
160. Kuhn EW, Slottosch I, Wahlers T, Liakopoulos OJ. Preoperative statin therapy for patients undergoing 
cardiac surgery. Cochrane Database Syst Rev. 2015(8):CD008493.
161. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, et al. Perioperative Rosuvastatin in Cardiac 
Surgery. N Engl J Med. 2016;374(18):1744-53.
162. Billings FTt, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG, et al. High-Dose 
Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized 
Clinical Trial. Jama. 2016;315(9):877-88.
163. Bellomo R. Perioperative Statins in Cardiac Surgery and Acute Kidney Injury. Jama. 
2016;315(9):873-4.
164. Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, et al. Intensive lipid-lowering 
with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am 
Coll Cardiol. 2008;51(20):1938-43.
165. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle 
symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement 
on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012-22.
166. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab 
and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 
2017;376(18):1713-22.
167. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of 
alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489-99.
168. Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC, et al. The impact 
of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and 
outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J. 
2016;37(6):536-45.
169. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: 
a systematic review and meta-analysis. The Lancet. 2010;375(9729):1875-84.
170. The ASG. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of 
Medicine. 2010;362(17):1563-74.
171. Filsoufi F, Rahmanian PB, Castillo JG, Scurlock C, Legnani PE, Adams DH. Predictors and outcome of 
gastrointestinal complications in patients undergoing cardiac surgery. Ann Surg. 2007;246(2):323-9.
172. van der Voort PH, Zandstra DF. Pathogenesis, risk factors, and incidence of upper gastrointestinal 
bleeding after cardiac surgery: is specific prophylaxis in routine bypass procedures needed? J 
Cardiothorac Vasc Anesth. 2000;14(3):293-9.
173. Shin JS, Abah U. Is routine stress ulcer prophylaxis of benefit for patients undergoing cardiac 
surgery? Interact Cardiovasc Thorac Surg. 2012;14(5):622-8.
174. Hata M, Shiono M, Sekino H, Furukawa H, Sezai A, Iida M, et al. Prospective randomized trial 
for optimal prophylactic treatment of the upper gastrointestinal complications after open heart 
surgery. Circ J. 2005;69(3):331-4.
175. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of 
pneumonia: a systematic review and meta-analysis. Cmaj. 2011;183(3):310-9.
176. Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after 
proton pump inhibitor prescription: population based study. Bmj. 2016;355.
177. Day JR, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. 
Int J Surg. 2005;3(2):129-40.
178. Whitlock RP, Chan S, Devereaux PJ, Sun J, Rubens FD, Thorlund K, et al. Clinical benefit of steroid 
use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur 
Heart J. 2008;29(21):2592-600.
179. Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, et al. Methylprednisolone in 
patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-
controlled trial. Lancet. 2015;386(10000):1243-53.
438
Chapter 16
180. Dieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, et al. Intraoperative 
high-dose dexamethasone for cardiac surgery: a randomized controlled trial. Jama. 2012;308(17):1761-7.
181. Dieleman JM, Van Dijk D. Corticosteroids for cardiac surgery: A summary of two large randomised 
trials. Netherlands Journal of Critical Care. 2016;24(5):6-10.
182. Liu MM, Reidy AB, Saatee S, Collard CD. Perioperative Steroid Management: Approaches Based on 
Current Evidence. Anesthesiology. 2017;127(1):166-72.
183. Fowler VG, O’Brien SM, Muhlbaier LH, Corey GR, Ferguson TB, Peterson ED. Clinical Predictors of 
Major Infections After Cardiac Surgery. Circulation. 2005;112(9 suppl):I-358-I-65.
184. Gelijns AC, Moskowitz AJ, Acker MA, Argenziano M, Geller NL, Puskas JD, et al. Management practices 
and major infections after cardiac surgery. J Am Coll Cardiol. 2014;64(4):372-81.
185. Kowalewski M, Pawliszak W, Zaborowska K, Navarese EP, Szwed KA, Kowalkowska ME, et al. 
Gentamicin-collagen sponge reduces the risk of sternal wound infections after heart surgery: Meta-
analysis. J Thorac Cardiovasc Surg. 2015;149(6):1631-40 e1-6.
186. Zelenitsky SA, Ariano RE, Harding GK, Silverman RE. Antibiotic pharmacodynamics in surgical 
prophylaxis: an association between intraoperative antibiotic concentrations and efficacy. Antimicrob 
Agents Chemother. 2002;46(9):3026-30.
187. Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese 
patients. Surgery. 1989;106(4):750-6; discussion 6-7.
188. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in 
adults. Lancet. 2010;375(9710):248-51.
189. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 
2007;27(8):1081-91.
190. Tamayo E, Gualis J, Florez S, Castrodeza J, Eiros Bouza JM, Alvarez FJ. Comparative study of single-
dose and 24-hour multiple-dose antibiotic prophylaxis for cardiac surgery. J Thorac Cardiovasc Surg. 
2008;136(6):1522-7.
191. Mertz D, Johnstone J, Loeb M. Does duration of perioperative antibiotic prophylaxis matter in cardiac 
surgery? A systematic review and meta-analysis. Ann Surg. 2011;254(1):48-54.
192. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after 
cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. 
Circulation. 2000;101(25):2916-21.
193. Bratzler DW, Houck PM, Richards C, Steele L, Dellinger EP, Fry DE, et al. Use of antimicrobial prophylaxis 
for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg. 
2005;140(2):174-82.
194. Sandoe JA, Kumar B, Stoddart B, Milton R, Dave J, Nair UR, et al. Effect of extended perioperative 
antibiotic prophylaxis on intravascular catheter colonization and infection in cardiothoracic surgery 
patients. J Antimicrob Chemother. 2003;52(5):877-9.
195. Niederhauser U, Vogt M, Vogt P, Genoni M, Kunzli A, Turina MI. Cardiac surgery in a high-risk group 
of patients: is prolonged postoperative antibiotic prophylaxis effective? J Thorac Cardiovasc Surg. 
1997;114(2):162-8.
196. Conte JE, Jr., Cohen SN, Roe BB, Elashoff RM. Antibiotic prophylaxis and cardiac surgery. A 
prospective double-blind comparison of single-dose versus multiple-dose regimens. Ann Intern Med. 
1972;76(6):943-9.
197. Trent Magruder J, Grimm JC, Dungan SP, Shah AS, Crow JR, Shoulders BR, et al. Continuous 
Intraoperative Cefazolin Infusion May Reduce Surgical Site Infections During Cardiac Surgical 
Procedures: A Propensity-Matched Analysis. J Cardiothorac Vasc Anesth. 2015;29(6):1582-7.
198. Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers W, American Academy 
of Orthopaedic S, American Association of Critical Care N, American Association of Nurse A, et al. 
Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection 
Prevention Project. Clin Infect Dis. 2004;38(12):1706-15.
199. Scher KS. Studies on the duration of antibiotic administration for surgical prophylaxis. Am Surg. 
1997;63(1):59-62.
439
Clinical guidelines on perioperative medication in adult cardiac surgery 
16
200. Swoboda SM, Merz C, Kostuik J, Trentler B, Lipsett PA. Does intraoperative blood loss affect 
antibiotic serum and tissue concentrations? Arch Surg. 1996;131(11):1165-71; discussion 71-2.
201. Lanckohr C, Horn D, Voeller S, Hempel G, Fobker M, Welp H, et al. Pharmacokinetic characteristics 
and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective 
cardiac surgery. J Thorac Cardiovasc Surg. 2016;152(2):603-10.
202. Gardlund B, Bitkover CY, Vaage J. Postoperative mediastinitis in cardiac surgery - microbiology and 
pathogenesis. Eur J Cardiothorac Surg. 2002;21(5):825-30.
203. Gudbjartsson T, Jeppsson A, Sjogren J, Steingrimsson S, Geirsson A, Friberg O, et al. Sternal wound 
infections following open heart surgery - a review. Scand Cardiovasc J. 2016;50(5-6):341-8.
204. Allegranzi B, Bischoff P, de Jonge S, Kubilay NZ, Zayed B, Gomes SM, et al. New WHO 
recommendations on preoperative measures for surgical site infection prevention: an evidence-
based global perspective. Lancet Infect Dis. 2016;16(12):e276-e87.
205. Bode LGM, Kluytmans JAJW, Wertheim HFL, Bogaers D, Vandenbroucke-Grauls CMJE, Roosendaal 
R, et al. Preventing Surgical-Site Infections in Nasal Carriers of Staphylococcus aureus. New England 
Journal of Medicine. 2010;362(1):9-17.
206. Sisto T, Laurikka J, Tarkka MR. Ceftriaxone vs cefuroxime for infection prophylaxis in coronary 
bypass surgery. Scand J Thorac Cardiovasc Surg. 1994;28(3-4):143-8.
207. Nooyen SM, Overbeek BP, Brutel de la Riviere A, Storm AJ, Langemeyer JJ. Prospective randomised 
comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery 
bypass grafting. Eur J Clin Microbiol Infect Dis. 1994;13(12):1033-7.
208. Kriaras I, Michalopoulos A, Turina M, Geroulanos S. Evolution of antimicrobial prophylaxis in 
cardiovascular surgery. Eur J Cardiothorac Surg. 2000;18(4):440-6.
209. Lador A, Nasir H, Mansur N, Sharoni E, Biderman P, Leibovici L, et al. Antibiotic prophylaxis in 
cardiac surgery: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy. 
2012;67(3):541-50.
210. Bolon MK, Morlote M, Weber SG, Koplan B, Carmeli Y, Wright SB. Glycopeptides are no more 
effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a 
meta-analysis. Clin Infect Dis. 2004;38(10):1357-63.
211. Cunha BA. Antibiotic selection in the penicillin-allergic patient. Med Clin North Am. 
2006;90(6):1257-64.
212. Massias L, Dubois C, de Lentdecker P, Brodaty O, Fischler M, Farinotti R. Penetration of vancomycin 
in uninfected sternal bone. Antimicrob Agents Chemother. 1992;36(11):2539-41.
213. Finkelstein R, Rabino G, Mashiah T, Bar-El Y, Adler Z, Kertzman V, et al. Vancomycin versus 
cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant 
staphylococcal infections. J Thorac Cardiovasc Surg. 2002;123(2):326-32.
214. Blumenthal KG, Shenoy ES, Varughese CA, Hurwitz S, Hooper DC, Banerji A. Impact of a clinical 
guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy. Ann 
Allergy Asthma Immunol. 2015;115(4):294-300 e2.
215. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin 
“allergy” in hospitalized patients: A cohort study. J Allergy Clin Immunol. 2014;133(3):790-6.
216. Frigas E, Park MA, Narr BJ, Volcheck GW, Danielson DR, Markus PJ, et al. Preoperative evaluation of 
patients with history of allergy to penicillin: comparison of 2 models of practice. Mayo Clin Proc. 
2008;83(6):651-62.
217. Anderson DJ, Podgorny K, Berríos-Torres SI, Bratzler DW, Dellinger EP, Greene L, et al. Strategies to 
Prevent Surgical Site Infections in Acute Care Hospitals: 2014 Update. Infect Control Hosp Epidemiol. 
2014;35(6):605-27.
218. Zangrillo A, Landoni G, Fumagalli L, Bove T, Bellotti F, Sottocorna O, et al. Methicillin-resistant 
Staphylococcus species in a cardiac surgical intensive care unit: a 5-year experience. J Cardiothorac 
Vasc Anesth. 2006;20(1):31-7.
440
Chapter 16
219. Bull AL, Worth LJ, Richards MJ. Impact of vancomycin surgical antibiotic prophylaxis on the 
development of methicillin-sensitive staphylococcus aureus surgical site infections: report from 
Australian Surveillance Data (VICNISS). Ann Surg. 2012;256(6):1089-92.
220. Uhlig C, Bluth T, Schwarz K, Deckert S, Heinrich L, De Hert S, et al. Effects of Volatile Anesthetics on 
Mortality and Postoperative Pulmonary and Other Complications in Patients Undergoing Surgery: 
A Systematic Review and Meta-analysis. Anesthesiology. 2016;124(6):1230-45.
221. Landoni G, Greco T, Biondi-Zoccai G, Nigro Neto C, Febres D, Pintaudi M, et al. Anaesthetic drugs 
and survival: a Bayesian network meta-analysis of randomized trials in cardiac surgery. Br J Anaesth. 
2013;111(6):886-96.
222. Landoni G, Isella F, Greco M, Zangrillo A, Royse CF. Benefits and risks of epidural analgesia in 
cardiac surgery. Br J Anaesth. 2015;115(1):25-32.
223. Bignami E, Greco T, Barile L, Silvetti S, Nicolotti D, Fochi O, et al. The effect of isoflurane on survival 
and myocardial infarction: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc 
Anesth. 2013;27(1):50-8.
224. Bignami E, Biondi-Zoccai G, Landoni G, Fochi O, Testa V, Sheiban I, et al. Volatile anesthetics reduce 
mortality in cardiac surgery. J Cardiothorac Vasc Anesth. 2009;23(5):594-9.
225. De Hert S, Vlasselaers D, Barbe R, Ory JP, Dekegel D, Donnadonni R, et al. A comparison of volatile 
and non-volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia. 
2009;64(9):953-60.
226. Jakobsen CJ, Berg H, Hindsholm KB, Faddy N, Sloth E. The influence of propofol versus sevoflurane 
anesthesia on outcome in 10,535 cardiac surgical procedures. J Cardiothorac Vasc Anesth. 
2007;21(5):664-71.
227. Landoni G, Biondi-Zoccai GG, Zangrillo A, Bignami E, D’Avolio S, Marchetti C, et al. Desflurane and 
sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc 
Anesth. 2007;21(4):502-11.
228. Likhvantsev VV, Landoni G, Levikov DI, Grebenchikov OA, Skripkin YV, Cherpakov RA. 
Sevoflurane Versus Total Intravenous Anesthesia for Isolated Coronary Artery Bypass Surgery With 
Cardiopulmonary Bypass: A Randomized Trial. J Cardiothorac Vasc Anesth. 2016;30(5):1221-7.
229. Mazzeffi M, Khelemsky Y. Poststernotomy pain: a clinical review. J Cardiothorac Vasc Anesth. 
2011;25(6):1163-78.
230. Gelinas C. Management of pain in cardiac surgery ICU patients: have we improved over time? 
Intensive Crit Care Nurs. 2007;23(5):298-303.
231. Schelling G, Richter M, Roozendaal B, Rothenhausler HB, Krauseneck T, Stoll C, et al. Exposure 
to high stress in the intensive care unit may have negative effects on health-related quality-of-life 
outcomes after cardiac surgery. Crit Care Med. 2003;31(7):1971-80.
232. Barr J, Fraser GL, Puntillo K, Ely EW, Gelinas C, Dasta JF, et al. Clinical practice guidelines for the 
management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care 
Med. 2013;41(1):263-306.
233. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management 
of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American 
Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ 
Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 
2016;17(2):131-57.
234. Zangrillo A, Bignami E, Biondi-Zoccai GG, Covello RD, Monti G, D’Arpa MC, et al. Spinal analgesia 
in cardiac surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 
2009;23(6):813-21.
235. Nader ND, Li CM, Dosluoglu HH, Ignatowski TA, Spengler RN. Adjuvant therapy with intrathecal 
clonidine improves postoperative pain in patients undergoing coronary artery bypass graft. Clin J 
Pain. 2009;25(2):101-6.
441
Clinical guidelines on perioperative medication in adult cardiac surgery 
16
236. Lena P, Balarac N, Arnulf JJ, Bigeon JY, Tapia M, Bonnet F. Fast-track coronary artery bypass grafting 
surgery under general anesthesia with remifentanil and spinal analgesia with morphine and 
clonidine. J Cardiothorac Vasc Anesth. 2005;19(1):49-53.
237. White PF, Rawal S, Latham P, Markowitz S, Issioui T, Chi L, et al. Use of a continuous local anesthetic 
infusion for pain management after median sternotomy. Anesthesiology. 2003;99(4):918-23.
238. McDonald SB, Jacobsohn E, Kopacz DJ, Desphande S, Helman JD, Salinas F, et al. Parasternal block 
and local anesthetic infiltration with levobupivacaine after cardiac surgery with desflurane: the 
effect on postoperative pain, pulmonary function, and tracheal extubation times. Anesth Analg. 
2005;100(1):25-32.
239. Cook TM, Counsell D, Wildsmith JA, Royal College of Anaesthetists Third National Audit P. Major 
complications of central neuraxial block: report on the Third National Audit Project of the Royal 
College of Anaesthetists. Br J Anaesth. 2009;102(2):179-90.
240. Richardson L, Dunning J, Hunter S. Is intrathecal morphine of benefit to patients undergoing 
cardiac surgery. Interact Cardiovasc Thorac Surg. 2009;8(1):117-22.
241. Engelman E, Marsala C. Efficacy of adding clonidine to intrathecal morphine in acute postoperative 
pain: meta-analysis. Br J Anaesth. 2013;110(1):21-7.
242. Yeung JH, Gates S, Naidu BV, Wilson MJ, Gao Smith F. Paravertebral block versus thoracic epidural 
for patients undergoing thoracotomy. Cochrane Database Syst Rev. 2016;2:CD009121.
243. Canto M, Sanchez MJ, Casas MA, Bataller ML. Bilateral paravertebral blockade for conventional 
cardiac surgery. Anaesthesia. 2003;58(4):365-70.
244. Nasr DA, Abdelhamid HM, Mohsen M, Aly AH. The analgesic efficacy of continuous presternal 
bupivacaine infusion through a single catheter after cardiac surgery. Ann Card Anaesth. 
2015;18(1):15-20.
245. Agarwal S, Nuttall GA, Johnson ME, Hanson AC, Oliver WC, Jr. A prospective, randomized, blinded 
study of continuous ropivacaine infusion in the median sternotomy incision following cardiac 
surgery. Reg Anesth Pain Med. 2013;38(2):145-50.
246. Kocabas S, Yedicocuklu D, Yuksel E, Uysallar E, Askar F. Infiltration of the sternotomy wound and 
the mediastinal tube sites with 0.25% levobupivacaine as adjunctive treatment for postoperative 
pain after cardiac surgery. Eur J Anaesthesiol. 2008;25(10):842-9.
247. Bainbridge D, Martin JE, Cheng DC. Patient-controlled versus nurse-controlled analgesia after 
cardiac surgery--a meta-analysis. Can J Anaesth. 2006;53(5):492-9.
248. Greco M, Landoni G, Biondi-Zoccai G, Cabrini L, Ruggeri L, Pasculli N, et al. Remifentanil in cardiac 
surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2012;26(1):110-
6.
249. Alavi SM, Ghoreishi SM, Chitsazan M, Ghandi I, Fard AJ, Hosseini SS, et al. Patient-controlled 
analgesia after coronary bypass: Remifentanil or sufentanil? Asian Cardiovasc Thorac Ann. 
2014;22(6):694-9.
250. Baltali S, Turkoz A, Bozdogan N, Demirturk OS, Baltali M, Turkoz R, et al. The efficacy of intravenous 
patient-controlled remifentanil versus morphine anesthesia after coronary artery surgery. J 
Cardiothorac Vasc Anesth. 2009;23(2):170-4.
251. Mamoun NF, Lin P, Zimmerman NM, Mascha EJ, Mick SL, Insler SR, et al. Intravenous acetaminophen 
analgesia after cardiac surgery: A randomized, blinded, controlled superiority trial. J Thorac 
Cardiovasc Surg. 2016;152(3):881-9 e1.
252. Jelacic S, Bollag L, Bowdle A, Rivat C, Cain KC, Richebe P. Intravenous Acetaminophen as an Adjunct 
Analgesic in Cardiac Surgery Reduces Opioid Consumption But Not Opioid-Related Adverse Effects: 
A Randomized Controlled Trial. J Cardiothorac Vasc Anesth. 2016;30(4):997-1004.
253. Cattabriga I, Pacini D, Lamazza G, Talarico F, Di Bartolomeo R, Grillone G, et al. Intravenous 
paracetamol as adjunctive treatment for postoperative pain after cardiac surgery: a double blind 
randomized controlled trial. Eur J Cardiothorac Surg. 2007;32(3):527-31.
442
Chapter 16
254. Ahlers SJ, Van Gulik L, Van Dongen EP, Bruins P, Tibboel D, Knibbe CA. Aminotransferase levels in 
relation to short-term use of acetaminophen four grams daily in postoperative cardiothoracic patients 
in the intensive care unit. Anaesth Intensive Care. 2011;39(6):1056-63.
255. Kulik A, Bykov K, Choudhry NK, Bateman BT. Non-steroidal anti-inflammatory drug administration 
after coronary artery bypass surgery: utilization persists despite the boxed warning. Pharmacoepidemiol 
Drug Saf. 2015;24(6):647-53.
256. Coxib, traditional NTC, Bhala N, Emberson J, Merhi A, Abramson S, et al. Vascular and upper 
gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual 
participant data from randomised trials. Lancet. 2013;382(9894):769-79.
257. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, et al. Duration of 
treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent 
myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. 
Circulation. 2011;123(20):2226-35.
258. Qazi SM, Sindby EJ, Norgaard MA. Ibuprofen - a Safe Analgesic During Cardiac Surgery Recovery? A 
Randomized Controlled Trial. J Cardiovasc Thorac Res. 2015;7(4):141-8.
259. Rafiq S, Steinbruchel DA, Wanscher MJ, Andersen LW, Navne A, Lilleoer NB, et al. Multimodal analgesia 
versus traditional opiate based analgesia after cardiac surgery, a randomized controlled trial. J 
Cardiothorac Surg. 2014;9:52.
260. Horbach SJ, Lopes RD, da CGJC, Martini F, Mehta RH, Petracco JB, et al. Naproxen as prophylaxis against 
atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med. 2011;124(11):1036-42.
261. Stepensky D, Rimon G. Competition between low-dose aspirin and other NSAIDs for COX-1 binding 
and its clinical consequences for the drugs’ antiplatelet effects. Expert Opin Drug Metab Toxicol. 
2015;11(1):41-52.
262. Acharya M, Dunning J. Does the use of non-steroidal anti-inflammatory drugs after cardiac surgery 
increase the risk of renal failure? Interact Cardiovasc Thorac Surg. 2010;11(4):461-7.
263. Bainbridge D, Cheng DC, Martin JE, Novick R, Evidence-Based Perioperative Clinical Outcomes 
Research G. NSAID-analgesia, pain control and morbidity in cardiothoracic surgery. Can J Anaesth. 
2006;53(1):46-59.
264. Fayaz MK, Abel RJ, Pugh SC, Hall JE, Djaiani G, Mecklenburgh JS. Opioid-sparing effects of diclofenac 
and paracetamol lead to improved outcomes after cardiac surgery. J Cardiothorac Vasc Anesth. 
2004;18(6):742-7.
265. Kulik A, Ruel M, Bourke ME, Sawyer L, Penning J, Nathan HJ, et al. Postoperative naproxen after 
coronary artery bypass surgery: a double-blind randomized controlled trial. Eur J Cardiothorac Surg. 
2004;26(4):694-700.
266. Oliveri L, Jerzewski K, Kulik A. Black box warning: is ketorolac safe for use after cardiac surgery? J 
Cardiothorac Vasc Anesth. 2014;28(2):274-9.
267. Engoren MC, Habib RH, Zacharias A, Dooner J, Schwann TA, Riordan CJ, et al. Postoperative analgesia 
with ketorolac is associated with decreased mortality after isolated coronary artery bypass graft 
surgery in patients already receiving aspirin: a propensity-matched study. J Cardiothorac Vasc Anesth. 
2007;21(6):820-6.
268. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, et al. Efficacy and safety of the 
cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass 
surgery. J Thorac Cardiovasc Surg. 2003;125(6):1481-92.
269. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the 
COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081-91.
270. Grosen K, Drewes AM, Hojsgaard A, Pfeiffer-Jensen M, Hjortdal VE, Pilegaard HK. Perioperative 
gabapentin for the prevention of persistent pain after thoracotomy: a randomized controlled trial. Eur 
J Cardiothorac Surg. 2014;46(1):76-85.
271. Mishriky BM, Waldron NH, Habib AS. Impact of pregabalin on acute and persistent postoperative pain: 
a systematic review and meta-analysis. Br J Anaesth. 2015;114(1):10-31.
443
Clinical guidelines on perioperative medication in adult cardiac surgery 
16
272. Nesher N, Serovian I, Marouani N, Chazan S, Weinbroum AA. Ketamine spares morphine consumption 
after transthoracic lung and heart surgery without adverse hemodynamic effects. Pharmacol Res. 
2008;58(1):38-44.
273. Kubal C, Srinivasan AK, Grayson AD, Fabri BM, Chalmers JA. Effect of risk-adjusted diabetes on 
mortality and morbidity after coronary artery bypass surgery. Ann Thorac Surg. 2005;79(5):1570-6.
274. Ascione R, Rogers CA, Rajakaruna C, Angelini GD. Inadequate blood glucose control is associated with 
in-hospital mortality and morbidity in diabetic and nondiabetic patients undergoing cardiac surgery. 
Circulation. 2008;118(2):113-23.
275. Gandhi GY, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, O’Brien PC, et al. Intensive intraoperative 
insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. 
Ann Intern Med. 2007;146(4):233-43.
276. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin 
therapy in critically ill patients. N Engl J Med. 2001;345(19):1359-67.
277. Haga KK, McClymont KL, Clarke S, Grounds RS, Ng KY, Glyde DW, et al. The effect of tight glycaemic 
control, during and after cardiac surgery, on patient mortality and morbidity: A systematic review and 
meta-analysis. J Cardiothorac Surg. 2011;6:3.
278. Giakoumidakis K, Eltheni R, Patelarou E, Theologou S, Patris V, Michopanou N, et al. Effects of intensive 
glycemic control on outcomes of cardiac surgery. Heart Lung. 2013;42(2):146-51.
279. Halkos ME, Puskas JD, Lattouf OM, Kilgo P, Kerendi F, Song HK, et al. Elevated preoperative hemoglobin 
A1c level is predictive of adverse events after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 
2008;136(3):631-40.
280. Marik PE. Tight glycemic control in acutely ill patients: low evidence of benefit, high evidence of harm! 
Intensive Care Med. 2016;42(9):1475-7.
281. Preiser JC, Straaten HM. Glycemic control: please agree to disagree. Intensive Care Med. 2016;42(9):1482-
4.
282. Bhamidipati CM, LaPar DJ, Stukenborg GJ, Morrison CC, Kern JA, Kron IL, et al. Superiority of moderate 
control of hyperglycemia to tight control in patients undergoing coronary artery bypass grafting. J 
Thorac Cardiovasc Surg. 2011;141(2):543-51.
283. Lazar HL, McDonnell MM, Chipkin S, Fitzgerald C, Bliss C, Cabral H. Effects of aggressive versus 
moderate glycemic control on clinical outcomes in diabetic coronary artery bypass graft patients. Ann 
Surg. 2011;254(3):458-63; discussion 63-4.
284. Buchleitner AM, Martinez-Alonso M, Hernandez M, Sola I, Mauricio D. Perioperative glycaemic control 
for diabetic patients undergoing surgery. Cochrane Database Syst Rev. 2012(9):CD007315.
285. Desai SP, Henry LL, Holmes SD, Hunt SL, Martin CT, Hebsur S, et al. Strict versus liberal target range 
for perioperative glucose in patients undergoing coronary artery bypass grafting: a prospective 
randomized controlled trial. J Thorac Cardiovasc Surg. 2012;143(2):318-25.
286. Umpierrez G, Cardona S, Pasquel F, Jacobs S, Peng L, Unigwe M, et al. Randomized Controlled Trial of 
Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft 
Surgery: GLUCO-CABG Trial. Diabetes Care. 2015;38(9):1665-72.
287. Investigators N-SS, Finfer S, Chittock DR, Su SY, Blair D, Foster D, et al. Intensive versus conventional 
glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283-97.
288. Kotagal M, Symons RG, Hirsch IB, Umpierrez GE, Dellinger EP, Farrokhi ET, et al. Perioperative 
hyperglycemia and risk of adverse events among patients with and without diabetes. Ann Surg. 
2015;261(1):97-103.
289. Greco G, Ferket BS, D’Alessandro DA, Shi W, Horvath KA, Rosen A, et al. Diabetes and the Association 
of Postoperative Hyperglycemia With Clinical and Economic Outcomes in Cardiac Surgery. Diabetes 
Care. 2016;39(3):408-17.
290. Mathioudakis N, Golden SH. A comparison of inpatient glucose management guidelines: implications 
for patient safety and quality. Curr Diab Rep. 2015;15(3):13.

Chapter 17
Mixing ‘apples and oranges’ in meta-analytic studies: 
dangerous or delicious?
Milojevic M, Sousa-Uva M, Durko AP, Head SJ. 
Eur J Cardiothorac Surg. 2018;53:1294-1298.
446
Chapter 17
447
Mixing ‘apples and oranges’ in meta-analytic studies: dangerous or delicious?
17
TO THE EDITOR:
Sá et al. (1) observed no significant difference regarding the risk of perioperative 
myocardial infarction (MI) if the administration of acetylsalicylic acid (ASA) was 
stopped or continued in patients before undergoing coronary artery bypass graft 
(CABG) surgery. Compared with a similar meta-analysis reported by Hastings et 
al. (2) in 2015, only the results from the more recently released ATACAS trial were 
added to the analysis. However, we have a major concern regarding the inclusion 
criteria of this meta-analysis.
First, the appropriateness for the inclusion criteria of a study is questionable. 
The variation in design across studies is high, i.e. from the continuation of ASA 
until the day of surgery to the initiation of ASA in na¨ıve patients on the day of 
surgery. For example, in the aspirin and tranexamic acid for coronary artery 
surgery (ATACAS) study (3), which consisted of approximately 50% of all patients 
included in this meta-analysis, patients were only eligible if they were not taking 
or stopped taking aspirin at least 4 days before surgery and were randomized to 
receive 100 mg of aspirin or placebo on the day of surgery. Therefore, patients 
who continued aspirin were not included in the trial, which is highly misleading 
with regard to the title of the article.
Moreover, if we wanted to test whether a single dose of aspirin on the day of 
surgery would reduce ischaemic events in patients who discontinued aspirin for 
at least 4 days before surgery, the given 100 mg dose would only result in partial 
platelet inhibition. When stopping the administration of aspirin, full platelet 
function recovery is observed after 96 h (4), and a (re)loading dose of at least 160 mg 
would be required to sufficiently inhibit platelet function (5). Second, since other 
included studies fulfilled the criteria of full platelet inhibition based on the dose 
of administered ASA, this meta-analysis mixes the results of patients with total and 
partial platelet inhibition, with potentially misleading consequences. The authors 
also performed a sensitivity analysis excluding the ATACAS study: the reported 
finding was still non-significant about the effect of continued ASA on the reduction 
in perioperative MI (risk ratio 0.62, 95% confidence interval 0.37–1.05; P = 0.074). 
This is particularly interesting in the light of a recent meta-analysis published 
by Hastings and colleagues from Melbourne (2). This study—neither cited nor 
discussed by the authors—demonstrated a significant reduction in perioperative 
MI with continued ASA (odds ratio 0.56, 95% confidence interval 0.33–0.96; 
P = 0.03)—with the exact same studies included as in the sensitivity analysis 
performed by Sa et al. (1). These results seem to depend on the effect measure that 
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is chosen and that by itself introduces a dilemma on how strong the evidence is. 
However, borderline P-values cannot be considered as a strong argument either 
for or against an intervention, and the risk–benefit ratio of thrombotic risk versus 
bleeding risk should be considered in treatment decision-making.
The recently published EACTS Guidelines on perioperative medication in adult 
cardiac surgery recommends that ‘in patients on ASA who need to undergo 
CABG surgery, continuing ASA throughout the preoperative period should be 
considered (Class IIa, Level of Evidence C)’ (6). This is mainly based on the meta-
analysis by Hasting et al. (2), where the use of ASA resulted in a 44% reduction in 
perioperative MI with an acceptable increase in the total chest blood drainage 
(mean + 168 ml).
On the basis of these arguments, we do not believe that the results of the ATACAS 
study and other studies that randomized patients to either ASA or placebo on the 
day of surgery are appropriate in a meta-analysis aiming to answer the question 
of whether to stop or continue ASA before CABG. From the perspective of recently 
published several clinical guidelines, this meta-analysis is confusing and may be 
potentially misleading due to its strong conclusions. On the basis of the risk–benefit 
ratio, we believe that ASA should be continued throughout the perioperative period 
in patients awaiting CABG who are not at a high bleeding risk.
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Chapter 1 is a general introduction to this thesis. This chapter gives an overview of 
the epidemiology and current trends in myocardial revascularization in Europe. 
Although both percutaneous coronary intervention (PCI) and coronary artery 
bypass grafting (CABG) are used in patients with left main (LM) disease and/or 
multivessel disease, the optimal patient selection and individualized medication 
strategies are crucial to ensure improved outcomes. Rigorously developed 
evidence-based recommendations in clinical guidelines can improve decision-
making and quality of health-care. The studies in this thesis should inform 
clinicians about specifically choosing revascularization strategies for patients 
with coronary artery disease. The aims and outline of this thesis are described in 
chapter 2.
Part 1. 
Current Practice in Bypass Surgery
Chapter 3 describes the outcome and life expectancy of the first venous CABG 
procedures during 40 years of follow-up. The 10-, 20-, 30and 40-year survival 
for the 1041 patients who underwent CABG between 1971 and 1980 was 77%, 
39%, 14% and 4%, respectively. Average life expectancy was 18 years while 
repeat revascularization was performed in 36% of patients. Factors associated 
with decreased late survival were the age at operation, diabetes mellitus (DM), 
multivessel disease and left ventricular ejection fraction under 50%. However, 
over the last four decades, surgical techniques have improved, increasing its safety 
and efficacy while at the same time reducing invasiveness and re-intervention 
demands. The proper use of surgical techniques is most closely linked to the 
revascularization success or failure. A critical evaluation of contemporary 
indications, techniques, and outcomes of bypass surgery are discussed in 
Chapter 4. This review suggests that, despite its improvements, several techniques 
for CABG surgery can be adopted more widely to further improve outcomes: use 
of intraoperative graft flow assessment, epiaortic scanning, more use of arterial 
conduits, and hybrid revascularization. 
To steer the choice of the most optimal technique, clinical practice guidelines 
are one of the most valuable tools. One of the major advances has been a class 
IC recommendation for the multidisciplinary “Heart Team” decision-making 
process in the North American and European guidelines for revascularization. 
Evidence to support the Heart Team is scarce, and some clinicians fear that the 
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requirement of a Heart Team discussion can delay treatments and be unsafe for 
patients. Chapter 5 provides evidence that real-world Heart Team meetings are 
feasible and safe in evaluating coronary artery disease complexity and additional 
comorbidities along with patient’s preferences to guide the most appropriate 
revascularization strategy. Approximately 90% of patients received treatment 
within 6 weeks, as recommended by the 2014 European Society of Cardiology 
(ESC) / European Association for Cardio-Thoracic Surgery (EACTS) Guidelines 
on myocardial revascularization. Delay was caused by the need for additional 
diagnostic tests to be performed, showing that logistics can be further improved.
Part 2. 
Bypass Surgery versus Stenting
Several multicenter randomized clinical trials (RCTs) have examined the clinical 
effects of PCI versus CABG across patients with multivessel and/or LM disease. 
One of these trials was the Synergy between Percutaneous Coronary Intervention 
with Taxus and Cardiac Surgery  (SYNTAX) trial; a large randomized multicenter 
study comparing PCI with first-generation drug-eluting stents (DES) (TAXUS™ 
Express™, Boston Scientific) to CABG for patients with three-vessel and/or LM 
disease.  A significant contribution of the SYNTAX trial was the development of 
the SYNTAX score, which has become a unique tool to score the complexity of 
coronary artery disease (CAD) and to help guide decision-making between PCI 
and CABG. 
The RCTs that have been performed used various composite endpoints with 
a varying clinical impact to boost the statistical power, but no study has been 
adequately powered to examine the mortality differences as the primary outcome. 
Chapter 6 provides an individual patient-data pooled analysis of 11518 patients from 
11 RCTs, which showed a significantly higher 5-year mortality rate after PCI than 
after CABG in patients with multivessel disease, especially in those with diabetes 
and higher coronary complexity according to the core laboratory SYNTAX scores. 
Furthermore, in patients with LM disease, no difference in mortality rate was seen 
between two treatment groups. In Chapter 7, the specific cause of mortality was 
examined based on data from the SYNTAX trial, demonstrating that cardiac death 
due to spontaneous myocardial infarction (MI) was markedly higher after PCI with 
TAXUS compared to CABG at 5-year of follow-up.
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Stroke following PCI and CABG, although rare, can be a devastating complication, 
associated with high rates of mortality and reduced health-related quality of 
life. In Chapter 8, we found, among 11518 patients randomized to CABG or PCI 
with stents, that PCI was associated with significantly lower 30-day stroke rates 
compared to CABG (0.4% versus 1.1%, respectively), but no difference was found 
between two treatment groups beyond 30-day after the procedures. Comparing 
CABG with PCI, diabetes had a significant effect on the occurrence of stroke during 
5 years of follow-up (2.6% versus 4.9%, P for Interaction = 0.004). The reason for 
the higher rates of stroke after CABG may be multifactorial, including the use of 
antifibrinolytics to reduce the risk of bleeding after surgery. Chapter 9 is a letter 
to the editor that stresses the importance of the correct intraoperative dose of 
antifibrinolytics-tranexamic acid (TXA) agent to prevent bleeding complications 
after CABG, but also highlights that the routine use of TXA may influence the 
perioperative stroke occurrence in CABG.
In chapter 10, additional analyses from the SYNTAX trial were conducted to 
explore the impact of repeat revascularization on the 5-year clinical outcome. 
Rates of repeat revascularization are higher after PCI compared with CABG at all-
time points. Our study reports that at 5-year follow-up, repeat revascularization 
rates were significantly higher after PCI compared to CABG (13.7% versus 25.9%, 
P<0.001), showing a significant correlation between any repeat revascularization 
after an initial PCI procedure and increase in the incidence of serious adverse 
events. Moreover, long-term results have also demonstrated a significantly 
higher need for multiple repeat revascularization after an initial PCI than 
after CABG (9.0% versus 2.8%, P=0.022; respectively). Independent predictors 
of repeat revascularization were diabetes, incomplete revascularization, the 
number of overlapping stents and absence of antiplatelet therapy among patients 
randomized to PCI while the treatment in the United States and the use of off-
pump technique were reliable predictors of repeat revascularization in the CABG 
group. 
Apart from the individual endpoints of mortality, myocardial infarction, stroke, 
and repeat revascularization, clinical trials often use composite endpoints 
to increase the statistical power of the analyses. Individual endpoints in 
composites are weighted equally, while the different individual components 
have evident varying impacts on long-term prognosis. Therefore, several novel 
approaches to assess the results of composite endpoints have been introduced. In 
chapter 11, a win ratio approach is applied on the SYNTAX trial to provide 
additional clinical insights into the results of the primary composite endpoint 
458
Chapter 18
of mortality, stroke, MI or repeat revascularization, also evaluating strengths 
and weaknesses of alternative methods for the analysis of composite endpoints. 
This study demonstrates that the critical advantage of CABG over multivessel PCI 
is the reduction of hard clinical endpoints such as mortality and MI. Moreover, 
this approach is readily applicable to analyze composite endpoints with multiple 
distinct events, while maintaining the integrity of the study results. 
Multiple factors can influence treatment decision-making. Patients with chronic 
kidney disease (CKD) and/or diabetes have a high prevalence of CAD and high 
risk of cardiovascular mortality. Whether the use of PCI or CABG would improve 
patient survival in patients with these associated diseases remains uncertain 
due to limited data from randomized comparisons and conflicting data from 
observational studies. To address this knowledge gap, the effect of CKD on 
5-year outcome after PCI and CABG in the SYNTAX trial has been investigated in 
chapter 12. This subgroup analysis shows that CABG appears to be the favorable 
revascularization strategy over PCI, mainly supporting the more significant use of 
CABG among diabetic patients complicated by CKD. A randomized study of 1905 
patients with LM disease, enrolled in the Evaluation of XIENCE versus Coronary 
Artery Bypass Surgery for Effectiveness of Left Main Revascularization  (EXCEL) 
trial compared CABG with second-generation DES. Patients with diabetes had 
a significantly higher rate of the 3-year composite primary endpoint of death, 
stroke or MI (12.9% versus 20.0%, P<0.001) (chapter 13). However, there was no 
difference in the primary endpoint between PCI and CABG in diabetic patients 
(20.7% versus 19.3%, P=0.87) and non-diabetic patients (12.9% versus 12.9%, 
P=0.89), suggesting that in selected diabetic patients with LM, PCI may be a 
reasonable treatment approach beyond CABG. 
The globalization of clinical trials has emerged as a new phenomenon describing 
the movement of trial location to lower-income countries to decrease costs 
and accelerate recruitment of trial participants. One of the major concerns is 
that the imbalance between the quality of care, patient health levels, treatment 
choice, and hospital infrastructures may influence the overall generalization 
of the trial results. Chapter 14 focuses on the influence of practice patterns on 
outcomes in specific countries within the SYNTAX trial. We found that baseline 
characteristics of included patients and clinical practice patterns are substantially 
different between participating countries, resulting in a significant difference in 
clinical outcomes, for which specific treatment recommendations were provided. 
Furthermore, relevant aspects for future trial design are discussed.
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Part 3.
Improving Outcomes in Cardiac Surgery
Advances in the whole spectrum of hospital care have resulted in significant 
improvements of in-hospital outcomes in patients undergoing CABG. However, 
CAD is a chronic progressive process that requires intensive postoperative 
medication therapy to slow  down the  progression of the disease and reduce the 
risks of future cardiovascular events. Clinical guidelines are developed to help in 
decision-making by  providing recommendations  that are supported by the best 
available evidence. Along with increasing awareness of clinical outcomes between 
different treatment modalities, clinical trials can provide valuable information 
about the use of guideline-recommended medical therapy (GDMT) in daily 
practice. In chapter 15, based on an individual patient-data analysis of 7085 
patients from 5 RCTs, we studied the compliance with GDMT after myocardial 
revascularization. The pooled analysis shows the suboptimal use of GDMT after 
CABG and significant correlation between the optimal use of medications and 
risks of adverse clinical outcomes at 5 years of follow-up. Moreover, in chapter 
16, we provide the evidence-based recommendations for perioperative medical 
therapies in adult cardiac surgery. Chapter 17 is a letter to the editor that discusses 
the evidence used to answer the question regarding stopping or continuing 
acetylsalicylic acid (ASA) until the day of CABG. The main finding of this meta-
analysis was opposite to our clinical guideline recommendations. Therefore, 
methodological comments on the inclusion and exclusion criteria for given meta-
analysis and the most important trials in this field are put into perspective to 
substantiate the recommendations in our treatment guidelines.
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This thesis aimed to identify patients with stable coronary disease who, based on 
projected outcomes, should be preferentially selected for CABG or PCI, but also to 
provide considerations for clinical decision-making and designs of future clinical 
trials. In this chapter, the main findings will be put into broader perspective, 
highlighting the implications for current clinical practice. Moreover, future 
directions for research are presented.
Current Practice in Bypass Surgery (Part 1)
Coronary artery bypass grafting (CABG) remains the most common operation 
performed by cardiac surgeons today (1). The procedure has significantly evolved 
over the past 50 years into a technique that is safe and efficient (2). Despite an 
increasingly higher risk profile of patients, advances in surgical techniques as 
well as in the whole spectrum of patient care are associated with a continuous 
reduction in postoperative complications even in contemporary practice. 
Fifty years ago, the use of the saphenous vein grafts helped to establish CABG 
as a standard of care for patients with refractory angina, but its tendency for 
progressive failure has caused a high incidence of repeat revascularization 
early after initial venous CABG. In a review of the literature on contemporary 
indications, practice patterns, and outcomes of CABG, we found that modern 
techniques can markedly improve the durability of myocardial revascularization 
with less need for repeat revascularization. Recent procedural achievements 
such as appropriate conduit selection, no-touch procedures, epiaortic scanning, 
intraoperative graft assessment, minimally invasive procedures, robotic-assisted 
surgery will undoubtedly bring less post-operative complications, particularly 
stroke, improving the life-expectancy and health-related quality of life. On the 
other hand, despite these proven benefits, low adoption rates of the essential 
surgical techniques in many surgical centers is deeply worrying. It is remarkable 
that use of single internal mammary artery (IMA) that  is considered the gold-
standard conduit in CABG for more than 30 years (3), remains far away from 
being widely accepted (4). With this knowledge as a reality, the hospital and 
national quality improvement programs should play a vital role in bridging the 
gaps between scientific evidence and clinical practice, to ensure patients access to 
efficient and high-quality care (5). 
Another crucial element to improve the outcomes of patients with CAD is patient 
selection on the basis of specific treatments that are individualized to the unique 
characteristics of the particular patient. It is well acknowledged that a variety of 
risk factors are known to influence postprocedural complications and long-term 
outcomes. According to the latest European and American revascularization 
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guidelines, the cornerstone for decision-making involves the formation of Heart 
Teams, which includes a multidisciplinary team consisting of a clinical/non-
invasive cardiologist, interventional cardiologist, and cardiac surgeon, with other 
specialists as needed (6, 7). The purpose of the Heart Team concept is to identify 
the most appropriate treatment for the particular patient and help patients and 
their family to reach the best treatment choice. These Heart Teams have a class I 
but the level of evidence C recommendation. There is no evidence from studies 
to support Heart Teams, and many clinics, therefore, lack a formal Heart Team 
discussion. One of the limitations may be an increase in waiting times for patients 
to undergo a procedure. We demonstrated that a real-world Heart Team approach 
is a feasible strategy for the management of patients with stable coronary artery 
disease (CAD) while it does not compromise the waiting time for treatment. 
Moreover, the final treatment decisions in the majority of cases were adherent to 
the recommendations of the guidelines, suggesting that this team approach can 
promote transparency in decision-making and minimize physician-related bias. 
Bypass Surgery versus Stenting (Part 2)
Improvements in outcomes of CABG surgery have been paralleled if not exceeded 
by improvements in outcomes after percutaneous coronary intervention (PCI). 
As a result, numerous randomized clinical trials (RCTs) have been performed 
to compare the safety and efficacy of PCI versus CABG in patients with CAD 
(Figure). While PCI is now an established first-line treatment for patients with 
acute indications and those with a relatively simple CAD, it remains unclear 
whether CABG or PCI should be preferred in patients with more complex disease 
as defined by multivessel coronary disease or involvement of the left main (LM) 
stem.
Several trials evaluated the effects of CABG versus PCI with balloon angioplasty, 
while later trials compared CABG with PCI with bare metal stent (BMS) among 
patients with multivessel disease. Over a median follow-up of 5.9 years, the pooled 
analysis of individual data on 7812 patients from these 10 RCTs shows no difference 
between CABG and PCI in the rates of death (8.4% versus 10.0%, P=0.12), but the 
composite outcome of death, MI or repeat revascularization was significantly 
lower after CABG than after PCI (20.1% versus 36.4%, P<0.001) (8). The superiority 
of CABG over PCI was established in patients with diabetes (12.3% versus 20.0%,) 
while mortality was similar between groups in non-diabetes patients (7.6% versus 
8.1%) (P for interaction=0.014). With the introduction of drug-eluting stents (DES) 
and dual antiplatelet therapy (DAPT) as the standard of care (9, 10), ischaemic 
complications and the need for repeat revascularization have been reduced after 
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PCI. As a result, PCI is increasingly considered to be a safe and effective approach 
for patients with multivessel and/or LM disease and diabetes (DM). These 
improvements have led to further comparisons between PCI with first-generation 
DES and CABG in several trials. The Synergy between Percutaneous Coronary 
Intervention with Taxus and Cardiac Surgery   (SYNTAX) trial is one of the most 
contemporary and influential trials, comparing PCI with first-generation DES 
(TAXUS™ Express™, Boston Scientific) to CABG in 1800 patients with three-
vessel and/or LM disease, who were deemed eligible for treatment by both CABG 
or PCI. The main results showed that CABG (with the use of at least one arterial 
graft) is superior to PCI in term of the primary composite endpoint of all-cause 
death, stroke, myocardial infarction (MI), and repeat revascularization with first-
generation DES, mainly due to the reduction of spontaneous MI and the need 
for repeat revascularization (11). The results of other clinical trials have reported 
similar outcomes as the SYNTAX trial. CABG reduced the rate of spontaneous MI 
and need for repeat revascularization while PCI was associated with lower rates of 
stroke. Second-generation DES with use of more effective antiplatelet agents were 
developed to further improve the outcomes after PCI but failed to demonstrate 
comparability to CABG among patients with multivessel disease enrolled in the 
Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel 
Coronary Artery Disease (BEST) trial. Nevertheless, available evidence from the 
Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness 
of Left Main Revascularization (EXCEL) trial that compared CABG with PCI 
using newer-generation DES among patients with LM disease suggested similar 
outcomes for the composite of death or stroke, or MI up to 3.5 years of follow-
up, but need for repeat revascularization remain significantly higher after PCI. 
These results have not been confirmed in the Nordic-Baltic-British Left Main 
Revascularization Study (NOBLE) trial. 
Since all individual RCTs were underpowered to detect a difference in mortality 
rates, a pooled analysis of individual data of 11518 patients from 11 RCTs was 
performed to examine the risk of mortality following CABG versus PCI with stents. 
The absolute difference in mortality at 5-year follow-up was small but significant 
(CABG 9.2% versus PCI 11.2%, P=0.004). While the investigated studies are different 
with regard to the inclusion criteria such as the anatomical complexity of CAD, we 
also found the advantage of CABG over PCI in patients with multivessel disease 
and diabetes, but not in patients with LM disease and those with multivessel 
disease without diabetes. Moreover, the death rate of PCI versus CABG was 
significantly increased with higher SYNTAX scores (linear trend test, P=0.011), 
confirming that the anatomical complexity assessed by SYNTAX score can be a 
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useful tool in selecting the proper revascularization strategy (12). The majority 
of patients with LM disease have in recent years been treated in a background 
context of consistent progress in contemporary PCI practice, including safer 
and more effective DES and better adherence to secondary prevention medical 
therapy, suggesting that PCI for LM disease has become a viable option in selected 
cases with the appropriate angiographic and clinical settings.
A post-hoc analysis of the SYNTAX trial aimed to determine the specific cause of 
mortality at 5-year follow-up. Although the Surgical Treatment for Ischemic Heart 
Failure (STICH) trial has shown a significant benefit of CABG over medical therapy 
in the reduction of sudden cardiac mortality or MI-related mortality events (13), the 
findings of the SYNTAX trial for the first time indicate that CABG-treated patients 
were at significantly lower risk of cardiac mortality than those managed with PCI. 
Furthermore, CABG particularly reduces the incidence of cardiac mortality events 
as a consequence of spontaneous MI. This reduction was most significant in patients 
with more complex lesion complexity (diabetes, three-vessel disease, or a SYNTAX 
score >=33) which strengthens the previous finding that was found in the pooled 
analysis of the individual patient data from 11 RCTs.
Beyond mortality, it is also important to consider other major cardiovascular 
events that can significantly impact the quality of life following myocardial 
revascularization, particularly stroke. The occurrence of stroke was infrequent 
in randomized trials and therefore insufficient to detect clinically meaningful 
differences between PCI and CABG (14, 15). In the pooled dataset of 11 RCTs, 
PCI retained an advantage over CABG regarding significantly lower 30-day and 
5-year rates of stroke, though the rates of stroke were similar between 31 days 
and 5 years. The mechanisms underlying the increased risk of periprocedural 
stroke with surgery are likely multifactorial including polyvascular disease, 
surgical techniques, routine use of prophylactic procoagulant agents and 
cerebral hypoperfusion during cardiopulmonary bypass. We found that the 
higher risk of stroke after CABG compared to PCI was restricted to patients with 
diabetes and multivessel disease, which may be associated with a higher burden 
of atherosclerotic disease not only in the coronary arteries but also in the aorta 
and carotid arteries. Different strategies can be used to combat emboli and their 
resultant stroke after CABG. These include aortic no-touch techniques, epiaortic 
scanning, monitoring of cerebral oximetry for early detection and treatment 
of cerebral hypoxia, avoiding the use of antifibrinolytic agents in patients at 
high risk of recurrent stroke, and the more aggressive start of postoperative 
anticoagulation in patients who have developed atrial fibrillation. 
468
Chapter 19
One of the main findings of the SYNTAX trial was that CABG compared with PCI, 
provides markedly less need for repeat revascularization (13.7% versus 25.9%, 
P<0.0001). Although in PCI with newer-generation DES, the incidence of in-stent 
restenosis and need for repeat revascularization is lower compared to PCI with 
first-generation stents (16), several studies performed after the SYNTAX trial have 
also reported higher rates of repeat revascularization (17). Repeat revascularization 
is often considered to be a benign endpoint in RCTs. However, no studies have 
provided an analysis to provide insights into incidence, characteristics, and 
outcomes of repeat revascularization. Therefore, we performed an in-depth 
investigation of repeat revascularization at 5-year follow-up in the SYNTAX trial. 
Importantly, we found that repeat revascularization was an independent predictor 
of hard clinical endpoints in the PCI group, driving the difference between CABG 
and PCI in the overall results. On the other hand, similar outcomes between PCI 
and CABG patients who did not undergo repeat revascularization suggests that 
careful patient selection by  Heart Team is essential to minimize risks of adverse 
events caused by the inappropriate choice of revascularization procedure (18). 
In addition to a previously published study that identified predictors of repeat 
revascularization after PCI with newer-generation DES (19), our results add 
significantly to the current body of evidence. The main results emphasized the 
importance of diabetes and incomplete revascularization after PCI and off-pump 
surgery after CABG as predictors of future repeat revascularization. Furthermore, 
as shown in our results, the importance of secondary prevention is essential to 
improving outcomes in this regard. 
The SYNTAX trial was unique in the inclusion of patients with mild-to-moderate 
chronic kidney disease (CKD). In the most recent European guideline, it remains 
unclear whether PCI or CABG should be preferred in patients with CKD (7). Thus, 
we provided the comparative effectiveness of the two revascularization strategies 
in patients with CKD (Chapter 12). We found a profound negative impact of CKD 
compared to patients with normal kidney function on 5-year survival following 
both PCI (26.7% versus 10.8%, P<0.001, respectively) and CABG (21.2% versus 
10.6%, P=0.005, respectively). We also found that concomitant diabetes was the 
most critical determinant of long-term survival after PCI (40.9% versus 17.7%, 
P=0.004). Additionally, deficiencies in the use of recommended medications after 
both CABG and PCI are noted. The benefit of secondary prevention therapies 
is crucial in patients with CKD to derive maximum benefit from myocardial 
revascularization (20, 21). Experience from numerous clinical trials in the field 
of cardiovascular medicine has shown a strong link between subgroup analyses 
and the future findings of dedicated RCTs if the results are interpreted correctly. 
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Although the SYNTAX trial has found that PCI was inferior to CABG for the 
primary outcome at 5 years (11), a secondary analysis suggested that subgroup 
of patients with LM disease and low-to-intermediate SYNTAX scores (0-32) had 
similar results with PCI and CABG (22). This hypothesis has been further tested by 
the EXCEL trial that compared PCI with newer-generation DES (XIENCE Family 
Stent System, Abbott Vascular) in 1905 patients with significant LM disease eligible 
for either PCI or CABG and a SYNTAX score <=32 (23). The primary composite 
endpoint of all-cause death, stroke or MI in this trial indicated that PCI with DES 
was noninferior to CABG for clinical and functional results at 3 years (24, 25). In 
a pre-specified subgroup analysis of the EXCEL trial we found that compared to 
non-diabetic patients, diabetic patients had higher 3-year rates of the composite 
primary endpoint, including higher rates of all-cause death, MI, and ischemia-
driven revascularization, again reinforcing the fact that diabetes is one of the most 
critical determinants of long-term outcomes after myocardial revascularization 
irrespective of the location of coronary lesion. In line with the findings from the 
pooled analysis of individual patient data from the PRECOMBAT and the SYNTAX 
trials (26), patients who underwent PCI had a similar rate of the 3-year primary 
composite endpoint of death, stroke or MI compared to those who underwent 
CABG, in both diabetes and non-diabetes-treated patients. However, similarly 
to the findings from the FREEDOM trial (27), we found the significant difference 
in all-cause mortality between PCI and CABG at 3 years in diabetic patients 
(13.6% versus 8.0%, P=0.046), but not in non-diabetic patients (5.5% versus 5.0%, 
P=0.71). Longer-term follow-up results are necessary to provide insights into the 
durability of PCI in LM patients with diabetes. These observations from subgroup 
analyses reinforce the need for experienced Heart Team to recommend PCI 
to achieve optimal outcomes in selected patients, but also assist clinicians in 
improving adherence to medication in patients with CKD. After all, long-term 
medication management mainly depends on the treating clinician who prescribes 
secondary prevention at discharge, rather than on primary care physicians, who 
will be reluctant to assume such responsibility themselves. 
An essential feature to reduce sample size, lower costs and the time for 
enrollment in clinical trials, is the use of composite endpoints. A growing number 
of clinical trials use composite outcomes, in which mortality and nonfatal events 
are combined into a single endpoint to compare treatment effects. Ideally, the 
events in composite outcomes need to be of high clinical importance and share 
similar severity. To date, clinical trials of myocardial revascularization were only 
powered to detect differences in the composite outcomes that incorporated a 
combination of three to six events with various clinical effects. These composite 
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outcomes may prove to be one of the leading challenges in the interpretation of 
trial results, particularly if the components are of widely differing importance 
for patients such as mortality and the need for repeat revascularization with 
PCI (28). Therefore, the conventional reporting of composite outcomes has an 
inherent limitation, and clinicians usually need to  develop rigorous habits of 
critical thinking between risks and benefits during the interpretation of trial 
results. To overcome these limitations, several alternative methods are designed 
to assess the composite outcomes, including the win ratio methodology (29, 30). 
Based on clinical impact, the win ratio approach was applied to the results of the 
SYNTAX trial, accounting for the severity of the individual components within the 
primary composite endpoint. We showed that the win ratio methodology was able 
to analyze the different components of the composite endpoint and also could 
adequately discriminate clinical outcomes between the two treatments. Although 
this analysis was “hypothesis-generating” only, our findings strengthen the 
results in favor of CABG, confirming that mortality and spontaneous MI occurred 
more frequently in patients treated with PCI. The win ratio analysis has also been 
applied and assessed within the TRILOGY ACS trial (31). In line with our findings, 
the authors concluded that the use of win ratio approach is a valuable alternative 
to a traditional time-to-event analysis especially in studies where multiple non-
fatal events are more common. We propose that future clinical trials should adopt 
this approach to provide additional insights into trial results, but also to maximize 
efficacy through the use of smaller sample sizes, and therefore, to decrease the 
cost of research. If it is not used as the primary method for analyzing clinical trial 
results, using the win ratio for sensitivity analyses will improve interpretation of 
results.
The previously mentioned clinical trials in the field of myocardial 
revascularization obtained their main results based on the collaboration between 
medical institutions from many different countries. Since the early 2000s, the 
rapid expansion and integration of industry-supported clinical trials at sites in 
developing countries can be attributed to several factors, including the lower 
cost of local investigators and treating patients, deregulation of bureaucratic 
and/or ethical standards, and accelerating patient recruitment (32). The main 
advantage of conducting clinical trials on a global scale is building supportive 
relationships among clinicians, but also answering clinical questions that are 
applicable worldwide and could serve as a basis for harmonization of clinical 
practice. At the same time, the results from cardiovascular trials showed 
differences between participating countries for many reasons (33), including the 
disparities in health care systems, medical infrastructure, local practice patterns, 
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and socioeconomic status of patients (34). In Chapter 14, we analyzed the 
treatment differences between participating countries and its impact on the final 
results of the SYNTAX trial. A significant finding was that patient characteristics, 
clinical patterns, medication regimens and outcomes were significantly different 
across investigated countries. In short, meaningful clinical differences in 
CABG techniques that may affect the outcomes such as the use of the single or 
bilateral IMAs, total arterial revascularization, and off-pump CABG were noted. 
Furthermore, substantial differences were observed in PCI-treated patients 
including the number of implanted stents and the use of DAPT at discharge. The 
discrepancy emphasizes the importance of country-level analyses as prespecified 
in the design of future trials. In addition, the rise of this information during local, 
national, and international meetings and its translation to clinical practice would 
contribute to the standardization of myocardial revascularization. 
Improving Outcomes in Cardiac Surgery (Part 3) 
Although in-hospital mortality rates have decreased in recent years as a 
consequence of tremendous progress achieved in perioperative patient care, the 
incidence of post-discharge adverse events remains high (35.36). Several studies 
have established that early cardiac rehabilitation with lifestyle modification and 
lifelong optimized medication therapies are paramount for improved survival 
and better quality of life (37). In line with these data, our studies have established 
the importance of using secondary prevention therapies as a fundamental 
approach in reducing the incidence of cardiovascular events. Based on individual 
data from 5 landmark RCTs of myocardial revascularization, a unique analysis of 
compliance with guideline-directed medical therapy (GDMT) after myocardial 
revascularization was conducted, including a total of 7085 patients (Chapter 
16). The pooled data showed poor compliance with GDMT (any antiplatelet 
agent, beta-blocker, and statin) of 54% at discharge that has declined to 51% at 
5 years of follow-up after CABG. Adherence to GDMT was consistently lower in 
CABG than in PCI patients at all-time points while our findings suggest a high 
correlation between low compliance rates and adverse clinical outcomes. The 
misunderstanding that CABG is a curative treatment for CAD is undoubtedly a 
relevant factor affecting the long-term consequences. Coronary artery disease 
has a progressive lifelong course that requires continued and permanent 
management. Based on our results, discharge of patients without optimal 
medication therapy reduces medication adherence in the years after CABG, 
although optimizing medication adherence is the fundamental factor in reducing 
adverse events. Therefore, dedicated clinical practice guidelines with a primary 
focus on the pharmacological agents that are used for  primary and secondary 
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prevention  in patients undergoing adult cardiac surgery are required to guide 
physicians on how to optimize medication use (Chapter 17). These projects 
brought together a multidisciplinary group of specialists including cardiac 
surgeons, cardiologists, anesthesiologists and clinical epidemiologists in a joint 
task force to systematically review and grade a large body of evidence. The goal was 
to develop evidence-based, patient-centered, clinical practice recommendations 
that are easy to adopt and useful in daily practice. Clear recommendations were 
provided on antiplatelet and anticoagulation therapies, different modalities 
of antihypertensive treatment, optimal glycaemic control, and lipid-lowering 
therapies as essential agents to prevent further cardiovascular events. However, 
if guidelines are to be effective, their dissemination and implementation need 
to be actively pursued. Several strategies  must be combined for widespread 
implementation of clinical guidelines: i) development of short summaries ‘pocket 
guidelines’, ii) enrollment of clinical leaders from different countries in the 
development process to promote coherence, iii) use of professional journal and 
the media for promotion, iii) use of the professional platforms, iv) presentation 
and discussion during meetings, workshops or seminars, and v) offering feedback 
and recommendations on compliance. The task force members responsible for 
guidelines development should also identify barriers to a broader guideline 
acceptance and work as a team to overcome implementation barriers. In chapter 
18, we express our concerns about the methodological aspects used in the meta-
analysis of clinical outcomes associated with stopping or continuing acetylsalicylic 
acid (ASA) before CABG. The authors use inappropriate inclusion criteria to 
evaluate the efficacy and safety of keeping ASA until the day of CABG, and there 
was substantial variation in the design of studies. Importantly, the results and 
definite conclusion of this meta-analysis are potentially hazardous and can 
generate resistance among clinicians to implement useful recommendations 
from the recently published guidelines (38, 39). Especially for these reasons, a task 
force that includes a methodologist is responsible for providing clinical practice 
guidelines, to ensure that evidence to support recommendations is summarized 
and interpreted correctly. In summary, continuous development and regular 
update of clinical practice guidelines in contemporary healthcare as well as their 
implantation and critical appraisal of the recommendations must be one of the 
ultimate goals of academic societies. 
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CONCLUSIONS 
The clinical goals in the care of each patient with stable CAD are to ensure the 
selection of the most appropriate treatment, using the best evidence to guide 
procedural techniques and to modify risk factors that can impact survival and 
health-related quality of life. In this thesis, developments in surgical procedures, 
post-procedural therapies, and the most important determinants of outcomes 
after surgical and catheter-based myocardial revascularization are provided, 
thereby aiding patients and their clinicians to make the most appropriate 
revascularization strategy based on an individualized risk-benefit ratio. With 
the increasing number of clinical studies and rigorously developed clinical 
guidelines, a future-directed intention is needed to ensure the implementation 
of continuous improvement programs to increase the use of evidence-based 
practice in the hospital and outpatient settings to enhance the quality and safety 
of patient care.
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Hoofdstuk 1 is een algemene introductie van dit proefschrift. Dit hoofdstuk 
geeft een overzicht van de epidemiologie en de huidige ontwikkelingen op het 
gebied van myocard revascularisatie in Europa. Ondanks dat zowel percutane 
coronaire interventie (PCI) als coronaire bypass chirurgie (CABG) worden 
toegepast in patiënten met coronaire hoofdstam en/of meervats-coronairlijden, 
zijn de optimale patiëntselectie en individuele medicatie strategieën cruciaal om 
verbeteringen in klinische uitkomsten te kunnen bereiken. Zorgvuldig ontwikkelde 
aanbevelingen, gebaseerd op het beste beschikbare medisch-wetenschappelijk 
bewijs, samengevat in klinische richtlijnen kunnen de besluitvorming en de 
kwaliteit van de gezondheidszorg verbeteren. De studies in dit proefschrift dienen 
clinici te informeren welke specifieke revascularisatie strategie gekozen dient te 
worden in patiënten met coronair vaatlijden. De doelstellingen en de opzet van dit 
proefschrift worden beschreven in Hoofdstuk 2.
Deel 1. 
Huidig Beleid in Coronaire Bypass Chirurgie
Hoofdstuk 3 beschrijft de uitkomsten en levensverwachtingen van de eerste 
veneuze CABG procedure gedurende 40-jaar follow-up. De 10-, 20-, 30en 40-
jaar overleving van de 1041 patiënten die CABG hebben ondergaan tussen 1971 en 
1980 was 77%, 39%, 14% en 4%, respectievelijk. De gemiddelde levensverwachting 
was 18 jaar, herhaalde revascularisatie werd uitgevoerd in 36% van de patiënten. 
Factoren die geassocieerd zijn met een afgenomen late overleving zijn: leeftijd ten 
tijde van operatie, diabetes mellitus (DM), meervats-coronairlijden en een linker 
ventrikel ejectie fractie (LVEF) lager dan 50%. De chirurgische technieken zijn in 
de afgelopen vier decennia verbeterd, waardoor de veiligheid en effectiviteit zijn 
toegenomen. Tegelijkertijd zijn de mate van invasiviteit en de noodzaak tot re-
interventies afgenomen. Het adequaat toepassen van de chirurgische technieken 
is het nauwst gecorreleerd met succes of het falen van revascularisatie. Een 
kritische evaluatie van de hedendaagse indicaties, technieken en uitkomsten 
van coronaire bypass chirurgie wordt besproken in Hoofdstuk 4. Dit review 
suggereert dat, ondanks verbeteringen, verschillende technieken voor CABG meer 
wijdverspreid toegepast kunnen worden om uitkomsten verder te verbeteren, 
zoals het gebruik van “intra-operative graft flow assesment”, epi-aortaal scannen, 
toename in gebruik van arteriële conduits, en hybride revascularisatie. 
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Klinische richtlijnen zijn één van de meest waardevolle instrumenten om de 
integratie van de optimale technieken te bevorderen en daarmee behandelingen 
te sturen. Een van de belangrijkste vooruitgangen zijn de publicaties van Noord-
Amerikaanse en Europese richtlijnen voor myocard revascularisatie, waarbij 
“Hart Team” besluitvorming als een klasse I C aanbeveling is opgenomen. Bewijs 
ter ondersteuning van een Hart-Team is schaars en sommige clinici vrezen 
vertragingen in het behandeltraject met onveilige situaties voor patiënten als 
gevolg. Hoofdstuk 5 toont aan dat “real-world” Hart-Team besluitvorming 
haalbaar en veilig is voor de evaluatie van de complexiteit van coronair 
vaatlijden van patiënten en eventuele comorbiditeiten. Samen met de voorkeur 
van de patiënt leidt dit tot de meeste geschikte strategie voor revascularisatie. 
Ongeveer 90% van de patiënten onderging revascularisatie binnen 6 weken, wat 
overeenkomt met de aanbeveling van de myocard revascularisatie richtlijn uit 2014 
van de Europese Vereniging voor Cardiologie (ESC) en de Europese Vereniging 
voor Cardio-Thoracale Chirurgie (EACTS). Vertragingen in het behandeltraject 
werden veroorzaakt door de behoefte aan aanvullende diagnostiek, wat aantoont 
dat de logistiek verder verbeterd kan worden.
Deel 2. 
Bypass Chirurgie versus Stenten
Meerdere gerandomiseerde klinische studies (RCT’s) hebben de klinische effecten 
van PCI versus CABG onderzocht in patiënten met meervats-coronairlijden en/
of hoofdstam coronair lijden. Een van deze studies is de “the Synergy between 
Percutaneous Coronary Intervention with Taxus and Cardiac Surgery  (SYNTAX) 
studie”; een grote gerandomiseerde multicenter studie die PCI met een eerste-
generatie medicijn-afgevende stent (TAXUS™ Express™, Boston Scientific) 
vergeleek met CABG in patiënten met drievats-coronair lijden en/of hoofdstam 
coronair lijden. De ontwikkeling van de SYNTAX score, een uniek instrument om 
de complexiteit van coronair vaatlijden te scoren en daarmee sturing te geven 
aan de keus tussen PCI en CABG, was een significante bijdrage van de SYNTAX 
studie. 
De RCT’s die zijn uitgevoerd, gebruikten verschillende samengestelde eindpunten 
met verschillende klinische impact om daarmee de statistische kracht te 
vergroten. Echter, geen enkele studie was krachtig genoeg om significante 
mortaliteitsverschillen als primair eindpunt aan te tonen. Hoofdstuk 6 beschrijft 
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een samengestelde patiënt-data analyse van 11.518 patiënten uit 11 RCT’s,. Deze 
studie toonde een significant hogere 5-jaars mortaliteit na PCI in vergelijk met 
CABG in patiënten met meervats-coronairlijden, met name bij patiënten met 
diabetes mellitus en hogere coronaire complexiteit volgens de SYNTAX score. In 
patiënten met hoofdstam coronair lijden werd geen verschil gezien in mortaliteit 
tussen de twee behandelingsstrategieën. In Hoofdstuk 7 werd de specifieke 
doodsoorzaak onderzocht middels data uit de SYNTAX studie. Deze studie toonde 
aan dat, na 5 jaar follow-up, cardiale dood door een mycoardinfarct aanzienlijk 
hoger was bij patiënten die PCI met TAXUS hebben ondergaan vergeleken met 
patiënten die CABG hebben ondergaan. 
Een beroerte na PCI en CABG, kan, ondanks dat dit zelden voorkomt, een 
desastreuze complicatie zijn welke geassocieerd is met hoge mortaliteit en een 
afgenomen kwaliteit van leven. In Hoofdstuk 8, toonden wij aan dat in 11.518 
patiënten welke gerandomiseerd waren naar CABG of PCI met medicatie-
afgevende stents, PCI geassocieerd is met een signifcant lager aantal beroertes 
in de eerste 30-dagen na behandeling vergeleken met CABG (0.4% versus 1.1%, 
respectievelijk). Echter werd er geen verschil gevonden in beroerte aantallen 
tussen de twee behandelingen na de eerste 30 dagen. Diabetes had een significant 
effect op het voorkomen van een beroerte tijdens 5 jaar follow-up wanneer 
PCI met CABG werd vergeleken (2.6% versus 4.9%, P voor Interactie = 0.004). 
De reden voor dit hoger aantal beroertes na CABG zou multifactorieel kunnen 
zijn, inclusief het routinematig gebruik van antifibrinolytica welke het risico 
op bloeding na chirurgie verlagen. Hoofdstuk 9 is een “letter to the editor” 
waarin het belang wordt onderstreept van de juiste intraoperatieve dosering van 
“antifibrinolytische-tranexaminezuur (TXA)” om bloedingscomplicaties na CABG 
te voorkomen. Tevens wordt benadrukt dat het routinematig gebruik van TXA het 
risico op beroerte na CABG kan beïnvloeden. 
In Hoofdstuk 10 zijn aanvullende analyses van de SYNTAX studie uitgevoerd om 
de gevolgen van herhaaldelijke revascularisatie op de 5-jaars klinische uitkomsten 
te bepalen. Het aantal herhaaldelijke revascularisaties is hoger na PCI vergeleken 
met CABG op alle tijdspunten. Onze studie toonde aan dat, na 5-jaar follow-up, 
het aantal herhaaldelijke revascularisaties significant hoger was na PCI vergeleken 
met CABG (25.9% versus 13.7%, P<0.001). Tevens was er een significante correlatie 
tussen herhaaldelijke revascularisaties na initiële PCI en een toegenomen 
incidentie van ernstige bijwerkingen. Lange-termijn uitkomsten hebben 
aangetoond dat er een significant hogere noodzaak was voor herhaaldelijke 
revascularisatie na de initiële PCI behandeling vergeleken met CABG (9.0% versus 
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2.8%, P=0.022; respectievelijk). Onafhankelijke voorspellers voor herhaaldelijke 
revascularisatie zijn diabetes mellitus, incomplete revascularisatie, het aantal 
overlappende stents en de afwezigheid van plaatjes-aggregatie remmers onder 
patiënten welke gerandomiseerd waren voor PCI. Behandeling in de Verenigde 
Staten van Amerika en het gebruik van een “off-pump” chirurgische techniek zijn 
betrouwbare voorspellers voor herhaaldelijke revascularisatie na CABG.
Afgezien van de individuele eindpunten zoals mortaliteit, myocard infarct 
(MI), beroerte en herhaaldelijke revascularisatie, gebruiken klinische studies 
vaak samengestelde uitkomsten om de statische kracht van de analyses te 
verbeteren. Individuele eindpunten in samengestelde eindpunten wegen even 
zwaar, terwijl verschillende individuele eindpunten duidelijk verschillende 
impact hebben op de lange-termijn prognose. Daarom zijn er meerdere nieuwe 
statistische benaderingen geïntroduceerd om deze samengestelde eindpunten 
te onderzoeken. In Hoofdstuk 11 is de statistische “win ratio” benadering op 
de data van de SYNTAX studie toegepast om aanvullende klinische inzichten te 
verschaffen in de primair samengestelde uitkomst van mortaliteit, beroerte, MI 
en herhaaldelijke revascularisatie, waarbij ook de sterke en zwakke punten van 
alternatieve statische methode ten behoeve van de analyse van samengestelde 
eindpunten worden beoordeeld. Deze studie laat een betere uitkomst van CABG 
ten opzichte van PCI zien, waarneembaar in een duidelijke afname van klinische 
eindpunten zoals mortaliteit en MI. Bovendien is deze methode gemakkelijk 
toepasbaar om samengestelde eindpunten te analyseren met meerdere 
afzonderlijke gebeurtenissen, terwijl de integriteit van de studieresultaten wordt 
gewaarborgd.
Meerdere factoren kunnen invloed hebben op besluitvorming omtrent de 
behandeling. Er is een hogere prevalentie van coronair vaatlijden en een 
verhoogd risico op cardiale dood onder patiënten met chronische nierziekte en/
of diabetes mellitus. Of het gebruik van PCI of CABG de overleving van dergelijke 
patiënten verbetert blijft onduidelijk vanwege de beperkt beschikbare data uit 
gerandomiseerde studies en tegenstrijdig bewijs uit observationele studies. 
Om deze kloof in klinische kennis te overbruggen, is het gevolg van chronische 
nierziekte op 5-jaars uitkomsten na PCI en CABG in de SYNTAX studie onderzocht 
in Hoofdstuk 12. Deze subgroep-analyse toont aan dat CABG de gewenste 
revascularisatie strategie blijkt te zijn ten opzichte van PCI, met name in patiënten 
met diabetes waarbij chronische nierziekte als complicatie is opgetreden. De 
gerandomiseerde studie onderzocht 1905 patiënten met hoofdstam coronair 
lijden, die geïncludeerd waren in de “Evaluation of XIENCE versus Coronary 
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Artery Bypass Surgery for Effectiveness of Left Main Revascularization  (EXCEL)” 
studie, welke PCI (met tweede generatie medicatie-afgevende stents) vergeleek 
met CABG. Deze studie toonde aan dat patiënten met diabetes, vergeleken met 
patiënten zonder diabetes, een significant hogere proportie van het samengesteld 
eindpunt (overlijden, beroerte en MI) hadden (20.0% versus 12.9%, P<0.001, 
respectievelijk) (Hoofdstuk 13). Echter, de propotie samengesteld eindpunt 
bleek gelijk te zijn na behandeling middels PCI en CABG in patiënten met 
diabetes mellitus (20.7% versus 19.3%, P=0.87) en patiënten zonder diabetes 
mellitus (12.9% versus 12.9%, P=0.89). Dit suggereert dat PCI, in geselecteerde 
patiënten met diabetes mellitus en hoofdstam coronair lijden, een haalbaar 
behandelingsalternatief is voor CABG.
De globalisering van klinische trials heeft zich ontwikkeld als nieuwe modaliteit en 
beschrijft de verplaatsing van klinische trials naar landen met lager inkomens om 
aldaar kosten te besparen en inclusie van studie-patiënten te versnellen. Een van 
de grootste zorgen is dat de onevenwichtigheid tussen de kwaliteit van de zorg, de 
gezondheid van de patiënt, de behandelkeuze en de ziekenhuisinfrastructuur de 
algehele generalisatie van de onderzoeksresultaten kan beïnvloeden. Hoofdstuk 
14 richt zich op de invloed van de unieke manier van werken in specifieke landen 
op de klinische uitkomsten in de SYNTAX studie. Hierbij ontdekten wij dat zowel 
de karakteristieken van patiënten in de SYNTAX studie, als de unieke manier van 
werken substantieel verschilt tussen de deelnemende landen. Dit resulteert in 
een significant verschil in klinische uitkomsten, waarvoor specifieke behandel-
aanbevelingen zijn aanbevolen. Tevens worden deze verschillen in het licht van 
toekomstige studieprotocollen bediscussieerd. 
Deel 3. 
Verbeteren van Uitkomsten in Hartchirurgie
Vooruitgang in het gehele spectrum van de gezondheidszorg heeft geleid tot 
significante verbeteringen in de klinische uitkomsten van patiënten die een 
CABG hebben ondergaan ten tijde van hun ziekenhuisopname. Echter, coronair 
vaatlijden is een chronisch progressieve ziekte die intensieve postoperatieve 
medicatie vereist om progressie van de ziekte te vertragen en het risico op 
toekomstige cardiovasculaire aandoeningen te verminderen. Klinische richtlijnen 
zijn ontwikkeld om medici te ondersteunen in het besluitvormingsproces door 
aanbevelingen te doen die worden ondersteund door het beste beschikbare 
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wetenschappelijk bewijs. Naast het toenemend besef over de verschillende 
klinische uitkomsten tussen verschillende behandelstrategieën kunnen klinische 
onderzoeken tevens waardevolle informatie verschaffen over het praktijkgebruik 
van de aanbevelingen uit klinische richtlijnen in de dagelijkse medische zorg. 
In Hoofdstuk 15, gebaseerd op een individuele patiëntendatabase-analyse van 
7085 patiënten uit 5 RCT’s, hebben wij de therapietrouw van de aanbevolen 
gezondheidszorg uit de klinische richtlijnen na myocard revascularisatie 
onderzocht. Deze analyse toont het suboptimaal gebruik van de door richtlijnen 
geadviseerde medische therapie na CABG aan en de significante correlatie tussen 
suboptimale medicatie van patiënten na chirurgie en het risico op ongunstige 
klinische uitkomsten na 5 jaar follow-up. In Hoofdstuk 16 presenteren wij 
de op wetenschappelijk onderzoek gebaseerde aanbevelingen omtrent de 
perioperatieve medicamenteuze zorg voor volwassen hartchirurgie. Hoofdstuk 
17 is een “letter to the editor” welke het bewijs betreffende staking of continuatie 
van acetylsalicylzuur (ASA) in de preoperatieve dagen voorafgaand aan bypass 
chirurgie. De belangrijkste bevinding van deze meta-analyse was in tegenspraak 
met wat de klinische richtlijn aanbeveelt. Daarom worden de methodologische 
aspecten omtrent de inen exclusiecriteria van de uitgevoerde meta-analyse 
samen met de belangrijkste studies in dit gebied in perspectief geplaatst om 
aanbevelingen in de klinische richtlijnen verder te ondersteunen.
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The clinical goals for the care of each patient with com-
plex coronary artery disease are to ensure that the most 
appropriate treatment is selected, and the best availa-
ble evidence is used to guide procedural techniques and 
modify risk factors that could impact life expectancy and 
health-related quality of life. In this thesis, efficient surgi-
cal techniques, post-procedural therapies, and the most 
critical determinants for clinical decision-making bet-
ween surgical and catheter-based myocardial revasculari-
zation are explored, thereby helping patients and treating 
physicians to choose the most appropriate revasculariza-
tion strategy and secondary prevention therapy based on 
an individualized risk-benefit ratio. With the increasing 
number of high-quality clinical studies and rigorously 
developed clinical practice guidelines, a future-directed 
intention needs to be the implementation of quality-im-
provement programs across clinical microsystems to in-
crease the use of evidence-based practice in hospitals and 
outpatient settings to enhance the efficacy and safety of 
patient care.
